

Plan for your best health

2024 Aetna Pharmacy Drug Guide

Advanced Control Plan - Aetna: Student Health CA

Visit www.aetna.com/formulary for the most up-to-date information. For a summary of your coverage or benefits plan log in to your secure member site. Or call the toll-free number on your member ID card.

The formulary is updated annually in July. The formulary is subject to change. Previous versions are no longer in effect.

The Medical plan names to which this document applies to in the state of California are listed below:

Aetna Plan Name

Elect Choice® EPO
OA Elect Choice® EPO
Open Choice PPO

Aetna is the brand name used for products and services provided by one or more of the Aetna group of subsidiary companies, including Aetna Life Insurance Company and its affiliates (Aetna). Aetna Pharmacy Management refers to an internal business unit of Aetna Health Management, LLC. Aetna Pharmacy Management administers, but does not offer, insure or otherwise underwrite the prescription drug benefits portion of your health plan and has no financial responsibility therefor.

Table of Contents

| | |
|--|-----|
| INFORMATIONAL SECTION..... | 4 |
| ANALGESICS - DRUGS TO TREAT PAIN AND INFLAMMATION..... | 17 |
| ANTI-INFECTIVES - DRUGS TO TREAT INFECTIONS..... | 32 |
| ANTINEOPLASTIC AGENTS - DRUGS TO TREAT CANCER..... | 50 |
| CARDIOVASCULAR - DRUGS TO TREAT HEART AND CIRCULATION CONDITIONS..... | 64 |
| CENTRAL NERVOUS SYSTEM - DRUGS TO TREAT NERVOUS SYSTEM DISORDERS..... | 83 |
| ENDOCRINE AND METABOLIC - DRUGS TO TREAT DIABETES AND REGULATE HORMONES..... | 131 |
| GASTROINTESTINAL - DRUGS TO TREAT STOMACH AND INTESTINAL DISORDERS..... | 179 |
| GENITOURINARY - DRUGS TO TREAT GENITAL AND URINARY TRACT CONDITIONS..... | 189 |
| HEMATOLOGIC - DRUGS TO TREAT BLOOD DISORDERS..... | 194 |
| IMMUNOLOGIC AGENTS - DRUGS TO TREAT DISORDERS OF THE IMMUNE SYSTEM..... | 204 |
| MEDICAL DEVICES..... | 223 |
| NUTRITIONAL/SUPPLEMENTS - VITAMINS AND SUPPLEMENTS..... | 232 |
| OPHTHALMIC - DRUGS TO TREAT EYE CONDITIONS..... | 239 |
| OTHER..... | 245 |
| RESPIRATORY - DRUGS TO TREAT BREATHING DISORDERS..... | 246 |
| TOPICAL - DRUGS TO TREAT EAR AND SKIN CONDITIONS..... | 261 |

Definitions

Brand name drug means a drug that is marketed under a proprietary, trademark-protected name. A brand name drug is listed in this formulary in all CAPITAL letters.

Coinurance means a percentage of the cost of a covered health care benefit that you pay after you have paid the deductible, if a deductible applies to the health care benefit.

Copayment means a fixed dollar amount that you pay for a covered health care benefit after you have paid the deductible, if a deductible applies to the health care benefit.

Deductible means the amount you pay for covered health care benefits that are subject to the deductible before your health insurer begins to pay. If your health insurance policy has a deductible, it may have either one deductible or separate deductibles for medical benefits and prescription drug benefits. After you pay your deductible, you usually pay only a copayment or coinsurance for covered health care benefits. Your insurance company pays the rest.

Drug Tier means a group of prescription drugs that correspond to a specified cost sharing tier in your health insurance policy. The drug tier in which a prescription drug is placed determines your portion of the cost for the drug.

Enrollee is a person enrolled in a health plan who is entitled to receive services from the plan.

Exception request means a request for coverage of a non-formulary drug. If you, your designee, or your prescribing health care provider submits a request for coverage of a non-formulary drug, your insurer must cover the non-formulary drug when it is medically necessary for you to take the drug.

Exigent circumstances means when you are suffering from a medical condition that may seriously jeopardize your life, health, or ability to regain maximum function, or when you are undergoing a current course of treatment using a non-formulary drug.

Formulary or prescription drug list means the list of drugs that is covered by your health insurance policy under the prescription drug benefit of the policy.

Generic drug means a drug that is the same as its brand name drug equivalent in dosage, strength, effect, how it is taken, quality, safety, and intended use. A generic drug is listed in this formulary in italicized lowercase letters.

Medically Necessary means health care benefits needed to diagnose, treat, or prevent a medical condition or its symptoms and that meet accepted standards of medicine. Health insurance usually does not cover health care benefits that are not medically necessary.

Non-formulary drug means a prescription drug that is not listed on this formulary.

Out-of-pocket costs means your expenses for health care benefits that aren't reimbursed by your health insurance. Out-of-pocket costs include deductibles, copayments, and coinsurance for covered health care benefits, plus all costs for health care benefits that are not covered.

Prescribing provider means a health care provider who can write a prescription for a drug to diagnose, treat, or prevent a medical condition.

Prescription means an oral, written, or electronic order from a prescribing provider authorizing a prescription drug to be provided to a specific individual.

Prescription drug means a drug that by law requires a prescription.

Prior Authorization means a decision by your health insurer that a health care benefit is medically necessary for you. If a prescription drug is subject to prior authorization in this formulary, your prescribing provider must request approval from your health insurer to cover the drug before you fill your prescription. Your health insurer must grant a prior authorization request when it is medically necessary for you to take the drug.

Step therapy means a specific sequence in which prescription drugs for a particular medical condition must be tried. If a drug is subject to step therapy in this formulary, you may have to try one or more other drugs before your health insurance policy will cover that drug for your medical condition. If your prescribing provider submits a request for an exception to the step therapy requirement, your health insurer must grant the request when it is medically necessary for you to take the drug.

Subscriber means the person who is responsible for payment to a plan or whose employment or other status, except for family dependency, is the basis for eligibility for membership in the plan.

How to use this guide

Your guide includes a list of commonly used drugs covered on your pharmacy plan. The amount you pay depends on the drug your doctor prescribes. It's either a flat fee or a percentage of the prescription's price after you meet your deductible, if applicable. Preferred generic drugs cost less. Preferred brand drugs will have a higher cost.

Refer to the Summary of Benefits for differences and information about the prescription drugs covered under your Outpatient prescription drugs and medical benefit in your plan.

A prescription drug may be located by looking up the therapeutic category and class to which the drug belongs or the brand or generic name of the drug in the alphabetical index; and

If a generic equivalent for a brand name drug is not available on the market or is not covered, the drug will not be separately listed by its generic name.

- A drug is listed alphabetically by its brand and generic names in the therapeutic category and class to which it belongs;
- The generic name for a brand name drug is included after the brand name in parentheses and all lowercase italicized letters. (For example: COREG (*carvedilol*))
- If a generic equivalent for a brand name drug is both available and covered, the generic drug will be listed separately from the brand name drug in all lowercase italicized letters; and (For example: *carvedilol*)
- If a generic drug is marketed under a proprietary, trademark-protected brand name, the brand name will be listed after the generic name in parentheses and regular typeface with the first letter of each word capitalized. (For example: *desogestrel-ethynodiol estradiol* (Azurette)).
- Inclusion of a prescription drug on the formulary does not guarantee that your provider will prescribe the drug for a particular medical condition.
- Therapeutic categories and classes are based on the Medispan therapeutic classification system.

Your plan includes

- Brand and generic drugs that are hand-picked for their quality and effectiveness
- A specialty pharmacy fills specialty drug prescriptions (ones that are injected, infused or taken by mouth) — and provides services that include personal support, helpful resources and training, and free secure home delivery
- A home delivery pharmacy that delivers maintenance drugs to your home or wherever you choose (for drugs that are taken regularly to treat conditions like diabetes or asthma)

What you can expect to pay

With your pharmacy plan, the amount you pay depends on the drug your doctor prescribes. It's either a flat fee or a percentage of the drug's/medicine price. If a pharmacy's retail price for a prescription drug is less than your total cost share amount, you will not be required to pay more than the retail drug price.

Each drug is grouped as a generic, a brand or a specialty drug. The preferred drugs within these groups will generally save you money compared to a non-preferred drug. Typically, generic drugs are less expensive than brands.

Specialty prescription drugs typically include higher-cost drugs that require special handling, special storage or monitoring. These types of drugs may include, but are not limited to, drugs that are injected, infused, inhaled or taken by mouth.

You're covered for all types of medicine — some more expensive, and some less.

- **Generic – G (tier 1):** the lowest cost share
- **Preferred brand – PB (tier 2):** a slightly higher cost share
- **Non-preferred brand – NPB (tier 3):** a higher cost share
- **Specialty – SP (tier 4):** lower cost share for specialty drugs
- **Copay Exception – CE:** Available to some members at no cost with a prescription from your provider when obtained at an in-network pharmacy. Certain limitations may apply.

Your pharmacy plan may not have all the coverage levels listed above so check your plan documents to see how much you will pay, for example your copayments and maximum dollar amounts.

For your exact coverage and cost, and to learn more about your plan

Visit the website that's on your member ID card. Then log in to your account, where you can:

- Find out the coverage and estimate of cost for specific drugs
- View your deductibles and plan limits
- Order medications
- Check your pharmacy order status
- Get a member ID card
- View your claims, Explanation of Benefits and more

Have more questions about your pharmacy benefits?

We're here to help. There are several ways you can learn more about your benefits:

- Check your Plan Design and Benefits Summary in your enrollment kit.
- Call the toll-free number on your member ID card.
- Review our pharmacy frequently asked questions (FAQs) and answers. Just visit the website that's on your member ID card to search for the "Pharmacy FAQ".

Specialty Pharmacy Network

An in-network specialty pharmacy can fill your prescriptions for specialty drugs. These are the types of drugs that may be injected, infused or taken by mouth. They often need special storage and handling. And they need to be delivered quickly. A nurse or pharmacist may monitor your treatment, if needed. With this type of pharmacy, you can get this medicine sent right to our mailbox.

How to get started with a specialty pharmacy

Ordering your prescriptions through our specialty pharmacy is easy. And we typically offer a 30-day medicine supply.

- **To transfer your prescription,** just call us toll-free at [1-866-353-1892 \(TTY: 711\)](tel:1-866-353-1892).
- **For a new prescription,** your doctor can send it to us in one of four ways:
 - 1. Electronically:** Through e-prescribe
 - 2. Fax: 1-800-323-2445**
 - 3. Phone: [1-800-237-2767 \(TTY: 711\)](tel:1-800-237-2767)**

If you mail in your own prescription, please send it with a completed Patient Profile Form. To find this form, just visit the website that's on your member ID card, to search for the "Patient Profile Form".

CVS Caremark Mail Service Pharmacy™

You can have maintenance drugs sent right to your home or anywhere else you choose with CVS Caremark Mail Service Pharmacy. These are drugs that are taken regularly for chronic conditions like diabetes or asthma. Depending on your plan, you can get up to a 90-day supply of medicine for less cost. It's fast and convenient, and standard shipping is always free.

Get started right away

You can submit your order using one of these options:

1. Online — Visit your secure member website and sign in to your account. There you can add or remove your prescriptions.

2. Phone — Call us toll-free, 24/7 at **1-888-792-3862** (**TTY: 711**). If you need the help of a telephone device for the hard of hearing, call **1-877-833-2779** (**TTY: 711**).

3. Mail — Get a new prescription from your doctor. Then mail it to us with a completed order form. You can find the form on your secure member website. The mailing address is on the form.

Your doctor can submit your order using one of these options:

1. Online — They can submit your prescriptions using the e-prescribe services on our provider website.

2. Fax — They can fax your prescription to **1-877-270-3317**. Make sure they include your member ID number, date of birth and mailing address on the fax cover sheet. Only a doctor may fax a prescription.

Frequently asked questions

How can I save on prescriptions?

Here are some tips to pay less out of pocket for your prescription drugs:

- Ask your doctor to consider prescribing drugs that are on the Pharmacy Drug Guide (formulary).
- Ask your doctor to consider prescribing generic drugs instead of brand-name drugs.
- Our home delivery service may save you money. For more information, visit the website on your member ID card and log in to your account.

What are generic drugs?

Generic drugs are proven to be just as safe and effective as brand-name drugs. They contain the same active ingredients in the same amounts as the brand-name drugs and work the same way. So they have the same risks and benefits as brand-name drugs. However, they typically cost less.

When appropriate, your doctor may decide to prescribe a generic drug or allow the pharmacist to substitute a generic drug.

What is precertification/prior authorization (PA)?

Prior authorization is one way that we can help you and your doctor find safe, appropriate drugs and keep costs down. Prior authorization means that you or your doctor need to get approval from the plan before certain drugs will be covered. Generally, Prior authorization applies to drugs that:

- Are often taken in the wrong way
- Should only be used for certain conditions
- Often cost more than other drugs that are proven to be just as effective

Keep in mind that your doctor must contact us to request approval of coverage for these drugs.

What is step therapy (ST)?

Some drugs require step therapy. This means that you must try one or more prerequisite drug(s) before a step therapy drug is covered.

The prerequisite drugs have U.S. Food and Drug Administration (FDA) approval and may cost less. They treat the same condition as the step therapy drug.

If you don't try the appropriate prerequisite drug(s) first, you may need to pay full cost for the step-therapy drug.

What are quantity limits (QL)?

Quantity limits help your doctor and pharmacist make sure that you use your drug correctly and safely. We use medical guidelines and FDA-approved recommendations from drug makers to set these coverage limits. The quantity limit program includes:

- **Dose efficiency edits** — Limits prescription coverage to one dose per day for drugs that have approval for once-daily dosing
- **Maximum daily dose** — If a prescription is lower than the minimum or higher than the maximum allowed dose, a message is sent to the pharmacy
- **Quantity limits over time** — Limits prescription coverage to a specific number of units over a specific amount of time

What if I need a drug that requires an exception to the prior authorization, step therapy or quantity limits requirements? Or what if I need a drug that's not covered under my plan?

In certain cases, you or your prescriber can request a medical exception to the prior authorization, step therapy or quantity limits requirement or for a drug that's not covered on your plan. Coverage determinations will be made within 72 hours of receiving non-urgent requests. You can ask for your request to be expedited. Expedited coverage decisions are made within 24 hours.

We'll then contact you or your prescriber with our decision. All medically necessary outpatient prescription drugs will be covered. If a medical exception is approved, you only need to pay the copay after the deductible. This amount is based on your pharmacy plan design.

Medical exceptions which are approved for non-urgent requests will cover the duration of the prescription, including refills. Approved medical exceptions for exigent circumstances will provide coverage for the duration of the exigency.

If your request is denied you have the right to file an appeal using the process described in the notification letter.

If a determination is not made for a prior authorization or step therapy exception request within 72 hours of receiving a non-urgent request and 24 hours of receiving a request based on exigent circumstances, the request is deemed approved and we may not deny the request thereafter.

In accordance with state law, members who are covered under small group health insurance policies and who have previously received approval from us for coverage of medications for the members' medical conditions will continue to have those medications covered, for as long as the prescriber continues prescribing them, provided that the drug is appropriately prescribed and is considered safe and effective for treating the member's medical condition.

How can your provider request a medical exception?

The following options will provide detail to help request a medical exception.

- Submit their request through our secure provider website on www.availity.com.
- Call the Aetna Pharmacy prior authorization unit: Non-Specialty **1-800-294-5979 (TTY: 711)** or Specialty **1-866-814-5506 (TTY: 711)**.
- Fax the completed request form to:
Non-Specialty **1-888-836-0730** or
Specialty **1-866-249-6155**.
- Mail the completed request form to:
Medical Exception to Pharmacy Prior Authorization
Unit 1300 East Campbell Road
Richardson, TX 75081

Can the formulary change during the year?

The formulary can change throughout the year. Some reasons why they can change include:

- New drugs are approved.
- Existing drugs are removed from the market.
- Prescription drugs may become available over the counter (without a prescription). Over-the-counter drugs are not generally covered in a formulary.
- Brand-name drugs lose patent protection and generic versions become available. When this happens, the generic drug will be covered in place of the brand-name drug. The brand-name drug is likely to become non-formulary or covered at a higher cost. See the "what are generic drugs?" section above for more information.

Pharmacy and Therapeutics (P&T) committee

The services of an independent National Pharmacy and Therapeutics Committee ("P&T Committee") are utilized to approve safe and clinically effective drug therapies. The P&T Committee is an external advisory body of clinical professionals from across the United States. The P&T Committee's voting members include physicians, pharmacists, a pharmacoeconomist and a medical ethicist, all of whom have a broad background of clinical and academic expertise regarding prescription drugs. Voting members of the P&T Committee are not employees of CVS Caremark and must disclose any financial relationship or conflicts of interest with any pharmaceutical manufacturers.

How do you find a pharmacy?

You can find a pharmacy in two ways:

- **Online:** By logging onto your secure member website at Aetna.com.
- **By phone:** Call the toll-free number on your ID card. During regular business hours, a representative can assist you. Our automated telephone assistant can give you this information 24 hours a day.

Assistive Technology

Persons using assistive technology may not be able to fully access the following information. For assistance, please call **1-888-802-3862 (TTY: 711)**.

Smartphone or Tablet

To view documents from your smartphone or tablet, the free WinZip app is required. It may be available from your App Store.

Non-Discrimination

Aetna complies with applicable California and Federal civil rights laws and does not discriminate, exclude or treat people differently based on their race, color, national origin, ancestry, religion, sex, marital status, age, gender, gender identity, sexual orientation or disability.

Aetna provides free aids/services to people with disabilities and to people who need language assistance.

If you need a qualified interpreter, written information in other formats, translation or other services, call the number on your ID card.

If you believe we have failed to provide these services or otherwise discriminated based on race, color, national origin, ancestry, religion, sex, marital status, age, gender, gender identity, sexual orientation or disability, you can also file a grievance with the Civil Rights Coordinator by contacting:

Civil Rights Coordinator

P.O. Box 24030, Fresno, CA 93779

1-800-648-7817 (TTY: 711), Fax: 860-262-7705

CRCoordinator@aetna.com.

You can also file a complaint with the California Department of Insurance at **www.insurance.ca.gov**, or at: Consumer Services Division, 300 Spring Street South Tower, Los Angeles CA 90013, or at **1-800-927-HELP (4357)**.

TDD: 1-800-482-4TDD (4833).

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights if there is a concern of discrimination based on race, color, national origin, age, disability, or sex.

You can file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights Complaint Portal, available at **https://ocrportal.hhs.gov/ocr/portal/lobby.jsf**, or at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, or at

1-800-368-1019, 1-800-537-7697 (TDD)

| English | To access language services at no cost to you, call the number on your ID card. |
|-------------------------|--|
| Albanian | Për shërbime përkthimi falas për ju, telefononi në numrin që gjendet në kartën tuaj të identitetit. |
| Amharic | የቃንቃ እና ልማልምና የለከፍያ ለማግኘት፡ በመተወቁያምኑ ለይ ያለውን ቅጥር ይደውሉ፡፡ |
| Arabic | للحصول على الخدمات اللغوية دون أي تكلفة، الرجاء الاتصال على الرقم الموجود على بطاقة اشتراكك. |
| Armenian | Զեր նախընտրած լեզվով ավագար խորհրդատվություն ստանալու համար զանգահարեք ձեր բժշկական ապահովության քարտի վրա նշված հերախոսահամարով |
| Bantu-Kirundi | Kugira uronke serivisi z'indimi ata kiguzi, hamagara inomero iri ku karangamuntu kawe |
| Bengali | আপনাকে বিনামূল্যে ভাষা পরিষেবা পেতে হলে আপনার পরিচয়পত্রে দেওয়া নম্বরে টেলিফোন করুন। |
| Burmese | သင့်အနေဖြင့် အခကြွေးငွေ မပေးရပဲ ဘာသာစကားဝန်ဆောင်မှုများ ရရှိနိုင်ရန်၊ သင့် ID ကတ်ပေါ်တွင်ရှိသော ဖုန်းနံပါတ်အား ခေါ်ဆိုပါ။ |
| Catalan | Per accedir a serveis lingüístics sense cap cost per a vostè, telefoni al número indicat a la seva targeta d'identificació. |
| Cebuano | Aron maakses ang mga serbisyo sa lengguwahe nga wala kay bayran, tawagi ang numero nga anaa sa imong kard sa ID. |
| Chamorro | Para un hago' i setbision lengguâhi ni dibâtde para hågu, ågang i numiru gi iyo-mu kard aidentifikasiōn. |
| Cherokee | QEYELJ KELIHELEJ T0aTHL0LJ L AGELJ JCEGWLJ ñY, OIABW0LJ TH0LJ J4ELJ hSA.ØYR O^T ID IH0LJ C10T. |
| Chinese Traditional | 如欲使用免費語言服務，請撥打您健康保險卡上所列的電話號碼 |
| Choctaw | Anumpa tosholi i toksvli ya peh pilla ho ish i payahinla kvt chi holocco kallo iskitini holhtena takanli ma i payah |
| Chuukese | Ren omw kopwe angei aninisin eman chon awewei (ese kamé), kopwe kééri ewe nampa mei mak won noum ena katen ID |
| Cushitic-Oromo | Tajaajiiloota afaanii gatii bilisaa ati argaachuuf,lakkoofsa fuula waraaqaa eenyummaa (ID) kee irraa jiruun bilbili. |
| Dutch | Voor gratis taaldiensten, bel het nummer op uw ziekteverzekeringskaart. |
| French | Pour accéder gratuitement aux services linguistiques, veuillez composer le numéro indiqué sur votre carte d'assurance santé. |
| French Creole (Haitian) | Pou ou jwenn sèvis gratis nan lang ou, rele nimewo telefòn ki sou kat idantifikasyon asirans sante ou. |
| German | Um auf den für Sie kostenlosen Sprachservice auf Deutsch zuzugreifen, rufen Sie die Nummer auf Ihrer ID-Karte an. |
| Greek | Για πρόσβαση στις υπηρεσίες γλώσσας χωρίς χρέωση, καλέστε τον αριθμό στην κάρτα ασφάλισής σας. |
| Gujarati | તમારે કોઈ પણ જાતના ખર્ચ વિના ભાષા સેવાઓ મેળવવા માટે, તમારા આઇડી કાર્ડ પર રહેલ નંબર પર કોલ કરવો. |

| | |
|----------------------|---|
| Hawaiian | No ka wala'au 'ana me ka lawelawe 'ōlelo e kahea aku i ka helu kelepona ma kāu kāleka ID. Kāki 'ole 'ia kēia kōkua nei. |
| Hindi | बिना किसी कीमत के भाषा सेवाओं का उपयोग करने के लिए, अपने आईडी कार्ड पर दिए नंबर पर कॉल करें। |
| Hmong | Yuav kom tau kev pab txhais lus tsis muaj nqi them rau koj, hu tus naj npawb ntawm koj daim npav ID. |
| Igbo | Inweta enyemaka asusụ na akwughi ụgwọ obụla, kpọọ nọmba nọ na kaadi njirimara gi |
| Ilocano | Tapno maakses dagiti serbisio ti pagsasao nga awanan ti bayadna, awagan ti numero nga adda ayan ti ID kardmo. |
| Indonesian | Untuk mengakses layanan bahasa tanpa dikenakan biaya, silakan hubungi nomor telepon di kartu asuransi Anda. |
| Italian | Per accedere ai servizi linguistici senza alcun costo per lei, chiami il numero sulla tessera identificativa. |
| Japanese | 無料の言語サービスは、IDカードにある番号にお電話ください。 |
| Karen | လာတ်ကမ္န်ကျိုတ်မာစာအောင်းတ်မာတဖုံး လာတ်အိုင်းအပူလာနကဘ်ဟုံးဒီအောင်း၊ ဂီးဘာ်လိုပါနိုင်းလာအိုင်းလာနိုင်းရိုး (ID) အလိုနှင့်တကူး။ |
| Korean | 무료 다국어 서비스를 이용하려면 보험 ID 카드에 수록된 번호로 전화해 주십시오. |
| Kru-Bassa | I nyuu kosna mahola ni language services ngui nsaa wogui wo, sebel i nsinga i ye ntilga i kat yong matibla |
| Kurdish | بۇ دەپپەر اگيىشتن بە خزمەتگوزارى زمان بەپىز تىچوون بۇ تو، پەپىوندى بىكە بە ژمارەسى سەر ئاي دى (ID) كارتى خوت. |
| Lao | ຕັ້ງອັນເຈົ້າຕົ້ງບໍລິການພາຫຼືບໍລະລົດທຳ, ໃຫ້ໃຫຍ່ເປັນໄທ້ໃນບັດປະຈຳຕົວຂອງທ່ານ. |
| Marathi | आपल्याला कोणत्याही शुल्काशिवाय भाषा सेवांपर्यंत पोहोचण्यासाठी, आपल्या ID कार्डावरील क्रमांकावर फोन करा. |
| Marshallese | Nan bōk jipañ kōn kajin ilo an ejjejok wōñean ñan kwe, kwōn kallok nōmba eo ilo kaat in ID eo am. |
| Micronesian-Ponapean | Pwehn alehdi sawas en lokaia kan ni sohte pweipwei, koahlih nempe nan amhw doaropwe en ID. |
| Mon-Khmer, Cambodian | ជីម្រើនកណ្តាលសរភាគមុខភាសាដែលត្រួតពិនិត្យសម្រាប់លោកអ្នក សូមហេរីនករសាងចោរកាន់លេខដែលមាននៅបៀបណ្តាលសម្រាប់លោកអ្នក។ |
| Navajo | T'áá ni nizaad k'eħjí beeníká a'doowoł doo bágh ílínígóó naaltsoos bee atah nílígóó nanitinígíí bee néého'dólzinígíí béésh bee hane'í biká'ígíí áají' hólne'. |
| Nepali | भाषासम्बन्धी सेवाहरूमाथि नि:शुल्क पहुँच राख्न आफ्नो कार्डमा रहेको नम्बरमा कल गर्नुहोस्। |
| Nilotic-Dinka | Tē koc̄ yin ran de wēer de thokic ke cīn wēu kōr keek tēnōj yin. Ke yin col ran ye koc̄ kuɔny nē namba de abac tö nē ID kard duōn de tiit de nyin de panakim kōu. |
| Norwegian | For tilgang til kostnadsfri språktjenester, ring nummeret på ID-kortet ditt. |
| Pennsylvanian-Dutch | Um Schprooch Services zu griegen mitaus Koscht, ruff die Nummer uff dei ID Kaart. |

| | |
|------------------|--|
| Persian Farsi | برای دسترسی به خدمات زبان به طور رایگان، با شماره قبض شده روی کارت شناسایی خود تماس بگیرید. |
| Polish | Aby uzyskać dostęp do bezpłatnych usług językowych, należy zadzwonić pod numer podany na karcie identyfikacyjnej. |
| Portuguese | Para aceder aos serviços linguísticos gratuitamente, ligue para o número indicado no seu cartão de identificação. |
| Punjabi | ਤੁਹਾਡੇ ਲਈ ਬਿਨਾਂ ਕਿਸੇ ਕੀਮਤ ਵਾਲੀਆਂ ਪੰਜਾਬੀ ਸੇਵਾਵਾਂ ਦੀ ਵਰਤੋਂ ਕਰਨ ਲਈ, ਆਪਣੇ ਆਈਡੀ ਕਾਰਡ 'ਤੇ ਇੱਤੇ ਨੰਬਰ 'ਤੇ ਛੋਨ ਕਰੋ। |
| Romanian | Pentru a accesa gratuit serviciile de limbă, apelați numărul de pe cardul de membru. |
| Russian | Для того чтобы бесплатно получить помощь переводчика, позвоните по телефону, приведенному на вашей идентификационной карте. |
| Samoan | Mō le mauaina o 'au'aunaga tau gagana e aunoa ma se totogi, vala'au le numera i luga o lau pepa ID. |
| Serbo-Croatian | Za besplatne prevodilačke usluge pozovite broj naveden na Vašoj identifikacionoj kartici. |
| Spanish | Para acceder a los servicios lingüísticos sin costo alguno, llame al número que figura en su tarjeta de identificación. |
| Sudanic Fulfulde | Heeba a naasta under ekkitol jaangirde woldeji walla yobugo, ewnu lamba je don windi ha do derowol maada. |
| Swahili | Kupata huduma za lugha bila malipo kwako, piga nambari iliyo kwenye kadi yako ya kitambulisho. |
| Syriac-Assyrian | لَا تَنْسِي تَذْكُرَ جَلِيلِكَيْتَ وَجَنَاحَكَيْتَ حَلَقَكَيْتَ مَنْجَفَكَيْتَ جَلِيلَكَيْتَ وَجَنَاحَكَيْتَ . |
| Tagalog | Upang ma-access ang mga serbisyo sa wika nang walang bayad, tawagan ang numero sa iyong ID card. |
| Telugu | భాష సేవలను మీకు ఖర్చు లేకుండా అందుకునేడుకు, మీ ఐ కార్డ్ ల్ని ఉన్న నంబరుకు కాల్ చేయండి. |
| Thai | หากท่านต้องการเข้าถึงการบริการทางด้านภาษาโดยไม่มีค่าใช้จ่าย โปรดโทรหมายเลขที่แสดงอยู่บนบัตรประจำตัวของท่าน |
| Tongan | Kapau 'oku ke fiema'u ta'etōtōngi 'a e ngaahi sēvesi kotoa pē he ngaahi lea kotoa, telefoni ki he fika 'oku hā atu 'i ho'o ID kaati. |
| Turkish | Dil hizmetlerine ücretsiz olarak erişmek için kimlik kartınızdaki numarayı arayın. |
| Ukrainian | Щоб безкоштовні отримати мовні послуги, задзвоніть за номером, вказаним на вашій ідентифікаційній картці. |
| Urdu | لسانی خدمات تک مفت رسائی کے لئے، اپنے بیمہ کے ID کارڈ پر درج نمبر پر کال کریں۔ |
| Vietnamese | Để sử dụng các dịch vụ ngôn ngữ miễn phí, vui lòng gọi số điện thoại ghi trên thẻ ID của quý vị. |
| Yiddish | זו באקומהון שפראך סערוויסעס פריי פון אפזאל, רופט דעם נומער אויף אייער ID קארטל. |
| Yoruba | Láti ráyèsí àwọn isé èdè fún o lófèé, pe nómbà tó wà lórí káàdì idánimò re. |

Remember to visit the website on your member ID card. Then sign in to your account for the most up-to-date information.

Please note that if your prescription drug benefits plan changes, the information here may no longer apply.

Medications on the Aetna Drug Guide, precertification, step-therapy and quantity limits lists are subject to change.

Health benefits and health insurance plans are offered, administered and/or underwritten by Aetna Health Inc., Aetna Health Insurance Company of New York, Aetna Health Assurance Pennsylvania Inc., Aetna Health Insurance company and/or Aetna Life Insurance Company (Aetna). In Florida, by Aetna Health Inc. and/or Aetna Life Insurance Company. In Utah and Wyoming by Aetna Health of Utah Inc. and Aetna Life Insurance Company. In Maryland, by Aetna Health Inc., 151 Farmington Avenue, Hartford, CT 06156. Pharmacy benefits are administered through an affiliated pharmacy benefit manager, CVS Caremark. Aetna is part of the CVS Health family of companies.

Not all health services are covered. See plan documents for a complete description of benefits, exclusions, limitations and conditions of coverage. To check coverage and copay information for a specific medicine, log into your member website. For questions, please call the toll-free number on the back of your member ID card.

The drugs on the Pharmacy Drug Guide (formulary), Formulary Exclusions, Precertification, and Quantity Limit Lists are subject to change. The quantity limits and step therapy drug coverage review programs are not available in all service areas. However, these programs are available to self-funded plans.

Information is subject to change. In accordance with state law or insurer policies, changes to drug coverage are not effective for commercial fully insured plans (including HMOs) in Louisiana, New York, Texas, and in most circumstances Connecticut and Vermont, until the plans' renewal date.

In accordance with state law, certain fully insured commercial California members (except Federal Employee Health Benefit Plan members) who obtained approval from an Aetna plan for coverage of drugs that are later added to the Preauthorization or Step Therapy Lists or removed from the Pharmacy Drug Guide will continue to have those drugs covered, for as long as the treating in-network provider continues prescribing them, provided that the drug is appropriately prescribed and is considered safe and effective for treating the enrollee's medical condition. Aetna reserves the right to periodically request clinical information from your provider to assess your medical condition and the appropriateness of your ongoing treatment. Failure to provide clinical information could result in subsequent denial of coverage for this medication.

In accordance with state law, fully insured Commercial Connecticut preferred provider organization (PPO) members (except Federal Employee Health Benefit Plan members) who are receiving coverage for drugs that are added to the Precertification or Step-Therapy Lists will continue to have those drugs covered for as long as the prescriber prescribes them, provided the drug is medically necessary and more medically beneficial than other covered drugs. Nothing in this section shall preclude the prescribing provider from prescribing another drug covered by the plan that is medically appropriate for the enrollee, nor shall anything in this section be construed to prohibit generic drug substitutions.

In accordance with state law, commercial fully insured (including HMO) members in Connecticut, Louisiana, New Mexico and Texas (except Federal Employee Health Benefit Plan members) who are receiving coverage for drugs that are added or removed from the Pharmacy Drug Guide and Specialty Drug List will continue to have those drugs covered at the same benefit level until their plan's renewal date. In Texas, preauthorization approval is known as "preservice utilization review." It is not "verification" as defined by Texas law. Preauthorization means a determination that healthcare services proposed to be provided to a patient are medically necessary and appropriate.

In certain states, including Arkansas, Colorado, Connecticut, Delaware, Georgia, Illinois, Louisiana, Maryland, Minnesota, North Dakota, Pennsylvania and Texas, step therapy programs do not apply to fully insured members utilizing prescription drugs for the treatment of stage-four advanced, metastatic cancer.

This document contains trademarks or registered trademarks of CVS Pharmacy, Inc. or one of its affiliates; it may also contain references to products that are trademarks or registered trademarks of entities not affiliated with CVS Health.

This material is for information only. It contains only a partial, general description of plan benefits or programs and does not constitute a contract. See plan documents for a complete description of benefits, exclusions, limitations and conditions of coverage. Plan features and availability may vary by location and are subject to change. Providers are independent contractors and are not agents of Aetna. Provider participation may change without notice. Aetna does not provide care or guarantee access to health services. Information is subject to change. CVS Caremark Mail Service Pharmacy is part of the CVS Health family of companies.

List of Abbreviations

CE: Copay Exception: Available to some members at no cost with a prescription from your provider when obtained at an in-network pharmacy. Certain limitations may apply.

G: Generic

NF: Non-formulary, not covered unless exception request granted

NPB: Non-Preferred Brand

PB: Preferred Brand

SP: Specialty

AL: Age Limit

IBC: Indication Based Coverage

LGC: Lowest Generic Copay Applies

N7: Drug tier when CE does not apply

N8: Drug Specific Coverage

PA: Prior Authorization

QL: Quantity Limit

QLR: Quantity Limit Restriction Based on Age

Select OTC: Select OTC Program if your pharmacy plan includes this program you may have coverage for products noted with a doctors prescription. Please see your plan benefit information for specific coverage details.

SPC : Select Plan Coverage: Only available for select plans. Refer to member plan documents for coverage.

ST: Step Therapy

STX: Safer and/or more effective treatments are available

Below is a list of drug name formatting patterns that may appear in the following pages.

List of Patterns

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

lowercase italics: Generic drugs

UPPERCASE: Brand name drugs

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| ANALGESICS - DRUGS TO TREAT PAIN AND INFLAMMATION | | |
| COX-2 INHIBITORS | | |
| CELEBREX ORAL CAPSULE 100 MG, 200 MG, 400 MG, 50 MG (<i>celecoxib</i>) | NF | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> | G | |
| ELYXYB ORAL SOLUTION 120 MG/4.8ML (<i>celecoxib (migraine)</i>) | NF | |
| GOUT | | |
| <i>allopurinol oral tablet 200 mg</i> | NF | |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | G | |
| GLOPERBA ORAL SOLUTION 0.6 MG/5ML (<i>colchicine</i>) | NF | |
| <i>probenecid oral tablet 500 mg</i> | G | |
| GOUT - DRUGS TO TREAT GOUT | | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>colchicine oral capsule 0.6 mg</i> | NF | |
| <i>colchicine oral tablet 0.6 mg</i> | G | QL (120 TABLETS per 25 DAYs) |
| <i>colchicine-probenecid oral tablet 0.5-500 mg</i> | G | |
| COLCRYS ORAL TABLET 0.6 MG (<i>colchicine</i>) | NF | |
| KRYSTEXXA INTRAVENOUS SOLUTION 8 MG/ML (<i>pegloticase</i>) | SP | PA |
| MITIGARE ORAL CAPSULE 0.6 MG (<i>colchicine</i>) | PB | QL (60 CAPSULES per 25 DAYs) |
| ULORIC ORAL TABLET 40 MG, 80 MG (<i>febuxostat</i>) | NF | |
| MISCELLANEOUS | | |
| PRIALT INTRATHECAL SOLUTION 100 MCG/ML, 500 MCG/20ML, 500 MCG/5ML (<i>ziconotide acetate</i>) | SP | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| NON-OPIOID ANALGESICS | | |
| ALLZITAL ORAL TABLET 25-325 MG (<i>butalbital-acetaminophen</i>) | NF | |
| <i>butalbital-acetaminophen</i> (Bupap Oral Tablet 50-300 Mg) | NF | |
| <i>butalbital-acetaminophen</i> oral capsule 50-300 mg | NF | |
| <i>butalbital-acetaminophen</i> oral tablet 50-325 mg | G | STX; QL (48 TABLETS per 25 DAYS) |
| <i>butalbital-apap-caffeine</i> oral capsule 50-300-40 mg, 50-325-40 mg | NF | |
| <i>butalbital-apap-caffeine</i> oral tablet 50-325-40 mg | G | STX; N8 (Listing does not include certain NDCs); QL (48 TABLETS per 25 days) |
| <i>butalbital-aspirin-caffeine</i> oral capsule 50-325-40 mg | G | STX; N8 (Listing does not include certain NDCs); QL (48 CAPSULES per 25 DAYS) |
| ESGIC ORAL TABLET 50-325-40 MG (<i>butalbital-apap-caffeine</i>) | NPB | STX; QL (48 TABLETS per 25 DAYS) |
| FIORICET ORAL CAPSULE 50-300-40 MG (<i>butalbital-apap-caffeine</i>) | NF | |
| NSAIDS | | |
| COXANTO ORAL CAPSULE 300 MG (<i>oxaprozin</i>) | NF | |
| <i>diclofenac epolamine</i> external patch 1.3 % | G | STX; QL (30 PATCHES per 25 days) |
| <i>diclofenac potassium</i> oral capsule 25 mg | NF | |
| <i>diclofenac potassium</i> oral tablet 25 mg | NF | |
| <i>diclofenac potassium</i> (migraine) oral packet 50 mg | NF | |
| <i>diclofenac sodium</i> external gel 3 % | G | PA; QL (100 G per 25 days) |
| <i>diclofenac sodium</i> external solution 1.5 % | G | PA; QL (300 ML per 21 days) |
| <i>diclofenac sodium</i> external solution 2 % | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| FLECTOR EXTERNAL PATCH 1.3 % (<i>diclofenac epolamine</i>) | NF | |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | G | STX |
| <i>indomethacin oral suspension 25 mg/5ml</i> | NF | |
| <i>indomethacin rectal suppository 50 mg</i> | NF | |
| <i>ketoprofen oral capsule 25 mg, 50 mg</i> | NF | |
| LICART EXTERNAL PATCH 24 HOUR 1.3 % (<i>diclofenac epolamine</i>) | NF | |
| <i>diclofenac potassium (Lofena Oral Tablet 25 Mg)</i> | NF | |
| <i>meloxicam oral capsule 10 mg, 5 mg</i> | NF | |
| <i>meloxicam oral suspension 7.5 mg/5ml</i> | NF | |
| <i>nabumetone oral tablet 500 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>naproxen oral suspension 125 mg/5ml</i> | NF | |
| <i>naproxen oral tablet delayed release 500 mg</i> | G | |
| <i>naproxen sodium oral tablet 550 mg</i> | G | |
| <i>oxaprozin oral capsule 300 mg</i> | NF | |
| PENNSAID EXTERNAL SOLUTION 2 % (<i>diclofenac sodium</i>) | NF | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | G | |
| TOLECTIN 600 ORAL TABLET 600 MG (<i>tolmetin sodium</i>) | NF | |
| <i>tolmetin sodium oral capsule 400 mg</i> | NF | |
| ZIPSOR ORAL CAPSULE 25 MG (<i>diclofenac potassium</i>) | NF | |
| NSAIDS - DRUGS TO TREAT PAIN AND INFLAMMATION | | |
| CAMBIA ORAL PACKET 50 MG (<i>diclofenac potassium(migraine)</i>) | NF | |
| <i>diclofenac potassium oral tablet 50 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>diclofenac sodium er oral tablet extended release 24 hour 100 mg</i> | G | |
| <i>diclofenac sodium oral tablet delayed release 25 mg, 50 mg, 75 mg</i> | G | |
| <i>etodolac er oral tablet extended release 24 hour 400 mg, 500 mg, 600 mg</i> | G | |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | G | |
| <i>etodolac oral tablet 400 mg, 500 mg</i> | G | |
| <i>fenoprofen calcium oral capsule 200 mg, 400 mg</i> | NF | |
| <i>fenoprofen calcium oral tablet 600 mg</i> | NF | |
| <i>flurbiprofen oral tablet 100 mg, 50 mg</i> | G | |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | G | N8 (Listing does not include certain NDCs) |
| INDOCIN ORAL SUSPENSION 25 MG/5ML (indomethacin) | NF | |
| <i>ketoprofen er oral capsule extended release 24 hour 200 mg</i> | NF | |
| <i>ketorolac tromethamine oral tablet 10 mg</i> | G | QL (20 TABLETS per 25 DAYs) |
| LODINE ORAL TABLET 400 MG (etodolac) | NF | |
| <i>meclofenamate sodium oral capsule 100 mg, 50 mg</i> | G | |
| <i>mefenamic acid oral capsule 250 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>nabumetone oral tablet 750 mg</i> | G | N8 (Listing does not include certain NDCs) |
| NAPRELAN ORAL TABLET EXTENDED RELEASE 24 HOUR 375 MG, 500 MG, 750 MG (naproxen sodium) | NF | |
| NAPROSYN ORAL SUSPENSION 125 MG/5ML (naproxen) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| naproxen oral tablet 250 mg, 375 mg, 500 mg | G | |
| naproxen oral tablet delayed release 375 mg | G | |
| naproxen sodium er oral tablet extended release 24 hour 375 mg, 500 mg, 750 mg | NF | |
| naproxen sodium oral tablet 275 mg | G | |
| oxaprozin oral tablet 600 mg | G | |
| piroxicam oral capsule 10 mg, 20 mg | G | |
| RELAFEN DS ORAL TABLET 1000 MG (<i>nabumetone</i>) | NF | |
| SPRIX NASAL SOLUTION 15.75 MG/SPRAY (<i>ketorolac tromethamine</i>) | NF | |
| ZORVOLEX ORAL CAPSULE 18 MG, 35 MG (<i>diclofenac</i>) | NF | |
| NSAIDS, COMBINATIONS | | |
| ARTHROTEC ORAL TABLET DELAYED RELEASE 50-0.2 MG, 75-0.2 MG (<i>diclofenac-misoprostol</i>) | NF | |
| <i>diclofenac-misoprostol</i> oral tablet delayed release 50-0.2 mg, 75-0.2 mg | G | |
| DUEXIS ORAL TABLET 800-26.6 MG (<i>ibuprofen-famotidine</i>) | NF | |
| <i>ibuprofen-famotidine</i> oral tablet 800-26.6 mg | NF | |
| naproxen-esomeprazole mg oral tablet delayed release 375-20 mg, 500-20 mg | NF | |
| VIMOVO ORAL TABLET DELAYED RELEASE 375-20 MG, 500-20 MG (<i>naproxen-esomeprazole</i>) | NF | |
| OPIOID AGONIST/ANTAGONIST | | |
| <i>pentazocine-naloxone hcl</i> oral tablet 50-0.5 mg | G | STX; N8 (Subject to initial limit.); QL (120 TABLETS per 25 DAYs) |
| OPIOID ANALGESICS | | |
| <i>acetaminophen-codeine</i> oral solution 120-12 mg/5ml | G | N8 (Subject to initial limit); QL (2700 ML per 25 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>acetaminophen-codeine oral tablet 300-15 mg</i> | G | N8 (Subject to initial limit); QL (400 TABLETS per 25 Days) |
| <i>acetaminophen-codeine oral tablet 300-30 mg</i> | G | N8 (Subject to initial limit); QL (360 TABLETS per 25 Days) |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i> | G | N8 (Subject to initial limit); QL (180 TABLETS per 25 Days) |
| <i>benzhydrocodone-acetaminophen oral tablet 4.08-325 mg, 6.12-325 mg, 8.16-325 mg</i> | NF | |
| <i>butalbital-asa-caff-codeine oral capsule 50-325-40-30 mg</i> | G | STX; QL (48 CAPSULES per 25 days) |
| <i>DILAUDID ORAL LIQUID 1 MG/ML (hydromorphone hcl)</i> | NPB | N8 (Subject to initial limit); QL (480 ML per 25 days) |
| <i>DILAUDID ORAL TABLET 4 MG (hydromorphone hcl)</i> | NPB | N8 (Subject to initial limit); QL (120 TABLETS per 25 days) |
| <i>hydrocodone bitartrate er oral capsule extended release 12 hour 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg</i> | NF | |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15ml</i> | G | N8 (Subject to initial limit); QL (2700 ML per 25 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg</i> | G | N8 (Subject to initial limit); QL (50 TABLETS per 25 days) |
| <i>hydromorphone hcl oral liquid 1 mg/ml</i> | G | N8 (Subject to initial limit); QL (480 ML per 25 days) |
| <i>hydromorphone hcl oral tablet 4 mg</i> | G | N8 (Subject to initial limit); QL (120 TABLETS per 25 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>hydromorphone hcl oral tablet 8 mg</i> | G | N8 (Subject to initial limit); QL (60 TABLETS per 25 days) |
| <i>levorphanol tartrate oral tablet 2 mg, 3 mg</i> | NF | |
| <i>methadone hcl (Methadone Hcl Intensol Oral Concentrate 10 Mg/Ml)</i> | G | ST; QL (45 ML per 25 days) |
| <i>methadone hcl oral solution 10 mg/5ml</i> | G | ST; QL (225 ML per 25 days) |
| <i>methadone hcl oral tablet 10 mg</i> | G | ST; QL (30 TABLETS per 25 days) |
| <i>methadone hcl oral tablet 5 mg</i> | G | ST; QL (90 TABLETS per 25 days) |
| <i>morphine sulfate (concentrate) oral solution 100 mg/5ml</i> | G | N8 (Subject to initial limit); QL (135 ML per 25 days) |
| <i>morphine sulfate er oral capsule extended release 24 hour 10 mg, 20 mg, 30 mg</i> | G | ST; QL (60 CAPSULES per 25 days) |
| <i>morphine sulfate er oral capsule extended release 24 hour 100 mg</i> | G | ST |
| <i>morphine sulfate er oral capsule extended release 24 hour 50 mg, 60 mg, 80 mg</i> | G | ST; QL (30 CAPSULES per 25 days) |
| NUCYNTA ER ORAL TABLET EXTENDED RELEASE 12 HOUR 100 MG, 150 MG, 200 MG, 250 MG, 50 MG (tapentadol hcl) | NF | |
| NUCYNTA ORAL TABLET 100 MG, 50 MG, 75 MG (tapentadol hcl) | NF | |
| <i>oxycodone hcl er oral tablet er 12 hour abuse-deterrant 10 mg, 20 mg</i> | G | ST; QL (60 TABLETS per 25 days) |
| <i>oxycodone hcl er oral tablet er 12 hour abuse-deterrant 40 mg, 80 mg</i> | G | ST |
| <i>oxycodone hcl oral capsule 5 mg</i> | G | N8 (Subject to initial limit); QL (180 CAPSULES per 25 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| oxycodone-acetaminophen oral solution 5-325 mg/5ml | NF | |
| oxycodone-acetaminophen oral tablet 2.5-325 mg | G | N8 (Subject to initial limit); QL (360 TABLETS per 25 days) |
| oxycodone-acetaminophen oral tablet 7.5-300 mg | NF | |
| ROXYBOND ORAL TABLET ABUSE-DETERRENT 15 MG, 30 MG, 5 MG (oxycodone hcl) | NF | |
| SEGLENTIS ORAL TABLET 56-44 MG (celecoxib-tramadol hcl) | NF | |
| SUBSYS SUBLINGUAL LIQUID 800 MCG (fentanyl) | NF | |
| tramadol hcl (er biphasic) oral tablet extended release 24 hour 100 mg | G | ST; QL (30 TABLETS per 25 days) |
| tramadol hcl (er biphasic) oral tablet extended release 24 hour 200 mg, 300 mg | G | ST |
| tramadol hcl er oral tablet extended release 24 hour 100 mg | G | ST; QL (30 TABLETS per 25 days) |
| tramadol hcl er oral tablet extended release 24 hour 200 mg, 300 mg | G | ST |
| tramadol hcl oral solution 5 mg/ml | NF | |
| tramadol hcl oral tablet 25 mg | NF | |
| tramadol-acetaminophen oral tablet 37.5-325 mg | G | N8 (Subject to initial limit); QL (40 TABLETS per 25 days) |
| XTAMPZA ER ORAL CAPSULE ER 12 HOUR ABUSE-DETERRENT 13.5 MG, 18 MG, 27 MG, 36 MG, 9 MG (oxycodone) | NF | |
| OPIOID ANALGESICS - DRUGS TO TREAT PAIN | | |
| APADAZ ORAL TABLET 4.08-325 MG, 6.12-325 MG, 8.16-325 MG (benzhydrocodone-acetaminophen) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>apap-caff-dihydrocodeine oral capsule 320.5-30-16 mg</i> | G | N8 (Subject to initial limit); QL (300 CAPSULES per 25 DAYs) |
| <i>butalbital-apap-caff-cod oral capsule 50-300-40-30 mg</i> | G | STX; N8 (Listing does not include certain NDCs); QL (48 CAPSULES per 25 DAYs) |
| <i>butalbital-apap-caff-cod oral capsule 50-325-40-30 mg</i> | G | STX; QL (48 CAPSULES per 25 DAYs) |
| <i>butorphanol tartrate nasal solution 10 mg/ml</i> | G | QL (2 BOTTLES per 25 DAYs) |
| <i>codeine sulfate oral tablet 30 mg</i> | G | N8 (Subject to initial limit); QL (42 TABLETS per 25 DAYs) |
| <i>codeine sulfate oral tablet 60 mg</i> | NPB | N8 (Subject to initial limit); QL (42 TABLETS per 25 DAYs) |
| CONZIP ORAL CAPSULE EXTENDED RELEASE 24 HOUR 100 MG (<i>tramadol hcl</i>) | NPB | ST; QL (30 CAPSULES per 25 DAYs) |
| CONZIP ORAL CAPSULE EXTENDED RELEASE 24 HOUR 200 MG, 300 MG (<i>tramadol hcl</i>) | NPB | ST |
| DILAUDID ORAL TABLET 2 MG (<i>hydromorphone hcl</i>) | NPB | N8 (Subject to initial limit); QL (180 TABLETS per 25 DAYs) |
| DILAUDID ORAL TABLET 8 MG (<i>hydromorphone hcl</i>) | NPB | N8 (Subject to initial limit); QL (60 TABLETS per 25 DAYs) |
| <i>fentanyl citrate buccal lozenge on a handle 1200 mcg, 1600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</i> | G | PA; QL (120 LOZENGES per 25 DAYs) |
| <i>fentanyl citrate buccal tablet 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</i> | G | PA; QL (120 TABLETS per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| fentanyl transdermal patch 72 hour 100 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr | G | ST |
| fentanyl transdermal patch 72 hour 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hr | G | ST; QL (10 PATCHES per 25 DAYs) |
| FENTORA BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG (<i>fentanyl citrate</i>) | NF | |
| FIORICET/CODEINE ORAL CAPSULE 50-300-40-30 MG (<i>butalbital-apap-caff-cod</i>) | NPB | STX; QL (48 CAPSULES per 25 DAYs) |
| hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrant 100 mg, 120 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg | NF | |
| hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 7.5-300 mg, 7.5-325 mg | G | N8 (Subject to initial limit); QL (180 TABLETS per 25 DAYs) |
| hydrocodone-acetaminophen oral tablet 5-300 mg, 5-325 mg | G | N8 (Subject to initial limit); QL (240 TABLETS per 25 DAYs) |
| hydrocodone-ibuprofen oral tablet 5-200 mg, 7.5-200 mg | G | N8 (Subject to initial limit); QL (50 TABLETS per 25 DAYs) |
| hydromorphone hcl er oral tablet extended release 24 hour 12 mg, 16 mg, 8 mg | G | ST; QL (30 TABLETS per 25 DAYs) |
| hydromorphone hcl er oral tablet extended release 24 hour 32 mg | G | ST |
| hydromorphone hcl oral tablet 2 mg | G | N8 (Subject to initial limit); QL (180 TABLETS per 25 DAYs) |
| HYSINGLA ER ORAL TABLET ER 24 HOUR ABUSE-DETERRENT 100 MG, 120 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG (<i>hydrocodone bitartrate</i>) | NF | |
| meperidine hcl oral solution 50 mg/5ml | NF | |
| meperidine hcl oral tablet 50 mg | NF | |
| methadone hcl oral concentrate 10 mg/ml | G | QL (30 ML per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>methadone hcl oral solution 5 mg/5ml</i> | G | ST; QL (450 ML per 25 DAYs) |
| <i>methadone hcl oral tablet soluble 40 mg</i> | G | QL (9 TABLETS per 25 DAYs) |
| METHADOSE ORAL CONCENTRATE 10 MG/ML (<i>methadone hcl</i>) | NPB | QL (30 ML per 25 DAYs) |
| METHADOSE SUGAR-FREE ORAL CONCENTRATE 10 MG/ML (<i>methadone hcl</i>) | NPB | QL (30 ML per 25 DAYs) |
| <i>morphine sulfate er beads oral capsule extended release 24 hour 120 mg</i> | G | ST |
| <i>morphine sulfate er beads oral capsule extended release 24 hour 30 mg, 45 mg, 60 mg, 75 mg, 90 mg</i> | G | ST; QL (30 CAPSULES per 25 DAYs) |
| <i>morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg</i> | G | ST |
| <i>morphine sulfate er oral tablet extended release 15 mg, 30 mg</i> | G | ST; QL (90 TABLETS per 25 DAYs) |
| <i>morphine sulfate oral solution 10 mg/5ml</i> | G | N8 (Subject to initial limit); QL (900 ML per 25 DAYs) |
| <i>morphine sulfate oral solution 20 mg/5ml</i> | G | N8 (Subject to initial limit); QL (675 ML per 25 DAYs) |
| <i>morphine sulfate oral tablet 15 mg</i> | G | N8 (Subject to initial limit); QL (180 TABLETS per 25 DAYs) |
| <i>morphine sulfate oral tablet 30 mg</i> | G | N8 (Subject to initial limit); QL (90 TABLETS per 25 DAYs) |
| MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 200 MG, 60 MG (<i>morphine sulfate</i>) | NPB | ST |
| MS CONTIN ORAL TABLET EXTENDED RELEASE 15 MG, 30 MG (<i>morphine sulfate</i>) | NPB | ST; QL (90 TABLETS per 25 DAYs) |
| <i>nalocet oral tablet 2.5-300 mg</i> | NF | |
| <i>OXAYDO ORAL TABLET 5 MG, 7.5 MG (oxycodone hcl)</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>oxycodone hcl oral concentrate 100 mg/5ml</i> | G | N8 (Subject to initial limit); QL (90 ML per 25 DAYs) |
| <i>oxycodone hcl oral solution 5 mg/5ml</i> | G | N8 (Subject to initial limit); QL (900 ML per 25 DAYs) |
| <i>oxycodone hcl oral tablet 10 mg, 5 mg</i> | G | N8 (Subject to initial limit); QL (180 TABLETS per 25 DAYs) |
| <i>oxycodone hcl oral tablet 15 mg</i> | G | N8 (Subject to initial limit); QL (120 TABLETS per 25 DAYs) |
| <i>oxycodone hcl oral tablet 20 mg</i> | G | N8 (Subject to initial limit); QL (90 TABLETS per 25 DAYs) |
| <i>oxycodone hcl oral tablet 30 mg</i> | G | N8 (Subject to initial limit); QL (60 TABLETS per 25 DAYs) |
| <i>oxycodone-acetaminophen oral solution 10-300 mg/5ml</i> | NF | |
| <i>oxycodone-acetaminophen oral tablet 10-300 mg, 2.5-300 mg, 5-300 mg</i> | NF | |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i> | G | N8 (Subject to initial limit); QL (180 TABLETS per 25 DAYs) |
| <i>oxycodone-acetaminophen oral tablet 5-325 mg</i> | G | N8 (Subject to initial limit); QL (360 TABLETS per 25 DAYs) |
| <i>oxycodone-acetaminophen oral tablet 7.5-325 mg</i> | G | N8 (Subject to initial limit); QL (240 TABLETS per 25 DAYs) |
| OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG (<i>oxycodone hcl</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>oxymorphone hcl er oral tablet extended release 12 hour 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg</i> | NF | |
| <i>oxymorphone hcl oral tablet 10 mg</i> | G | N8 (Subject to initial limit); QL (90 TABLETS per 25 DAYs) |
| <i>oxymorphone hcl oral tablet 5 mg</i> | G | N8 (Subject to initial limit); QL (180 TABLETS per 25 DAYs) |
| PERCOCET ORAL TABLET 10-325 MG, 2.5-325 MG, 5-325 MG, 7.5-325 MG (<i>oxycodone-acetaminophen</i>) | NF | |
| PROLATE ORAL SOLUTION 10-300 MG/5ML (<i>oxycodone-acetaminophen</i>) | NF | |
| PROLATE ORAL TABLET 10-300 MG, 5-300 MG, 7.5-300 MG (<i>oxycodone-acetaminophen</i>) | NF | |
| QDOLO ORAL SOLUTION 5 MG/ML (<i>tramadol hcl</i>) | NF | |
| ROXICODONE ORAL TABLET 15 MG (<i>oxycodone hcl</i>) | NPB | N8 (Subject to initial limit); QL (120 TABLETS per 25 DAYs) |
| ROXICODONE ORAL TABLET 30 MG (<i>oxycodone hcl</i>) | NPB | N8 (Subject to initial limit); QL (60 TABLETS per 25 DAYs) |
| <i>tramadol hcl (er biphasic) oral capsule extended release 24 hour 100 mg, 200 mg, 300 mg</i> | NF | |
| <i>tramadol hcl oral tablet 100 mg</i> | NF | |
| <i>tramadol hcl oral tablet 50 mg</i> | G | N8 (Subject to initial limit); QL (180 TABLETS per 25 DAYs) |
| OPIOID PARTIAL AGONISTS | | |
| BELBUCA BUCCAL FILM 150 MCG, 300 MCG, 450 MCG, 75 MCG (<i>buprenorphine hcl</i>) | PB | ST; QL (60 FILMS per 25 DAYs) |
| BELBUCA BUCCAL FILM 600 MCG, 750 MCG, 900 MCG (<i>buprenorphine hcl</i>) | PB | ST |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| buprenorphine transdermal patch weekly 10 mcg/hr, 5 mcg/hr, 7.5 mcg/hr | G | ST; QL (4 PATCHES per 25 DAYS) |
| buprenorphine transdermal patch weekly 15 mcg/hr, 20 mcg/hr | G | ST |
| BUTTRANS TRANSDERMAL PATCH WEEKLY 10 MCG/HR, 15 MCG/HR, 20 MCG/HR, 5 MCG/HR, 7.5 MCG/HR (buprenorphine) | NF | |
| SUBLOCADE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.5ML, 300 MG/1.5ML (buprenorphine) | SP | |
| SALICYLATES | | |
| aspirin childrens oral tablet chewable 81 mg | CE | N7 (Not Covered); QL (100 TABLETS per 30 DAYS); AL (Min 12 Years and Max 59 Years) |
| aspirin oral tablet delayed release 81 mg | CE | N7 (Not Covered); QL (100 TABLETS per 30 Days); AL (Min 12 Years and Max 59 Years) |
| diflunisal oral tablet 500 mg | G | N8 (Listing does not include certain NDCs) |
| VISCOSUPPLEMENTS | | |
| DUROLANE INTRA-ARTICULAR PREFILLED SYRINGE 60 MG/3ML (sodium hyaluronate (viscosup)) | SP | PA |
| EUFLEXXA INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 20 MG/2ML (sodium hyaluronate (viscosup)) | SP | PA |
| GEL-ONE INTRA-ARTICULAR PREFILLED SYRINGE 30 MG/3ML (cross-linked hyaluronate) | NF | |
| GELSYN-3 INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 16.8 MG/2ML (sodium hyaluronate (viscosup)) | SP | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| GENVISC 850 INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 25 MG/2.5ML (<i>sodium hyaluronate (viscosup)</i>) | NF | |
| HYALGAN INTRA-ARTICULAR SOLUTION 20 MG/2ML (<i>sodium hyaluronate (viscosup)</i>) | NF | |
| HYALGAN INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 20 MG/2ML (<i>sodium hyaluronate (viscosup)</i>) | NF | |
| HYMOVIS INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 24 MG/3ML (<i>hyaluronan</i>) | NF | |
| MONOVISC INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 88 MG/4ML (<i>hyaluronan</i>) | NF | |
| ORTHOVISC INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 30 MG/2ML (<i>hyaluronan</i>) | NF | |
| SUPARTZ FX INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 25 MG/2.5ML (<i>sodium hyaluronate (viscosup)</i>) | SP | PA |
| SYNOJOYNT INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 20 MG/2ML (<i>sodium hyaluronate (viscosup)</i>) | NF | |
| SYNVISC INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 16 MG/2ML (<i>hylan g-f 20</i>) | NF | |
| SYNVISC ONE INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 48 MG/6ML (<i>hylan g-f 20</i>) | NF | |
| TRILURON INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 20 MG/2ML (<i>sodium hyaluronate (viscosup)</i>) | NF | |
| TRIVISC INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 25 MG/2.5ML (<i>sodium hyaluronate (viscosup)</i>) | NF | |
| VISCO-3 INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 25 MG/2.5ML (<i>sodium hyaluronate (viscosup)</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ANTI-INFECTIVES - DRUGS TO TREAT INFECTIONS | | |
| ANTHELMINTICS - DRUGS FOR WORM INFECTION | | |
| <i>albendazole oral tablet 200 mg</i> | G | QL (336 TABLETS per 365 days) |
| BILTRICIDE ORAL TABLET 600 MG (<i>praziquantel</i>) | NPB | QL (24 TABLETS per 365 days) |
| EMVERM ORAL TABLET CHEWABLE 100 MG (<i>mebendazole</i>) | PB | QL (12 TABLETS per 365 days) |
| <i>ivermectin oral tablet 3 mg</i> | G | PA; QL (9 TABLETS per 75 days) |
| <i>praziquantel oral tablet 600 mg</i> | G | QL (24 TABLETS per 365 days) |
| ANTI-BACTERIALS - MISCELLANEOUS | | |
| ARIKAYCE INHALATION SUSPENSION 590 MG/8.4ML (<i>amikacin sulfate liposome</i>) | SP | PA |
| HUMATIN ORAL CAPSULE 250 MG (<i>paromomycin sulfate</i>) | NF | |
| <i>neomycin sulfate oral tablet 500 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>sulfadiazine oral tablet 500 mg</i> | NF | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | G | |
| ANTIFUNGALS - DRUGS TO TREAT FUNGAL INFECTIONS | | |
| BREXAFEMME ORAL TABLET 150 MG (<i>ibrexafungerp citrate</i>) | NPB | ST; QL (4 TABLETS per 7 DAYS) |
| CRESEMBA ORAL CAPSULE 186 MG, 74.5 MG (<i>isavuconazonium sulfate</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>fluconazole oral suspension reconstituted 10 mg/ml, 40 mg/ml</i> | G | |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | G | |
| <i>flucytosine oral capsule 250 mg</i> | G | STX |
| <i>flucytosine oral capsule 500 mg</i> | NF | |
| <i>griseofulvin microsize oral suspension 125 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>griseofulvin microsize oral tablet 500 mg</i> | G | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i> | G | |
| <i>itraconazole oral capsule 100 mg</i> | G | |
| <i>itraconazole oral solution 10 mg/ml</i> | G | PA |
| KERYDIN EXTERNAL SOLUTION 5 % (tavaborole) | NF | |
| <i>ketoconazole oral tablet 200 mg</i> | G | PA; STX |
| NOXAFL ORAL PACKET 300 MG (posaconazole) | NF | |
| NOXAFL ORAL SUSPENSION 40 MG/ML (posaconazole) | NF | |
| NOXAFL ORAL TABLET DELAYED RELEASE 100 MG (posaconazole) | NF | |
| <i>nystatin oral tablet 500000 unit</i> | G | N8 (Listing does not include certain NDCs) |
| <i>posaconazole oral suspension 40 mg/ml</i> | NF | |
| <i>posaconazole oral tablet delayed release 100 mg</i> | NF | |
| SPORANOX ORAL CAPSULE 100 MG (itraconazole) | NF | |
| SPORANOX ORAL SOLUTION 10 MG/ML (itraconazole) | NF | |
| <i>terbinafine hcl oral tablet 250 mg</i> | G | |
| <i>tolsura oral capsule 65 mg</i> | NF | |
| VIVJOA ORAL CAPSULE THERAPY PACK 150 MG (oteseconazole) | NPB | PA; QL (18 CAPSULES per 336 DAYs) |
| <i>voriconazole oral suspension reconstituted 40 mg/ml</i> | G | |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| ANTIMALARIALS - DRUGS TO TREAT MALARIA | | |
| ARAKODA ORAL TABLET 100 MG (<i>tafenoquine succinate</i>) | NF | |
| <i>atovaquone-proguanil hcl oral tablet 250-100 mg, 62.5-25 mg</i> | G | |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | G | |
| <i>hydroxychloroquine sulfate oral tablet 100 mg, 300 mg, 400 mg</i> | NF | |
| KRINTAFEL ORAL TABLET 150 MG (<i>tafenoquine succinate</i>) | NF | |
| <i>mefloquine hcl oral tablet 250 mg</i> | G | |
| <i>primaquine phosphate oral tablet 26.3 (15 base) mg</i> | G | |
| <i>quinine sulfate oral capsule 324 mg</i> | G | |
| SOVUNA ORAL TABLET 300 MG (<i>hydroxychloroquine sulfate</i>) | NF | |
| ANTIRETROVIRAL AGENTS - DRUGS TO SUPPRESS HIV/AIDS INFECTION | | |
| <i>abacavir sulfate oral solution 20 mg/ml</i> | G | QL (900 ML per 30 DAYs) |
| <i>abacavir sulfate oral tablet 300 mg</i> | G | QL (60 TABLETS per 30 DAYs) |
| APTIVUS ORAL CAPSULE 250 MG (<i>tipranavir</i>) | NF | |
| <i>atazanavir sulfate oral capsule 150 mg, 300 mg</i> | G | QL (30 CAPSULES per 30 DAYs) |
| <i>atazanavir sulfate oral capsule 200 mg</i> | G | QL (60 CAPSULES per 30 DAYs) |
| <i>darunavir oral tablet 600 mg</i> | G | QL (60 TABLETS per 30 DAYs) |
| <i>darunavir oral tablet 800 mg</i> | G | QL (30 TABLETS per 30 DAYs) |
| EDURANT ORAL TABLET 25 MG (<i>rilpivirine hcl</i>) | NF | |
| <i>efavirenz oral capsule 200 mg, 50 mg</i> | G | QL (90 CAPSULES per 30 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>efavirenz oral tablet 600 mg</i> | G | QL (30 TABLETS per 30 days) |
| <i>emtricitabine oral capsule 200 mg</i> | G | QL (30 TABLETS per 30 DAYs) |
| EMTRIVA ORAL CAPSULE 200 MG (<i>emtricitabine</i>) | PB | QL (30 CAPSULES per 30 DAYs) |
| EMTRIVA ORAL SOLUTION 10 MG/ML (<i>emtricitabine</i>) | PB | QL (680 ML per 28 DAYs) |
| EPIVIR ORAL SOLUTION 10 MG/ML (<i>lamivudine</i>) | NPB | QL (900 ML per 30 DAYs) |
| EPIVIR ORAL TABLET 150 MG (<i>lamivudine</i>) | NPB | QL (60 TABLETS per 30 DAYs) |
| EPIVIR ORAL TABLET 300 MG (<i>lamivudine</i>) | NPB | QL (30 TABLETS per 30 DAYs) |
| <i>etravirine oral tablet 100 mg</i> | G | QL (120 TABLETS per 30 DAYs) |
| <i>etravirine oral tablet 200 mg</i> | G | QL (60 TABLETS per 30 DAYs) |
| <i>fosamprenavir calcium oral tablet 700 mg</i> | G | QL (120 TABLETS per 30 DAYs) |
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90 MG (<i>enfuvirtide</i>) | SP | QL (60 VIALS per 30 days) |
| INTELENCE ORAL TABLET 100 MG, 200 MG, 25 MG (<i>etravirine</i>) | NF | |
| ISENTRESS HD ORAL TABLET 600 MG (<i>raltegravir potassium</i>) | PB | QL (60 TABLETS per 30 DAYs) |
| ISENTRESS ORAL PACKET 100 MG (<i>raltegravir potassium</i>) | PB | QL (60 PACKETS per 30 DAYs) |
| ISENTRESS ORAL TABLET 400 MG (<i>raltegravir potassium</i>) | PB | QL (120 TABLETS per 30 DAYs) |
| ISENTRESS ORAL TABLET CHEWABLE 100 MG, 25 MG (<i>raltegravir potassium</i>) | PB | QL (180 TABLETS per 30 DAYs) |
| <i>lamivudine oral solution 10 mg/ml</i> | G | QL (900 ML per 30 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>lamivudine oral tablet 150 mg</i> | G | QL (60 TABLETS per 30 DAYs) |
| <i>lamivudine oral tablet 300 mg</i> | G | QL (30 TABLETS per 30 DAYs) |
| LEXIVA ORAL SUSPENSION 50 MG/ML (<i>fosamprenavir calcium</i>) | NF | |
| LEXIVA ORAL TABLET 700 MG (<i>fosamprenavir calcium</i>) | NF | |
| <i>maraviroc oral tablet 150 mg</i> | G | QL (60 TABLETS per 30 DAYs) |
| <i>maraviroc oral tablet 300 mg</i> | G | QL (120 TABLETS per 30 DAYs) |
| <i>nevirapine er oral tablet extended release 24 hour 400 mg</i> | G | QL (30 TABLETS per 30 DAYs) |
| <i>nevirapine oral suspension 50 mg/5ml</i> | G | QL (1200 ML per 30 DAYs) |
| <i>nevirapine oral tablet 200 mg</i> | G | QL (60 TABLETS per 30 DAYs) |
| NORVIR ORAL PACKET 100 MG (<i>ritonavir</i>) | NF | |
| NORVIR ORAL TABLET 100 MG (<i>ritonavir</i>) | NF | |
| PIFELTRO ORAL TABLET 100 MG (<i>doravirine</i>) | NPB | QL (60 TABLETS per 30 DAYs) |
| PREZISTA ORAL SUSPENSION 100 MG/ML (<i>darunavir</i>) | NF | |
| PREZISTA ORAL TABLET 150 MG, 600 MG, 75 MG, 800 MG (<i>darunavir</i>) | NF | |
| RETROVIR ORAL CAPSULE 100 MG (<i>zidovudine</i>) | NPB | QL (180 CAPSULES per 30 DAYs) |
| RETROVIR ORAL SYRUP 50 MG/5ML (<i>zidovudine</i>) | NPB | QL (1800 ML per 30 DAYs) |
| REYATAZ ORAL CAPSULE 200 MG, 300 MG (<i>atazanavir sulfate</i>) | NF | |
| REYATAZ ORAL PACKET 50 MG (<i>atazanavir sulfate</i>) | NF | |
| <i>ritonavir oral tablet 100 mg</i> | G | QL (360 TABLETS per 30 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HOUR 600 MG (<i>fostemsavir tromethamine</i>) | NPB | QL (60 TABLETS per 30 days) |
| SELZENTRY ORAL SOLUTION 20 MG/ML (<i>maraviroc</i>) | NF | |
| SELZENTRY ORAL TABLET 150 MG, 25 MG, 300 MG, 75 MG (<i>maraviroc</i>) | NF | |
| SUNLENCA ORAL TABLET THERAPY PACK 4 X 300 MG (<i>lenacapavir sodium</i>) | NPB | QL (4 TABLETS per 2 days) |
| SUNLENCA ORAL TABLET THERAPY PACK 5 X 300 MG (<i>lenacapavir sodium</i>) | NPB | QL (5 TABLETS per 8 days) |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | G | QL (30 TABLETS per 30 DAYs) |
| TIVICAY ORAL TABLET 10 MG (<i>dolutegravir sodium</i>) | PB | QL (240 TABLETS per 30 DAYs) |
| TIVICAY ORAL TABLET 25 MG, 50 MG (<i>dolutegravir sodium</i>) | PB | QL (60 TABLETS per 30 DAYs) |
| TIVICAY PD ORAL TABLET SOLUBLE 5 MG (<i>dolutegravir sodium</i>) | PB | QL (360 TABLETS per 30 DAYs) |
| TYBOST ORAL TABLET 150 MG (<i>cobicistat</i>) | NPB | QL (30 TABLETS per 30 DAYs) |
| VIRACEPT ORAL TABLET 250 MG, 625 MG (<i>nelfinavir mesylate</i>) | NF | |
| VIREAD ORAL POWDER 40 MG/GM (<i>tenofovir disoproxil fumarate</i>) | NPB | QL (240 G per 30 DAYs) |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG, 300 MG (<i>tenofovir disoproxil fumarate</i>) | NPB | QL (30 TABLETS per 30 DAYs) |
| ZIAGEN ORAL SOLUTION 20 MG/ML (<i>abacavir sulfate</i>) | NPB | QL (900 ML per 30 DAYs) |
| <i>zidovudine oral capsule 100 mg</i> | G | QL (180 CAPSULES per 30 days) |
| <i>zidovudine oral syrup 50 mg/5ml</i> | G | QL (1800 ML per 30 DAYs) |
| <i>zidovudine oral tablet 300 mg</i> | G | QL (60 TABLETS per 30 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| ANTIRETROVIRAL COMBINATION AGENTS - DRUGS TO SUPPRESS HIV/AIDS INFECTION | | |
| abacavir sulfate-lamivudine oral tablet 600-300 mg | G | QL (30 TABLETS per 30 days) |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG (<i>bictegravir-emtricitab-tenofovir</i>) | PB | QL (30 TABLETS per 30 DAYs) |
| CIMDUO ORAL TABLET 300-300 MG (<i>lamivudine-tenofovir</i>) | PB | QL (30 TABLETS per 30 DAYs) |
| COMBIVIR ORAL TABLET 150-300 MG (<i>lamivudine-zidovudine</i>) | NPB | QL (60 TABLETS per 30 DAYs) |
| COMPLERA ORAL TABLET 200-25-300 MG (<i>emtricitabrilipivir-tenofovir</i>) | NPB | QL (30 TABLETS per 30 days) |
| DELSTRIGO ORAL TABLET 100-300-300 MG (<i>doravirin-lamivudin-tenofovir df</i>) | NPB | QL (30 TABLETS per 30 days) |
| DESCOVY ORAL TABLET 120-15 MG (<i>emtricitabine-tenofovir af</i>) | PB | N8 (\$0 copay applies for pre-exposure prophylaxis only); QL (30 TABLETS per 30 DAYs) |
| DESCOVY ORAL TABLET 200-25 MG (<i>emtricitabine-tenofovir af</i>) | PB | N8 (Exception process available for \$0 copay when medically necessary for pre-exposure prophylaxis); QL (30 TABLETS per 30 DAYs) |
| DOVATO ORAL TABLET 50-300 MG (<i>dolutegravir-lamivudine</i>) | PB | QL (30 TABLETS per 30 DAYs) |
| <i>efavirenz-emtricitab-tenofo df oral tablet 600-200-300 mg</i> | G | QL (30 TABLETS per 30 Days) |
| <i>efavirenz-lamivudine-tenofovir oral tablet 400-300-300 mg, 600-300-300 mg</i> | G | QL (30 TABLETS per 30 DAYs) |
| <i>emtricitabine-tenofovir df oral tablet 100-150 mg, 133-200 mg, 167-250 mg</i> | G | QL (30 TABLETS per 30 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>emtricitabine-tenofovir df oral tablet 200-300 mg</i> | CE | N7 (G); N8 (\$0 copay applies for pre-exposure prophylaxis only); QL (30 TABLETS per 30 DAYs) |
| EPZICOM ORAL TABLET 600-300 MG (<i>abacavir sulfate-lamivudine</i>) | NPB | QL (30 TABLETS per 30 DAYs) |
| EVOTAZ ORAL TABLET 300-150 MG (<i>atazanavir-cobicistat</i>) | NPB | QL (30 TABLETS per 30 days) |
| GENVOYA ORAL TABLET 150-150-200-10 MG (<i>elviteg-cobic-emtricit-tenofaf</i>) | PB | QL (30 TABLETS per 30 DAYs) |
| JULUCA ORAL TABLET 50-25 MG (<i>dolutegravir-rilpivirine</i>) | NPB | QL (30 TABLETS per 30 DAYs) |
| KALETRA ORAL SOLUTION 400-100 MG/5ML (<i>lopinavir-ritonavir</i>) | NF | |
| KALETRA ORAL TABLET 100-25 MG, 200-50 MG (<i>lopinavir-ritonavir</i>) | NF | |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | G | QL (60 TABLETS per 30 DAYs) |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5ml</i> | G | QL (480 ML per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> | G | QL (300 TABLETS per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> | G | QL (120 TABLETS per 30 DAYs) |
| ODEFSEY ORAL TABLET 200-25-25 MG (<i>emtricitab-rilpivir-tenofovir af</i>) | PB | QL (30 TABLETS per 30 DAYs) |
| PREZCOBIX ORAL TABLET 800-150 MG (<i>darunavir-cobicistat</i>) | NPB | QL (30 TABLETS per 30 days) |
| STRIBILD ORAL TABLET 150-150-200-300 MG (<i>elviteg-cobic-emtricit-tenofdf</i>) | NPB | QL (30 TABLETS per 30 days) |
| SYMFI LO ORAL TABLET 400-300-300 MG (<i>efavirenz-lamivudine-tenofovir</i>) | NPB | QL (30 TABLETS per 30 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| SYMFI ORAL TABLET 600-300-300 MG (<i>efavirenz-lamivudine-tenofovir</i>) | NPB | QL (30 TABLETS per 30 DAYS) |
| SYMTUZA ORAL TABLET 800-150-200-10 MG (<i>darun-cobic-emtricit-tenofaf</i>) | PB | QL (30 TABLETS per 30 DAYS) |
| TRIUMEQ ORAL TABLET 600-50-300 MG (<i>abacavir-dolutegravir-lamivud</i>) | PB | QL (30 TABLETS per 30 DAYS) |
| TRIUMEQ PD ORAL TABLET SOLUBLE 60-5-30 MG (<i>abacavir-dolutegravir-lamivud</i>) | PB | QL (180 TABLETS per 30 days) |
| TRUVADA ORAL TABLET 100-150 MG, 133-200 MG, 167-250 MG, 200-300 MG (<i>emtricitabine-tenofovir df</i>) | NF | |
| ANTITUBERCULAR AGENTS - DRUGS TO TREAT TUBERCULOSIS | | |
| cycloserine oral capsule 250 mg | G | |
| ethambutol hcl oral tablet 100 mg, 400 mg | G | |
| isoniazid oral syrup 50 mg/5ml | G | |
| isoniazid oral tablet 100 mg | G | |
| isoniazid oral tablet 300 mg | G | N8 (Listing does not include certain NDCs) |
| pretomanid oral tablet 200 mg | NPB | PA |
| pyrazinamide oral tablet 500 mg | G | |
| rifabutin oral capsule 150 mg | G | |
| rifampin oral capsule 150 mg, 300 mg | G | N8 (Listing does not include certain NDCs) |
| SIRTURO ORAL TABLET 100 MG, 20 MG (<i>bedaquiline fumarate</i>) | SP | PA |
| ANTIVIRALS - DRUGS TO TREAT VIRAL INFECTIONS | | |
| acyclovir oral capsule 200 mg | G | |
| acyclovir oral suspension 200 mg/5ml | G | |
| acyclovir oral tablet 400 mg, 800 mg | G | |
| cidofovir intravenous solution 75 mg/ml | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| famciclovir oral tablet 125 mg, 250 mg, 500 mg | G | |
| ganciclovir intravenous solution 500 mg/250ml | NF | |
| ganciclovir sodium intravenous solution 500 mg/10ml | NF | |
| ganciclovir sodium intravenous solution reconstituted 500 mg | G | |
| LIVTENCITY ORAL TABLET 200 MG (<i>maribavir</i>) | SP | PA; QL (120 TABLETS per 30 days) |
| oseltamivir phosphate oral capsule 30 mg | G | QL (40 CAPSULES per 90 days) |
| oseltamivir phosphate oral capsule 45 mg, 75 mg | G | QL (20 CAPSULES per 90 days) |
| oseltamivir phosphate oral suspension reconstituted 6 mg/ml | G | QL (360 ML per 90 DAYs) |
| PAXLOVID (150/100) ORAL TABLET THERAPY PACK 10 X 150 MG & 10 X 100MG (<i>nirmatrelvir-ritonavir</i>) | NPB | QL (40 TABLETS per 30 DAYs) |
| PAXLOVID (300/100) ORAL TABLET THERAPY PACK 20 X 150 MG & 10 X 100MG (<i>nirmatrelvir-ritonavir</i>) | NPB | QL (60 TABLETS per 30 DAYs) |
| PREVYMIS ORAL TABLET 240 MG, 480 MG (<i>letermovir</i>) | NPB | QL (1 TAB per 1 DAY) |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/ACT (<i>zanamivir</i>) | PB | QL (2 INHALERS per 90 days) |
| rimantadine hcl oral tablet 100 mg | G | |
| SITAVIG BUCCAL TABLET 50 MG (<i>acyclovir</i>) | NF | |
| TAMIFLU ORAL CAPSULE 30 MG (<i>oseltamivir phosphate</i>) | NPB | QL (40 CAPSULES per 90 DAYs) |
| TAMIFLU ORAL CAPSULE 45 MG, 75 MG (<i>oseltamivir phosphate</i>) | NPB | QL (20 CAPSULES per 90 DAYs) |
| TAMIFLU ORAL SUSPENSION RECONSTITUTED 6 MG/ML (<i>oseltamivir phosphate</i>) | NPB | QL (360 ML per 90 DAYs) |
| valacyclovir hcl oral tablet 1 gm, 500 mg | G | |
| VALCYTE ORAL SOLUTION RECONSTITUTED 50 MG/ML (<i>valganciclovir hcl</i>) | NF | |
| VALCYTE ORAL TABLET 450 MG (<i>valganciclovir hcl</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>valganciclovir hcl oral solution reconstituted 50 mg/ml</i> | G | PA; QL (1000 ML per 30 DAYs) |
| <i>valganciclovir hcl oral tablet 450 mg</i> | G | PA; QL (120 TABLETS per 30 days) |
| VALTREX ORAL TABLET 1 GM, 500 MG (<i>valacyclovir hcl</i>) | NF | |
| XERESE EXTERNAL CREAM 5-1 % (<i>acyclovir-hydrocortisone</i>) | NF | |
| XOFLUZA (40 MG DOSE) ORAL TABLET THERAPY PACK 1 X 40 MG (<i>baloxavir marboxil</i>) | NF | |
| XOFLUZA (80 MG DOSE) ORAL TABLET THERAPY PACK 1 X 80 MG (<i>baloxavir marboxil</i>) | NF | |
| CEPHALOSPORINS - DRUGS TO TREAT INFECTIONS | | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | G | |
| <i>cefaclor oral suspension reconstituted 250 mg/5ml</i> | G | |
| <i>cefadroxil oral capsule 500 mg</i> | G | |
| <i>cefadroxil oral suspension reconstituted 250 mg/5ml, 500 mg/5ml</i> | G | |
| <i>cefadroxil oral tablet 1 gm</i> | G | |
| <i>cefdinir oral capsule 300 mg</i> | G | |
| <i>cefdinir oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | G | |
| <i>cefixime oral capsule 400 mg</i> | G | |
| <i>cefixime oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i> | G | |
| <i>cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml</i> | G | |
| <i>cefpodoxime proxetil oral tablet 100 mg, 200 mg</i> | G | |
| <i>cefprozil oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | G | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | G | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>cephalexin oral capsule 750 mg</i> | G | |
| <i>cephalexin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | G | |
| <i>cephalexin oral tablet 250 mg, 500 mg</i> | G | |
| ERYTHROMYCINS/MACROLIDES - DRUGS TO TREAT INFECTIONS | | |
| <i>azithromycin oral packet 1 gm</i> | G | |
| <i>azithromycin oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>azithromycin oral tablet 250 mg, 500 mg, 600 mg</i> | G | |
| <i>clarithromycin er oral tablet extended release 24 hour 500 mg</i> | G | |
| <i>clarithromycin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | G | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | G | |
| DIFICID ORAL SUSPENSION RECONSTITUTED 40 MG/ML (<i>fidaxomicin</i>) | PB | |
| DIFICID ORAL TABLET 200 MG (<i>fidaxomicin</i>) | PB | |
| E.E.S. GRANULES ORAL SUSPENSION RECONSTITUTED 200 MG/5ML (<i>erythromycin ethylsuccinate</i>) | NF | |
| ERYPED 200 ORAL SUSPENSION RECONSTITUTED 200 MG/5ML (<i>erythromycin ethylsuccinate</i>) | NF | |
| ERYPED 400 ORAL SUSPENSION RECONSTITUTED 400 MG/5ML (<i>erythromycin ethylsuccinate</i>) | NF | |
| <i>erythromycin base (Ery-Tab Oral Tablet Delayed Release 250 Mg, 333 Mg, 500 Mg)</i> | G | |
| ERYTHROCIN STEARATE ORAL TABLET 250 MG (<i>erythromycin stearate</i>) | G | |
| <i>erythromycin base oral capsule delayed release particles 250 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>erythromycin base oral tablet 250 mg, 500 mg</i> | G | |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 200 mg/5ml, 400 mg/5ml</i> | G | |
| <i>erythromycin ethylsuccinate oral tablet 400 mg</i> | G | |
| FLUOROQUINOLONES - DRUGS TO TREAT INFECTIONS | | |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg</i> | G | |
| <i>levofloxacin oral solution 25 mg/ml</i> | G | |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | G | |
| <i>moxifloxacin hcl oral tablet 400 mg</i> | G | |
| HEPATITIS B | | |
| <i>adefovir dipivoxil oral tablet 10 mg</i> | G | |
| <i>BARACLUDE ORAL SOLUTION 0.05 MG/ML (entecavir)</i> | SP | PA; QL (630 ML per 30 days) |
| <i>BARACLUDE ORAL TABLET 0.5 MG, 1 MG (entecavir)</i> | NF | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> | G | QL (30 TABLETS per 30 days) |
| <i>lamivudine oral tablet 100 mg</i> | G | |
| <i>VEMLIDY ORAL TABLET 25 MG (tenofovir alafenamide fumarate)</i> | SP | QL (30 TABLETS per 30 days) |
| HEPATITIS C | | |
| <i>EPCLUSIA ORAL PACKET 150-37.5 MG (sofosbuvir-velpatasvir)</i> | PB | PA; IBC (Preferred for all genotypes); QL (28 PELLETS per 28 DAYS) |
| <i>EPCLUSIA ORAL PACKET 200-50 MG (sofosbuvir-velpatasvir)</i> | PB | PA; IBC (Preferred for all genotypes); QL (56 PELLETS per 28 days) |
| <i>EPCLUSIA ORAL TABLET 200-50 MG, 400-100 MG (sofosbuvir-velpatasvir)</i> | PB | PA; IBC (Preferred for all genotypes); QL (28 TABLETS per 28 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| HARVONI ORAL PACKET 33.75-150 MG (<i>ledipasvir-sofosbuvir</i>) | PB | PA; QL (28 PELLETS per 28 DAYS) |
| HARVONI ORAL PACKET 45-200 MG (<i>ledipasvir-sofosbuvir</i>) | PB | PA; QL (56 PELLETS per 28 days) |
| HARVONI ORAL TABLET 45-200 MG, 90-400 MG (<i>ledipasvir-sofosbuvir</i>) | PB | PA; IBC (Preferred for genotypes 1,4,5,6); QL (28 TABLETS per 28 DAYS) |
| <i>ledipasvir-sofosbuvir oral tablet 90-400 mg</i> | NF | |
| MAVYRET ORAL PACKET 50-20 MG (<i>glecaprevir-pibrentasvir</i>) | NF | |
| MAVYRET ORAL TABLET 100-40 MG (<i>glecaprevir-pibrentasvir</i>) | NF | |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML (<i>peginterferon alfa-2a</i>) | SP | PA |
| PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 180 MCG/0.5ML (<i>peginterferon alfa-2a</i>) | SP | PA |
| <i>ribavirin oral capsule 200 mg</i> | G | PA |
| <i>ribavirin oral tablet 200 mg</i> | G | PA |
| <i>sofosbuvir-velpatasvir oral tablet 400-100 mg</i> | NF | |
| SOVALDI ORAL PACKET 150 MG (<i>sofosbuvir</i>) | SP | PA; QL (28 PELLETS per 28 days) |
| SOVALDI ORAL PACKET 200 MG (<i>sofosbuvir</i>) | SP | PA; QL (56 PELLETS per 28 days) |
| SOVALDI ORAL TABLET 200 MG, 400 MG (<i>sofosbuvir</i>) | SP | PA; QL (28 TABLETS per 28 days) |
| VOSEVI ORAL TABLET 400-100-100 MG (<i>sofosbuvir-velpatasvir-voxilaprev</i>) | SP | PA; IBC (Preferred for all genotypes); QL (28 TABLETS per 28 DAYS) |
| ZEPATIER ORAL TABLET 50-100 MG (<i>elbasvir-grazoprevir</i>) | SP | PA; ST; QL (28 TABLETS per 28 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| MISCELLANEOUS | | |
| ALINIA ORAL SUSPENSION RECONSTITUTED 100 MG/5ML (<i>nitazoxanide</i>) | NPB | QL (540 ML per 25 days); AL (Min 1 Years) |
| ALINIA ORAL TABLET 500 MG (<i>nitazoxanide</i>) | NPB | QL (20 TABLETS per 25 days); AL (Min 12 Years) |
| <i>atovaquone oral suspension 750 mg/5ml</i> | G | |
| <i>clindamycin hcl oral capsule 150 mg, 75 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>clindamycin hcl oral capsule 300 mg</i> | G | |
| <i>clindamycin palmitate hcl oral solution reconstituted 75 mg/5ml</i> | G | |
| <i>colistimethate sodium (cba) injection solution reconstituted 150 mg</i> | G | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | G | |
| DARAPRIM ORAL TABLET 25 MG (<i>pyrimethamine</i>) | NF | |
| FIRVANQ ORAL SOLUTION RECONSTITUTED 25 MG/ML, 50 MG/ML (<i>vancomycin hcl</i>) | NF | |
| LIKMEZ ORAL SUSPENSION 500 MG/5ML (<i>metronidazole</i>) | NF | |
| <i>linezolid oral suspension reconstituted 100 mg/5ml</i> | G | PA |
| <i>linezolid oral tablet 600 mg</i> | G | PA; N8 (Listing does not include certain NDCs) |
| MACRODANTIN ORAL CAPSULE 100 MG, 25 MG, 50 MG (<i>nitrofurantoin macrocrystal</i>) | NF | |
| MEPRON ORAL SUSPENSION 750 MG/5ML (<i>atovaquone</i>) | PB | |
| <i>methenamine hippurate oral tablet 1 gm</i> | G | |
| <i>methenamine mandelate oral tablet 0.5 gm, 1 gm</i> | G | |
| <i>metronidazole oral capsule 375 mg</i> | G | |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | G | N8 (Listing does not include certain NDCs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>nitazoxanide oral tablet 500 mg</i> | G | QL (20 TABLETS per 25 days); AL (Min 12 Years) |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg</i> | G | |
| <i>nitrofurantoin monohyd macro oral capsule 100 mg</i> | G | |
| <i>nitrofurantoin oral suspension 25 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>nitrofurantoin oral suspension 50 mg/5ml</i> | NF | |
| <i>pentamidine isethionate inhalation solution reconstituted 300 mg</i> | G | |
| <i>pyrimethamine oral tablet 25 mg</i> | G | |
| SIVEXTRO ORAL TABLET 200 MG (tedizolid phosphate) | NPB | PA |
| SOLOSEC ORAL PACKET 2 GM (secnidazole) | NF | |
| VANCOCIN ORAL CAPSULE 125 MG (vancomycin hcl) | NPB | QL (80 capsules per 10 days) |
| VANCOCIN ORAL CAPSULE 250 MG (vancomycin hcl) | NPB | QL (80 CAPSULES per 10 days) |
| <i>vancomycin hcl oral capsule 125 mg, 250 mg</i> | G | QL (80 CAPSULES per 10 days) |
| <i>vancomycin hcl oral solution reconstituted 25 mg/ml, 50 mg/ml</i> | NF | |
| XIFAXAN ORAL TABLET 200 MG (rifaximin) | NF | |
| XIFAXAN ORAL TABLET 550 MG (rifaximin) | PB | PA |
| ZYVOX ORAL SUSPENSION RECONSTITUTED 100 MG/5ML (linezolid) | NF | |
| ZYVOX ORAL TABLET 600 MG (linezolid) | NF | |
| PENICILLINS - DRUGS TO TREAT INFECTIONS | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>amoxicillin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>amoxicillin oral suspension reconstituted 200 mg/5ml</i> | G | |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>amoxicillin oral tablet chewable 125 mg, 250 mg</i> | G | |
| <i>amoxicillin suspension reconstituted 400 mg/5ml oral</i> | G | |
| <i>amoxicillin suspension reconstituted 400 mg/5ml oral</i> | NF | |
| <i>amoxicillin-pot clavulanate er oral tablet extended release 12 hour 1000-62.5 mg</i> | G | |
| <i>amoxicillin-pot clavulanate oral suspension reconstituted 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5ml, 600-42.9 mg/5ml</i> | G | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg</i> | G | |
| <i>amoxicillin-pot clavulanate oral tablet 875-125 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>amoxicillin-pot clavulanate oral tablet chewable 200-28.5 mg, 400-57 mg</i> | G | |
| <i>ampicillin oral capsule 500 mg</i> | G | |
| <i>dicloxacillin sodium oral capsule 250 mg, 500 mg</i> | G | |
| <i>penicillin v potassium oral solution reconstituted 125 mg/5ml, 250 mg/5ml</i> | G | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | G | |
| TETRACYCLINES - DRUGS TO TREAT INFECTIONS | | |
| <i>demeclacycline hcl oral tablet 150 mg, 300 mg</i> | G | |
| <i>DORYX MPC ORAL TABLET DELAYED RELEASE 120 MG, 60 MG (doxycycline hyclate)</i> | NF | |
| <i>DORYX ORAL TABLET DELAYED RELEASE 50 MG (doxycycline hyclate)</i> | NF | |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i> | G | |
| <i>doxycycline hyclate oral tablet 100 mg</i> | G | |
| <i>doxycycline hyclate oral tablet 150 mg, 50 mg, 75 mg</i> | NF | |
| <i>doxycycline hyclate oral tablet 20 mg</i> | G | N8 (Listing does not include certain NDCs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>doxycycline hyclate oral tablet delayed release 100 mg, 150 mg, 200 mg, 50 mg, 75 mg, 80 mg</i> | NF | |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i> | G | |
| <i>doxycycline monohydrate oral capsule 150 mg, 75 mg</i> | NF | |
| <i>doxycycline monohydrate oral suspension reconstituted 25 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>doxycycline monohydrate oral tablet 100 mg, 150 mg, 75 mg</i> | G | |
| <i>doxycycline monohydrate oral tablet 50 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>minocycline hcl er oral capsule extended release 24 hour 135 mg, 45 mg, 90 mg</i> | NF | |
| <i>minocycline hcl er oral tablet extended release 24 hour 105 mg, 115 mg, 135 mg, 45 mg, 55 mg, 65 mg, 80 mg, 90 mg</i> | NF | |
| <i>minocycline hcl oral capsule 100 mg, 50 mg, 75 mg</i> | G | |
| <i>minocycline hcl oral tablet 100 mg, 50 mg, 75 mg</i> | G | |
| MINOLIRA ORAL TABLET EXTENDED RELEASE 24 HOUR 105 MG, 135 MG (minocycline hcl) | NF | |
| NUZYRA ORAL TABLET 150 MG (omadacycline tosylate) | SP | PA; QL (30 TABLETS per 14 DAYS) |
| SEYSARA ORAL TABLET 100 MG, 150 MG, 60 MG (sarecycline hcl) | NF | |
| SOLODYN ORAL TABLET EXTENDED RELEASE 24 HOUR 105 MG, 115 MG, 55 MG, 65 MG, 80 MG (minocycline hcl) | NF | |
| <i>doxycycline hyclate (Targadox Oral Tablet 50 Mg)</i> | NF | |
| <i>tetracycline hcl oral capsule 250 mg, 500 mg</i> | G | QL (120 CAPSULES per 25 days) |
| <i>tetracycline hcl oral tablet 250 mg, 500 mg</i> | NF | |
| VIBRAMYCIN ORAL SUSPENSION RECONSTITUTED 25 MG/5ML (doxycycline monohydrate) | NPB | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| XIMINO ORAL CAPSULE EXTENDED RELEASE 24 HOUR 135 MG, 45 MG, 90 MG (<i>minocycline hcl</i>) | NF | |
| ANTINEOPLASTIC AGENTS - DRUGS TO TREAT CANCER | | |
| ALKYLATING AGENTS | | |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i> | CE | N7 (G) |
| GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG (<i>lomustine</i>) | CE | N7 (SP) |
| LEUKERAN ORAL TABLET 2 MG (<i>chlorambucil</i>) | CE | N7 (PB) |
| MATULANE ORAL CAPSULE 50 MG (<i>procarbazine hcl</i>) | CE | N7 (SP) |
| MYLERAN ORAL TABLET 2 MG (<i>busulfan</i>) | CE | N7 (PB) |
| <i>temozolomide oral capsule 100 mg, 140 mg, 180 mg, 20 mg, 250 mg, 5 mg</i> | CE | PA; N7 (G) |
| ALKYLATING AGENTS - CHEMOTHERAPY DRUGS | | |
| <i>melphalan oral tablet 2 mg</i> | CE | N7 (G) |
| ANTIMETABOLITES | | |
| <i>capecitabine oral tablet 150 mg, 500 mg</i> | CE | PA; N7 (G) |
| INQOVI ORAL TABLET 35-100 MG (<i>decitabine-cedazuridine</i>) | CE | PA; N7 (SP); QL (5 TABLETS per 28 days) |
| JYLAMVO ORAL SOLUTION 2 MG/ML (<i>methotrexate</i>) | CE | N7 (NF) |
| LONSURF ORAL TABLET 15-6.14 MG (<i>trifluridine-tipiracil</i>) | CE | PA; N7 (SP); QL (100 TABLETS per 30 days) |
| LONSURF ORAL TABLET 20-8.19 MG (<i>trifluridine-tipiracil</i>) | CE | PA; N7 (SP); QL (80 TABLETS per 30 days) |
| ONUREG ORAL TABLET 200 MG, 300 MG (<i>azacitidine</i>) | CE | PA; N7 (SP); QL (14 TABLETS per 28 days) |
| TABLOID ORAL TABLET 40 MG (<i>thioguanine</i>) | CE | N7 (PB) |
| XELODA ORAL TABLET 150 MG, 500 MG (<i>capecitabine</i>) | CE | PA; ST; N7 (SP) |
| ANTIMETABOLITES - CHEMOTHERAPY DRUGS | | |
| <i>mercaptopurine oral tablet 50 mg</i> | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>methotrexate sodium (pf) injection solution 1 gm/40ml, 250 mg/10ml, 50 mg/2ml</i> | G | |
| <i>methotrexate sodium injection solution 250 mg/10ml, 50 mg/2ml</i> | G | |
| <i>methotrexate sodium injection solution reconstituted 1 gm</i> | G | |
| PURIXAN ORAL SUSPENSION 2000 MG/100ML <i>(mercaptopurine)</i> | CE | PA; N7 (SP) |
| TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG <i>(methotrexate sodium)</i> | CE | N7 (PB) |
| XATMEP ORAL SOLUTION 2.5 MG/ML (<i>methotrexate</i>) | CE | N7 (SP) |
| ANTINEOPLASTIC, BCL-2 INHIBITORS | | |
| VENCLEXTA ORAL TABLET 10 MG, 50 MG (<i>venetoclax</i>) | CE | PA; N7 (SP); QL (120 TABLETS per 30 DAYS) |
| VENCLEXTA ORAL TABLET 100 MG (<i>venetoclax</i>) | CE | PA; N7 (SP); QL (180 TABLETS per 30 DAYS) |
| VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK 10 & 50 & 100 MG (<i>venetoclax</i>) | CE | PA; N7 (SP); QL (1 PACK per 28 DAYS) |
| BIOLOGIC RESPONSE MODIFIERS | | |
| BESREMI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 500 MCG/ML (<i>ropginterferon alfa-2b-njft</i>) | SP | PA; QL (2 SYRINGES per 28 days) |
| DAURISMO ORAL TABLET 100 MG, 25 MG (<i>glasdegib maleate</i>) | CE | N7 (NF) |
| ERIVEDGE ORAL CAPSULE 150 MG (<i>vismodegib</i>) | CE | PA; N7 (SP); QL (30 CAPSULES per 30 DAYS) |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG (<i>pomalidomide</i>) | CE | PA; N7 (SP); QL (21 CAPSULES per 28 days) |
| REVLIMID ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 5 MG (<i>lenalidomide</i>) | CE | PA; N7 (SP); QL (28 CAPSULES per 28 days) |
| REVLIMID ORAL CAPSULE 20 MG, 25 MG (<i>lenalidomide</i>) | CE | PA; N7 (SP); QL (21 CAPSULES per 28 days) |
| THALOMID ORAL CAPSULE 100 MG, 50 MG (<i>thalidomide</i>) | SP | PA; QL (28 CAPSULES per 28 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| THALOMID ORAL CAPSULE 150 MG, 200 MG (<i>thalidomide</i>) | SP | PA; QL (56 CAPSULES per 28 days) |
| HORMONAL ANTINEOPLASTIC AGENTS | | |
| <i>abiraterone acetate oral tablet 250 mg</i> | CE | PA; N7 (SP); QL (120 TABLETS per 30 DAYS) |
| <i>abiraterone acetate oral tablet 500 mg</i> | CE | PA; N7 (SP); QL (60 TABLETS per 30 DAYS) |
| AKEEGA ORAL TABLET 100-500 MG, 50-500 MG (<i>niraparib-abiraterone acetate</i>) | CE | N7 (NF) |
| <i>anastrozole oral tablet 1 mg</i> | CE | N7 (G); AL (Min 35 Years) |
| <i>bicalutamide oral tablet 50 mg</i> | CE | N7 (G) |
| ELIGARD SUBCUTANEOUS KIT 22.5 MG (<i>leuprolide acetate (3 month)</i>) | SP | PA |
| ELIGARD SUBCUTANEOUS KIT 30 MG (<i>leuprolide acetate (4 month)</i>) | SP | PA |
| ELIGARD SUBCUTANEOUS KIT 45 MG (<i>leuprolide acetate (6 month)</i>) | SP | PA |
| ELIGARD SUBCUTANEOUS KIT 7.5 MG (<i>leuprolide acetate</i>) | SP | PA |
| ERLEADA ORAL TABLET 240 MG (<i>apalutamide</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| ERLEADA ORAL TABLET 60 MG (<i>apalutamide</i>) | CE | PA; N7 (SP); QL (120 TABLETS per 30 DAYS) |
| EULEXIN ORAL CAPSULE 125 MG (<i>flutamide</i>) | CE | N7 (NF) |
| <i>exemestane oral tablet 25 mg</i> | CE | N7 (G); AL (Min 35 Years) |
| FASLODEX INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 250 MG/5ML (<i>fulvestrant</i>) | SP | PA |
| FIRMAGON (240 MG DOSE) SUBCUTANEOUS SOLUTION RECONSTITUTED 120 MG/VIAL (<i>degarelix acetate</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG (<i>degarelix acetate</i>) | NF | |
| <i>fulvestrant intramuscular solution prefilled syringe 250 mg/5ml</i> | SP | PA |
| <i>letrozole oral tablet 2.5 mg</i> | CE | N7 (G) |
| <i>leuprolide acetate injection kit 1 mg/0.2ml</i> | G | PA |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 3.75 MG (<i>leuprolide acetate</i>) | SP | PA |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 7.5 MG (<i>leuprolide acetate</i>) | NF | |
| LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 11.25 MG (<i>leuprolide acetate (3 month)</i>) | SP | PA |
| LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 22.5 MG (<i>leuprolide acetate (3 month)</i>) | NF | |
| LUPRON DEPOT (4-MONTH) INTRAMUSCULAR KIT 30 MG (<i>leuprolide acetate (4 month)</i>) | NF | |
| LUPRON DEPOT (6-MONTH) INTRAMUSCULAR KIT 45 MG (<i>leuprolide acetate (6 month)</i>) | NF | |
| LYSODREN ORAL TABLET 500 MG (<i>mitotane</i>) | CE | N7 (SP) |
| <i>megestrol acetate oral tablet 20 mg, 40 mg</i> | CE | N7 (G) |
| NILANDRON ORAL TABLET 150 MG (<i>nilutamide</i>) | CE | N7 (NF) |
| <i>nilutamide oral tablet 150 mg</i> | CE | N7 (G) |
| NUBEQA ORAL TABLET 300 MG (<i>darolutamide</i>) | CE | PA; N7 (SP); QL (120 TABLETS per 30 DAYS) |
| ORGOVYX ORAL TABLET 120 MG (<i>relugolix</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 days) |
| ORSERDU ORAL TABLET 345 MG, 86 MG (<i>elacestrant hydrochloride</i>) | CE | N7 (NF) |
| <i>tamoxifen citrate oral tablet 10 mg, 20 mg</i> | CE | N7 (G); AL (Min 35 Years) |
| <i>toremifene citrate oral tablet 60 mg</i> | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25 MG, 22.5 MG, 3.75 MG (<i>triptorelin pamoate</i>) | NF | |
| XTANDI ORAL CAPSULE 40 MG (<i>enzalutamide</i>) | CE | PA; N7 (SP); QL (120 CAPSULES per 30 DAYS) |
| XTANDI ORAL TABLET 40 MG (<i>enzalutamide</i>) | CE | PA; N7 (SP); QL (120 TABLETS per 30 DAYS) |
| XTANDI ORAL TABLET 80 MG (<i>enzalutamide</i>) | CE | PA; N7 (SP); QL (60 TABLETS per 30 DAYS) |
| YONSA ORAL TABLET 125 MG (<i>abiraterone acetate micronized</i>) | CE | PA; N7 (SP); QL (120 TABLETS per 30 days) |
| ZYTIGA ORAL TABLET 250 MG, 500 MG (<i>abiraterone acetate</i>) | CE | N7 (NF) |
| KINASE INHIBITORS | | |
| AFINITOR DISPERZ ORAL TABLET SOLUBLE 2 MG, 3 MG, 5 MG (<i>everolimus</i>) | CE | N7 (NF) |
| AFINITOR ORAL TABLET 10 MG, 2.5 MG, 5 MG, 7.5 MG (<i>everolimus</i>) | CE | N7 (NF) |
| ALECensa ORAL CAPSULE 150 MG (<i>alectinib hcl</i>) | CE | PA; N7 (SP); QL (240 CAPSULES per 30 DAYS) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG (<i>brigatinib</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| ALUNBRIG ORAL TABLET 30 MG (<i>brigatinib</i>) | CE | PA; N7 (SP); QL (120 TABLETS per 30 DAYS) |
| ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180 MG (<i>brigatinib</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| AUGTYRO ORAL CAPSULE 40 MG (<i>repotrectinib</i>) | CE | PA; N7 (SP); QL (240 CAPSULES per 30 DAYS) |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG (<i>avapritinib</i>) | CE | N7 (NF) |
| BALVERSA ORAL TABLET 3 MG (<i>erdafitinib</i>) | CE | PA; N7 (SP); QL (84 TABLETS per 28 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| BALVERSA ORAL TABLET 4 MG (<i>erdafitinib</i>) | CE | PA; N7 (SP); QL (56 TABLETS per 28 DAYS) |
| BALVERSA ORAL TABLET 5 MG (<i>erdafitinib</i>) | CE | PA; N7 (SP); QL (28 TABLETS per 28 DAYS) |
| BOSULIF ORAL CAPSULE 100 MG (<i>bosutinib</i>) | CE | PA; N7 (SP); QL (300 CAPSULES per 30 DAYS) |
| BOSULIF ORAL CAPSULE 50 MG (<i>bosutinib</i>) | CE | PA; N7 (SP); QL (30 CAPSULES per 30 DAYS) |
| BOSULIF ORAL TABLET 100 MG (<i>bosutinib</i>) | CE | PA; N7 (SP); QL (90 TABLETS per 30 DAYS) |
| BOSULIF ORAL TABLET 400 MG, 500 MG (<i>bosutinib</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| BRAFTOVI ORAL CAPSULE 75 MG (<i>encorafenib</i>) | CE | PA; N7 (SP); QL (180 CAPSULES per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG (<i>zanubrutinib</i>) | CE | PA; N7 (SP); QL (120 CAPSULES per 30 DAYS) |
| CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG (<i>cabozantinib s-malate</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| CALQUENCE ORAL TABLET 100 MG (<i>acalabrutinib maleate</i>) | CE | PA; N7 (SP); QL (60 TABLETS per 30 DAYS) |
| CAPRELSA ORAL TABLET 100 MG (<i>vandetanib</i>) | CE | PA; N7 (SP); QL (60 TABLETS per 30 DAYS) |
| CAPRELSA ORAL TABLET 300 MG (<i>vandetanib</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG (<i>cabozantinib s-malate</i>) | CE | PA; N7 (SP); QL (56 CAPSULES per 28 DAYS) |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG (<i>cabozantinib s-malate</i>) | CE | PA; N7 (SP); QL (112 CAPSULES per 28 DAYS) |
| COMETRIQ (60 MG DAILY DOSE) ORAL KIT 20 MG (<i>cabozantinib s-malate</i>) | CE | PA; N7 (SP); QL (1 KIT per 28 DAYS) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG (<i>duvelisib</i>) | CE | PA; N7 (SP); QL (56 CAPSULES per 28 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| COTELLIC ORAL TABLET 20 MG (<i>cobimetinib fumarate</i>) | CE | PA; N7 (SP); QL (63 TABLETS per 21 DAYS) |
| <i>erlotinib hcl oral tablet 100 mg, 150 mg</i> | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| <i>erlotinib hcl oral tablet 25 mg</i> | CE | PA; N7 (SP); QL (60 TABLETS per 30 days) |
| <i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i> | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| <i>everolimus oral tablet soluble 2 mg, 5 mg</i> | CE | PA; N7 (SP); QL (60 TABLETS per 30 DAYS) |
| <i>everolimus oral tablet soluble 3 mg</i> | CE | PA; N7 (SP); QL (90 TABLETS per 30 DAYS) |
| EXKIVITY ORAL CAPSULE 40 MG (<i>mobocertinib succinate</i>) | CE | N7 (NF) |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG (<i>tivozanib hcl</i>) | CE | N7 (NF) |
| FRUZAQLA ORAL CAPSULE 1 MG, 5 MG (<i>fruquintinib</i>) | CE | N7 (NF) |
| GAVRETO ORAL CAPSULE 100 MG (<i>pralsetinib</i>) | CE | PA; N7 (SP); QL (120 CAPSULES per 30 days) |
| <i>gefitinib oral tablet 250 mg</i> | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG (<i>afatinib dimaleate</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 days) |
| GLEEVEC ORAL TABLET 100 MG, 400 MG (<i>imatinib mesylate</i>) | CE | N7 (NF) |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG (<i>palbociclib</i>) | CE | PA; N7 (SP); QL (21 CAPSULES per 28 days) |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG (<i>palbociclib</i>) | CE | PA; N7 (SP); QL (21 TABLETS per 28 days) |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG (<i>ponatinib hcl</i>) | CE | N7 (NF) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| imatinib mesylate oral tablet 100 mg | CE | PA; N7 (G); QL (120 TABLETS per 30 days) |
| imatinib mesylate oral tablet 400 mg | CE | PA; N7 (G); QL (60 TABLETS per 30 DAYS) |
| IMBRUVICA ORAL CAPSULE 140 MG, 70 MG (<i>ibrutinib</i>) | CE | N7 (NF) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML (<i>ibrutinib</i>) | CE | N7 (NF) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG (<i>ibrutinib</i>) | CE | N7 (NF) |
| INLYTA ORAL TABLET 1 MG (<i>axitinib</i>) | CE | PA; N7 (SP); QL (240 TABLETS per 30 days) |
| INLYTA ORAL TABLET 5 MG (<i>axitinib</i>) | CE | PA; N7 (SP); QL (120 TABLETS per 30 DAYS) |
| INREBIC ORAL CAPSULE 100 MG (<i>fedratinib hcl</i>) | CE | N7 (NF) |
| IRESSA ORAL TABLET 250 MG (<i>gefitinib</i>) | CE | N7 (NF) |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG (<i>ruxolitinib phosphate</i>) | CE | PA; IBC (Not covered for polycythemia vera.); N7 (SP); QL (60 TABLETS per 30 DAYS) |
| JAYPIRCA ORAL TABLET 100 MG, 50 MG (<i>pirtobrutinib</i>) | CE | N7 (NF) |
| KISQALI (200 MG DOSE) ORAL TABLET THERAPY PACK 200 MG (<i>ribociclib succinate</i>) | CE | PA; N7 (SP); QL (63 TABLETS per 28 days) |
| KISQALI (400 MG DOSE) ORAL TABLET THERAPY PACK 200 MG (<i>ribociclib succinate</i>) | CE | PA; N7 (SP); QL (63 TABLETS per 28 days) |
| KISQALI (600 MG DOSE) ORAL TABLET THERAPY PACK 200 MG (<i>ribociclib succinate</i>) | CE | PA; N7 (SP); QL (63 TABLETS per 28 days) |
| KISQALI FEMARA (200 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG (<i>ribociclib-letrazole</i>) | CE | PA; N7 (SP); QL (49 TABLETS per 28 days) |
| KISQALI FEMARA (400 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG (<i>ribociclib-letrazole</i>) | CE | PA; N7 (SP); QL (70 TABLETS per 28 days) |
| KISQALI FEMARA (600 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG (<i>ribociclib-letrazole</i>) | CE | PA; N7 (SP); QL (91 TABLETS per 28 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| KOSELUGO ORAL CAPSULE 10 MG (<i>selumetinib sulfate</i>) | CE | PA; N7 (SP); QL (240 CAPSULES per 30 DAYS) |
| KOSELUGO ORAL CAPSULE 25 MG (<i>selumetinib sulfate</i>) | CE | PA; N7 (SP); QL (120 CAPSULES per 30 DAYS) |
| <i>lapatinib ditosylate oral tablet 250 mg</i> | CE | PA; N7 (SP); QL (180 TABLETS per 30 DAYS) |
| LENVIMA (10 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG (<i>lenvatinib mesylate</i>) | CE | PA; N7 (SP); QL (30 CAPSULES per 30 DAYS) |
| LENVIMA (12 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 3 X 4 MG (<i>lenvatinib mesylate</i>) | CE | PA; N7 (SP); QL (90 CAPSULES per 30 DAYS) |
| LENVIMA (14 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 & 4 MG (<i>lenvatinib mesylate</i>) | CE | PA; N7 (SP); QL (60 CAPSULES per 30 DAYS) |
| LENVIMA (18 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG & 2 X 4 MG (<i>lenvatinib mesylate</i>) | CE | PA; N7 (SP); QL (90 CAPSULES per 30 DAYS) |
| LENVIMA (20 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG (<i>lenvatinib mesylate</i>) | CE | PA; N7 (SP); QL (60 CAPSULES per 30 DAYS) |
| LENVIMA (24 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG & 4 MG (<i>lenvatinib mesylate</i>) | CE | PA; N7 (SP); QL (90 CAPSULES per 30 DAYS) |
| LENVIMA (4 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 4 MG (<i>lenvatinib mesylate</i>) | CE | PA; N7 (SP); QL (30 CAPSULES per 30 DAYS) |
| LENVIMA (8 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 4 MG (<i>lenvatinib mesylate</i>) | CE | PA; N7 (SP); QL (60 CAPSULES per 30 DAYS) |
| LORBRENA ORAL TABLET 100 MG, 25 MG (<i>lorlatinib</i>) | CE | N7 (NF) |
| LYTGOBI (12 MG DAILY DOSE) ORAL TABLET THERAPY PACK 4 MG (<i>futibatinib</i>) | CE | N7 (NF) |
| LYTGOBI (16 MG DAILY DOSE) ORAL TABLET THERAPY PACK 4 MG (<i>futibatinib</i>) | CE | N7 (NF) |
| LYTGOBI (20 MG DAILY DOSE) ORAL TABLET THERAPY PACK 4 MG (<i>futibatinib</i>) | CE | N7 (NF) |
| MEKINIST ORAL SOLUTION RECONSTITUTED 0.05 MG/ML (<i>trametinib dimethyl sulfoxide</i>) | CE | N7 (NF) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| MEKINIST ORAL TABLET 0.5 MG, 2 MG (<i>trametinib dimethyl sulfoxide</i>) | CE | N7 (NF) |
| MEKTOVI ORAL TABLET 15 MG (<i>binimatinib</i>) | CE | PA; N7 (SP); QL (180 TABLETS per 30 days) |
| NERLYNX ORAL TABLET 40 MG (<i>neratinib maleate</i>) | CE | PA; N7 (SP); QL (180 TABLETS per 30 DAYS) |
| NEXAVAR ORAL TABLET 200 MG (<i>sorafenib tosylate</i>) | CE | N7 (NF) |
| OJEMDA ORAL SUSPENSION RECONSTITUTED 25 MG/ML (<i>tovorafenib</i>) | CE | N7 (NF) |
| OJEMDA ORAL TABLET 100 MG (<i>tovorafenib</i>) | CE | N7 (NF) |
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG (<i>mometotinib dihydrochloride</i>) | NF | |
| pazopanib hcl oral tablet 200 mg | CE | PA; N7 (SP); QL (120 TABLETS per 30 DAYS) |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG (<i>pemigatinib</i>) | CE | N7 (NF) |
| PIQRAY (200 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 MG (<i>alpelisib</i>) | CE | PA; N7 (SP); QL (28 TABLETS per 28 DAYS) |
| PIQRAY (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 & 50 MG (<i>alpelisib</i>) | CE | PA; N7 (SP); QL (56 TABLETS per 28 DAYS) |
| PIQRAY (300 MG DAILY DOSE) ORAL TABLET THERAPY PACK 2 X 150 MG (<i>alpelisib</i>) | CE | PA; N7 (SP); QL (56 TABLETS per 28 DAYS) |
| QINLOCK ORAL TABLET 50 MG (<i>ripretinib</i>) | CE | N7 (NF) |
| RETEVMO ORAL CAPSULE 40 MG (<i>selpercatinib</i>) | CE | PA; N7 (SP); QL (60 TABLETS per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG (<i>selpercatinib</i>) | CE | PA; N7 (SP); QL (120 TABLETS per 30 days) |
| ROZLYTREK ORAL CAPSULE 100 MG (<i>entrectinib</i>) | CE | PA; N7 (SP); QL (30 CAPSULES per 30 DAYS) |
| ROZLYTREK ORAL CAPSULE 200 MG (<i>entrectinib</i>) | CE | PA; N7 (SP); QL (90 CAPSULES per 30 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ROZLYTREK ORAL PACKET 50 MG (<i>entrectinib</i>) | CE | PA; N7 (SP); QL (8 CARTONS per 28 DAYS) |
| RYDAPT ORAL CAPSULE 25 MG (<i>midostaurin</i>) | CE | PA; N7 (SP); QL (224 CAPSULES per 28 days) |
| SCEMBLIX ORAL TABLET 20 MG, 40 MG (<i>asciminib hcl</i>) | CE | N7 (NF) |
| <i>sorafenib tosylate oral tablet 200 mg</i> | CE | PA; N7 (SP); QL (120 TABLETS per 30 DAYS) |
| SPRYCEL ORAL TABLET 100 MG, 140 MG, 50 MG, 70 MG, 80 MG (<i>dasatinib</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| SPRYCEL ORAL TABLET 20 MG (<i>dasatinib</i>) | CE | PA; N7 (SP); QL (90 TABLETS per 30 DAYS) |
| STIVARGA ORAL TABLET 40 MG (<i>regorafenib</i>) | CE | PA; N7 (SP); QL (84 TABLETS per 28 DAYS) |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | CE | PA; N7 (SP); QL (30 CAPSULES per 30 DAYS) |
| SUTENT ORAL CAPSULE 12.5 MG, 25 MG, 37.5 MG, 50 MG (<i>sunitinib malate</i>) | CE | N7 (NF) |
| TABRECTA ORAL TABLET 150 MG, 200 MG (<i>capmatinib hcl</i>) | CE | N7 (NF) |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG (<i>dabrafenib mesylate</i>) | CE | N7 (NF) |
| TAFINLAR ORAL TABLET SOLUBLE 10 MG (<i>dabrafenib mesylate</i>) | CE | N7 (NF) |
| TAGRISSO ORAL TABLET 40 MG, 80 MG (<i>osimertinib mesylate</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| TARCEVA ORAL TABLET 100 MG, 150 MG (<i>erlotinib hcl</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYS) |
| TARCEVA ORAL TABLET 25 MG (<i>erlotinib hcl</i>) | CE | PA; N7 (SP); QL (60 TABLETS per 30 DAYS) |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG (<i>nilotinib hcl</i>) | CE | N7 (NF) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| TEPMETKO ORAL TABLET 225 MG (<i>tepotinib hcl</i>) | CE | N7 (NF) |
| TRUQAP ORAL TABLET 160 MG, 200 MG (<i>capivasertib</i>) | CE | N7 (NF) |
| TUKYSA ORAL TABLET 150 MG, 50 MG (<i>tucatinib</i>) | CE | PA; N7 (SP); QL (120 TABLETS per 30 DAYS) |
| TURALIO ORAL CAPSULE 125 MG (<i>pexidartinib hcl</i>) | CE | N7 (NF) |
| TYKERB ORAL TABLET 250 MG (<i>lapatinib ditosylate</i>) | CE | PA; N7 (SP); QL (180 TABLETS per 30 DAYS) |
| VANFLYTA ORAL TABLET 17.7 MG, 26.5 MG (<i>quizartinib dihydrochloride</i>) | CE | N7 (NF) |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG (<i>abemaciclib</i>) | CE | PA; N7 (SP); QL (56 TABLETS per 28 days) |
| VITRAKVI ORAL CAPSULE 100 MG (<i>larotrectinib sulfate</i>) | CE | PA; N7 (SP); QL (60 CAPSULES per 30 DAYS) |
| VITRAKVI ORAL CAPSULE 25 MG (<i>larotrectinib sulfate</i>) | CE | PA; N7 (SP); QL (180 CAPSULES per 30 DAYS) |
| VITRAKVI ORAL SOLUTION 20 MG/ML (<i>larotrectinib sulfate</i>) | CE | PA; N7 (SP); QL (300 ML per 30 DAYS) |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG (<i>dacomitinib</i>) | CE | N7 (NF) |
| VONJO ORAL CAPSULE 100 MG (<i>pacritinib citrate</i>) | CE | PA; N7 (SP); QL (120 CAPSULES per 30 days) |
| VOTRIENT ORAL TABLET 200 MG (<i>pazopanib hcl</i>) | CE | N7 (NF) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG (<i>crizotinib</i>) | CE | N7 (NF) |
| XALKORI ORAL CAPSULE SPRINKLE 150 MG (<i>crizotinib</i>) | CE | PA; N7 (SP); QL (180 CAPSULES per 30 DAYS) |
| XALKORI ORAL CAPSULE SPRINKLE 20 MG, 50 MG (<i>crizotinib</i>) | CE | PA; N7 (SP); QL (120 CAPSULES per 30 DAYS) |
| XOSPATA ORAL TABLET 40 MG (<i>gilteritinib fumarate</i>) | CE | PA; N7 (SP); QL (90 TABLETS per 30 DAYS) |
| ZELBORAF ORAL TABLET 240 MG (<i>vemurafenib</i>) | CE | PA; N7 (SP); QL (240 TABLETS per 30 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| ZYDELIG ORAL TABLET 100 MG, 150 MG (<i>idelalisib</i>) | CE | PA; N7 (SP); QL (60 TABLETS per 30 days) |
| ZYKADIA ORAL TABLET 150 MG (<i>ceritinib</i>) | CE | PA; N7 (SP); QL (90 TABLETS per 30 DAYS) |
| MISCELLANEOUS | | |
| <i>bexarotene oral capsule 75 mg</i> | CE | PA; N7 (SP) |
| <i>hydroxyurea oral capsule 500 mg</i> | CE | N7 (G) |
| IDHIFA ORAL TABLET 100 MG, 50 MG (<i>enasidenib mesylate</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 days) |
| IWILFIN ORAL TABLET 192 MG (<i>eflornithine hcl</i>) | CE | PA; N7 (SP); QL (240 TABLETS per 30 DAYS) |
| KRAZATI ORAL TABLET 200 MG (<i>adagrasib</i>) | CE | PA; N7 (SP); QL (180 TABLETS per 30 days) |
| LUMAKRAS ORAL TABLET 120 MG (<i>sotorasib</i>) | CE | PA; N7 (SP); QL (240 TABLETS per 30 DAYS) |
| LUMAKRAS ORAL TABLET 320 MG (<i>sotorasib</i>) | CE | PA; N7 (SP); QL (90 TABLETS per 30 DAYS) |
| LYNPARZA ORAL TABLET 100 MG, 150 MG (<i>olaparib</i>) | CE | PA; N7 (SP); QL (120 TABLETS per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG (<i>sonidegib phosphate</i>) | CE | PA; N7 (SP); QL (30 CAPSULES per 30 DAYS) |
| OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG (<i>nirogacestat hydrobromide</i>) | CE | N7 (NF) |
| REZLIDHIA ORAL CAPSULE 150 MG (<i>olutasidenib</i>) | CE | N7 (NF) |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG (<i>rucaparib camsylate</i>) | CE | N7 (NF) |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG (<i>talazoparib tosylate</i>) | CE | N7 (NF) |
| TARGETIN ORAL CAPSULE 75 MG (<i>bexarotene</i>) | CE | N7 (NF) |
| TAZVERIK ORAL TABLET 200 MG (<i>tazemetostat hbr</i>) | CE | N7 (NF) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| TIBSOVO ORAL TABLET 250 MG (<i>ivosidenib</i>) | CE | PA; N7 (SP); QL (60 TABLETS per 30 days) |
| <i>tretinoi</i> n oral capsule 10 mg | CE | N7 (G) |
| VISTOGARD ORAL PACKET 10 GM (<i>uridine triacetate</i>) | SP | QL (20 PACKETS per 5 DAYs) |
| WELIREG ORAL TABLET 40 MG (<i>belzutifan</i>) | CE | N7 (NF) |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG (<i>selinexor</i>) | CE | PA; N7 (SP); QL (8 TABLETS per 28 days) |
| XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG (<i>selinexor</i>) | CE | PA; N7 (SP); QL (4 TABLETS per 28 days) |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG (<i>selinexor</i>) | CE | PA; N7 (SP); QL (8 TABLETS per 28 days) |
| XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG (<i>selinexor</i>) | CE | PA; N7 (SP); QL (4 TABLETS per 28 days) |
| XPOVIO (60 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG (<i>selinexor</i>) | CE | PA; N7 (SP); QL (24 TABLETS per 28 days) |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG (<i>selinexor</i>) | CE | PA; N7 (SP); QL (8 TABLETS per 28 days) |
| XPOVIO (80 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG (<i>selinexor</i>) | CE | PA; N7 (SP); QL (32 TABLETS per 28 days) |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG (<i>niraparib tosylate</i>) | CE | PA; N7 (SP); QL (30 TABLETS per 30 DAYs) |
| ZOLINZA ORAL CAPSULE 100 MG (<i>vorinostat</i>) | CE | PA; N7 (SP); QL (120 CAPSULES per 30 days) |
| PROTEASOME INHIBITORS | | |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG (<i>ixazomib citrate</i>) | CE | PA; N7 (SP); QL (3 CAPSULES per 28 DAYs) |
| PROTECTIVE AGENTS | | |
| <i>leucovorin calcium</i> oral tablet 10 mg, 15 mg, 25 mg, 5 mg | CE | N7 (G) |
| TOPOISOMERASE INHIBITORS | | |
| <i>etoposide</i> oral capsule 50 mg | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| HYCAMTIN ORAL CAPSULE 0.25 MG, 1 MG (<i>topotecan hcl</i>) | CE | PA; N7 (SP) |
| CARDIOVASCULAR - DRUGS TO TREAT HEART AND CIRCULATION CONDITIONS | | |
| ACE INHIBITOR COMBINATIONS - DRUGS TO TREAT HIGH BLOOD PRESSURE | | |
| <i>amlodipine besy-benazepril hcl oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | G | LGC |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | G | LGC |
| <i>captopril-hydrochlorothiazide oral tablet 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg</i> | NF | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | G | LGC |
| <i>fosinopril sodium-hctz oral tablet 10-12.5 mg, 20-12.5 mg</i> | G | LGC |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | G | LGC |
| PRESTALIA ORAL TABLET 14-10 MG, 3.5-2.5 MG, 7-5 MG (<i>perindopril arg-amlodipine</i>) | NF | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg</i> | NF | LGC |
| <i>quinapril-hydrochlorothiazide oral tablet 20-12.5 mg, 20-25 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| <i>trandolapril-verapamil hcl er oral tablet extended release 1-240 mg</i> | G | |
| ZESTORETIC ORAL TABLET 10-12.5 MG, 20-12.5 MG, 20-25 MG (<i>lisinopril-hydrochlorothiazide</i>) | NF | |
| ACE INHIBITORS - DRUGS TO TREAT HIGH BLOOD PRESSURE | | |
| <i>benazepril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | G | LGC |
| <i>enalapril maleate oral solution 1 mg/ml</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| EPANED ORAL SOLUTION 1 MG/ML (<i>enalapril maleate</i>) | NF | |
| <i>fosinopril sodium oral tablet 10 mg, 20 mg, 40 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| <i>lisinopril oral tablet 30 mg, 40 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>moexipril hcl oral tablet 15 mg, 7.5 mg</i> | G | |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | G | LGC |
| <i>quinapril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | G | LGC |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | G | LGC |
| ALDOSTERONE RECEPTOR ANTAGONISTS - DRUGS TO TREAT HIGH BLOOD PRESSURE | | |
| <i>CAROSPIR ORAL SUSPENSION 25 MG/5ML (<i>spironolactone</i>)</i> | NF | |
| <i>spironolactone oral suspension 25 mg/5ml</i> | NF | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | G | LGC |
| ALDOSTERONE RECEPTOR ANTAGONISTS - DRUGS TO TREAT HIBLOOD PRESSURE | | |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> | G | |
| ALPHA BLOCKERS - DRUGS TO TREAT HIGH BLOOD PRESSURE | | |
| <i>prazosin hcl oral capsule 1 mg, 2 mg, 5 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| ANGIOTENSIN II RECEPTOR ANTAGONIST COMBINATIONS - DRUGS TO TREAT HIGH BLOOD PRESSURE | | |
| <i>amlodipine-valsartan-hctz oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | G | |
| AZOR ORAL TABLET 10-20 MG, 10-40 MG, 5-20 MG, 5-40 MG (<i>amlodipine-olmesartan</i>) | NF | |
| BENICAR HCT ORAL TABLET 20-12.5 MG, 40-12.5 MG, 40-25 MG (<i>olmesartan medoxomil-hctz</i>) | NF | |
| <i>candesartan cilexetil-hctz oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | G | LGC |
| HYZAAR ORAL TABLET 100-12.5 MG, 100-25 MG, 50-12.5 MG (<i>losartan potassium-hctz</i>) | NF | |
| <i>olmesartan medoxomil-hctz oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | G | LGC |
| <i>telmisartan-hctz oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | G | LGC |
| <i>valsartan-hydrochlorothiazide oral tablet 160-25 mg, 320-25 mg, 80-12.5 mg</i> | G | LGC |
| ANGIOTENSIN II RECEPTOR ANTAGONIST COMBINATIONS - DRUGS TO TREAT HIGH BLOOD PRESSURE | | |
| <i>amlodipine besylate-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | G | LGC |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> | G | LGC |
| ATACAND HCT ORAL TABLET 16-12.5 MG, 32-12.5 MG, 32-25 MG (<i>candesartan cilexetil-hctz</i>) | NF | |
| DIOVAN HCT ORAL TABLET 160-12.5 MG, 160-25 MG, 320-12.5 MG, 320-25 MG, 80-12.5 MG (<i>valsartan-hydrochlorothiazide</i>) | NF | |
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG (<i>azilsartan-chlorthalidone</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| EXFORGE HCT ORAL TABLET 10-160-12.5 MG, 10-160-25 MG, 10-320-25 MG, 5-160-12.5 MG, 5-160-25 MG (amlodipine-valsartan-hctz) | NF | |
| EXFORGE ORAL TABLET 10-160 MG, 10-320 MG, 5-160 MG, 5-320 MG (amlodipine besylate-valsartan) | NF | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | G | LGC |
| <i>losartan potassium-hctz oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | G | LGC |
| MICARDIS HCT ORAL TABLET 40-12.5 MG, 80-12.5 MG, 80-25 MG (telmisartan-hctz) | NF | |
| <i>olmesartan-amlodipine-hctz oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | G | LGC |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | G | LGC |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 320-12.5 mg</i> | G | LGC |
| ANGIOTENSIN II RECEPTOR ANTAGONISTS - DRUGS TO TREAT HIGH BLOOD PRESSURE | | |
| BENICAR ORAL TABLET 20 MG, 40 MG, 5 MG (olmesartan medoxomil) | NF | |
| COZAAR ORAL TABLET 100 MG, 25 MG, 50 MG (losartan potassium) | NF | |
| <i>losartan potassium oral tablet 100 mg, 25 mg, 50 mg</i> | G | LGC |
| <i>olmesartan medoxomil oral tablet 20 mg, 40 mg, 5 mg</i> | G | LGC |
| <i>valsartan oral solution 4 mg/ml</i> | NF | |
| ANGIOTENSIN II RECEPTOR ANTAGONISTS - DRUGS TO TREAT HIGH BLOOD PRESSURE | | |
| ATACAND ORAL TABLET 16 MG, 32 MG, 4 MG, 8 MG (candesartan cilexetil) | NF | |
| <i>candesartan cilexetil oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | G | LGC |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| DIOVAN ORAL TABLET 160 MG, 320 MG, 40 MG, 80 MG (<i>valsartan</i>) | NF | |
| EDARBI ORAL TABLET 40 MG, 80 MG (<i>azilsartan medoxomil</i>) | NF | |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | G | LGC |
| MICARDIS ORAL TABLET 20 MG, 40 MG, 80 MG (<i>telmisartan</i>) | NF | |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | G | LGC |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> | G | LGC |
| ANTIARRHYTHMICS - DRUGS TO CONTROL HEART RHYTHM | | |
| <i>amiodarone hcl oral tablet 100 mg, 200 mg, 400 mg</i> | G | |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> | G | |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> | SP | PA |
| <i>flecainide acetate oral tablet 100 mg, 50 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>flecainide acetate oral tablet 150 mg</i> | G | |
| MULTAQ ORAL TABLET 400 MG (<i>dronedarone hcl</i>) | PB | |
| NORPACE ORAL CAPSULE 100 MG, 150 MG (<i>disopyramide phosphate</i>) | NF | |
| <i>propafenone hcl er oral capsule extended release 12 hour 225 mg, 325 mg, 425 mg</i> | G | |
| <i>propafenone hcl oral tablet 150 mg, 225 mg, 300 mg</i> | G | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | NF | |
| <i>sotalol hcl (af) oral tablet 120 mg</i> | G | LGC |
| <i>sotalol hcl (af) oral tablet 160 mg, 80 mg</i> | G | |
| <i>sotalol hcl oral tablet 120 mg, 80 mg</i> | G | LGC |
| <i>sotalol hcl oral tablet 160 mg, 240 mg</i> | G | |
| TIKOSYN ORAL CAPSULE 125 MCG, 250 MCG, 500 MCG (<i>dofetilide</i>) | SP | PA; ST |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ANTIPIEMICS, ACL INHIBITORS/COMBINATIONS | | |
| NEXLETOL ORAL TABLET 180 MG (<i>bempedoic acid</i>) | PB | |
| NEXLIZET ORAL TABLET 180-10 MG (<i>bempedoic acid-ezetimibe</i>) | PB | |
| ANTIPIEMICS, BILE ACID RESINS | | |
| <i>colesevelam hcl oral tablet 625 mg</i> | G | |
| <i>colestipol hcl oral granules 5 gm</i> | G | |
| <i>colestipol hcl oral packet 5 gm</i> | G | |
| <i>colestipol hcl oral tablet 1 gm</i> | G | |
| ANTIPIEMICS, BILE ACID RESINS - DRUGS TO TREAT HIGH CHOLESTEROL | | |
| <i>cholestyramine light oral packet 4 gm</i> | G | |
| <i>cholestyramine light oral powder 4 gm/dose</i> | G | |
| <i>cholestyramine oral packet 4 gm</i> | G | |
| <i>cholestyramine oral powder 4 gm/dose</i> | G | N8 (Listing does not include certain NDCs) |
| <i>colesevelam hcl oral packet 3.75 gm</i> | G | |
| ANTIPIEMICS, CHOLESTEROL ABSORPTION INHIBITOR | | |
| <i>ezetimibe oral tablet 10 mg</i> | G | |
| ANTIPIEMICS, CHOLESTEROL ABSORPTION INHIBITOR - DRUGS TO TREAT HIGH CHOLESTEROL | | |
| ZETIA ORAL TABLET 10 MG (<i>ezetimibe</i>) | NF | |
| ANTIPIEMICS, FIBRATES | | |
| <i>fenofibrate micronized oral capsule 130 mg</i> | NF | |
| <i>fenofibrate micronized oral capsule 43 mg</i> | G | |
| <i>fenofibrate oral capsule 150 mg</i> | G | |
| <i>fenofibrate oral capsule 50 mg</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>fenofibrate oral tablet 120 mg, 40 mg</i> | NF | |
| <i>fenofibrate oral tablet 54 mg</i> | G | |
| <i>fenofibric acid oral capsule delayed release 135 mg, 45 mg</i> | G | |
| <i>fenofibric acid oral tablet 105 mg, 35 mg</i> | G | |
| FENOGLIDE ORAL TABLET 120 MG (<i>fenofibrate</i>) | NF | |
| FIBRICOR ORAL TABLET 105 MG (<i>fenofibric acid</i>) | NF | |
| <i>gemfibrozil oral tablet 600 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| TRICOR ORAL TABLET 145 MG, 48 MG (<i>fenofibrate</i>) | NF | |
| ANTI-LIPEMICS, FIBRATES - DRUGS TO TREAT HIGH CHOLESTEROL | | |
| <i>fenofibrate micronized oral capsule 134 mg, 67 mg</i> | G | |
| <i>fenofibrate oral capsule 200 mg</i> | G | |
| <i>fenofibrate oral tablet 145 mg, 160 mg, 48 mg</i> | G | |
| ANTI-LIPEMICS, HMG-COA REDUCTASE INHIBITORS | | |
| ALTOPREV ORAL TABLET EXTENDED RELEASE 24 HOUR 20 MG, 40 MG, 60 MG (<i>lovastatin</i>) | NF | |
| <i>atorvastatin calcium oral tablet 10 mg, 20 mg</i> | CE | LGC; N7 (G); AL (Min 40 Years and Max 75 Years) |
| <i>atorvastatin calcium oral tablet 40 mg, 80 mg</i> | G | LGC; N8 (Exception process available for \$0 copay for members age 40 through 75 when medically necessary for primary prevention of cardiovascular disease) |
| EZALLOR SPRINKLE ORAL CAPSULE SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG (<i>rosuvastatin calcium</i>) | NF | |
| <i>flolipid oral suspension 20 mg/5ml, 40 mg/5ml</i> | NF | |
| <i>fluvastatin sodium er oral tablet extended release 24 hour 80 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>fluvastatin sodium oral capsule 20 mg, 40 mg</i> | G | |
| LESCOL XL ORAL TABLET EXTENDED RELEASE 24 HOUR 80 MG (<i>fluvastatin sodium</i>) | NF | |
| LIPITOR ORAL TABLET 10 MG, 20 MG, 80 MG (<i>atorvastatin calcium</i>) | NF | |
| LIVALO ORAL TABLET 1 MG, 2 MG, 4 MG (<i>pitavastatin calcium</i>) | NF | |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | G | LGC |
| <i>pravastatin sodium oral tablet 10 mg, 20 mg, 40 mg</i> | G | LGC |
| <i>simvastatin oral tablet 80 mg</i> | G | LGC; N8 (Exception process available for \$0 copay for members age 40 through 75 when medically necessary for primary prevention of cardiovascular disease) |
| ZYPITAMAG ORAL TABLET 2 MG, 4 MG (<i>pitavastatin magnesium</i>) | NF | |
| ANTIPIPEMICS, HMG-COA REDUCTASE INHIBITORS - DRUGS TO TREAT HIGH CHOLESTEROL | | |
| ATORVALIQ ORAL SUSPENSION 20 MG/5ML (<i>atorvastatin calcium</i>) | NF | |
| CRESTOR ORAL TABLET 10 MG, 20 MG, 40 MG, 5 MG (<i>rosuvastatin calcium</i>) | NF | |
| LIPITOR ORAL TABLET 40 MG (<i>atorvastatin calcium</i>) | NF | |
| <i>pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg</i> | NF | |
| <i>pravastatin sodium oral tablet 80 mg</i> | G | LGC |
| <i>rosuvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | G | LGC |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | CE | LGC; N7 (G); AL (Min 40 Years and Max 75 Years) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| ANTIPIPEMICS, HMG-COA REDUCTASE INHIBITORS/COMBINATIONS | | |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg</i> | G | |
| ROSZET ORAL TABLET 10-10 MG, 10-20 MG, 10-40 MG, 10-5 MG (<i>ezetimibe-rosuvastatin</i>) | NF | |
| ANTIPIPEMICS, HMG-COA REDUCTASE INHIBITORS/COMBINATIONS - DRUGS TO TREAT HIGH CHOLESTEROL | | |
| <i>ezetimibe-rosuvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-5 mg</i> | NF | |
| ANTIPIPEMICS, MISCELLANEOUS - DRUGS TO TREAT HIGH CHOLESTEROL | | |
| JUXTAPIID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG (<i>lomitapide mesylate</i>) | NF | |
| <i>niacin er (antihyperlipidemic) oral tablet extended release 1000 mg, 500 mg, 750 mg</i> | G | |
| NIACOR ORAL TABLET 500 MG (<i>niacin (antihyperlipidemic)</i>) | NF | |
| ANTIPIPEMICS, OMEGA-3 FATTY ACIDS | | |
| <i>omega-3-acid ethyl esters oral capsule 1 gm</i> | G | |
| ANTIPIPEMICS, OMEGA-3 FATTY ACIDS - DRUGS TO TREAT HIGH CHOLESTEROL | | |
| <i>icosapent ethyl oral capsule 0.5 gm, 1 gm</i> | G | |
| LOVAZA ORAL CAPSULE 1 GM (<i>omega-3-acid ethyl esters</i>) | NF | |
| VASCEPA ORAL CAPSULE 0.5 GM, 1 GM (<i>icosapent ethyl</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| ANTIPIEMICS, PCSK9 INHIBITORS - DRUGS TO TREAT HIGH CHOLESTEROL | | |
| PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML, 75 MG/ML (<i>alirocumab</i>) | NF | |
| REPATHA PUSHTRONEX SYSTEM SUBCUTANEOUS SOLUTION CARTRIDGE 420 MG/3.5ML (<i>evolocumab</i>) | SP | PA; QL (1 cartridge per 28 days) |
| REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140 MG/ML (<i>evolocumab</i>) | SP | PA; QL (3 syringes per 28 days) |
| REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML (<i>evolocumab</i>) | SP | PA; QL (3 pens per 28 days) |
| BETA-BLOCKER/DIURETIC COMBINATIONS - DRUGS TO TREAT HIGH BLOOD PRESSURE AND HEART CONDITIONS | | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg</i> | G | LGC |
| <i>metoprolol-hydrochlorothiazide oral tablet 100-50 mg</i> | G | |
| BETA-BLOCKER/DIURETIC COMBINATIONS - DRUGS TO TREAT HIGH BLOOD PRESSURE AND HEART CONDITIONS | | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg</i> | G | |
| <i>atenolol-chlorthalidone oral tablet 50-25 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>bisoprolol-hydrochlorothiazide oral tablet 2.5-6.25 mg, 5-6.25 mg</i> | G | LGC |
| <i>metoprolol-hydrochlorothiazide oral tablet 100-25 mg, 50-25 mg</i> | G | |
| BETA-BLOCKERS - DRUGS TO TREAT HIGH BLOOD PRESSURE AND HEART CONDITIONS | | |
| <i>acebutolol hcl oral capsule 200 mg, 400 mg</i> | G | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | G | LGC |
| BETAPACE AF ORAL TABLET 120 MG, 160 MG, 80 MG (<i>sotalol hcl af</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| BETAPACE ORAL TABLET 120 MG, 160 MG, 80 MG (<i>sotalol hcl</i>) | NF | |
| <i>betaxolol hcl oral tablet 10 mg, 20 mg</i> | G | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | G | |
| BYSTOLIC ORAL TABLET 10 MG, 2.5 MG, 20 MG, 5 MG (<i>nebivolol hcl</i>) | NF | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | G | LGC |
| <i>carvedilol phosphate er oral capsule extended release 24 hour 10 mg, 20 mg, 40 mg, 80 mg</i> | G | N8 (Listing does not include certain NDCs) |
| COREG CR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 10 MG, 20 MG, 40 MG, 80 MG (<i>carvedilol phosphate</i>) | NF | |
| INDERAL LA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 160 MG, 60 MG, 80 MG (<i>propranolol hcl</i>) | NF | |
| INDERAL XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 80 MG (<i>propranolol hcl sr beads</i>) | NF | |
| INNOPRAN XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 80 MG (<i>propranolol hcl sr beads</i>) | NF | |
| KAPSPARGO SPRINKLE ORAL CAPSULE ER 24 HOUR SPRINKLE 100 MG, 200 MG, 25 MG, 50 MG (<i>metoprolol succinate</i>) | NF | |
| <i>labetalol hcl oral tablet 100 mg, 200 mg, 300 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>metoprolol succinate er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 50 mg</i> | G | |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg</i> | G | LGC |
| <i>metoprolol tartrate oral tablet 37.5 mg, 75 mg</i> | G | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | G | |
| <i>nebivolol hcl oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | G | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>propranolol hcl er oral capsule extended release 24 hour 120 mg, 160 mg, 60 mg, 80 mg</i> | G | |
| <i>propranolol hcl oral solution 20 mg/5ml, 40 mg/5ml</i> | G | |
| <i>propranolol hcl oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | G | LGC |
| <i>propranolol hcl oral tablet 60 mg</i> | G | |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | G | |
| TOPROL XL ORAL TABLET EXTENDED RELEASE 24 HOUR 100 MG, 200 MG, 25 MG, 50 MG (<i>metoprolol succinate</i>) | NF | |
| CALCIUM CHANNEL BLOCKER/ANTILIPEMIC COMBINATIONS | | |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | G | LGC |
| CALCIUM CHANNEL BLOCKER/ANTILIPEMIC COMBINATIONS - DRUGS TO TREAT HIGH BLOOD PRESSURE AND HEART CONDITIONS | | |
| <i>amlodipine-atorvastatin oral tablet 2.5-10 mg, 2.5-20 mg, 2.5-40 mg</i> | G | LGC |
| CALCIUM CHANNEL BLOCKERS - DRUGS TO TREAT HIGH BLOOD PRESSURE AND HEART CONDITIONS | | |
| <i>amlodipine besylate oral tablet 10 mg, 2.5 mg, 5 mg</i> | G | LGC |
| CARDIZEM CD ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG, 300 MG, 360 MG (<i>diltiazem hcl coated beads</i>) | NF | |
| CARDIZEM LA ORAL TABLET EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG, 300 MG, 360 MG, 420 MG (<i>diltiazem hcl</i>) | NF | |
| CARDIZEM ORAL TABLET 120 MG, 30 MG, 60 MG (<i>diltiazem hcl</i>) | NF | |
| CONJUPRI ORAL TABLET 2.5 MG, 5 MG (<i>levamlodipine maleate</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| diltiazem hcl er beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | G | |
| diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg, 360 mg | G | |
| diltiazem hcl er oral capsule extended release 12 hour 120 mg, 60 mg, 90 mg | G | |
| diltiazem hcl er oral tablet extended release 24 hour 120 mg | NF | |
| diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg | G | LGC |
| dilt-xr oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg | G | |
| felodipine er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg | G | N8 (Listing does not include certain NDCs) |
| isradipine oral capsule 2.5 mg, 5 mg | G | |
| KATERZIA ORAL SUSPENSION 1 MG/ML (amlodipine benzoate) | NF | |
| levamlodipine maleate oral tablet 2.5 mg, 5 mg | NF | |
| diltiazem hcl (Matzim La Oral Tablet Extended Release 24 Hour 180 Mg, 240 Mg, 300 Mg, 360 Mg, 420 Mg) | NF | |
| nicardipine hcl oral capsule 20 mg, 30 mg | G | N8 (Listing does not include certain NDCs) |
| nifedipine er oral tablet extended release 24 hour 30 mg, 60 mg, 90 mg | G | |
| nifedipine er osmotic release oral tablet extended release 24 hour 30 mg, 60 mg, 90 mg | G | N8 (Listing does not include certain NDCs) |
| nifedipine oral capsule 10 mg, 20 mg | G | N8 (Listing does not include certain NDCs) |
| nimodipine oral capsule 30 mg | G | |
| nisoldipine er oral tablet extended release 24 hour 17 mg, 20 mg, 25.5 mg, 30 mg, 34 mg, 40 mg, 8.5 mg | G | |
| NORLIQVA ORAL SOLUTION 1 MG/ML (amlodipine besylate) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| NORVASC ORAL TABLET 10 MG, 2.5 MG, 5 MG (amlodipine besylate) | NF | |
| verapamil hcl er capsule extended release 24 hour 100 mg oral | NF | |
| verapamil hcl er capsule extended release 24 hour 100 mg oral | G | |
| verapamil hcl er oral capsule extended release 24 hour 120 mg, 180 mg, 200 mg, 240 mg, 300 mg, 360 mg | G | |
| verapamil hcl er oral tablet extended release 120 mg | G | LGC |
| verapamil hcl er oral tablet extended release 180 mg, 240 mg | G | |
| verapamil hcl oral tablet 120 mg, 40 mg, 80 mg | G | LGC; N8 (Listing does not include certain NDCs) |
| DIGITALIS GLYCOSIDES - DRUGS TO TREAT HEART CONDITIONS | | |
| digoxin oral solution 0.05 mg/ml | G | |
| digoxin oral tablet 125 mcg, 250 mcg, 62.5 mcg | G | |
| LANOXIN ORAL TABLET 125 MCG, 250 MCG (digoxin) | NF | |
| DIRECT RENIN INHIBITORS/COMBINATIONS - DRUGS TO TREAT HEART CONDITIONS | | |
| aliskiren fumarate oral tablet 150 mg, 300 mg | G | |
| DIURETICS - DRUGS TO TREAT HEART CONDITIONS | | |
| acetazolamide er oral capsule extended release 12 hour 500 mg | G | N8 (Listing does not include certain NDCs) |
| acetazolamide oral tablet 125 mg, 250 mg | G | N8 (Listing does not include certain NDCs) |
| amiloride hcl oral tablet 5 mg | G | |
| amiloride-hydrochlorothiazide oral tablet 5-50 mg | G | LGC |
| bumetanide oral tablet 0.5 mg, 1 mg, 2 mg | G | |
| chlorthalidone oral tablet 25 mg, 50 mg | G | |
| dichlorphenamide oral tablet 50 mg | SP | PA; QL (120 TABLETS per 30 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| DYRENIUM ORAL CAPSULE 100 MG, 50 MG (triamterene) | NF | |
| <i>ethacrynic acid oral tablet 25 mg</i> | G | |
| <i>furosemide oral tablet 20 mg, 40 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| <i>furosemide oral tablet 80 mg</i> | G | LGC |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | G | LGC |
| <i>hydrochlorothiazide oral tablet 12.5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>hydrochlorothiazide oral tablet 25 mg, 50 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | G | |
| KEVEYIS ORAL TABLET 50 MG (<i>dichlorphenamide</i>) | SP | PA; QL (120 TABLETS per 30 DAYs) |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | G | |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | G | |
| SOAANZ ORAL TABLET 20 MG, 40 MG, 60 MG (torsemide) | NF | |
| <i>spironolactone-hctz oral tablet 25-25 mg</i> | G | |
| THALITONE ORAL TABLET 15 MG (<i>chlorthalidone</i>) | NF | |
| <i>torsemide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>triamterene oral capsule 100 mg, 50 mg</i> | G | |
| <i>triamterene-hctz oral capsule 37.5-25 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| <i>triamterene-hctz oral tablet 37.5-25 mg, 75-50 mg</i> | G | LGC |
| HEART FAILURE | | |
| CORLANOR ORAL TABLET 5 MG, 7.5 MG (<i>ivabradine hcl</i>) | PB | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG (<i>sacubitril-valsartan</i>) | PB | |
| INPEFA ORAL TABLET 200 MG, 400 MG (<i>sotagliflozin</i>) | NF | |
| <i>isosorb dinitrate-hydralazine oral tablet 20-37.5 mg</i> | G | |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG (<i>vericiguat</i>) | PB | |
| MISCELLANEOUS | | |
| ASPRUZY SPRINKLE ORAL PACKET 1000 MG, 500 MG (<i>ranolazine</i>) | NF | |
| CAMZYOS ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 5 MG (<i>mavacamten</i>) | SP | PA; QL (30 CAPSULES per 30 days) |
| <i>clonidine hcl er oral tablet extended release 24 hour 0.17 mg</i> | NF | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | G | LGC |
| <i>clonidine transdermal patch weekly 0.1 mg/24hr, 0.2 mg/24hr, 0.3 mg/24hr</i> | G | N8 (Listing does not include certain NDCs) |
| DEMSER ORAL CAPSULE 250 MG (<i>metyrosine</i>) | SP | PA; QL (480 CAPSULES per 30 DAYs) |
| DIBENZYLINE ORAL CAPSULE 10 MG (<i>phenoxybenzamine hcl</i>) | NPB | ST; QL (360 CAPSULES per 25 DAYs) |
| <i>droxidopa oral capsule 100 mg</i> | SP | PA; QL (90 CAPSULES per 30 days) |
| <i>droxidopa oral capsule 200 mg, 300 mg</i> | SP | PA; QL (180 CAPSULES per 30 days) |
| <i>guanfacine hcl oral tablet 1 mg, 2 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>hydralazine hcl oral tablet 10 mg, 100 mg, 50 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>hydralazine hcl oral tablet 25 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| LODOCORAL TABLET 0.5 MG (<i>colchicine</i>) | NF | |
| <i>methyldopa oral tablet 250 mg, 500 mg</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-----------------------------------|
| metyrosine oral capsule 250 mg | SP | PA; QL (480 CAPSULES per 30 days) |
| midodrine hcl oral tablet 10 mg, 2.5 mg, 5 mg | G | |
| minoxidil oral tablet 10 mg, 2.5 mg | G | |
| NEXICLON XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.17 MG (clonidine hcl) | NF | |
| NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG (droxidopa) | NF | |
| phenoxybenzamine hcl oral capsule 10 mg | G | |
| ranolazine er oral tablet extended release 12 hour 1000 mg, 500 mg | G | |
| VECAMYL ORAL TABLET 2.5 MG (mecamylamine hcl) | NPB | PA |
| VYNDAMAX ORAL CAPSULE 61 MG (tafamidis) | SP | PA; QL (30 CAPSULES per 30 days) |
| VYNDAQEL ORAL CAPSULE 20 MG (tafamidis meglumine (cardiac)) | NF | |
| NITRATES - DRUGS TO TREAT HEART CONDITIONS | | |
| ISORDIL TITRADOSE ORAL TABLET 40 MG, 5 MG (isosorbide dinitrate) | NF | |
| isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg | G | |
| isosorbide dinitrate oral tablet 40 mg | NF | |
| isosorbide mononitrate er oral tablet extended release 24 hour 120 mg, 30 mg, 60 mg | G | |
| isosorbide mononitrate oral tablet 10 mg, 20 mg | G | |
| nitroglycerin sublingual tablet sublingual 0.3 mg, 0.4 mg, 0.6 mg | G | |
| nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr | G | |
| nitroglycerin translingual solution 0.4 mg/spray | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| PULMONARY ARTERIAL HYPERTENSION - DRUGS TO TREAT PULMONARY HYPERTENSION | | |
| ADCIRCA ORAL TABLET 20 MG (<i>tadalafil (pah)</i>) | NF | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG (<i>riociguat</i>) | SP | PA; QL (90 TABLETS per 30 DAYs) |
| <i>tadalafil (pah)</i> (Alyq Oral Tablet 20 Mg) | SP | PA; QL (60 TABLETS per 30 days) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | SP | PA; QL (30 TABLETS per 30 DAYs) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | SP | PA; QL (60 TABLETS per 30 days) |
| <i>epoprostenol sodium intravenous solution reconstituted 0.5 mg, 1.5 mg</i> | SP | PA |
| FLOLAN INTRAVENOUS SOLUTION RECONSTITUTED 0.5 MG, 1.5 MG (<i>epoprostenol sodium</i>) | SP | PA |
| LETAIRIS ORAL TABLET 10 MG, 5 MG (<i>ambrisentan</i>) | NF | |
| LIQREV ORAL SUSPENSION 10 MG/ML (<i>sildenafil citrate</i>) | NF | |
| OPSUMIT ORAL TABLET 10 MG (<i>macitentan</i>) | SP | PA; QL (30 TABLETS per 30 DAYs) |
| OPSYNVI ORAL TABLET 10-20 MG, 10-40 MG (<i>macitentan-tadalafil</i>) | NF | |
| ORENITRAM MONTH 1 ORAL TABLET EXTENDED RELEASE THERAPY PACK 0.125 & 0.25 MG (<i>treprostинil diolamine</i>) | SP | PA |
| ORENITRAM MONTH 2 ORAL TABLET EXTENDED RELEASE THERAPY PACK 0.125 & 0.25 MG (<i>treprostинil diolamine</i>) | SP | PA |
| ORENITRAM MONTH 3 ORAL TABLET EXTENDED RELEASE THERAPY PACK 0.125 & 0.25 &1 MG (<i>treprostинil diolamine</i>) | SP | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG (<i>treprostинil diolamine</i>) | SP | PA |
| REMODULIN INJECTION SOLUTION 100 MG/20ML, 20 MG/20ML, 200 MG/20ML, 50 MG/20ML (<i>treprostинil</i>) | NF | |
| REVATIO ORAL SUSPENSION RECONSTITUTED 10 MG/ML (<i>sildenafil citrate</i>) | NF | |
| REVATIO ORAL TABLET 20 MG (<i>sildenafil citrate</i>) | NF | |
| <i>sildenafil citrate oral suspension reconstituted 10 mg/ml</i> | SP | PA; QL (784 ML per 30 days) |
| <i>sildenafil citrate oral tablet 20 mg</i> | G | PA; QL (360 TABLETS per 30 days) |
| <i>tadalafil (pah) oral tablet 20 mg</i> | SP | PA; QL (60 TABLETS per 30 DAYS) |
| TADLIQ ORAL SUSPENSION 20 MG/5ML (<i>tadalafil (pah)</i>) | SP | PA; QL (300 ML per 30 days) |
| TRACLEER ORAL TABLET 125 MG, 62.5 MG (<i>bosentan</i>) | NF | |
| TRACLEER ORAL TABLET SOLUBLE 32 MG (<i>bosentan</i>) | NF | |
| <i>treprostинil injection solution 100 mg/20ml, 20 mg/20ml, 200 mg/20ml, 50 mg/20ml</i> | SP | PA |
| TYVASO DPI MAINTENANCE KIT INHALATION POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG (<i>treprostинil</i>) | NF | |
| TYVASO DPI TITRATION KIT INHALATION POWDER 112 X 16MCG & 84 X 32MCG, 16 & 32 & 48 MCG (<i>treprostинil</i>) | NF | |
| TYVASO INHALATION SOLUTION 0.6 MG/ML (<i>treprostинil</i>) | SP | PA; QL (28 AMPULES per 28 DAYS) |
| TYVASO REFILL INHALATION SOLUTION 0.6 MG/ML (<i>treprostинil</i>) | SP | PA; QL (28 AMPULES per 28 DAYS) |
| TYVASO STARTER INHALATION SOLUTION 0.6 MG/ML (<i>treprostинil</i>) | SP | PA; QL (28 AMPULES per 28 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 400 MCG, 600 MCG, 800 MCG (<i>selexipag</i>) | SP | PA; QL (60 TABLETS per 30 DAYs) |
| UPTRAVI ORAL TABLET 200 MCG (<i>selexipag</i>) | SP | PA; QL (140 TABLETS per 28 DAYs) |
| UPTRAVI TITRATION ORAL TABLET THERAPY PACK 200 & 800 MCG (<i>selexipag</i>) | SP | PA; QL (1 PACK per 28 DAYs) |
| VELETRI INTRAVENOUS SOLUTION RECONSTITUTED 0.5 MG, 1.5 MG (<i>epoprostenol sodium</i>) | SP | PA |
| VENTAVIS INHALATION SOLUTION 10 MCG/ML, 20 MCG/ML (<i>iloprost</i>) | SP | PA; QL (270 AMPULES per 30 DAYs) |
| WINREVAIR SUBCUTANEOUS KIT 2 X 45 MG, 2 X 60 MG, 45 MG, 60 MG (<i>sotatercept-csrk</i>) | NF | |
| CENTRAL NERVOUS SYSTEM - DRUGS TO TREAT NERVOUS SYSTEM DISORDERS | | |
| ALCOHOL DETERRENTS | | |
| acamprosate calcium oral tablet delayed release 333 mg | G | |
| disulfiram oral tablet 250 mg | G | |
| disulfiram oral tablet 500 mg | NF | |
| ANTIANXIETY - DRUGS TO TREAT ANXIETY | | |
| alprazolam er oral tablet extended release 24 hour 0.5 mg, 1 mg, 2 mg | G | QL (150 TABLETS per 25 DAYs) |
| alprazolam er oral tablet extended release 24 hour 3 mg | G | QL (90 TABLETS per 25 DAYs) |
| ALPRAZOLAM INTENSOL ORAL CONCENTRATE 1 MG/ML (<i>alprazolam</i>) | NPB | QL (300 ML per 25 DAYs) |
| alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg | G | QL (150 TABLETS per 25 DAYs) |
| alprazolam oral tablet dispersible 0.25 mg, 0.5 mg, 1 mg, 2 mg | G | QL (150 TABLETS per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ANAFRANIL ORAL CAPSULE 25 MG, 50 MG <i>(clomipramine hcl)</i> | NPB | QLR (QL applies to members age 65 and older); QL (150 CAPSULES per 25 days); AL (Max 65 Years) |
| ANAFRANIL ORAL CAPSULE 75 MG <i>(clomipramine hcl)</i> | NPB | QLR (QL applies to members age 65 and older); QL (90 CAPSULES per 25 days); AL (Max 65 Years) |
| ATIVAN ORAL TABLET 0.5 MG, 1 MG, 2 MG <i>(lorazepam)</i> | NF | |
| <i>buspirone hcl oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | G | |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | G | N8 (Listing does not include certain NDCs); QL (360 CAPSULES per 25 DAYS) |
| <i>clomipramine hcl oral capsule 25 mg, 50 mg</i> | G | QLR (QL applies to members age 65 and older); QL (150 CAPSULES per 25 days); AL (Max 65 Years) |
| <i>clomipramine hcl oral capsule 75 mg</i> | G | QLR (QL applies to members age 65 and older); QL (90 CAPSULES per 25 days); AL (Max 65 Years) |
| <i>fluvoxamine maleate er oral capsule extended release 24 hour 100 mg, 150 mg</i> | G | |
| <i>fluvoxamine maleate oral tablet 100 mg, 25 mg, 50 mg</i> | G | |
| <i>lorazepam (Lorazepam Intensol Oral Concentrate 2 Mg/ML)</i> | G | N8 (Listing does not include certain NDCs); QL (150 ML per 25 DAYS) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i> | G | QL (150 TABLETS per 25 days) |
| <i>lorazepam oral tablet 2 mg</i> | G | QL (150 TABLETS per 25 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| LOREEV XR ORAL CAPSULE ER 24 HOUR SPRINKLE 1 MG, 1.5 MG, 2 MG (<i>lorazepam</i>) | NPB | QL (150 CAPSULES per 25 days) |
| LOREEV XR ORAL CAPSULE ER 24 HOUR SPRINKLE 3 MG (<i>lorazepam</i>) | NPB | QL (90 CAPSULES per 25 days) |
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | G | QL (120 CAPSULES per 25 DAYs) |
| XANAX ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG (<i>alprazolam</i>) | NF | |
| XANAX XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.5 MG, 1 MG, 2 MG, 3 MG (<i>alprazolam</i>) | NF | |
| ANTIDEMENTIA - DRUGS TO TREAT DEMENTIA AND MEMORY LOSS | | |
| ADLARITY TRANSDERMAL PATCH WEEKLY 10 MG/DAY, 5 MG/DAY (<i>donepezil hcl</i>) | NF | |
| <i>donepezil hcl oral tablet 10 mg, 23 mg, 5 mg</i> | G | |
| <i>donepezil hcl oral tablet dispersible 10 mg, 5 mg</i> | G | |
| <i>ergoloid mesylates oral tablet 1 mg</i> | G | STX |
| <i>galantamine hydrobromide er oral capsule extended release 24 hour 16 mg, 24 mg, 8 mg</i> | G | |
| <i>galantamine hydrobromide oral solution 4 mg/ml</i> | G | |
| <i>galantamine hydrobromide oral tablet 12 mg, 4 mg, 8 mg</i> | G | |
| <i>memantine hcl er oral capsule extended release 24 hour 14 mg, 21 mg, 28 mg, 7 mg</i> | G | |
| <i>memantine hcl oral solution 2 mg/ml</i> | G | |
| <i>memantine hcl oral tablet 10 mg, 5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>memantine hcl oral tablet 28 x 5 mg & 21 x 10 mg</i> | G | |
| NAMENDA XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 14 MG, 21 MG, 28 MG (<i>memantine hcl</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| NAMZARIC ORAL CAPSULE ER 24 HOUR THERAPY PACK 7 & 14 & 21 &28 -10 MG (<i>memantine hcl-donepezil hcl</i>) | PB | |
| NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG (<i>memantine hcl-donepezil hcl</i>) | PB | |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | G | |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24hr, 4.6 mg/24hr, 9.5 mg/24hr</i> | G | |
| ANTIDEPRESSANTS - DRUGS TO TREAT DEPRESSION | | |
| <i>amitriptyline hcl oral tablet 10 mg</i> | G | QLR (QL applies to members age 65 and older); QL (150 TABLETS per 25 days); AL (Max 65 Years) |
| <i>amitriptyline hcl oral tablet 100 mg, 150 mg, 75 mg</i> | G | N8 (Members 65 and older subject to PA); AL (Max 65 Years) |
| <i>amitriptyline hcl oral tablet 25 mg</i> | G | QLR (QL applies to members age 65 and older); QL (60 TABLETS per 25 days); AL (Max 65 Years) |
| <i>amitriptyline hcl oral tablet 50 mg</i> | G | QLR (QL applies to members age 65 and older); QL (30 TABLETS per 25 days); AL (Max 65 Years) |
| <i>amoxapine oral tablet 100 mg, 25 mg, 50 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (90 TABLETS per 25 days); AL (Max 65 Years) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>amoxapine oral tablet 150 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (60 TABLETS per 25 days); AL (Max 65 Years) |
| APLENZIN ORAL TABLET EXTENDED RELEASE 24 HOUR 174 MG, 348 MG, 522 MG (<i>bupropion hbr</i>) | NF | |
| AUVELITY ORAL TABLET EXTENDED RELEASE 45-105 MG (<i>dextromethorphan-bupropion</i>) | NF | |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg, 150 mg, 200 mg</i> | G | |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg, 300 mg</i> | G | |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 450 mg</i> | NF | |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>citalopram hydrobromide oral capsule 30 mg</i> | NF | |
| <i>citalopram hydrobromide oral solution 10 mg/5ml</i> | G | |
| <i>citalopram hydrobromide oral tablet 10 mg, 20 mg, 40 mg</i> | G | LGC |
| CYMBALTA ORAL CAPSULE DELAYED RELEASE PARTICLES 20 MG, 30 MG, 60 MG (<i>duloxetine hcl</i>) | NF | |
| <i>desipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (90 TABLETS per 25 days); AL (Max 65 Years) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>desipramine hcl oral tablet 100 mg, 150 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (30 TABLETS per 25 days); AL (Max 65 Years) |
| <i>desipramine hcl oral tablet 75 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (60 TABLETS per 25 days); AL (Max 65 Years) |
| <i>desvenlafaxine er oral tablet extended release 24 hour 100 mg</i> | NF | |
| <i>desvenlafaxine er tablet extended release 24 hour 50 mg oral</i> | NF | |
| <i>desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg</i> | G | |
| <i>doxepin hcl oral capsule 10 mg, 25 mg, 50 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (90 CAPSULES per 25 days); AL (Max 65 Years) |
| <i>doxepin hcl oral capsule 100 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (30 CAPSULES per 25 days); AL (Max 65 Years) |
| <i>doxepin hcl oral capsule 150 mg</i> | G | QLR (QL applies to members age 65 and older); QL (30 CAPSULES per 25 days); AL (Max 65 Years) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>doxepin hcl oral capsule 75 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (60 CAPSULES per 25 days); AL (Max 65 Years) |
| <i>doxepin hcl oral concentrate 10 mg/ml</i> | G | QLR (QL applies to members age 65 and older); QL (450 ML per 25 days); AL (Max 65 Years) |
| <i>duloxetine hcl oral capsule delayed release particles 20 mg, 30 mg, 40 mg, 60 mg</i> | G | |
| EFFEXOR XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 150 MG, 37.5 MG, 75 MG (venlafaxine hcl) | NF | |
| <i>escitalopram oxalate oral solution 5 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> | G | |
| FETZIMA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 20 MG, 40 MG, 80 MG (levomilnacipran hcl) | NF | |
| FETZIMA TITRATION ORAL CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG (levomilnacipran hcl) | NF | |
| <i>fluoxetine hcl (pmdd) oral tablet 10 mg, 20 mg</i> | NF | |
| <i>fluoxetine hcl oral capsule 10 mg, 20 mg, 40 mg</i> | G | LGC |
| <i>fluoxetine hcl oral capsule delayed release 90 mg</i> | G | |
| <i>fluoxetine hcl oral solution 20 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>fluoxetine hcl oral tablet 10 mg, 20 mg</i> | G | |
| <i>fluoxetine hcl oral tablet 60 mg</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>imipramine hcl oral tablet 10 mg</i> | G | QLR (QL applies to members age 65 and older); QL (120 TABLETS per 25 days); AL (Max 65 Years) |
| <i>imipramine hcl oral tablet 25 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (120 TABLETS per 25 days); AL (Max 65 Years) |
| <i>imipramine hcl oral tablet 50 mg</i> | G | QLR (QL applies to members age 65 and older); QL (60 TABLETS per 25 days); AL (Max 65 Years) |
| <i>imipramine pamoate oral capsule 100 mg, 75 mg</i> | G | QLR (QL applies to members age 65 and older); QL (30 CAPSULES per 25 days); AL (Max 65 Years) |
| <i>imipramine pamoate oral capsule 125 mg, 150 mg</i> | G | AL (Max 65 Years) |
| LEXAPRO ORAL TABLET 10 MG, 20 MG, 5 MG (escitalopram oxalate) | NF | |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg, 7.5 mg</i> | G | |
| <i>mirtazapine oral tablet dispersible 15 mg, 30 mg, 45 mg</i> | G | |
| <i>nefazodone hcl oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | G | STX |
| NORPRAMIN ORAL TABLET 10 MG, 25 MG (desipramine hcl) | NPB | QLR (QL applies to members age 65 and older); QL (90 TABLETS per 25 days); AL (Max 65 Years) |
| <i>nortriptyline hcl oral capsule 10 mg</i> | G | QLR (QL applies to members age 65 and older); QL (150 CAPSULES per 25 days); AL (Max 65 Years) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>nortriptyline hcl oral capsule 25 mg</i> | G | QLR (QL applies to members age 65 and older); QL (60 CAPSULES per 25 days); AL (Max 65 Years) |
| <i>nortriptyline hcl oral capsule 50 mg</i> | G | QLR (QL applies to members age 65 and older); QL (30 CAPSULES per 25 days); AL (Max 65 Years) |
| <i>nortriptyline hcl oral capsule 75 mg</i> | G | AL (Max 65 Years) |
| <i>nortriptyline hcl oral solution 10 mg/5ml</i> | G | QLR (QL applies to members age 65 and older); QL (750 ML per 25 days); AL (Max 65 Years) |
| PAMELOR ORAL CAPSULE 10 MG (<i>nortriptyline hcl</i>) | NPB | QLR (QL applies to members age 65 and older); QL (150 CAPSULES per 25 days); AL (Max 65 Years) |
| PAMELOR ORAL CAPSULE 25 MG (<i>nortriptyline hcl</i>) | NPB | QLR (QL applies to members age 65 and older); QL (60 CAPSULES per 25 days); AL (Max 65 Years) |
| PAMELOR ORAL CAPSULE 50 MG (<i>nortriptyline hcl</i>) | NPB | QLR (QL applies to members age 65 and older); QL (30 CAPSULES per 25 days); AL (Max 65 Years) |
| PAMELOR ORAL CAPSULE 75 MG (<i>nortriptyline hcl</i>) | NPB | AL (Max 65 Years) |
| <i>paroxetine hcl er oral tablet extended release 24 hour 12.5 mg, 25 mg</i> | G | |
| <i>paroxetine hcl er oral tablet extended release 24 hour 37.5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>paroxetine hcl oral suspension 10 mg/5ml</i> | NF | |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg, 40 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>paroxetine mesylate oral capsule 7.5 mg</i> | NF | |
| PAXIL CR ORAL TABLET EXTENDED RELEASE 24 HOUR 12.5 MG, 25 MG, 37.5 MG (<i>paroxetine hcl</i>) | NF | |
| PAXIL ORAL SUSPENSION 10 MG/5ML (<i>paroxetine hcl</i>) | NF | |
| PAXIL ORAL TABLET 10 MG, 20 MG, 30 MG, 40 MG (<i>paroxetine hcl</i>) | NF | |
| <i>phenelzine sulfate oral tablet 15 mg</i> | G | |
| PRISTIQ ORAL TABLET EXTENDED RELEASE 24 HOUR 100 MG, 25 MG, 50 MG (<i>desvenlafaxine succinate</i>) | NF | |
| <i>protriptyline hcl oral tablet 10 mg</i> | G | QLR (QL applies to members age 65 and older); QL (60 TABLETS per 25 days); AL (Max 65 Years) |
| <i>protriptyline hcl oral tablet 5 mg</i> | G | QLR (QL applies to members age 65 and older); QL (90 TABLETS per 25 days); AL (Max 65 Years) |
| PROZAC ORAL CAPSULE 10 MG, 20 MG, 40 MG (<i>fluoxetine hcl</i>) | NF | |
| <i>sertraline hcl oral capsule 150 mg, 200 mg</i> | NF | |
| <i>sertraline hcl oral concentrate 20 mg/ml</i> | G | |
| <i>sertraline hcl oral tablet 100 mg, 25 mg, 50 mg</i> | G | LGC |
| SPRAVATO (56 MG DOSE) NASAL SOLUTION THERAPY PACK 28 MG/DEVICE (<i>esketamine hcl</i>) | SP | PA |
| SPRAVATO (84 MG DOSE) NASAL SOLUTION THERAPY PACK 28 MG/DEVICE (<i>esketamine hcl</i>) | SP | PA |
| <i>tranylcypromine sulfate oral tablet 10 mg</i> | G | |
| <i>trazodone hcl oral tablet 100 mg, 150 mg, 300 mg, 50 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>trimipramine maleate oral capsule 100 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (30 CAPSULES per 25 days); AL (Max 65 Years) |
| <i>trimipramine maleate oral capsule 25 mg, 50 mg</i> | G | QLR (QL applies to members age 65 and older); N8 (Listing does not include certain NDCs); QL (60 CAPSULES per 25 days); AL (Max 65 Years) |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG (vortioxetine hbr) | PB | ST |
| <i>venlafaxine besylate er oral tablet extended release 24 hour 112.5 mg</i> | NF | |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 150 mg, 37.5 mg, 75 mg</i> | G | |
| <i>venlafaxine hcl er oral tablet extended release 24 hour 150 mg, 37.5 mg, 75 mg</i> | NF | |
| <i>venlafaxine hcl er oral tablet extended release 24 hour 225 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>venlafaxine hcl oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | G | |
| VIBRYD ORAL TABLET 10 MG, 20 MG, 40 MG (vilazodone hcl) | NF | |
| <i>vilazodone hcl oral tablet 10 mg, 20 mg, 40 mg</i> | NF | |
| WELLBUTRIN XL ORAL TABLET EXTENDED RELEASE 24 HOUR 150 MG, 300 MG (bupropion hcl) | NF | |
| ZOLOFT ORAL CONCENTRATE 20 MG/ML (sertraline hcl) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| ZOLOFT ORAL TABLET 100 MG, 25 MG, 50 MG <i>(sertraline hcl)</i> | NF | |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG (<i>zuranolone</i>) | SP | PA; QL (28 CAPSULES per 14 DAYs) |
| ZURZUVAE ORAL CAPSULE 30 MG (<i>zuranolone</i>) | SP | PA; QL (14 CAPSULES per 14 DAYs) |
| ANTIPARKINSONIAN AGENTS - DRUGS TO TREAT PARKINSONS DISEASE | | |
| <i>amantadine hcl oral capsule 100 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>amantadine hcl oral solution 50 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>amantadine hcl oral tablet 100 mg</i> | G | |
| APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE 30 MG/3ML (<i>apomorphine hcl</i>) | NF | |
| <i>apomorphine hcl subcutaneous solution cartridge 30 mg/3ml</i> | NF | |
| <i>benztropine mesylate oral tablet 0.5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>benztropine mesylate oral tablet 1 mg, 2 mg</i> | G | |
| <i>bromocriptine mesylate oral capsule 5 mg</i> | G | |
| <i>bromocriptine mesylate oral tablet 2.5 mg</i> | G | |
| <i>carbidopa oral tablet 25 mg</i> | G | |
| <i>carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg</i> | G | |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> | G | |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | G | |
| DHIVY ORAL TABLET 25-100 MG (<i>carbidopa-levodopa</i>) | NPB | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-----------------------------------|
| DUOPA ENTERAL SUSPENSION 4.63-20 MG/ML (carbidopa-levodopa) | SP | PA |
| entacapone oral tablet 200 mg | G | |
| GOCOVRI ORAL CAPSULE EXTENDED RELEASE 24 HOUR 137 MG, 68.5 MG (amantadine hcl) | NF | |
| INBRIJA INHALATION CAPSULE 42 MG (levodopa) | SP | PA; QL (300 CAPSULES per 30 DAYS) |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24HR, 2 MG/24HR, 3 MG/24HR, 4 MG/24HR, 6 MG/24HR, 8 MG/24HR (rotigotine) | PB | |
| NOURIANZ ORAL TABLET 20 MG, 40 MG (istradefylline) | NF | |
| ONGENTYS ORAL CAPSULE 25 MG, 50 MG (opicapone) | NF | |
| OSMOLEX ER ORAL TABLET EXTENDED RELEASE 24 HOUR 129 MG, 193 MG (amantadine hcl) | NF | |
| pramipexole dihydrochloride er oral tablet extended release 24 hour 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg | G | |
| pramipexole dihydrochloride oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg | G | |
| rasagiline mesylate oral tablet 0.5 mg, 1 mg | G | |
| ropinirole hcl er oral tablet extended release 24 hour 12 mg, 2 mg, 4 mg, 6 mg, 8 mg | G | |
| ropinirole hcl oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg | G | |
| RYTARY ORAL CAPSULE EXTENDED RELEASE 23.75-95 MG, 36.25-145 MG, 48.75-195 MG, 61.25-245 MG (carbidopa-levodopa) | PB | |
| selegiline hcl oral capsule 5 mg | G | |
| selegiline hcl oral tablet 5 mg | G | |
| SINEMET ORAL TABLET 10-100 MG, 25-100 MG (carbidopa-levodopa) | NPB | |
| tolcapone oral tablet 100 mg | G | STX |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>trihexyphenidyl hcl oral solution 0.4 mg/ml</i> | G | |
| <i>trihexyphenidyl hcl oral tablet 2 mg, 5 mg</i> | G | |
| XADAGO ORAL TABLET 100 MG, 50 MG (<i>safinamide mesylate</i>) | NF | |
| ZELAPAR ORAL TABLET DISPERSIBLE 1.25 MG (<i>selegiline hcl</i>) | NF | |
| ANTIPSYCHOTICS - DRUGS TO TREAT PSYCHOSES | | |
| ABILIFY ASIMTUFII INTRAMUSCULAR PREFILLED SYRINGE 720 MG/2.4ML, 960 MG/3.2ML (<i>aripiprazole</i>) | NF | |
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300 MG, 400 MG (<i>aripiprazole</i>) | PB | |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300 MG, 400 MG (<i>aripiprazole</i>) | PB | |
| ABILIFY ORAL TABLET 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG (<i>aripiprazole</i>) | NF | |
| <i>aripiprazole oral solution 1 mg/ml</i> | G | |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> | G | |
| <i>aripiprazole oral tablet dispersible 10 mg, 15 mg</i> | G | |
| ARISTADA INITIO INTRAMUSCULAR PREFILLED SYRINGE 675 MG/2.4ML (<i>aripiprazole lauroxil</i>) | NPB | |
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 1064 MG/3.9ML, 441 MG/1.6ML, 662 MG/2.4ML, 882 MG/3.2ML (<i>aripiprazole lauroxil</i>) | NPB | |
| <i>asenapine maleate sublingual tablet sublingual 10 mg, 2.5 mg, 5 mg</i> | G | |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG (<i>lumateperone tosylate</i>) | NPB | |
| <i>chlorpromazine hcl oral concentrate 100 mg/ml, 30 mg/ml</i> | NF | |
| <i>chlorpromazine hcl oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | G | |
| <i>clozapine oral tablet dispersible 100 mg, 12.5 mg, 150 mg, 200 mg, 25 mg</i> | G | |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG (<i>iloperidone</i>) | NPB | ST |
| FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6 MG (<i>iloperidone</i>) | NPB | ST |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | G | |
| <i>fluphenazine hcl oral elixir 2.5 mg/5ml</i> | G | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | G | |
| GEODON INTRAMUSCULAR SOLUTION RECONSTITUTED 20 MG (<i>ziprasidone mesylate</i>) | NF | |
| GEODON ORAL CAPSULE 20 MG, 40 MG, 60 MG, 80 MG (<i>ziprasidone hcl</i>) | NF | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | G | |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | G | |
| INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1092 MG/3.5ML, 1560 MG/5ML (<i>paliperidone palmitate</i>) | NF | |
| INVEGA ORAL TABLET EXTENDED RELEASE 24 HOUR 3 MG, 9 MG (<i>paliperidone</i>) | NPB | PA; QL (30 TABLETS per 25 DAYS) |
| INVEGA ORAL TABLET EXTENDED RELEASE 24 HOUR 6 MG (<i>paliperidone</i>) | NPB | PA; QL (60 TABLETS per 25 DAYS) |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546 MG/1.75ML, 819 MG/2.63ML (<i>paliperidone palmitate</i>) | NF | |
| LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG (<i>lurasidone hcl</i>) | NF | |
| <i>loxapine succinate oral capsule 10 mg, 5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>loxapine succinate oral capsule 25 mg, 50 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>lurasidone hcl oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | G | |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG (olanzapine-samidorphan) | NF | |
| NUPLAZID ORAL CAPSULE 34 MG (pimavanserin tartrate) | SP | PA; QL (30 CAPSULES per 30 days) |
| NUPLAZID ORAL TABLET 10 MG (pimavanserin tartrate) | SP | PA; QL (30 TABLETS per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg</i> | G | |
| <i>olanzapine oral tablet dispersible 10 mg, 15 mg, 20 mg, 5 mg</i> | G | |
| <i>paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 6 mg, 9 mg</i> | G | |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | G | |
| PERSERIS SUBCUTANEOUS PREFILLED SYRINGE 120 MG, 90 MG (risperidone) | PB | |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> | G | |
| <i>quetiapine fumarate oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> | G | |
| <i>quetiapine fumarate oral tablet 150 mg</i> | NF | |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG (brexpiprazole) | NPB | PA; QL (30 TABLETS per 30 days) |
| <i>risperidone microspheres er intramuscular suspension reconstituted er 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | G | |
| <i>risperidone oral solution 1 mg/ml</i> | G | |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 2 mg, 3 mg, 4 mg</i> | G | |
| <i>risperidone oral tablet 1 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>risperidone oral tablet dispersible 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| RYKINDO INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 25 MG, 37.5 MG, 50 MG (<i>risperidone</i>) | NF | |
| SAPHRIS SUBLINGUAL TABLET SUBLINGUAL 10 MG, 2.5 MG, 5 MG (<i>asenapine maleate</i>) | NPB | |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24HR, 5.7 MG/24HR, 7.6 MG/24HR (<i>asenapine</i>) | NF | |
| SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150 MG, 200 MG, 300 MG, 400 MG, 50 MG (<i>quetiapine fumarate</i>) | NF | |
| <i>thioridazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | G | |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | G | |
| <i>trifluoperazine hcl oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | G | |
| UZEDY SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 100 MG/0.28ML, 125 MG/0.35ML, 150 MG/0.42ML, 200 MG/0.56ML, 250 MG/0.7ML, 50 MG/0.14ML, 75 MG/0.21ML (<i>risperidone</i>) | NF | |
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG (<i>cariprazine hcl</i>) | PB | PA; QL (60 CAPSULES per 25 days) |
| VRAYLAR ORAL CAPSULE 4.5 MG, 6 MG (<i>cariprazine hcl</i>) | PB | PA; QL (30 CAPSULES per 25 days) |
| VRAYLAR ORAL CAPSULE THERAPY PACK 1.5 & 3 MG (<i>cariprazine hcl</i>) | PB | PA; QL (60 CAPSULES per 25 days) |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> | G | |
| <i>ziprasidone mesylate intramuscular solution reconstituted 20 mg</i> | G | |
| ANTISEIZURE AGENTS - DRUGS TO TREAT SEIZURES | | |
| APTIOM ORAL TABLET 200 MG, 400 MG, 600 MG, 800 MG (<i>eslicarbazepine acetate</i>) | PB | |
| BANZEL ORAL SUSPENSION 40 MG/ML (<i>rufinamide</i>) | NF | |
| BANZEL ORAL TABLET 200 MG, 400 MG (<i>rufinamide</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| BRIVIACT ORAL SOLUTION 10 MG/ML (<i>brivaracetam</i>) | NPB | PA |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG (<i>brivaracetam</i>) | NPB | PA |
| <i>carbamazepine er oral capsule extended release 12 hour 100 mg, 200 mg, 300 mg</i> | G | |
| <i>carbamazepine er oral tablet extended release 12 hour 100 mg, 200 mg, 400 mg</i> | G | |
| <i>carbamazepine oral suspension 100 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>carbamazepine oral tablet 200 mg</i> | G | |
| <i>carbamazepine oral tablet chewable 100 mg</i> | G | |
| <i>clobazam oral suspension 2.5 mg/ml</i> | G | |
| <i>clobazam oral tablet 10 mg, 20 mg</i> | G | |
| <i>clonazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | G | N8 (Listing does not include certain NDCs); QL (300 TABLETS per 25 days) |
| <i>clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | G | QL (300 TABLETS per 25 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | G | QL (180 TABLETS per 25 days) |
| DEPAKOTE ER ORAL TABLET EXTENDED RELEASE 24 HOUR 250 MG, 500 MG (<i>divalproex sodium</i>) | NF | |
| DEPAKOTE ORAL TABLET DELAYED RELEASE 125 MG, 250 MG, 500 MG (<i>divalproex sodium</i>) | NF | |
| DEPAKOTE SPRINKLES ORAL CAPSULE DELAYED RELEASE SPRINKLE 125 MG (<i>divalproex sodium</i>) | NF | |
| DIACOMIT ORAL CAPSULE 250 MG, 500 MG (<i>stiripentol</i>) | NF | |
| DIACOMIT ORAL PACKET 250 MG, 500 MG (<i>stiripentol</i>) | NF | |
| DIASTAT ACUDIAL RECTAL GEL 10 MG, 20 MG (<i>diazepam</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| diazepam (Diazepam Intensol Oral Concentrate 5 Mg/Ml) | G | QL (240 ML per 25 days) |
| diazepam oral solution 5 mg/5ml | G | QL (1200 ML per 25 days) |
| diazepam oral tablet 10 mg, 2 mg, 5 mg | G | QL (120 TABLETS per 25 days) |
| diazepam rectal gel 10 mg, 2.5 mg, 20 mg | G | |
| DILANTIN INFATABS ORAL TABLET CHEWABLE 50 MG (<i>phenytoin</i>) | NF | |
| DILANTIN ORAL CAPSULE 100 MG, 30 MG (<i>phenytoin sodium extended</i>) | NF | |
| DILANTIN ORAL SUSPENSION 125 MG/5ML (<i>phenytoin</i>) | NF | |
| divalproex sodium er oral tablet extended release 24 hour 250 mg, 500 mg | G | |
| divalproex sodium oral capsule delayed release sprinkle 125 mg | G | |
| divalproex sodium oral tablet delayed release 125 mg, 500 mg | G | |
| divalproex sodium oral tablet delayed release 250 mg | G | N8 (Listing does not include certain NDCs) |
| ELEPSIA XR ORAL TABLET EXTENDED RELEASE 24 HOUR 1000 MG, 1500 MG (<i>levetiracetam</i>) | NF | |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML (<i>cannabidiol</i>) | SP | PA; QL (800 ML per 30 days) |
| EPRONTIA ORAL SOLUTION 25 MG/ML (<i>topiramate</i>) | NF | |
| ethosuximide oral capsule 250 mg | G | |
| ethosuximide oral solution 250 mg/5ml | G | |
| felbamate oral suspension 600 mg/5ml | G | |
| felbamate oral tablet 400 mg, 600 mg | G | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML (<i>fenfluramine hcl</i>) | NF | |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML (<i>perampanel</i>) | PB | |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG (<i>perampanel</i>) | PB | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>gabapentin oral capsule 100 mg, 300 mg, 400 mg</i> | G | QL (6 CAPSULES per 1 day) |
| <i>gabapentin oral solution 250 mg/5ml</i> | G | QL (72 ML per 1 day) |
| <i>gabapentin oral tablet 600 mg</i> | G | QL (6 TABLETS per 1 day) |
| <i>gabapentin oral tablet 800 mg</i> | G | QL (4 TABLETS per 1 day) |
| KEPPRA ORAL SOLUTION 100 MG/ML (<i>levetiracetam</i>) | NF | |
| KEPPRA ORAL TABLET 1000 MG, 250 MG, 500 MG, 750 MG (<i>levetiracetam</i>) | NF | |
| KEPPRA XR ORAL TABLET EXTENDED RELEASE 24 HOUR 500 MG, 750 MG (<i>levetiracetam</i>) | NF | |
| KLONOPIN ORAL TABLET 0.5 MG, 1 MG, 2 MG (<i>clonazepam</i>) | NPB | QL (300 TABLETS per 25 days) |
| <i>lacosamide oral solution 10 mg/ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | G | |
| LAMICTAL ODT ORAL KIT 21 X 25 MG & 7 X 50 MG, 25 & 50 & 100 MG, 42 X 50 MG & 14X100 MG (<i>lamotrigine</i>) | NF | |
| LAMICTAL ODT ORAL TABLET DISPERSIBLE 100 MG, 200 MG, 25 MG, 50 MG (<i>lamotrigine</i>) | NF | |
| LAMICTAL ORAL TABLET 100 MG, 150 MG, 200 MG, 25 MG (<i>lamotrigine</i>) | NF | |
| LAMICTAL ORAL TABLET CHEWABLE 25 MG, 5 MG (<i>lamotrigine</i>) | NF | |
| LAMICTAL STARTER ORAL KIT 35 X 25 MG, 42 X 25 MG & 7 X 100 MG, 84 X 25 MG & 14X100 MG (<i>lamotrigine</i>) | NF | |
| LAMICTAL XR ORAL KIT 21 X 25 MG & 7 X 50 MG, 25 & 50 & 100 MG, 50 & 100 & 200 MG (<i>lamotrigine</i>) | NF | |
| LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100 MG, 200 MG, 25 MG, 250 MG, 300 MG, 50 MG (<i>lamotrigine</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| lamotrigine er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg | G | N8 (Listing does not include certain NDCs) |
| lamotrigine oral kit 25 & 50 & 100 mg | G | |
| lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg | G | |
| lamotrigine oral tablet chewable 25 mg, 5 mg | G | |
| lamotrigine oral tablet dispersible 100 mg, 200 mg, 25 mg, 50 mg | G | |
| lamotrigine starter kit-blue oral kit 35 x 25 mg | G | |
| lamotrigine starter kit-green oral kit 84 x 25 mg & 14x100 mg | G | |
| lamotrigine starter kit-orange oral kit 42 x 25 mg & 7 x 100 mg | G | |
| levetiracetam er oral tablet extended release 24 hour 500 mg, 750 mg | G | |
| levetiracetam oral solution 100 mg/ml | G | |
| levetiracetam oral tablet 1000 mg, 250 mg, 500 mg, 750 mg | G | |
| LIBERVANT BUCCAL FILM 10 MG, 12.5 MG, 15 MG, 5 MG, 7.5 MG (diazepam) | NF | |
| LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 225 MG, 25 MG, 300 MG, 50 MG, 75 MG (pregabalin) | NF | |
| LYRICA ORAL SOLUTION 20 MG/ML (pregabalin) | NF | |
| MOTPOLY XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 100 MG, 150 MG, 200 MG (lacosamide) | NF | |
| NAYZILAM NASAL SOLUTION 5 MG/0.1ML (midazolam (anticonvulsant)) | PB | QL (10 SOLUTION per 25 days) |
| NEURONTIN ORAL CAPSULE 100 MG, 300 MG, 400 MG (gabapentin) | NPB | QL (6 CAPSULES per 1 day) |
| NEURONTIN ORAL SOLUTION 250 MG/5ML (gabapentin) | NPB | QL (72 ML per 1 day) |
| NEURONTIN ORAL TABLET 600 MG (gabapentin) | NPB | QL (6 TABLETS per 1 day) |
| NEURONTIN ORAL TABLET 800 MG (gabapentin) | NPB | QL (4 TABLETS per 1 day) |
| ONFI ORAL SUSPENSION 2.5 MG/ML (clobazam) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ONFI ORAL TABLET 10 MG, 20 MG (<i>clobazam</i>) | NF | |
| <i>oxcarbazepine oral suspension 300 mg/5ml</i> | G | |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | G | |
| OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150 MG, 300 MG, 600 MG (<i>oxcarbazepine</i>) | PB | |
| <i>phenobarbital oral elixir 20 mg/5ml</i> | G | |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | G | |
| <i>phenytoin oral suspension 125 mg/5ml</i> | G | |
| <i>phenytoin oral tablet chewable 50 mg</i> | G | |
| <i>phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg</i> | G | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | G | QL (120 CAPSULES per 25 days) |
| <i>pregabalin oral capsule 200 mg</i> | G | QL (90 CAPSULES per 25 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> | G | QL (60 CAPSULES per 25 days) |
| <i>pregabalin oral solution 20 mg/ml</i> | G | QL (900 ML per 25 days) |
| <i>primidone oral tablet 125 mg</i> | NF | |
| <i>primidone oral tablet 250 mg</i> | G | |
| <i>primidone oral tablet 50 mg</i> | G | N8 (Listing does not include certain NDCs) |
| QUDEXY XR ORAL CAPSULE ER 24 HOUR SPRINKLE 100 MG, 150 MG, 200 MG, 25 MG, 50 MG (<i>topiramate</i>) | NPB | |
| <i>rufinamide oral suspension 40 mg/ml</i> | G | PA |
| <i>rufinamide oral tablet 200 mg, 400 mg</i> | G | PA |
| SABRIL ORAL PACKET 500 MG (<i>vigabatrin</i>) | NF | |
| SABRIL ORAL TABLET 500 MG (<i>vigabatrin</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 1000 MG, 250 MG, 500 MG, 750 MG <i>(levetiracetam)</i> | NF | |
| SYMPAZAN ORAL FILM 10 MG, 20 MG, 5 MG <i>(clobazam)</i> | NF | |
| TEGRETOL ORAL SUSPENSION 100 MG/5ML <i>(carbamazepine)</i> | NF | |
| TEGRETOL-XR ORAL TABLET EXTENDED RELEASE 12 HOUR 100 MG, 200 MG, 400 MG <i>(carbamazepine)</i> | NF | |
| <i>tiagabine hcl oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | G | |
| <i>topiramate er oral capsule er 24 hour sprinkle 100 mg, 150 mg, 200 mg, 25 mg, 50 mg</i> | NF | |
| <i>topiramate er oral capsule extended release 24 hour 100 mg, 200 mg, 25 mg, 50 mg</i> | G | |
| <i>topiramate oral capsule sprinkle 15 mg, 25 mg</i> | G | |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | G | |
| TRILEPTAL ORAL SUSPENSION 300 MG/5ML <i>(oxcarbazepine)</i> | NF | |
| TRILEPTAL ORAL TABLET 150 MG, 300 MG, 600 MG <i>(oxcarbazepine)</i> | NF | |
| VALIUM ORAL TABLET 10 MG, 2 MG, 5 MG <i>(diazepam)</i> | NPB | QL (120 TABLETS per 25 days) |
| <i>valproic acid oral capsule 250 mg</i> | G | |
| <i>valproic acid oral solution 250 mg/5ml</i> | G | |
| VALTOCO 10 MG DOSE NASAL LIQUID 10 MG/0.1ML <i>(diazepam)</i> | PB | QL (10 BLISTER per 25 days) |
| VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 7.5 MG/0.1ML <i>(diazepam)</i> | PB | QL (10 BLISTER per 25 days) |
| VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 10 MG/0.1ML <i>(diazepam)</i> | PB | QL (10 BLISTER per 25 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| VALTOCO 5 MG DOSE NASAL LIQUID 5 MG/0.1ML <i>(diazepam)</i> | PB | QL (10 BLISTER per 25 days) |
| vigabatrin oral packet 500 mg | SP | PA; QL (180 PACKETS per 30 days) |
| vigabatrin oral tablet 500 mg | SP | PA; N8 (Listing does not include certain NDCs); QL (180 TABLETS per 30 days) |
| vigabatrin (Vigadron Oral Packet 500 Mg) | SP | PA; QL (180 PACKETS per 30 days) |
| VIMPAT ORAL SOLUTION 10 MG/ML (<i>lacosamide</i>) | NF | |
| VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG (<i>lacosamide</i>) | NF | |
| XCOPRI (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 100 & 150 MG (<i>cenobamate</i>) | PB | |
| XCOPRI (350 MG DAILY DOSE) ORAL TABLET THERAPY PACK 150 & 200 MG (<i>cenobamate</i>) | PB | |
| XCOPRI ORAL TABLET 100 MG, 150 MG, 200 MG, 25 MG, 50 MG (<i>cenobamate</i>) | PB | |
| XCOPRI ORAL TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG, 14 X 150 MG & 14 X 200 MG, 14 X 50 MG & 14 X 100 MG (<i>cenobamate</i>) | PB | |
| ZONEGRAN ORAL CAPSULE 100 MG, 25 MG (<i>zonisamide</i>) | NF | |
| ZONISADE ORAL SUSPENSION 100 MG/5ML (<i>zonisamide</i>) | NF | |
| <i>zonisamide</i> oral capsule 100 mg, 25 mg, 50 mg | G | |
| ZTALMY ORAL SUSPENSION 50 MG/ML (<i>ganaxolone</i>) | NF | |
| ATTENTION DEFICIT HYPERACTIVITY DISORDER - DRUGS TO TREAT ADHD | | |
| ADDERALL ORAL TABLET 10 MG, 12.5 MG, 15 MG, 20 MG, 30 MG, 5 MG, 7.5 MG (<i>amphetamine-dextroamphetamine</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|-----------------------------------|
| ADDERALL XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 10 MG, 15 MG, 20 MG, 25 MG, 30 MG, 5 MG (<i>amphetamine-dextroamphetamine</i>) | NF | |
| ADZENYS XR-ODT ORAL TABLET EXTENDED RELEASE DISPERSIBLE 12.5 MG, 15.7 MG, 18.8 MG, 3.1 MG, 6.3 MG, 9.4 MG (<i>amphetamine</i>) | NF | |
| <i>amphetamine sulfate oral tablet 10 mg, 5 mg</i> | G | STX; QL (120 TABLETS per 25 days) |
| <i>amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 5 mg</i> | G | QL (90 CAPSULES per 25 days) |
| <i>amphetamine-dextroamphet er oral capsule extended release 24 hour 15 mg, 20 mg, 25 mg, 30 mg</i> | G | QL (30 CAPSULES per 25 days) |
| <i>amphetamine-dextroamphetamine oral tablet 10 mg</i> | G | QL (90 TABLETS per 25 DAYs) |
| <i>amphetamine-dextroamphetamine oral tablet 12.5 mg, 5 mg, 7.5 mg</i> | G | QL (90 TABLETS per 25 days) |
| <i>amphetamine-dextroamphetamine oral tablet 15 mg</i> | G | QL (60 TABLETS per 25 days) |
| <i>amphetamine-dextroamphetamine oral tablet 20 mg</i> | G | QL (60 TABLETS per 25 DAYs) |
| <i>amphetamine-dextroamphetamine oral tablet 30 mg</i> | G | QL (30 TABLETS per 25 days) |
| <i>amphet-dextroamphet 3-bead er oral capsule extended release 24 hour 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | NF | |
| APTENSIO XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG (<i>methylphenidate hcl</i>) | NF | |
| <i>atomoxetine hcl oral capsule 10 mg, 18 mg, 25 mg</i> | G | QL (120 CAPSULES per 25 DAYs) |
| <i>atomoxetine hcl oral capsule 100 mg, 60 mg, 80 mg</i> | G | QL (30 CAPSULES per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|-----------------------------------|
| atomoxetine hcl oral capsule 40 mg | G | QL (60 CAPSULES per 25 DAYs) |
| AZSTARYS ORAL CAPSULE 26.1-5.2 MG, 39.2-7.8 MG, 52.3-10.4 MG (<i>serdexmethylphen-dexmethylphen</i>) | PB | QL (30 CAPSULES per 25 DAYs) |
| CONCERTA ORAL TABLET EXTENDED RELEASE 18 MG, 27 MG, 36 MG, 54 MG (<i>methylphenidate hcl</i>) | NF | |
| COTEMPLA XR-ODT ORAL TABLET EXTENDED RELEASE DISPERSIBLE 17.3 MG, 25.9 MG, 8.6 MG (<i>methylphenidate</i>) | NF | |
| DAYTRANA TRANSDERMAL PATCH 10 MG/9HR, 15 MG/9HR, 20 MG/9HR, 30 MG/9HR (<i>methylphenidate</i>) | NF | |
| DESOXYN ORAL TABLET 5 MG (<i>methamphetamine hcl</i>) | NPB | QL (150 TABLETS per 25 days) |
| DEXEDRINE ORAL CAPSULE EXTENDED RELEASE 24 HOUR 10 MG (<i>dextroamphetamine sulfate</i>) | NPB | ST; QL (120 CAPSULES per 25 DAYs) |
| <i>dexamphetamine hcl er oral capsule extended release 24 hour 10 mg, 15 mg, 20 mg, 5 mg</i> | G | QL (60 CAPSULES per 25 DAYs) |
| <i>dexamphetamine hcl er oral capsule extended release 24 hour 25 mg, 30 mg, 35 mg, 40 mg</i> | G | QL (30 CAPSULES per 25 DAYs) |
| <i>dexamphetamine hcl oral tablet 10 mg</i> | G | QL (60 TABLETS per 25 DAYs) |
| <i>dexamphetamine hcl oral tablet 2.5 mg, 5 mg</i> | G | QL (120 TABLETS per 25 DAYs) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 10 mg, 5 mg</i> | G | QL (120 CAPSULES per 25 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 15 mg</i> | G | QL (60 CAPSULES per 25 days) |
| <i>dextroamphetamine sulfate oral solution 5 mg/5ml</i> | G | QL (1200 ML per 25 DAYs) |
| <i>dextroamphetamine sulfate oral tablet 10 mg, 5 mg</i> | G | QL (120 TABLETS per 25 DAYs) |
| DYANAVEL XR ORAL SUSPENSION EXTENDED RELEASE 2.5 MG/ML (<i>amphetamine</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| DYANAVEL XR ORAL TABLET CHEWABLE EXTENDED RELEASE 10 MG, 15 MG, 20 MG, 5 MG (<i>amphetamine</i>) | NF | |
| EVEKEO ODT ORAL TABLET DISPERSIBLE 10 MG, 15 MG, 20 MG, 5 MG (<i>amphetamine sulfate</i>) | NF | |
| EVEKEO ORAL TABLET 10 MG, 5 MG (<i>amphetamine sulfate</i>) | NF | |
| FOCALIN ORAL TABLET 10 MG (<i>dexmethylphenidate hcl</i>) | NPB | QL (60 TABLETS per 25 DAYs) |
| FOCALIN ORAL TABLET 2.5 MG, 5 MG (<i>dexmethylphenidate hcl</i>) | NPB | QL (120 TABLETS per 25 DAYs) |
| FOCALIN XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 10 MG, 15 MG, 20 MG, 25 MG, 30 MG, 35 MG, 40 MG, 5 MG (<i>dexmethylphenidate hcl</i>) | NF | |
| <i>guanfacine hcl er oral tablet extended release 24 hour 1 mg, 2 mg, 3 mg, 4 mg</i> | G | |
| INTUNIV ORAL TABLET EXTENDED RELEASE 24 HOUR 1 MG, 2 MG, 3 MG, 4 MG (<i>guanfacine hcl</i>) | NF | |
| JORNAY PM ORAL CAPSULE EXTENDED RELEASE 24 HOUR 100 MG, 20 MG, 40 MG, 60 MG, 80 MG (<i>methylphenidate hcl</i>) | NF | |
| KAPVAY ORAL TABLET EXTENDED RELEASE 12 HOUR 0.1 MG (<i>clonidine hcl</i>) | NF | |
| <i>lisdexamfetamine dimesylate oral capsule 10 mg, 20 mg, 30 mg</i> | G | QL (60 CAPSULES per 25 DAYs) |
| <i>lisdexamfetamine dimesylate oral capsule 40 mg, 50 mg, 60 mg, 70 mg</i> | G | QL (30 CAPSULES per 25 DAYs) |
| <i>lisdexamfetamine dimesylate oral tablet chewable 10 mg, 20 mg, 30 mg</i> | G | QL (60 TABLETS per 25 DAYs) |
| <i>lisdexamfetamine dimesylate oral tablet chewable 40 mg, 50 mg, 60 mg</i> | G | QL (30 TABLETS per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-----------------------------------|
| METADATE CD ORAL CAPSULE EXTENDED RELEASE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG (<i>methylphenidate hcl</i>) | NF | |
| <i>methamphetamine hcl oral tablet 5 mg</i> | G | STX; QL (150 TABLETS per 25 days) |
| METHYLIN ORAL SOLUTION 10 MG/5ML (<i>methylphenidate hcl</i>) | NPB | QL (900 ML per 25 DAYS) |
| METHYLIN ORAL SOLUTION 5 MG/5ML (<i>methylphenidate hcl</i>) | NPB | QL (1800 ML per 25 DAYS) |
| <i>methylphenidate hcl er (cd) oral capsule extended release 10 mg, 20 mg, 30 mg</i> | G | QL (60 CAPSULES per 25 DAYS) |
| <i>methylphenidate hcl er (cd) oral capsule extended release 40 mg, 50 mg, 60 mg</i> | G | QL (30 CAPSULES per 25 days) |
| <i>methylphenidate hcl er (la) oral capsule extended release 24 hour 10 mg, 20 mg, 30 mg</i> | G | QL (60 CAPSULES per 25 DAYS) |
| <i>methylphenidate hcl er (la) oral capsule extended release 24 hour 40 mg, 60 mg</i> | G | QL (30 CAPSULES per 25 DAYS) |
| <i>methylphenidate hcl er (osm) oral tablet extended release 18 mg</i> | G | QL (60 TABLETS per 25 days) |
| <i>methylphenidate hcl er (osm) oral tablet extended release 27 mg, 36 mg</i> | G | QL (60 tablets per 25 days) |
| <i>methylphenidate hcl er (osm) oral tablet extended release 45 mg, 63 mg</i> | NF | |
| <i>methylphenidate hcl er (osm) oral tablet extended release 54 mg</i> | G | QL (30 tablets per 25 days) |
| <i>methylphenidate hcl er (osm) oral tablet extended release 72 mg</i> | G | QL (30 TABLETS per 25 days) |
| <i>methylphenidate hcl er (xr) oral capsule extended release 24 hour 10 mg, 15 mg, 20 mg, 30 mg</i> | G | QL (60 CAPSULES per 25 DAYS) |
| <i>methylphenidate hcl er (xr) oral capsule extended release 24 hour 40 mg, 50 mg, 60 mg</i> | G | QL (30 CAPSULES per 25 DAYS) |
| <i>methylphenidate hcl er oral tablet extended release 10 mg, 20 mg</i> | G | QL (90 TABLETS per 25 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| methylphenidate hcl er oral tablet extended release 24 hour 18 mg, 27 mg, 36 mg | G | QL (60 TABLETS per 25 days) |
| methylphenidate hcl er oral tablet extended release 24 hour 54 mg | G | QL (30 TABLETS per 25 days) |
| methylphenidate hcl oral solution 10 mg/5ml | G | QL (900 ML per 25 DAYs) |
| methylphenidate hcl oral solution 5 mg/5ml | G | QL (1800 ML per 25 DAYs) |
| methylphenidate hcl oral tablet 10 mg, 5 mg | G | QL (180 TABLETS per 25 DAYs) |
| methylphenidate hcl oral tablet 20 mg | G | QL (90 TABLETS per 25 DAYs) |
| methylphenidate hcl oral tablet chewable 10 mg, 2.5 mg, 5 mg | G | QL (180 TABLETS per 25 DAYs) |
| methylphenidate transdermal patch 10 mg/9hr, 15 mg/9hr, 20 mg/9hr, 30 mg/9hr | NF | |
| MYDAYIS ORAL CAPSULE EXTENDED RELEASE 24 HOUR 12.5 MG, 25 MG, 37.5 MG, 50 MG (<i>amphetamine-dextroamphetamine</i>) | NF | |
| dextroamphetamine sulfate (Procentra Oral Solution 5 Mg/5ML) | G | QL (1200 ML per 25 days) |
| QELBREE ORAL CAPSULE EXTENDED RELEASE 24 HOUR 100 MG, 150 MG, 200 MG (<i>viloxazine hcl</i>) | PB | QL (90 CAPSULES per 25 days) |
| QUILLICHEW ER ORAL TABLET CHEWABLE EXTENDED RELEASE 20 MG, 30 MG, 40 MG (<i>methylphenidate hcl</i>) | NF | |
| QUILLIVANT XR ORAL SUSPENSION RECONSTITUTED ER 25 MG/5ML (<i>methylphenidate hcl</i>) | NF | |
| RELEXXII ORAL TABLET EXTENDED RELEASE 18 MG, 27 MG, 36 MG, 45 MG, 54 MG, 63 MG, 72 MG (<i>methylphenidate hcl</i>) | NF | |
| RITALIN LA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 10 MG, 20 MG, 30 MG (<i>methylphenidate hcl</i>) | NPB | QL (60 CAPSULES per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| RITALIN LA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 40 MG (<i>methylphenidate hcl</i>) | NPB | QL (30 CAPSULES per 25 DAYs) |
| RITALIN ORAL TABLET 10 MG, 5 MG (<i>methylphenidate hcl</i>) | NPB | QL (180 TABLETS per 25 DAYs) |
| RITALIN ORAL TABLET 20 MG (<i>methylphenidate hcl</i>) | NPB | QL (90 TABLETS per 25 DAYs) |
| STRATTERA ORAL CAPSULE 10 MG, 18 MG, 25 MG (<i>atomoxetine hcl</i>) | NPB | QL (120 CAPSULES per 25 DAYs) |
| STRATTERA ORAL CAPSULE 100 MG, 60 MG, 80 MG (<i>atomoxetine hcl</i>) | NPB | QL (30 CAPSULES per 25 DAYs) |
| STRATTERA ORAL CAPSULE 40 MG (<i>atomoxetine hcl</i>) | NPB | QL (60 CAPSULES per 25 DAYs) |
| VYVANSE ORAL CAPSULE 10 MG, 20 MG, 30 MG (<i>lisdexamfetamine dimesylate</i>) | NPB | QL (60 CAPSULES per 25 days) |
| VYVANSE ORAL CAPSULE 40 MG, 50 MG, 60 MG, 70 MG (<i>lisdexamfetamine dimesylate</i>) | NPB | QL (30 CAPSULES per 25 days) |
| VYVANSE ORAL TABLET CHEWABLE 10 MG, 20 MG, 30 MG (<i>lisdexamfetamine dimesylate</i>) | NPB | QL (60 TABLETS per 25 days) |
| VYVANSE ORAL TABLET CHEWABLE 40 MG, 50 MG, 60 MG (<i>lisdexamfetamine dimesylate</i>) | NPB | QL (30 TABLETS per 25 days) |
| XELSTRYM TRANSDERMAL PATCH 13.5 MG/9HR, 18 MG/9HR, 4.5 MG/9HR, 9 MG/9HR (<i>dextroamphetamine</i>) | NF | |
| <i>dextroamphetamine sulfate</i> (Zenedi Oral Tablet 15 Mg, 20 Mg) | G | QL (60 TABLETS per 25 days) |
| <i>dextroamphetamine sulfate</i> (Zenedi Oral Tablet 2.5 Mg, 7.5 Mg) | G | QL (120 TABLETS per 25 days) |
| <i>dextroamphetamine sulfate</i> (Zenedi Oral Tablet 30 Mg) | G | QL (30 TABLETS per 25 days) |
| BOTULINUM TOXINS | | |
| BOTOX INJECTION SOLUTION RECONSTITUTED 100 UNIT, 200 UNIT (<i>onabotulinumtoxina</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| DYSPORT INTRAMUSCULAR SOLUTION RECONSTITUTED 300 UNIT, 500 UNIT (<i>abobotulinumtoxina</i>) | SP | PA |
| XEOMIN INTRAMUSCULAR SOLUTION RECONSTITUTED 100 UNIT, 200 UNIT, 50 UNIT (<i>incobotulinumtoxina</i>) | SP | PA |
| FIBROMYALGIA | | |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG (<i>milnacipran hcl</i>) | NPB | ST |
| SAVELLA TITRATION PACK ORAL 12.5 & 25 & 50 MG (<i>milnacipran hcl</i>) | NPB | ST |
| HYPNOTICS - DRUGS TO TREAT INSOMNIA | | |
| AMBIEN CR ORAL TABLET EXTENDED RELEASE 12.5 MG, 6.25 MG (<i>zolpidem tartrate</i>) | NPB | ST; QL (15 TABLETS per 25 DAYs) |
| AMBIEN ORAL TABLET 10 MG, 5 MG (<i>zolpidem tartrate</i>) | NPB | ST; QL (15 TABLETS per 25 DAYs) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG (<i>suvorexant</i>) | NF | |
| DAYVIGO ORAL TABLET 10 MG, 5 MG (<i>lemborexant</i>) | NF | |
| DORAL ORAL TABLET 15 MG (<i>quazepam</i>) | NPB | STX; QL (15 TABLETS per 25 days) |
| <i>doxepin hcl oral tablet 3 mg, 6 mg</i> | G | QLR (QL applies to members age 65 and older); QL (30 TABLETS per 25 days); AL (Max 65 Years) |
| EDLUAR SUBLINGUAL TABLET SUBLINGUAL 10 MG, 5 MG (<i>zolpidem tartrate</i>) | NF | |
| <i>estazolam oral tablet 1 mg, 2 mg</i> | G | QL (15 TABLETS per 25 DAYs) |
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> | G | QL (15 TABLETS per 25 DAYs) |
| <i>flurazepam hcl oral capsule 15 mg, 30 mg</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| HALCION ORAL TABLET 0.25 MG (<i>triazolam</i>) | NPB | QL (10 TABLETS per 25 DAYs) |
| HETLIOZ LQ ORAL SUSPENSION 4 MG/ML (<i>tasimelteon</i>) | SP | PA; QL (5 ML per 1 DAY) |
| HETLIOZ ORAL CAPSULE 20 MG (<i>tasimelteon</i>) | SP | PA; QL (30 CAPSULES per 30 DAYs) |
| LUNESTA ORAL TABLET 1 MG, 2 MG, 3 MG (<i>eszopiclone</i>) | NF | |
| <i>midazolam hcl oral syrup 2 mg/ml</i> | G | |
| <i>quazepam oral tablet 15 mg</i> | NF | |
| QUVIVIQ ORAL TABLET 25 MG, 50 MG (<i>daridorexant hcl</i>) | NF | |
| <i>ramelteon oral tablet 8 mg</i> | G | QL (15 TABLETS per 25 DAYs) |
| RESTORIL ORAL CAPSULE 15 MG, 22.5 MG, 30 MG, 7.5 MG (<i>temazepam</i>) | NPB | QL (15 CAPSULES per 25 DAYs) |
| ROZEREM ORAL TABLET 8 MG (<i>ramelteon</i>) | NF | |
| SILENOR ORAL TABLET 3 MG, 6 MG (<i>doxepin hcl</i>) | NF | |
| <i>tasimelteon oral capsule 20 mg</i> | SP | PA; QL (30 CAPSULES per 30 DAYs) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> | G | QL (15 CAPSULES per 25 DAYs) |
| <i>temazepam oral capsule 22.5 mg, 7.5 mg</i> | G | QL (15 CAPSULES per 25 days) |
| <i>triazolam oral tablet 0.125 mg, 0.25 mg</i> | G | QL (10 TABLETS per 25 DAYs) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | G | QL (15 CAPSULES per 25 DAYs) |
| <i>zolpidem tartrate er oral tablet extended release 12.5 mg, 6.25 mg</i> | G | ST; QL (15 TABLETS per 25 DAYs) |
| <i>zolpidem tartrate oral capsule 7.5 mg</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>zolpidem tartrate oral tablet 10 mg, 5 mg</i> | G | QL (15 TABLETS per 25 DAYS) |
| <i>zolpidem tartrate sublingual tablet sublingual 1.75 mg, 3.5 mg</i> | NF | |
| MIGRAINE - DRUGS TO TREAT SEVERE HEADACHES | | |
| AIMOVIG SUBCUTANEOUS SOLUTION AUTO- INJECTOR 140 MG/ML, 70 MG/ML (<i>erenumab-aoe</i>) | NF | |
| AJOVY SUBCUTANEOUS SOLUTION AUTO- INJECTOR 225 MG/1.5ML (<i>fremanezumab-vfrm</i>) | PB | ST; QL (3 SYRINGES per 75 days) |
| AJOVY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 225 MG/1.5ML (<i>fremanezumab-vfrm</i>) | PB | ST; QL (3 SYRINGES per 75 days) |
| <i>almotriptan malate oral tablet 12.5 mg, 6.25 mg</i> | G | QL (12 TABLETS per 25 DAYS) |
| <i>dihydroergotamine mesylate injection solution 1 mg/ml</i> | G | |
| <i>dihydroergotamine mesylate nasal solution 4 mg/ml</i> | NF | |
| <i>eletriptan hydrobromide oral tablet 20 mg, 40 mg</i> | G | QL (12 TABLETS per 25 DAYS) |
| EMGALITY (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML (<i>galcanezumab-gnlm</i>) | PB | ST; QL (3 SYRINGES per 25 days) |
| EMGALITY SUBCUTANEOUS SOLUTION AUTO- INJECTOR 120 MG/ML (<i>galcanezumab-gnlm</i>) | PB | ST; N8 (Quantity limit will be 2 syringes for the initial month); QL (2 syringes first month, then 1 syringe per 25 days) |
| EMGALITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120 MG/ML (<i>galcanezumab-gnlm</i>) | PB | ST; N8 (Quantity limit will be 2 syringes for the initial month); QL (2 syringes first month, then 1 syringe per 25 days) |
| FROVA ORAL TABLET 2.5 MG (<i>frovatriptan succinate</i>) | NPB | ST; QL (18 TABLETS per 25 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| frovatriptan succinate oral tablet 2.5 mg | G | QL (18 TABLETS per 25 days) |
| IMITREX NASAL SOLUTION 20 MG/ACT (<i>sumatriptan</i>) | NPB | ST; QL (12 SPRAYS per 25 DAYs) |
| IMITREX NASAL SOLUTION 5 MG/ACT (<i>sumatriptan</i>) | NPB | ST; QL (24 SPRAYS per 25 DAYs) |
| IMITREX ORAL TABLET 100 MG, 25 MG, 50 MG (<i>sumatriptan succinate</i>) | NPB | ST; QL (12 TABLETS per 25 DAYs) |
| IMITREX STATDOSE REFILL SUBCUTANEOUS SOLUTION CARTRIDGE 4 MG/0.5ML (<i>sumatriptan succinate</i>) | NPB | ST; QL (18 SYRINGES per 25 DAYs) |
| IMITREX STATDOSE REFILL SUBCUTANEOUS SOLUTION CARTRIDGE 6 MG/0.5ML (<i>sumatriptan succinate</i>) | NPB | ST; QL (12 SOLUTION CARTRIDGE per 25 DAYs) |
| IMITREX STATDOSE SYSTEM SUBCUTANEOUS SOLUTION AUTO-INJECTOR 4 MG/0.5ML (<i>sumatriptan succinate</i>) | NPB | ST; QL (18 SYRINGES per 25 DAYs) |
| IMITREX STATDOSE SYSTEM SUBCUTANEOUS SOLUTION AUTO-INJECTOR 6 MG/0.5ML (<i>sumatriptan succinate</i>) | NPB | ST; QL (12 SOLUTION AUTO-INJECTOR per 25 DAYs) |
| MAXALT ORAL TABLET 10 MG (<i>rizatriptan benzoate</i>) | NF | |
| MAXALT-MLT ORAL TABLET DISPERSIBLE 10 MG (<i>rizatriptan benzoate</i>) | NF | |
| MIGERGOT RECTAL SUPPOSITORY 2-100 MG (<i>ergotamine-caffeine</i>) | NF | |
| MIGRANAL NASAL SOLUTION 4 MG/ML (<i>dihydroergotamine mesylate</i>) | NF | |
| <i>naratriptan hcl</i> oral tablet 1 mg, 2.5 mg | G | QL (12 TABLETS per 25 DAYs) |
| NURTEC ORAL TABLET DISPERSIBLE 75 MG (<i>rimegepant sulfate</i>) | PB | ST; QL (16 TABLETS per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ONZETRA XSAIL NASAL EXHALER POWDER 11 MG/NOSEPC (<i>sumatriptan succinate</i>) | NPB | ST; QL (8 POUCHES per 25 DAYs) |
| QULIPTA ORAL TABLET 10 MG, 30 MG, 60 MG (<i>atogepant</i>) | PB | ST; QL (30 TABLETS per 25 days) |
| RELPAX ORAL TABLET 20 MG, 40 MG (<i>eletriptan hydrobromide</i>) | NPB | ST; QL (12 TABLETS per 25 DAYs) |
| REYVOW ORAL TABLET 100 MG (<i>lasmiditan succinate</i>) | NPB | ST; QL (8 TABLETS per 25 days) |
| REYVOW ORAL TABLET 50 MG (<i>lasmiditan succinate</i>) | NPB | ST; QL (4 TABLETS per 25 days) |
| <i>rizatriptan benzoate oral tablet 10 mg, 5 mg</i> | G | QL (18 TABLETS per 25 DAYs) |
| <i>rizatriptan benzoate oral tablet dispersible 10 mg, 5 mg</i> | G | QL (18 TABLETS per 25 DAYs) |
| <i>sumatriptan nasal solution 20 mg/act</i> | G | QL (12 SPRAYS per 25 DAYs) |
| <i>sumatriptan nasal solution 5 mg/act</i> | G | QL (24 SPRAYS per 25 DAYs) |
| <i>sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg</i> | G | QL (12 TABLETS per 25 DAYs) |
| <i>sumatriptan succinate refill subcutaneous solution cartridge 4 mg/0.5ml</i> | G | QL (18 SYRINGES per 25 days) |
| <i>sumatriptan succinate refill subcutaneous solution cartridge 6 mg/0.5ml</i> | G | QL (12 SOLUTION CARTRIDGE per 25 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5ml</i> | G | QL (12 VIALS per 25 DAYs) |
| <i>sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml</i> | G | QL (18 SYRINGES per 25 DAYs) |
| <i>sumatriptan succinate subcutaneous solution auto-injector 6 mg/0.5ml</i> | G | QL (12 SOLUTION AUTO-INJECTOR per 25 days) |
| <i>sumatriptan-naproxen sodium oral tablet 85-500 mg</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-----------------------------------|
| TOSYMRA NASAL SOLUTION 10 MG/ACT (<i>sumatriptan</i>) | NF | |
| TREXIMET ORAL TABLET 85-500 MG (<i>sumatriptan-naproxen sodium</i>) | NF | |
| TRUDHESA NASAL AEROSOL SOLUTION 0.725 MG/ACT (<i>dihydroergotamine mesylate hfa</i>) | NPB | QL (3 PACKAGES per 25 days) |
| UBRELVY ORAL TABLET 100 MG, 50 MG (<i>ubrogepant</i>) | PB | ST; QL (16 TABLETS per 25 DAYS) |
| ZAVZPRET NASAL SOLUTION 10 MG/ACT (<i>zavegeptan hcl</i>) | NF | |
| ZEMBRACE SYMTOUCH SUBCUTANEOUS SOLUTION AUTO-INJECTOR 3 MG/0.5ML (<i>sumatriptan succinate</i>) | NPB | ST; QL (24 INJECTORS per 25 DAYS) |
| <i>zolmitriptan nasal solution 5 mg</i> | G | QL (12 SPRAYS per 25 days) |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> | G | QL (12 TABLETS per 25 DAYS) |
| <i>zolmitriptan oral tablet dispersible 2.5 mg, 5 mg</i> | G | QL (12 TABLETS per 25 days) |
| ZOMIG NASAL SOLUTION 2.5 MG, 5 MG (<i>zolmitriptan</i>) | NPB | ST; QL (12 SPRAYS per 25 days) |
| ZOMIG ORAL TABLET 2.5 MG, 5 MG (<i>zolmitriptan</i>) | NPB | ST; QL (12 TABLETS per 25 days) |
| MISCELLANEOUS | | |
| DAYBUE ORAL SOLUTION 200 MG/ML (<i>trofinetide</i>) | SP | PA; QL (3600 ML per 30 DAYS) |
| EVRYSDI ORAL SOLUTION RECONSTITUTED 0.75 MG/ML (<i>risdiplam</i>) | SP | PA; QL (2 BOTTLES per 24 DAYS) |
| EXSERVAN ORAL FILM 50 MG (<i>riluzole</i>) | NF | |
| FIRDAPSE ORAL TABLET 10 MG (<i>amifampridine phosphate</i>) | SP | PA; QL (240 TABLETS per 30 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>lithium carbonate er oral tablet extended release 300 mg, 450 mg</i> | G | |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | G | |
| <i>lithium carbonate oral tablet 300 mg</i> | G | |
| <i>lithium oral solution 8 meq/5ml</i> | NF | |
| MESTINON ORAL SOLUTION 60 MG/5ML (pyridostigmine bromide) | NF | |
| MESTINON ORAL TABLET 60 MG (pyridostigmine bromide) | NF | |
| <i>pyridostigmine bromide er oral tablet extended release 180 mg</i> | G | |
| <i>pyridostigmine bromide oral solution 60 mg/5ml</i> | G | |
| <i>pyridostigmine bromide oral tablet 30 mg</i> | NF | |
| <i>pyridostigmine bromide oral tablet 60 mg</i> | G | |
| RADICAVA ORS ORAL SUSPENSION 105 MG/5ML (edaravone) | SP | PA; QL (50 ML per 28 DAYS) |
| RADICAVA ORS STARTER KIT ORAL SUSPENSION 105 MG/5ML (edaravone) | SP | PA; QL (70 ML per 28 DAYS) |
| RELYVRIORAL PACKET 3-1 GM (phenylbutyrate-taurursodiol) | NF | |
| <i>riluzole oral tablet 50 mg</i> | G | |
| SKYCLARYS ORAL CAPSULE 50 MG (omaveloxolone) | SP | PA; QL (90 CAPSULES per 30 days) |
| TIGLUTIK ORAL SUSPENSION 50 MG/10ML (riluzole) | NF | |
| ZILBRYSQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 16.6 MG/0.416ML, 23 MG/0.574ML, 32.4 MG/0.81ML (zilucoplan sodium) | NF | |
| MOVEMENT DISORDERS | | |
| AUSTEDO ORAL TABLET 12 MG, 9 MG (deutetrabenazine) | SP | PA; QL (120 TABLETS per 30 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-------------------------------------|
| AUSTEDO ORAL TABLET 6 MG (<i>deutetetrabenazine</i>) | SP | PA; QL (60 TABLETS per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG (<i>deutetetrabenazine</i>) | SP | PA; QL (120 TABLETS per 30 DAYs) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 24 MG (<i>deutetetrabenazine</i>) | SP | PA; QL (60 TABLETS per 30 DAYs) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 6 MG (<i>deutetetrabenazine</i>) | SP | PA; QL (90 TABLETS per 30 DAYs) |
| AUSTEDO XR PATIENT TITRATION ORAL TABLET EXTENDED RELEASE THERAPY PACK 6 & 12 & 24 MG (<i>deutetetrabenazine</i>) | SP | PA; QL (42 TABLETS per 28 DAYs) |
| INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG (<i>valbenazine tosylate</i>) | SP | PA; QL (30 CAPSULES per 30 days) |
| INGREZZA ORAL CAPSULE THERAPY PACK 40 & 80 MG (<i>valbenazine tosylate</i>) | SP | PA; QL (1 PACK per 28 days) |
| <i>tetrabenazine oral tablet 12.5 mg</i> | SP | PA; QL (240 TABLETS per 30 days) |
| <i>tetrabenazine oral tablet 25 mg</i> | SP | PA; QL (120 TABLETS per 30 days) |
| XENAZINE ORAL TABLET 12.5 MG, 25 MG (<i>tetrabenazine</i>) | NF | |
| MULTIPLE SCLEROSIS AGENTS - DRUGS TO TREAT MULTIPLE SCLEROSIS | | |
| AMPYRA ORAL TABLET EXTENDED RELEASE 12 HOUR 10 MG (<i>dalfampridine</i>) | SP | PA; ST; QL (60 TABLETS per 30 DAYs) |
| AUBAGIO ORAL TABLET 14 MG, 7 MG (<i>teriflunomide</i>) | NF | |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30 MCG/0.5ML (<i>interferon beta-1a</i>) | SP | PA; QL (4 SYRINGES per 28 days) |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30 MCG/0.5ML (<i>interferon beta-1a</i>) | SP | PA; QL (4 SYRINGES per 28 days) |
| BAFIERTAM ORAL CAPSULE DELAYED RELEASE 95 MG (<i>monomethyl fumarate</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| BETASERON SUBCUTANEOUS KIT 0.3 MG (<i>interferon beta-1b</i>) | PB | PA; QL (14 INJECTIONS per 28 DAYs) |
| COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML (<i>glatiramer acetate</i>) | NF | |
| COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/ML (<i>glatiramer acetate</i>) | PB | PA; QL (12 SYRINGES per 28 DAYs) |
| <i>dalfampridine er oral tablet extended release 12 hour 10 mg</i> | SP | PA; QL (60 TABLETS per 30 days) |
| <i>dimethyl fumarate oral capsule delayed release 120 mg</i> | SP | PA; N8 (Listing does not include certain NDCs); QL (14 CAPSULES per 28 DAYs) |
| <i>dimethyl fumarate oral capsule delayed release 240 mg</i> | SP | PA; QL (60 CAPSULES per 30 DAYs) |
| <i>dimethyl fumarate starter pack oral capsule delayed release therapy pack 120 & 240 mg</i> | SP | PA; QL (1 KIT per 30 days) |
| EXTAVIA SUBCUTANEOUS KIT 0.3 MG (<i>interferon beta-1b</i>) | NF | |
| <i>fingolimod hcl oral capsule 0.5 mg</i> | G | PA; QL (30 CAPSULES per 30 DAYs) |
| GILENYA ORAL CAPSULE 0.25 MG, 0.5 MG (<i>fingolimod hcl</i>) | PB | PA; QL (30 CAPSULES per 30 DAYs) |
| <i>glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml</i> | G | PA; QL (30 INJECTIONS per 30 DAYs) |
| <i>glatiramer acetate subcutaneous solution prefilled syringe 40 mg/ml</i> | G | PA; QL (12 SYRINGES per 28 DAYs) |
| <i>glatiramer acetate (Glatopa Subcutaneous Solution Prefilled Syringe 20 Mg/ML)</i> | G | PA; QL (30 INJECTIONS per 30 DAYs) |
| <i>glatiramer acetate (Glatopa Subcutaneous Solution Prefilled Syringe 40 Mg/ML)</i> | G | PA; QL (12 SYRINGES per 28 DAYs) |
| KESIMPTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 20 MG/0.4ML (<i>ofatumumab</i>) | SP | PA; QL (1 PEN per 28 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---------------------------------------|
| MAVENCLAD (10 TABS) ORAL TABLET THERAPY PACK 10 MG (<i>cladribine</i>) | SP | PA; QL (20 TABLETS per 270 DAYs) |
| MAVENCLAD (4 TABS) ORAL TABLET THERAPY PACK 10 MG (<i>cladribine</i>) | SP | PA; QL (20 TABLETS per 270 DAYs) |
| MAVENCLAD (5 TABS) ORAL TABLET THERAPY PACK 10 MG (<i>cladribine</i>) | SP | PA; QL (20 TABLETS per 270 DAYs) |
| MAVENCLAD (6 TABS) ORAL TABLET THERAPY PACK 10 MG (<i>cladribine</i>) | SP | PA; QL (20 TABLETS per 270 DAYs) |
| MAVENCLAD (7 TABS) ORAL TABLET THERAPY PACK 10 MG (<i>cladribine</i>) | SP | PA; QL (20 TABLETS per 270 DAYs) |
| MAVENCLAD (8 TABS) ORAL TABLET THERAPY PACK 10 MG (<i>cladribine</i>) | SP | PA; QL (20 TABLETS per 270 DAYs) |
| MAVENCLAD (9 TABS) ORAL TABLET THERAPY PACK 10 MG (<i>cladribine</i>) | SP | PA; QL (20 TABLETS per 270 DAYs) |
| MAYZENT ORAL TABLET 0.25 MG (<i>siponimod fumarate</i>) | PB | PA; QL (12 TABLETS per 5 days) |
| MAYZENT ORAL TABLET 1 MG (<i>siponimod fumarate</i>) | PB | PA; QL (30 TABLETS per 30 days) |
| MAYZENT ORAL TABLET 2 MG (<i>siponimod fumarate</i>) | PB | PA; QL (30 TABLETS per 30 DAYs) |
| MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 12 X 0.25 MG (<i>siponimod fumarate</i>) | PB | PA; QL (12 tablets per 5 days) |
| MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 7 X 0.25 MG (<i>siponimod fumarate</i>) | PB | PA; QL (7 TABLETS per 4 days) |
| PLEGRIDY INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 125 MCG/0.5ML (<i>peginterferon beta-1a</i>) | SP | PA; ST; QL (2 INJECTIONS per 28 days) |
| PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PEN-INJECTOR 63 & 94 MCG/0.5ML (<i>peginterferon beta-1a</i>) | SP | PA; ST; QL (2 INJECTIONS per 28 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---------------------------------------|
| PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 63 & 94 MCG/0.5ML (<i>peginterferon beta-1a</i>) | SP | PA; ST; QL (2 INJECTIONS per 28 days) |
| PLEGRIDY SUBCUTANEOUS SOLUTION PEN-INJECTOR 125 MCG/0.5ML (<i>peginterferon beta-1a</i>) | SP | PA; ST; QL (2 INJECTIONS per 28 days) |
| PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MCG/0.5ML (<i>peginterferon beta-1a</i>) | SP | PA; ST; QL (2 INJECTIONS per 28 days) |
| PONVORY ORAL TABLET 20 MG (<i>ponesimod</i>) | SP | PA; QL (30 TABLETS per 30 days) |
| PONVORY STARTER PACK ORAL TABLET THERAPY PACK 2-3-4-5-6-7-8-9 & 10 MG (<i>ponesimod</i>) | SP | PA; QL (14 TABLETS per 14 days) |
| REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR 22 MCG/0.5ML, 44 MCG/0.5ML (<i>interferon beta-1a</i>) | PB | PA; QL (12 PENS per 28 days) |
| REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 6X8.8 & 6X22 MCG (<i>interferon beta-1a</i>) | PB | PA; QL (1 BOX per 28 DAYs) |
| REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 22 MCG/0.5ML, 44 MCG/0.5ML (<i>interferon beta-1a</i>) | PB | PA; QL (12 SYRINGES per 28 DAYs) |
| REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6X8.8 & 6X22 MCG (<i>interferon beta-1a</i>) | PB | PA; QL (1 BOX per 28 DAYs) |
| TASCENO ODT ORAL TABLET DISPERSIBLE 0.25 MG, 0.5 MG (<i>fingolimod lauryl sulfate</i>) | NF | |
| TECFIDERA ORAL CAPSULE DELAYED RELEASE 120 MG, 240 MG (<i>dimethyl fumarate</i>) | NF | |
| TECFIDERA ORAL CAPSULE DELAYED RELEASE THERAPY PACK 120 & 240 MG (<i>dimethyl fumarate</i>) | NF | |
| teriflunomide oral tablet 14 mg, 7 mg | G | PA; QL (30 TABLETS per 30 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| TYSABRI INTRAVENOUS CONCENTRATE 300 MG/15ML (<i>natalizumab</i>) | PB | PA; QL (1 VIAL per 28 DAYS) |
| VUMERITY ORAL CAPSULE DELAYED RELEASE 231 MG (<i>diroximel fumarate</i>) | SP | PA; QL (120 CAPSULES per 30 DAYS) |
| ZEPOSIA 7-DAY STARTER PACK ORAL CAPSULE THERAPY PACK 4 X 0.23MG & 3 X 0.46MG (<i>ozanimod hcl</i>) | SP | PA; ST; IBC (Preferred agent for Ulcerative Colitis); QL (1 PACK per 7 days) |
| ZEPOSIA ORAL CAPSULE 0.92 MG (<i>ozanimod hcl</i>) | SP | PA; ST; IBC (Preferred agent for Ulcerative Colitis); QL (30 CAPSULES per 30 days) |
| ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG & 0.46MG 0.92MG(21) (<i>ozanimod hcl</i>) | SP | PA; ST; IBC (Preferred agent for Ulcerative Colitis); QL (1 KIT per 28 DAYS) |
| MUSCULOSKELETAL THERAPY AGENTS | | |
| <i>baclofen oral solution 10 mg/5ml, 5 mg/5ml</i> | NF | |
| <i>baclofen oral suspension 25 mg/5ml</i> | NF | |
| <i>baclofen oral tablet 15 mg</i> | NF | |
| <i>carisoprodol oral tablet 350 mg</i> | G | N8 (Listing does not include certain NDCs); QL (84 TABLETS per 28 days) |
| <i>cyclobenzaprine hcl oral tablet 5 mg</i> | G | |
| <i>cyclobenzaprine hcl oral tablet 7.5 mg</i> | NF | |
| FLEQSUVY ORAL SUSPENSION 25 MG/5ML (<i>baclofen</i>) | NF | |
| LYVISPAH ORAL PACKET 10 MG, 20 MG, 5 MG (<i>baclofen</i>) | PB | PA; QL (120 PACKETS per 25 days) |
| <i>metaxalone oral tablet 800 mg</i> | G | |
| <i>orphenadrine-aspirin-caffeine</i> (Norgesic Oral Tablet 25-385-30 Mg) | NF | |
| <i>orphenadrine-aspirin-caffeine</i> oral tablet 25-385-30 mg | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>orphenadrine-aspirin-caffeine</i> (Orphengesic Forte Oral Tablet 50-770-60 Mg) | NF | |
| OZOBAX DS ORAL SOLUTION 10 MG/5ML (<i>baclofen</i>) | NF | |
| SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 10 MG, 2.5 MG, 5 MG (<i>palovarotene</i>) | NF | |
| <i>tizanidine hcl oral tablet</i> 2 mg, 4 mg | G | |
| MUSCULOSKELETAL THERAPY AGENTS - DRUGS TO TREAT MUSCLE SPASMS | | |
| AMRIX ORAL CAPSULE EXTENDED RELEASE 24 HOUR 15 MG, 30 MG (<i>cyclobenzaprine hcl</i>) | NF | |
| <i>baclofen oral tablet</i> 10 mg, 20 mg, 5 mg | G | |
| <i>carisoprodol oral tablet</i> 250 mg | NF | |
| <i>chlorzoxazone oral tablet</i> 250 mg, 375 mg, 750 mg | NF | |
| <i>chlorzoxazone oral tablet</i> 500 mg | G | N8 (Listing does not include certain NDCs) |
| <i>cyclobenzaprine hcl er oral capsule extended release 24 hour</i> 15 mg, 30 mg | NF | |
| <i>cyclobenzaprine hcl oral tablet</i> 10 mg | G | |
| <i>dantrolene sodium oral capsule</i> 100 mg, 25 mg, 50 mg | G | |
| <i>metaxalone oral tablet</i> 400 mg | NF | |
| <i>methocarbamol oral tablet</i> 500 mg, 750 mg | G | N8 (Listing does not include certain NDCs) |
| <i>norgesic forte oral tablet</i> 50-770-60 mg | NF | |
| OZOBAX ORAL SOLUTION 5 MG/5ML (<i>baclofen</i>) | NF | |
| SOMA ORAL TABLET 250 MG, 350 MG (<i>carisoprodol</i>) | NPB | QL (84 TABLETS per 28 DAYS) |
| <i>tizanidine hcl oral capsule</i> 2 mg, 4 mg, 6 mg | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|-------------------------------------|
| NARCOLEPSY/CATAPLEXY - DRUGS FOR SLEEP DISORDERS | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg</i> | G | PA; QL (30 TABLETS per 25 days) |
| <i>armodafinil oral tablet 50 mg</i> | G | PA; QL (60 TABLETS per 25 days) |
| LUMRYZ ORAL PACKET 4.5 GM, 6 GM, 7.5 GM, 9 GM <i>(sodium oxybate)</i> | SP | PA; QL (30 PACKETS per 30 DAYs) |
| <i>modafinil oral tablet 100 mg, 200 mg</i> | G | PA; QL (60 TABLETS per 25 days) |
| NUVIGIL ORAL TABLET 150 MG, 200 MG, 250 MG, 50 MG <i>(armodafinil)</i> | NF | |
| PROVIGIL ORAL TABLET 100 MG, 200 MG (<i>modafinil</i>) | NF | |
| <i>sodium oxybate oral solution 500 mg/ml</i> | NF | |
| SUNOSI ORAL TABLET 150 MG, 75 MG (<i>solriamfetol hcl</i>) | PB | PA; QL (30 TABLETS per 25 days) |
| WAKIX ORAL TABLET 17.8 MG, 4.45 MG (<i>pitolisant hcl</i>) | SP | PA; QL (60 TABLETS per 30 days) |
| XYREM ORAL SOLUTION 500 MG/ML (<i>sodium oxybate</i>) | NF | |
| XYWAV ORAL SOLUTION 500 MG/ML (<i>ca, mg, k, and na oxybates</i>) | SP | PA; QL (540 ML per 30 days) |
| OPIOID AGONIST/ANTAGONIST | | |
| <i>buprenorphine hcl-naloxone hcl sublingual film 12-3 mg</i> | G | QL (60 FILMS per 25 days) |
| <i>buprenorphine hcl-naloxone hcl sublingual film 2-0.5 mg, 4-1 mg, 8-2 mg</i> | G | QL (90 FILMS per 25 days) |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5 mg, 8-2 mg</i> | CE | N7 (G); QL (90 TABLETS per 25 days) |
| SUBOXONE SUBLINGUAL FILM 12-3 MG, 2-0.5 MG, 4-1 MG, 8-2 MG (<i>buprenorphine hcl-naloxone hcl</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---------------------------------------|
| ZUBSOLV SUBLINGUAL TABLET SUBLINGUAL 0.7-0.18 MG, 1.4-0.36 MG, 2.9-0.71 MG, 5.7-1.4 MG (<i>buprenorphine hcl-naloxone hcl</i>) | PB | QL (90 TABLET SUBLINGUAL per 25 days) |
| ZUBSOLV SUBLINGUAL TABLET SUBLINGUAL 11.4-2.9 MG (<i>buprenorphine hcl-naloxone hcl</i>) | PB | QL (30 TABLET SUBLINGUAL per 25 days) |
| ZUBSOLV SUBLINGUAL TABLET SUBLINGUAL 8.6-2.1 MG (<i>buprenorphine hcl-naloxone hcl</i>) | PB | QL (60 TABLET SUBLINGUAL per 25 days) |
| OPIOID ANTAGONIST | | |
| KLOXXADO NASAL LIQUID 8 MG/0.1ML (<i>naloxone hcl</i>) | NPB | QL (4 SPRAYS per 25 days) |
| <i>naloxone hcl injection solution 0.4 mg/ml, 4 mg/10ml</i> | G | |
| <i>naloxone hcl injection solution cartridge 0.4 mg/ml</i> | G | |
| <i>naloxone hcl injection solution prefilled syringe 2 mg/2ml</i> | G | |
| <i>naloxone hcl nasal liquid 4 mg/0.1ml</i> | G | QL (4 SPRAYS per 25 days) |
| <i>naltrexone hcl oral tablet 50 mg</i> | CE | N7 (G) |
| NARCAN NASAL LIQUID 4 MG/0.1ML (<i>naloxone hcl</i>) | NPB | QL (4 SPRAYS per 25 days) |
| OPVEE NASAL SOLUTION 2.7 MG/0.1ML (<i>nalmefene hcl</i>) | NF | |
| RIVIVE NASAL LIQUID 3 MG/0.1ML (<i>naloxone hcl</i>) | NPB | QL (4 SPRAYS per 25 DAYs) |
| VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380 MG (<i>naltrexone</i>) | SP | QL (380 MG per 28 days) |
| ZIMHI INJECTION SOLUTION PREFILLED SYRINGE 5 MG/0.5ML (<i>naloxone hcl</i>) | NF | |
| OPIOID PARTIAL AGONISTS | | |
| <i>buprenorphine hcl sublingual tablet sublingual 2 mg, 8 mg</i> | CE | N7 (G); QL (90 TABLETS per 25 days) |
| POSTHERPETIC NEURALGIA (PHN) | | |
| <i>gabapentin (once-daily) oral tablet 300 mg</i> | G | ST; QL (150 TABLETS per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>gabapentin (once-daily) oral tablet 600 mg</i> | G | ST; QL (90 TABLETS per 25 DAYs) |
| GRALISE ORAL TABLET 300 MG (<i>gabapentin (once-daily)</i>) | PB | ST; QL (150 TABLETS per 25 DAYs) |
| GRALISE ORAL TABLET 450 MG, 600 MG (<i>gabapentin (once-daily)</i>) | PB | ST; QL (90 TABLETS per 25 DAYs) |
| GRALISE ORAL TABLET 750 MG, 900 MG (<i>gabapentin (once-daily)</i>) | PB | ST; QL (60 TABLETS per 25 DAYs) |
| HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG, 600 MG (<i>gabapentin enacarbil</i>) | NF | |
| LYRICA CR ORAL TABLET EXTENDED RELEASE 24 HOUR 165 MG, 330 MG, 82.5 MG (<i>pregabalin</i>) | NF | |
| <i>pregabalin er oral tablet extended release 24 hour 165 mg, 330 mg, 82.5 mg</i> | NF | |
| PSYCHOTHERAPEUTIC DRUGS | | |
| <i>cvs nicotine mouth/throat gum 4 mg</i> | CE | N7 (G); N8 (\$0 limited to 2 treatment cycles/year); QL (2 treatment cycles per 365 days) |
| <i>cvs nicotine polacrilex mouth/throat lozenge 4 mg</i> | CE | N7 (G); N8 (\$0 limited to 2 treatment cycles/year); QL (2 treatment cycles per 365 days) |
| <i>cvs nicotine transdermal patch 24 hour 14 mg/24hr</i> | CE | N7 (G); N8 (\$0 limited to 2 treatment cycles/year); QL (2 treatment cycles per 365 days) |
| PSYCHOTHERAPEUTIC-MISC | | |
| ADDYI ORAL TABLET 100 MG (<i>flibanserin</i>) | NPB | SPC |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>chlordiazepoxide-amitriptyline oral tablet 10-25 mg</i> | G | QLR (QL applies to members age 65 and older); QL (60 TABLETS per 25 days); AL (Max 65 Years) |
| <i>chlordiazepoxide-amitriptyline oral tablet 5-12.5 mg</i> | G | QLR (QL applies to members age 65 and older); QL (120 TABLETS per 25 days); AL (Max 65 Years) |
| LUCEMYRA ORAL TABLET 0.18 MG (<i>lofexidine hcl</i>) | NPB | QL (16 TABLETS per 1 DAY) |
| NUEDEXTA ORAL CAPSULE 20-10 MG (<i>dextromethorphan-quinidine</i>) | NF | |
| <i>olanzapine-fluoxetine hcl oral capsule 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg</i> | G | STX |
| <i>perphenazine-amitriptyline oral tablet 2-10 mg</i> | G | QLR (QL applies to members age 65 and older); QL (150 TABLET per 25 days); AL (Max 65 Years) |
| <i>perphenazine-amitriptyline oral tablet 2-25 mg, 4-25 mg</i> | G | QLR (QL applies to members age 65 and older); QL (60 TABLET per 25 days); AL (Max 65 Years) |
| <i>perphenazine-amitriptyline oral tablet 4-10 mg</i> | G | QLR (QL applies to members age 65 and older); QL (120 TABLET per 25 days); AL (Max 65 Years) |
| <i>perphenazine-amitriptyline oral tablet 4-50 mg</i> | G | QLR (QL applies to members age 65 and older); QL (30 TABLET per 25 days); AL (Max 65 Years) |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | G | |
| VYLEESI SUBCUTANEOUS SOLUTION AUTO-INJECTOR 1.75 MG/0.3ML (<i>bremelanotide acetate</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| SMOKING DETERRENTS | | |
| bupropion hcl er (smoking det) oral tablet extended release 12 hour 150 mg | CE | N7 (G); N8 (\$0 limited to 2 treatment cycles/year); QL (2 TREATMENT per 365 days) |
| cvs nicotine polacrilex mouth/throat gum 2 mg | CE | N7 (G); N8 (\$0 limited to 2 treatment cycles/year); QL (2 TREATMENT per 365 days) |
| cvs nicotine polacrilex mouth/throat gum 4 mg | CE | N7 (G); N8 (\$0 limited to 2 treatment cycles/year); QL (2 TREATMENT CYCLES per 365 Days) |
| cvs nicotine polacrilex mouth/throat lozenge 2 mg | CE | N7 (G); N8 (\$0 limited to 2 treatment cycles/year); QL (2 TREATMENT per 365 days) |
| cvs nicotine transdermal patch 24 hour 21 mg/24hr, 7 mg/24hr | CE | N7 (G); N8 (\$0 limited to 2 treatment cycles/year); QL (2 TREATMENT per 365 days) |
| NICOTROL INHALATION INHALER 10 MG (nicotine) | CE | N7 (NPB); N8 (\$0 limited to 2 treatment cycles/year); QL (168 DAYS OF TREATMENT per 365 days) |
| NICOTROL NS NASAL SOLUTION 10 MG/ML (nicotine) | CE | N7 (NPB); N8 (\$0 limited to 2 treatment cycles/year); QL (168 DAYS OF TREATMENT per 365 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>varenicline tartrate (starter) oral tablet therapy pack 0.5 mg x 11 & 1 mg x 42</i> | CE | N7 (G); N8 (\$0 limited to 2 treatment cycles/year); QL (2 TREATMENT CYCLES per 365 Days) |
| <i>varenicline tartrate oral tablet 0.5 mg, 1 mg</i> | CE | N7 (G); N8 (\$0 limited to 2 treatment cycles/year); QL (2 TREATMENT per 365 DAYS) |
| ENDOCRINE AND METABOLIC - DRUGS TO TREAT DIABETES AND REGULATE HORMONES | | |
| ACROMEGALY - DRUGS TO TREAT CONDITIONS THAT CAUSE EXCESSIVE GROWTH | | |
| <i>lanreotide acetate subcutaneous solution 120 mg/0.5ml</i> | NF | |
| MYCAPSSA ORAL CAPSULE DELAYED RELEASE 20 MG (octreotide acetate) | NF | |
| <i>octreotide acetate injection solution 100 mcg/ml, 50 mcg/ml, 500 mcg/ml</i> | G | PA; QL (90 ML per 30 days) |
| <i>octreotide acetate injection solution 1000 mcg/ml</i> | G | PA; QL (45 ML per 30 days) |
| <i>octreotide acetate injection solution 200 mcg/ml</i> | G | PA; QL (225 ML per 30 days) |
| <i>octreotide acetate subcutaneous solution prefilled syringe 100 mcg/ml, 50 mcg/ml, 500 mcg/ml</i> | G | PA; QL (90 ML per 30 DAYS) |
| SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML (octreotide acetate) | SP | PA; QL (90 ML per 30 days) |
| SANDOSTATIN LAR DEPOT INTRAMUSCULAR KIT 10 MG, 20 MG, 30 MG (octreotide acetate) | NF | |
| SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 120 MG/0.5ML, 60 MG/0.2ML, 90 MG/0.3ML (lanreotide acetate) | SP | PA; QL (1 INJECTION per 28 days) |
| SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED 10 MG, 15 MG, 20 MG, 25 MG, 30 MG (pegvisomant) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ANDROGENS - DRUGS TO REGULATE MALE HORMONES | | |
| ANDRODERM TRANSDERMAL PATCH 24 HOUR 2 MG/24HR, 4 MG/24HR (<i>testosterone</i>) | NPB | PA |
| ANDROGEL PUMP TRANSDERMAL GEL 20.25 MG/ACT (1.62%) (<i>testosterone</i>) | NF | |
| AVEED INTRAMUSCULAR SOLUTION 750 MG/3ML (<i>testosterone undecanoate</i>) | SP | PA |
| FORTESTA TRANSDERMAL GEL 10 MG/ACT (2%) (<i>testosterone</i>) | NF | |
| JATENZO ORAL CAPSULE 158 MG, 198 MG, 237 MG (<i>testosterone undecanoate</i>) | NPB | PA |
| KYZATREX ORAL CAPSULE 100 MG, 150 MG, 200 MG (<i>testosterone undecanoate</i>) | NF | |
| <i>methitest oral tablet 10 mg</i> | NPB | PA; STX |
| <i>methyltestosterone oral capsule 10 mg</i> | G | PA; STX |
| NATESTO NASAL GEL 5.5 MG/ACT (<i>testosterone</i>) | PB | PA |
| TESTIM TRANSDERMAL GEL 50 MG/5GM (1%) (<i>testosterone</i>) | NF | |
| <i>testosterone cypionate injection solution 200 mg/ml</i> | NF | |
| <i>testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml</i> | G | PA |
| <i>testosterone enanthate intramuscular solution 200 mg/ml</i> | G | PA |
| <i>testosterone transdermal gel 10 mg/act (2%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%)</i> | G | PA |
| <i>testosterone transdermal gel 12.5 mg/act (1%), 50 mg/5gm (1%)</i> | G | PA; N8 (Listing does not include certain NDCs) |
| <i>testosterone transdermal solution 30 mg/act</i> | G | PA |
| TLANDO ORAL CAPSULE 112.5 MG (<i>testosterone undecanoate</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| VOGELXO PUMP TRANSDERMAL GEL 12.5 MG/ACT (1%) (<i>testosterone</i>) | NF | |
| VOGELXO TRANSDERMAL GEL 50 MG/5GM (1%) (<i>testosterone</i>) | NF | |
| XYOSTED SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/0.5ML, 50 MG/0.5ML, 75 MG/0.5ML (<i>testosterone enanthate</i>) | PB | PA |
| ANTIDIABETICS, ALPHA-GLUCOSIDASE INHIBITORS | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>miglitol oral tablet 100 mg, 25 mg, 50 mg</i> | G | |
| ANTIDIABETICS, AMYLIN ANALOGS | | |
| SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR 2700 MCG/2.7ML (<i>pramlintide acetate</i>) | PB | ST |
| SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR 1500 MCG/1.5ML (<i>pramlintide acetate</i>) | PB | ST |
| ANTIDIABETICS, BIGUANIDE | | |
| GLUMETZA ORAL TABLET EXTENDED RELEASE 24 HOUR 1000 MG, 500 MG (<i>metformin hcl</i>) | NF | |
| <i>metformin hcl er (mod) oral tablet extended release 24 hour 1000 mg, 500 mg</i> | NF | |
| <i>metformin hcl er (osm) oral tablet extended release 24 hour 1000 mg, 500 mg</i> | NF | |
| <i>metformin hcl er oral tablet extended release 24 hour 500 mg</i> | G | LGC |
| <i>metformin hcl er oral tablet extended release 24 hour 750 mg</i> | G | |
| <i>metformin hcl oral solution 500 mg/5ml</i> | G | |
| <i>metformin hcl oral tablet 1000 mg, 500 mg</i> | G | LGC |
| <i>metformin hcl oral tablet 625 mg</i> | NF | |
| <i>metformin hcl oral tablet 850 mg</i> | CE | LGC; N7 (G); AL (Min 35 Years and Max 70 Years) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| RIOMET ORAL SOLUTION 500 MG/5ML (<i>metformin hcl</i>) | NF | |
| ANTIDIABETICS, BIGUANIDE/ SULFONYLUREA COMBINATIONS | | |
| <i>glipizide-metformin hcl oral tablet 2.5-250 mg, 2.5-500 mg, 5-500 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| ANTIDIABETICS, DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR COMBINATIONS | | |
| <i>alogliptin-metformin hcl oral tablet 12.5-1000 mg, 12.5-500 mg</i> | NF | |
| <i>alogliptin-pioglitazone oral tablet 12.5-30 mg, 25-15 mg, 25-30 mg, 25-45 mg</i> | NF | |
| JANUMET ORAL TABLET 50-1000 MG, 50-500 MG (<i>sitagliptin-metformin hcl</i>) | PB | ST |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG, 50-1000 MG, 50-500 MG (<i>sitagliptin-metformin hcl</i>) | PB | ST |
| JENTADUETO ORAL TABLET 2.5-1000 MG, 2.5-500 MG, 2.5-850 MG (<i>linagliptin-metformin hcl</i>) | NF | |
| JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5-1000 MG, 5-1000 MG (<i>linagliptin-metformin hcl</i>) | NF | |
| KAZANO ORAL TABLET 12.5-1000 MG, 12.5-500 MG (<i>alogliptin-metformin hcl</i>) | NF | |
| KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5-1000 MG, 5-1000 MG, 5-500 MG (<i>saxagliptin-metformin</i>) | NF | |
| OSENI ORAL TABLET 12.5-30 MG, 25-15 MG, 25-30 MG, 25-45 MG (<i>alogliptin-pioglitazone</i>) | NF | |
| <i>saxagliptin-metformin er oral tablet extended release 24 hour 2.5-1000 mg, 5-1000 mg, 5-500 mg</i> | NF | |
| TRIJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-5-1000 MG, 12.5-2.5-1000 MG, 25-5-1000 MG, 5-2.5-1000 MG (<i>empagliflozin-linagliptin-metformin</i>) | PB | ST |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| ANTIDIABETICS, DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS | | |
| <i>alogliptin benzoate oral tablet 12.5 mg, 25 mg, 6.25 mg</i> | G | |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG (<i>sitagliptin phosphate</i>) | PB | ST |
| NESINA ORAL TABLET 12.5 MG, 25 MG, 6.25 MG (<i>alogliptin benzoate</i>) | NF | |
| ONGLYZA ORAL TABLET 2.5 MG, 5 MG (<i>saxagliptin hcl</i>) | NF | |
| <i>saxagliptin hcl oral tablet 2.5 mg, 5 mg</i> | NF | |
| <i>sitagliptin oral tablet 100 mg, 25 mg, 50 mg</i> | NF | |
| TRADJENTA ORAL TABLET 5 MG (<i>linagliptin</i>) | NF | |
| <i>zituvio oral tablet 100 mg, 25 mg, 50 mg</i> | NF | |
| ANTIDIABETICS, DOPAMINE RECEPTOR AGONISTS | | |
| CYCLOSET ORAL TABLET 0.8 MG (<i>bromocriptine mesylate</i>) | NF | |
| ANTIDIABETICS, INCRETIN MIMETIC AGENTS | | |
| BYDUREON BCISE SUBCUTANEOUS AUTO-INJECTOR 2 MG/0.85ML (<i>exenatide</i>) | NF | |
| BYETTA 10 MCG PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 10 MCG/0.04ML (<i>exenatide</i>) | NF | |
| BYETTA 5 MCG PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 5 MCG/0.02ML (<i>exenatide</i>) | NF | |
| MOUNJARO SUBCUTANEOUS SOLUTION PEN-INJECTOR 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML, 2.5 MG/0.5ML, 5 MG/0.5ML, 7.5 MG/0.5ML (<i>tirzepatide</i>) | PB | PA; QL (4 PENS per 21 days) |
| OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML (<i>semaglutide</i>) | PB | PA; QL (1 PEN per 28 DAYs) |
| OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML (<i>semaglutide</i>) | PB | PA; QL (1 PEN per 28 DAYs) |
| OZEMPIC (2 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 8 MG/3ML (<i>semaglutide</i>) | PB | PA; QL (1 PEN per 28 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG (<i>semaglutide</i>) | PB | PA; QL (30 TABLETS per 30 days) |
| TRULICITY SUBCUTANEOUS SOLUTION PEN-INJECTOR 0.75 MG/0.5ML, 1.5 MG/0.5ML, 3 MG/0.5ML, 4.5 MG/0.5ML (<i>dulaglutide</i>) | PB | PA; QL (4 PENS per 21 DAYs) |
| VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR 18 MG/3ML (<i>liraglutide</i>) | PB | PA; QL (3 PENS per 25 DAYs) |
| ANTIDIABETICS, INCRETIN MIMETIC COMBINATION AGENTS | | |
| SOLIQUA SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-33 UNT-MCG/ML (<i>insulin glargine-lixisenatide</i>) | PB | ST |
| XULTOPHY SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-3.6 UNIT-MG/ML (<i>insulin degludec-liraglutide</i>) | PB | ST |
| ANTIDIABETICS, INSULIN | | |
| ADMELOG INJECTION SOLUTION 100 UNIT/ML (<i>insulin lispro</i>) | NF | |
| ADMELOG SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin lispro</i>) | NF | |
| AFREZZA INHALATION POWDER 12 UNIT, 4 UNIT, 60X4 & 60X8 & 60X12 UNIT, 8 UNIT, 90 X 4 UNIT & 90X8 UNIT, 90 X 8 UNIT & 90X12 UNIT (<i>insulin regular human</i>) | NF | |
| APIDRA INJECTION SOLUTION 100 UNIT/ML (<i>insulin glulisine</i>) | NF | |
| APIDRA SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin glulisine</i>) | NF | |
| BASAGLAR KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin glargine</i>) | NF | |
| BASAGLAR TEMPO PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin glargine</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| FIASP FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin aspart (w/niacinamide)</i>) | PB | |
| FIASP INJECTION SOLUTION 100 UNIT/ML (<i>insulin aspart (w/niacinamide)</i>) | PB | |
| FIASP PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML (<i>insulin aspart (w/niacinamide)</i>) | PB | N8 (Listing does not include certain NDCs) |
| FIASP PUMPCART SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML (<i>insulin aspart (w/niacinamide)</i>) | NF | |
| HUMALOG INJECTION SOLUTION 100 UNIT/ML (<i>insulin lispro</i>) | NF | |
| HUMALOG JUNIOR KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin lispro</i>) | NF | |
| HUMALOG KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML (<i>insulin lispro</i>) | NF | |
| HUMALOG MIX 50/50 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (50-50) 100 UNIT/ML (<i>insulin lispro prot & lispro</i>) | NF | |
| HUMALOG MIX 50/50 SUBCUTANEOUS SUSPENSION (50-50) 100 UNIT/ML (<i>insulin lispro prot & lispro</i>) | NF | |
| HUMALOG MIX 75/25 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (75-25) 100 UNIT/ML (<i>insulin lispro prot & lispro</i>) | NF | |
| HUMALOG MIX 75/25 SUBCUTANEOUS SUSPENSION (75-25) 100 UNIT/ML (<i>insulin lispro prot & lispro</i>) | NF | |
| HUMALOG SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML (<i>insulin lispro</i>) | NF | |
| HUMALOG TEMPO PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin lispro</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| HUMULIN 70/30 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML (<i>insulin nph isophane & regular</i>) | NF | |
| HUMULIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML (<i>insulin nph isophane & regular</i>) | NF | |
| HUMULIN N KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML (<i>insulin nph human (isophane)</i>) | NF | |
| HUMULIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML (<i>insulin nph human (isophane)</i>) | NF | |
| HUMULIN R INJECTION SOLUTION 100 UNIT/ML (<i>insulin regular human</i>) | NF | |
| HUMULIN R U-500 (CONCENTRATED) SUBCUTANEOUS SOLUTION 500 UNIT/ML (<i>insulin regular human</i>) | PB | |
| HUMULIN R U-500 KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 500 UNIT/ML (<i>insulin regular human</i>) | PB | |
| <i>insulin asp prot & asp flexpen subcutaneous suspension pen-injector (70-30) 100 unit/ml</i> | NF | |
| <i>insulin aspart flexpen subcutaneous solution pen-injector 100 unit/ml</i> | NF | |
| <i>insulin aspart injection solution 100 unit/ml</i> | NF | |
| <i>insulin aspart penfill subcutaneous solution cartridge 100 unit/ml</i> | NF | |
| <i>insulin aspart prot & aspart subcutaneous suspension (70-30) 100 unit/ml</i> | NF | |
| <i>insulin degludec flextouch subcutaneous solution pen-injector 100 unit/ml, 200 unit/ml</i> | NF | |
| <i>insulin degludec subcutaneous solution 100 unit/ml</i> | NF | |
| <i>insulin glargine max solostar subcutaneous solution pen-injector 300 unit/ml</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>insulin glargine solostar subcutaneous solution pen-injector 300 unit/ml</i> | NF | |
| <i>insulin glargine-yfgn subcutaneous solution 100 unit/ml</i> | NF | |
| <i>insulin glargine-yfgn subcutaneous solution pen-injector 100 unit/ml</i> | NF | |
| <i>insulin lispro (1 unit dial) subcutaneous solution pen-injector 100 unit/ml</i> | NF | |
| <i>insulin lispro injection solution 100 unit/ml</i> | NF | |
| <i>insulin lispro junior kwikpen subcutaneous solution pen-injector 100 unit/ml</i> | NF | |
| <i>insulin lispro prot & lispro subcutaneous suspension pen-injector (75-25) 100 unit/ml</i> | NF | |
| LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin glargine</i>) | PB | |
| LANTUS SUBCUTANEOUS SOLUTION 100 UNIT/ML (<i>insulin glargine</i>) | PB | |
| LEVEMIR FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin detemir</i>) | NF | |
| LEVEMIR SUBCUTANEOUS SOLUTION 100 UNIT/ML (<i>insulin detemir</i>) | NF | |
| LYUMJEV INJECTION SOLUTION 100 UNIT/ML (<i>insulin lispro-aabc</i>) | NF | |
| LYUMJEV KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML (<i>insulin lispro-aabc</i>) | NF | |
| LYUMJEV TEMPO PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin lispro-aabc</i>) | NF | |
| MYXREDLIN INTRAVENOUS SOLUTION 100-0.9 UT/100ML-% (<i>insulin regular(human) in nacl</i>) | NF | |
| NOVOLIN 70/30 FLEXPEN RELION SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML (<i>insulin nph isophane & regular</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| NOVOLIN 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML (<i>insulin nph isophane & regular</i>) | PB | |
| NOVOLIN 70/30 RELION SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML (<i>insulin nph isophane & regular</i>) | NF | |
| NOVOLIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML (<i>insulin nph isophane & regular</i>) | PB | |
| NOVOLIN N FLEXPEN RELION SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML (<i>insulin nph human (isophane)</i>) | NF | |
| NOVOLIN N FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML (<i>insulin nph human (isophane)</i>) | PB | |
| NOVOLIN N RELION SUBCUTANEOUS SUSPENSION 100 UNIT/ML (<i>insulin nph human (isophane)</i>) | NF | |
| NOVOLIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML (<i>insulin nph human (isophane)</i>) | PB | |
| NOVOLIN R FLEXPEN INJECTION SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin regular human</i>) | PB | |
| NOVOLIN R FLEXPEN RELION INJECTION SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin regular human</i>) | NF | |
| NOVOLIN R INJECTION SOLUTION 100 UNIT/ML (<i>insulin regular human</i>) | PB | |
| NOVOLIN R RELION INJECTION SOLUTION 100 UNIT/ML (<i>insulin regular human</i>) | NF | |
| NOVOLOG 70/30 FLEXPEN RELION SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML (<i>insulin aspart prot & aspart</i>) | NF | |
| NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML (<i>insulin aspart</i>) | PB | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| NOVOLOG INJECTION SOLUTION 100 UNIT/ML <i>(insulin aspart)</i> | PB | |
| NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML <i>(insulin aspart prot & aspart)</i> | PB | |
| NOVOLOG MIX 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML <i>(insulin aspart prot & aspart)</i> | PB | |
| NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML <i>(insulin aspart)</i> | PB | |
| REZVOGLAR KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML <i>(insulin glargine-aglr)</i> | NF | |
| SEMGLEE (YFGN) SUBCUTANEOUS SOLUTION 100 UNIT/ML <i>(insulin glargine-yfgn)</i> | NF | |
| SEMGLEE (YFGN) SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML <i>(insulin glargine-yfgn)</i> | NF | |
| TOUJEO MAX SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML <i>(insulin glargine)</i> | PB | |
| TOUJEO SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML <i>(insulin glargine)</i> | PB | |
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML <i>(insulin degludec)</i> | PB | |
| TRESIBA SUBCUTANEOUS SOLUTION 100 UNIT/ML <i>(insulin degludec)</i> | PB | |
| ANTIDIABETICS, INSULIN SENSITIZER | | |
| ACTOS ORAL TABLET 15 MG, 30 MG, 45 MG <i>(pioglitazone hcl)</i> | NF | |
| <i>pioglitazone hcl oral tablet 15 mg, 30 mg, 45 mg</i> | G | LGC |
| ANTIDIABETICS, INSULIN SENSITIZER/BIGUANIDE COMBINATION | | |
| <i>pioglitazone hcl-metformin hcl oral tablet 15-500 mg, 15-850 mg</i> | G | LGC |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| ANTIDIABETICS, INSULIN SENSITIZER/SULFONYLUREA COMBINATION | | |
| <i>pioglitazone hcl-glimepiride oral tablet 30-2 mg, 30-4 mg</i> | G | |
| ANTIDIABETICS, MEGLITINIDE | | |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | G | LGC |
| <i>repaglinide oral tablet 0.5 mg, 1 mg, 2 mg</i> | G | LGC |
| ANTIDIABETICS, MISCELLANEOUS | | |
| <i>KORLYM ORAL TABLET 300 MG (mifepristone)</i> | NF | |
| <i>mifepristone oral tablet 300 mg</i> | NF | |
| ANTIDIABETICS, SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITOR COMBINATIONS | | |
| <i>dapagliflozin pro-metformin er oral tablet extended release 24 hour 10-1000 mg, 5-1000 mg</i> | NF | |
| <i>INVOKAMET ORAL TABLET 150-1000 MG, 150-500 MG, 50-1000 MG, 50-500 MG (canagliflozin-metformin hcl)</i> | NF | |
| <i>INVOKAMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150-1000 MG, 150-500 MG, 50-1000 MG, 50-500 MG (canagliflozin-metformin hcl)</i> | NF | |
| <i>SEGLUROMET ORAL TABLET 2.5-1000 MG, 2.5-500 MG, 7.5-1000 MG, 7.5-500 MG (ertugliflozin-metformin hcl)</i> | NF | |
| <i>SYNJARDY ORAL TABLET 12.5-1000 MG, 12.5-500 MG, 5-1000 MG, 5-500 MG (empagliflozin-metformin hcl)</i> | PB | ST |
| <i>SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 12.5-1000 MG, 25-1000 MG, 5-1000 MG (empagliflozin-metformin hcl)</i> | PB | ST |
| <i>XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 10-500 MG, 2.5-1000 MG, 5-1000 MG, 5-500 MG (dapagliflozin prop-metformin)</i> | PB | ST |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| ANTIDIABETICS, SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITOR/DPP-4 INHIBITOR COMBINATIONS | | |
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG (<i>empagliflozin-linagliptin</i>) | PB | ST |
| QTERN ORAL TABLET 10-5 MG, 5-5 MG (<i>dapagliflozin-saxagliptin</i>) | NF | |
| STEGLUJAN ORAL TABLET 15-100 MG, 5-100 MG (<i>ertugliflozin-sitagliptin</i>) | NF | |
| ANTIDIABETICS, SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS | | |
| <i>bexagliflozin oral tablet 20 mg</i> | NF | |
| BRENZAVVY ORAL TABLET 20 MG (<i>bexagliflozin</i>) | NF | |
| <i>dapagliflozin propanediol oral tablet 10 mg, 5 mg</i> | NF | |
| FARXIGA ORAL TABLET 10 MG, 5 MG (<i>dapagliflozin propanediol</i>) | PB | ST |
| INVOKANA ORAL TABLET 100 MG, 300 MG (<i>canagliflozin</i>) | NF | |
| JARDIANCE ORAL TABLET 10 MG, 25 MG (<i>empagliflozin</i>) | PB | ST |
| STEGLATRO ORAL TABLET 15 MG, 5 MG (<i>ertugliflozin l-pyroglyutamic acid</i>) | NF | |
| ANTIDIABETICS, SULFONYLUREA | | |
| <i>glimepiride oral tablet 1 mg, 2 mg, 4 mg</i> | G | LGC |
| <i>glipizide er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i> | G | LGC |
| <i>glipizide oral tablet 10 mg, 5 mg</i> | G | LGC |
| <i>glipizide oral tablet 2.5 mg</i> | NF | |
| ANTIOBESITY | | |
| ADIPEX-P ORAL TABLET 37.5 MG (<i>phentermine hcl</i>) | NPB | PA; QL (30 TABLETS per 25 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---------------------------------------|
| benzphetamine hcl oral tablet 50 mg | G | PA; QL (90 TABLETS per 25 days) |
| CONTRAVE ORAL TABLET EXTENDED RELEASE 12 HOUR 8-90 MG (<i>naltrexone-bupropion hcl</i>) | NF | |
| diethylpropion hcl er oral tablet extended release 24 hour 75 mg | G | PA; QL (30 TABLETS per 25 days) |
| diethylpropion hcl oral tablet 25 mg | G | PA; QL (90 TABLETS per 25 days) |
| LOMAIRA ORAL TABLET 8 MG (<i>phentermine hcl</i>) | NF | |
| orlistat oral capsule 120 mg | G | PA; QL (90 CAPSULES per 25 days) |
| phendimetrazine tartrate er oral capsule extended release 24 hour 105 mg | NF | |
| phendimetrazine tartrate oral tablet 35 mg | G | PA; SPC; QL (180 TABLETS per 25 days) |
| phentermine hcl oral capsule 15 mg | G | PA; QL (60 CAPSULES per 25 days) |
| phentermine hcl oral capsule 30 mg | G | PA; SPC; QL (30 CAPSULES per 25 days) |
| phentermine hcl oral capsule 37.5 mg | G | PA; QL (30 CAPSULES per 25 days) |
| phentermine hcl oral tablet 37.5 mg | G | PA; QL (30 TABLETS per 25 days) |
| QSYMIA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 11.25-69 MG, 15-92 MG, 3.75-23 MG, 7.5-46 MG (<i>phentermine-topiramate</i>) | PB | PA; QL (30 CAPSULES per 25 days) |
| SAXENDA SUBCUTANEOUS SOLUTION PEN-INJECTOR 18 MG/3ML (<i>liraglutide -weight management</i>) | PB | PA; QL (5 PENS per 25 days) |
| WEGOVY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 0.25 MG/0.5ML, 0.5 MG/0.5ML, 1 MG/0.5ML, 1.7 MG/0.75ML, 2.4 MG/0.75ML (<i>semaglutide-weight management</i>) | PB | PA; QL (4 PENS per 21 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| XENICAL ORAL CAPSULE 120 MG (<i>orlistat</i>) | NF | |
| ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML, 2.5 MG/0.5ML, 5 MG/0.5ML, 7.5 MG/0.5ML (<i>tirzepatide-weight management</i>) | PB | PA; SPC; QL (4 PENS per 21 DAYS) |
| CALCIUM RECEPTOR AGONISTS | | |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>calcitriol oral solution 1 mcg/ml</i> | G | |
| <i>cinacalcet hcl oral tablet 30 mg, 60 mg</i> | SP | PA; QL (60 TABLETS per 30 DAYS) |
| <i>cinacalcet hcl oral tablet 90 mg</i> | SP | PA; QL (120 TABLETS per 30 DAYS) |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg</i> | G | |
| PARSABIV INTRAVENOUS SOLUTION 10 MG/2ML, 2.5 MG/0.5ML, 5 MG/ML (<i>etelcalcetide hcl</i>) | NF | |
| RAYALDEE ORAL CAPSULE EXTENDED RELEASE 30 MCG (<i>calcifediol</i>) | NPB | ST |
| SENSIPAR ORAL TABLET 30 MG, 60 MG (<i>cinacalcet hcl</i>) | SP | PA; QL (60 TABLETS per 30 DAYS) |
| SENSIPAR ORAL TABLET 90 MG (<i>cinacalcet hcl</i>) | SP | PA; QL (120 TABLETS per 30 DAYS) |
| CALCIUM REGULATORS, BISPHOSPHONATES - DRUGS TO TREAT BONE LOSS | | |
| ACTONEL ORAL TABLET 150 MG (<i>risedronate sodium</i>) | NPB | ST; QL (1 TAB per 21 days) |
| ACTONEL ORAL TABLET 35 MG (<i>risedronate sodium</i>) | NPB | ST; QL (4 TABLETS per 21 days) |
| <i>alendronate sodium oral solution 70 mg/75ml</i> | G | |
| <i>alendronate sodium oral tablet 10 mg, 35 mg, 5 mg, 70 mg</i> | G | |
| ATELVIA ORAL TABLET DELAYED RELEASE 35 MG (<i>risedronate sodium</i>) | NPB | ST; QL (4 TABLETS per 21 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| BINOSTO ORAL TABLET EFFERVESCENT 70 MG (alendronate sodium) | NPB | ST; QL (4 TABLETS per 21 days) |
| FOSAMAX ORAL TABLET 70 MG (alendronate sodium) | NPB | ST; QL (4 TABLETS per 21 days) |
| FOSAMAX PLUS D ORAL TABLET 70-2800 MG-UNIT, 70-5600 MG-UNIT (alendronate-cholecalciferol) | NPB | ST; QL (4 TABLETS per 21 days) |
| <i>ibandronate sodium intravenous solution 3 mg/3ml</i> | G | |
| <i>ibandronate sodium oral tablet 150 mg</i> | G | |
| <i>pamidronate disodium intravenous solution 30 mg/10ml, 90 mg/10ml</i> | G | |
| <i>pamidronate disodium intravenous solution 6 mg/ml</i> | SP | |
| RECLAST INTRAVENOUS SOLUTION 5 MG/100ML (zoledronic acid) | SP | PA |
| <i>risedronate sodium oral tablet 150 mg, 30 mg, 35 mg, 5 mg</i> | G | |
| <i>risedronate sodium oral tablet delayed release 35 mg</i> | G | |
| <i>zoledronic acid intravenous concentrate 4 mg/5ml</i> | G | PA |
| <i>zoledronic acid intravenous solution 4 mg/100ml</i> | SP | PA |
| <i>zoledronic acid intravenous solution 5 mg/100ml</i> | G | PA |
| CALCIUM REGULATORS, MISCELLANEOUS | | |
| <i>calcitonin (salmon) nasal solution 200 unit/act</i> | G | |
| PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 60 MG/ML (denosumab) | SP | PA; QL (60 MG per 168 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7ML (denosumab) | SP | PA |
| CALCIUM REGULATORS, PARATHYROID HORMONES | | |
| FORTEO SUBCUTANEOUS SOLUTION PEN- INJECTOR 600 MCG/2.4ML (teriparatide (recombinant)) | SP | PA; QL (1 PEN per 28 days) |
| <i>teriparatide (recombinant) subcutaneous solution pen-injector 620 mcg/2.48ml</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>teriparatide subcutaneous solution pen-injector 600 mcg/2.4ml</i> | SP | PA; QL (1 PEN per 28 DAYS) |
| TYMLOS SUBCUTANEOUS SOLUTION PEN-INJECTOR 3120 MCG/1.56ML (<i>abaloparatide</i>) | SP | PA; QL (1 PEN per 30 days) |
| CARNITINE DEFICIENCY AGENTS | | |
| CARNITOR ORAL SOLUTION 1 GM/10ML (<i>levocarnitine</i>) | NF | |
| CARNITOR ORAL TABLET 330 MG (<i>levocarnitine</i>) | NF | |
| CARNITOR SF ORAL SOLUTION 1 GM/10ML (<i>levocarnitine</i>) | NF | |
| <i>levocarnitine oral solution 1 gm/10ml</i> | G | |
| <i>levocarnitine oral tablet 330 mg</i> | G | |
| CENTRAL PRECOCIOUS PUBERTY - DRUGS TO SUPPRESS PITUITARY HORMONES | | |
| LUPRON DEPOT-PED (1-MONTH) INTRAMUSCULAR KIT 11.25 MG, 15 MG, 7.5 MG (<i>leuprolide acetate</i>) | SP | PA |
| LUPRON DEPOT-PED (3-MONTH) INTRAMUSCULAR KIT 11.25 MG, 30 MG (<i>leuprolide acetate (3 month)</i>) | SP | PA |
| TRIPTODUR INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 22.5 MG (<i>triptorelin pamoate</i>) | NF | |
| CHELATIN AGENTS | | |
| CUPRIMINE ORAL CAPSULE 250 MG (<i>penicillamine</i>) | NF | |
| CUVRIOR ORAL TABLET 300 MG (<i>trientine tetrahydrochloride</i>) | NF | |
| <i>deferasirox granules oral packet 180 mg, 360 mg, 90 mg</i> | SP | PA |
| <i>deferasirox oral tablet 180 mg, 360 mg, 90 mg</i> | SP | PA |
| <i>deferasirox oral tablet soluble 125 mg, 250 mg, 500 mg</i> | SP | PA |
| <i>deferiprone oral tablet 1000 mg, 500 mg</i> | SP | PA |
| <i>deferoxamine mesylate injection solution reconstituted 2 gm, 500 mg</i> | SP | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| DEPEN TITRATABS ORAL TABLET 250 MG (<i>penicillamine</i>) | NPB | PA |
| DESFERAL INJECTION SOLUTION RECONSTITUTED 500 MG (<i>deferoxamine mesylate</i>) | NF | |
| EXJADE ORAL TABLET SOLUBLE 125 MG, 250 MG, 500 MG (<i>deferasirox</i>) | NF | |
| FERRIPROX ORAL SOLUTION 100 MG/ML (<i>deferiprone</i>) | NF | |
| FERRIPROX ORAL TABLET 1000 MG, 500 MG (<i>deferiprone</i>) | NF | |
| FERRIPROX TWICE-A-DAY ORAL TABLET 1000 MG (<i>deferiprone</i>) | NF | |
| JADENU ORAL TABLET 180 MG, 360 MG, 90 MG (<i>deferasirox</i>) | NF | |
| JADENU SPRINKLE ORAL PACKET 180 MG, 360 MG, 90 MG (<i>deferasirox</i>) | NF | |
| <i>penicillamine oral capsule 250 mg</i> | SP | PA |
| <i>penicillamine oral tablet 250 mg</i> | G | PA |
| SYPRINE ORAL CAPSULE 250 MG (<i>trientine hcl</i>) | NF | |
| <i>trientine hcl oral capsule 250 mg, 500 mg</i> | SP | PA |
| CONTRACEPTIVES - PRODUCTS FOR BIRTH CONTROL | | |
| <i>levonorgestrel-ethynodiol dihydrogen phosphate</i> (Afirmelle Oral Tablet 0.1-20 Mg-Mcg) | CE | N7 (G) |
| AFTERA ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| AFTERPILL ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| <i>levonorgestrel-ethynodiol dihydrogen phosphate</i> (Altavera Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| <i>alyacen 1/35 oral tablet 1-35 mg-mcg</i> | CE | N7 (G) |
| <i>alyacen 7/7/7 oral tablet 0.5/0.75/1-35 mg-mcg</i> | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|-----------------------------------|
| <i>levonorgestrel-ethinyl estrad</i> (Amethyst Oral Tablet 90-20 Mcg) | CE | N7 (G) |
| ANNOVERA VAGINAL RING 0.013-0.15 MG/24HR (<i>segesterone-ethinyl estradiol</i>) | CE | N7 (PB); QL (1 RING per 300 DAYS) |
| <i>desogestrel-ethinyl estradiol</i> (Apri Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethin-eth estrad triphasic</i> (Aranelle Oral Tablet 0.5/1/0.5-35 Mg-Mcg) | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day</i> (Ashlyna Oral Tablet 0.15-0.03 &0.01 Mg) | CE | N7 (G) |
| <i>levonorgestrel-ethinyl estrad</i> (Aubra Eq Oral Tablet 0.1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone acet-ethinyl est</i> (Aurovela 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone acet-ethinyl est</i> (Aurovela 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Aurovela 24 Fe Oral Tablet 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Aurovela Fe 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Aurovela Fe 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>levonorgestrel-ethinyl estrad</i> (Aviane Oral Tablet 0.1-20 Mg-Mcg) | CE | N7 (G) |
| <i>levonorgestrel-ethinyl estrad</i> (Ayuna Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| <i>desogestrel-ethinyl estradiol</i> (Azurette Oral Tablet 0.15-0.02/0.01 Mg (21/5)) | CE | N7 (G) |
| BALCOLTRA ORAL TABLET 0.1-20 MG-MCG(21) (<i>levonorgest-eth estrad-fe bisg</i>) | NF | |
| <i>norethindrone-eth estradiol</i> (Balziva Oral Tablet 0.4-35 Mg-Mcg) | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| BEYAZ ORAL TABLET 3-0.02-0.451 MG (<i>drosipрен-ет</i> <i>естрад-левомефол</i>) | NF | |
| <i>norethin ace-eth estrad-fe</i> (Blisovi 24 Fe Oral Tablet 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Blisovi Fe 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Blisovi Fe 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>brielllyn oral tablet 0.4-35 mg-mcg</i> | CE | N7 (G) |
| <i>norethindrone</i> (Camila Oral Tablet 0.35 Mg) | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day</i> (Camrese Lo Oral Tablet 0.1-0.02 & 0.01 Mg) | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day</i> (Camrese Oral Tablet 0.15-0.03 &0.01 Mg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Charlotte 24 Fe Oral Tablet Chewable 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>levonorgestrel-ethynodiol estrad</i> (Chateal Eq Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| <i>condoms</i> | CE | N7 (Not Covered); QL (12 CONDOMS per 25 DAYs) |
| <i>norgestrel-ethynodiol estradiol</i> (Cryselle-28 Oral Tablet 0.3-30 Mg-Mcg) | CE | N7 (G) |
| CURAE ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| <i>desogestrel-ethynodiol estradiol</i> (Cyred Eq Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone-eth estradiol</i> (Dasetta 1/35 Oral Tablet 1-35 Mg-Mcg) | CE | N7 (G) |
| <i>norethin-eth estrad triphasic</i> (Dasetta 7/7/7 Oral Tablet 0.5/0.75/1-35 Mg-Mcg) | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day</i> (Daysee Oral Tablet 0.15-0.03 &0.01 Mg) | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|-----------------------------------|
| <i>norethindrone</i> (Deblitane Oral Tablet 0.35 Mg) | CE | N7 (G) |
| <i>levonorgestrel-ethinyl estrad</i> (Delyla Oral Tablet 0.1-20 Mg-Mcg) | CE | N7 (G) |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 104 MG/0.65ML (<i>medroxyprogesterone acetate</i>) | CE | N7 (NF) |
| <i>desogestrel-ethinyl estradiol</i> oral tablet 0.15-0.02/0.01 mg (21/5) | CE | N7 (G) |
| <i>levonorgestrel-ethinyl estrad</i> (Dolishale Oral Tablet 90-20 Mcg) | CE | N7 (G) |
| <i>drospirene-eth estrad-levomefol</i> oral tablet 3-0.02-0.451 mg, 3-0.03-0.451 mg | CE | N7 (G) |
| <i>drospirenone-ethinyl estradiol</i> oral tablet 3-0.02 mg, 3-0.03 mg | CE | N7 (G) |
| ECONTRA ONE-STEP ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| <i>norgestrel-ethinyl estradiol</i> (Elinest Oral Tablet 0.3-30 Mg-Mcg) | CE | N7 (G) |
| ELLA ORAL TABLET 30 MG (<i>ulipristal acetate</i>) | CE | N7 (NPB) |
| <i>levonorg-eth estrad triphasic</i> (Enpresse-28 Oral Tablet 50-30/75-40/ 125-30 Mcg) | CE | N7 (G) |
| <i>desogestrel-ethinyl estradiol</i> (Enskyce Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone</i> (Errin Oral Tablet 0.35 Mg) | CE | N7 (G) |
| <i>norgestimate-eth estradiol</i> (Estarylla Oral Tablet 0.25-35 Mg-Mcg) | CE | N7 (G) |
| <i>ethynodiol diac-eth estradiol</i> oral tablet 1-35 mg-mcg, 1-50 mg-mcg | CE | N7 (G) |
| <i>etonogestrel-ethinyl estradiol vaginal ring</i> 0.12-0.015 mg/24hr | CE | N7 (G); QL (13 RING per 300 days) |
| <i>levonorgestrel-ethinyl estrad</i> (Falmina Oral Tablet 0.1-20 Mg-Mcg) | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---------------------------------------|
| FC2 FEMALE CONDOM (<i>condoms - female</i>) | CE | N7 (NPB); QL (12 CONDOMS per 25 days) |
| <i>norethin ace-eth estrad-fe</i> (Finzala Oral Tablet Chewable 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Gemmily Oral Capsule 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>norethindrone acet-ethinyl est</i> (Hailey 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Hailey 24 Fe Oral Tablet 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Hailey Fe 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Hailey Fe 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone</i> (Heather Oral Tablet 0.35 Mg) | CE | N7 (G) |
| HER STYLE ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| <i>levonorgest-eth estrad 91-day</i> (Iclevia Oral Tablet 0.15-0.03 Mg) | CE | N7 (G) |
| <i>norethindrone</i> (Incassia Oral Tablet 0.35 Mg) | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day</i> (Introvale Oral Tablet 0.15-0.03 Mg) | CE | N7 (G) |
| <i>desogestrel-ethinyl estradiol</i> (Isibloom Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day</i> (Jaimiess Oral Tablet 0.15-0.03 &0.01 Mg) | CE | N7 (G) |
| <i>drospirenone-ethinyl estradiol</i> (Jasmiel Oral Tablet 3-0.02 Mg) | CE | N7 (G) |
| <i>norethindrone</i> (Jencycla Oral Tablet 0.35 Mg) | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day</i> (Jolessa Oral Tablet 0.15-0.03 Mg) | CE | N7 (G) |
| <i>levonorgest-eth estrad-fe bisg</i> (Joyeaux Oral Tablet 0.1-20 Mg-Mcg(21)) | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>desogestrel-ethinyl estradiol</i> (Juleber Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone acet-ethinyl est</i> (Junel 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone acet-ethinyl est</i> (Junel 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Junel Fe 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Junel Fe 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Junel Fe 24 Oral Tablet 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>norethin-eth estradiol-fe</i> (Kaitlib Fe Oral Tablet Chewable 0.8-25 Mg-Mcg) | CE | N7 (G) |
| <i>desogestrel-ethinyl estradiol</i> (Kalliga Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| <i>desogestrel-ethinyl estradiol</i> (Kariva Oral Tablet 0.15-0.02/0.01 Mg (21/5)) | CE | N7 (G) |
| <i>ethynodiol diac-eth estradiol</i> (Kelnor 1/35 Oral Tablet 1-35 Mg-Mcg) | CE | N7 (G) |
| <i>ethynodiol diac-eth estradiol</i> (Kelnor 1/50 Oral Tablet 1-50 Mg-Mcg) | CE | N7 (G) |
| <i>levonorgestrel-ethinyl estrad</i> (Kurvelo Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| KYLEENA INTRAUTERINE INTRAUTERINE DEVICE 19.5 MG (<i>levonorgestrel</i>) | CE | N7 (PB); QL (1 INTRAUTERINE DEVICE per 300 DAYS) |
| <i>norethindrone acet-ethinyl est</i> (Larin 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone acet-ethinyl est</i> (Larin 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>norethin ace-eth estrad-fe</i> (Larin 24 Fe Oral Tablet 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Larin Fe 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Larin Fe 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norethin-eth estradiol-fe</i> (Layolis Fe Oral Tablet Chewable 0.8-25 Mg-Mcg) | CE | N7 (G) |
| <i>norethin-eth estrad triphasic</i> (Leena Oral Tablet 0.5/1/0.5-35 Mg-Mcg) | CE | N7 (G) |
| <i>levonorgestrel-ethynodiol-estradiol</i> (Lessina Oral Tablet 0.1-20 Mg-Mcg) | CE | N7 (G) |
| <i>levonorg-eth estrad triphasic</i> (Levonest Oral Tablet 50-30/75-40/ 125-30 Mcg) | CE | N7 (G) |
| <i>levonorgest-eth est & eth est oral tablet 42-21-21-7 days</i> | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day oral tablet 0.1-0.02 & 0.01 mg, 0.15-0.03 & 0.01 mg, 0.15-0.03 mg</i> | CE | N7 (G) |
| <i>levonorgestrel oral tablet 1.5 mg</i> | CE | N7 (Not Covered) |
| <i>levonorgestrel-ethynodiol-estradiol oral tablet 0.1-20 mg-mcg, 0.15-30 mg-mcg, 90-20 mcg</i> | CE | N7 (G) |
| <i>levonorg-eth estrad triphasic oral tablet 50-30/75-40/ 125-30 mcg</i> | CE | N7 (G) |
| <i>levonorgestrel-ethynodiol-estradiol</i> (Levora 0.15/30 (28) Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| LILETTA (52 MG) INTRAUTERINE INTRAUTERINE DEVICE 20.1 MCG/DAY (<i>levonorgestrel</i>) | CE | N7 (NF) |
| LO LOESTRIN FE ORAL TABLET 1 MG-10 MCG / 10 MCG (<i>norethin-eth estrad-fe biphas</i>) | CE | N7 (PB) |
| <i>norethindrone acet-ethynodiol est</i> (Loestrin 1.5/30 (21) Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>norethindrone acet-ethinyl est</i> (Loestrin 1/20 (21) Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Loestrin Fe 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Loestrin Fe 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day</i> (Lojaimiess Oral Tablet 0.1-0.02 & 0.01 Mg) | CE | N7 (G) |
| <i>drospirenone-ethinyl estradiol</i> (Loryna Oral Tablet 3-0.02 Mg) | CE | N7 (G) |
| <i>norgestrel-ethinyl estradiol</i> (Low-Ogestrel Oral Tablet 0.3-30 Mg-Mcg) | CE | N7 (G) |
| <i>drospirenone-ethinyl estradiol</i> (Lo-Zumandimine Oral Tablet 3-0.02 Mg) | CE | N7 (G) |
| <i>levonorgestrel-ethinyl estrad</i> (Lutera Oral Tablet 0.1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone</i> (Lyleq Oral Tablet 0.35 Mg) | CE | N7 (G) |
| <i>norethindrone</i> (Lyza Oral Tablet 0.35 Mg) | CE | N7 (G) |
| <i>marlissa oral tablet 0.15-30 mg-mcg</i> | CE | N7 (G) |
| <i>medroxyprogesterone acetate intramuscular suspension 150 mg/ml</i> | CE | N7 (G); QL (4 INJ per 300 DAYs) |
| <i>medroxyprogesterone acetate intramuscular suspension prefilled syringe 150 mg/ml</i> | CE | N7 (G); QL (4 INJ per 300 DAYs) |
| <i>norethin ace-eth estrad-fe</i> (Merzee Oral Capsule 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Mibelas 24 Fe Oral Tablet Chewable 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>norethindrone acet-ethinyl est</i> (Microgestin 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone acet-ethinyl est</i> (Microgestin 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>norethin ace-eth estrad-fe</i> (Microgestin 24 Fe Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Microgestin Fe 1.5/30 Oral Tablet 1.5-30 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Microgestin Fe 1/20 Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norgestimate-eth estradiol</i> (Mili Oral Tablet 0.25-35 Mg-Mcg) | CE | N7 (G) |
| MINASTRIN 24 FE ORAL TABLET CHEWABLE 1-20 MG-MCG(24) (<i>norethin ace-eth estrad-fe</i>) | NF | |
| MIRENA (52 MG) INTRAUTERINE INTRAUTERINE DEVICE 20 MCG/DAY (<i>levonorgestrel</i>) | CE | N7 (PB); QL (1 Untrauterine Device per 300 days) |
| <i>norgestimate-eth estradiol</i> (Mono-Linyah Oral Tablet 0.25-35 Mg-Mcg) | CE | N7 (G) |
| MY CHOICE ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| MY WAY ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| NATAZIA ORAL TABLET 3/2-2/2-3/1 MG (<i>estradiol valerate-dienogest</i>) | CE | N7 (PB) |
| <i>norethindrone-eth estradiol</i> (Necon 0.5/35 (28) Oral Tablet 0.5-35 Mg-Mcg) | CE | N7 (G) |
| NEW DAY ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| NEXPLANON SUBCUTANEOUS IMPLANT 68 MG (<i>etonogestrel</i>) | CE | N7 (NPB); QL (1 IMPLANT per 300 days) |
| NEXTSTELLIS ORAL TABLET 3-14.2 MG (<i>drosipренон-естетрол</i>) | CE | N7 (NF) |
| <i>drosipренон-этинил эстрадиол</i> (Nikki Oral Tablet 3-0.02 Mg) | CE | N7 (G) |
| <i>norethindrone</i> (Nora-Be Oral Tablet 0.35 Mg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe oral capsule</i> 1-20 mg-mcg(24) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe oral tablet</i> 1-20 mg-mcg, 1.5-30 mg-mcg | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>norethin ace-eth estrad-fe oral tablet chewable 1-20 mg-mcg(24)</i> | CE | N7 (G) |
| <i>norethindrone acet-ethinyl est oral tablet 1-20 mg-mcg, 1.5-30 mg-mcg</i> | CE | N7 (G) |
| <i>norethindrone oral tablet 0.35 mg</i> | CE | N7 (G) |
| <i>norethindron-ethinyl estrad-fe oral tablet 1-20/1-30/1-35 mg-mcg</i> | CE | N7 (G) |
| <i>norethin-eth estradiol-fe oral tablet chewable 0.4-35 mg-mcg, 0.8-25 mg-mcg</i> | CE | N7 (G) |
| <i>norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg</i> | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-25 mcg, 0.18/0.215/0.25 mg-35 mcg</i> | CE | N7 (G) |
| <i>norethindrone (Norlyroc Oral Tablet 0.35 Mg)</i> | CE | N7 (G) |
| <i>norethindrone-eth estradiol (Nortrel 0.5/35 (28) Oral Tablet 0.5-35 Mg-Mcg)</i> | CE | N7 (G) |
| <i>norethindrone-eth estradiol (Nortrel 1/35 (21) Oral Tablet 1-35 Mg-Mcg)</i> | CE | N7 (G) |
| <i>norethin-eth estrad triphasic (Nortrel 7/7/7 Oral Tablet 0.5/0.75/1-35 Mg-Mcg)</i> | CE | N7 (G) |
| NUVARING VAGINAL RING 0.12-0.015 MG/24HR (etonogestrel-ethinyl estradiol) | NF | |
| <i>norethindrone-eth estradiol (Nylia 1/35 Oral Tablet 1-35 Mg-Mcg)</i> | CE | N7 (G) |
| <i>norethin-eth estrad triphasic (Nylia 7/7/7 Oral Tablet 0.5/0.75/1-35 Mg-Mcg)</i> | CE | N7 (G) |
| <i>norgestimate-eth estradiol (Nymyo Oral Tablet 0.25-35 Mg-Mcg)</i> | CE | N7 (G) |
| <i>drospirenone-ethinyl estradiol (Ocella Oral Tablet 3-0.03 Mg)</i> | CE | N7 (G) |
| OPCICON ONE-STEP ORAL TABLET 1.5 MG (levonorgestrel) | CE | N7 (Not Covered) |
| OPILL ORAL TABLET 0.075 MG (norgestrel) | CE | N7 (Not Covered) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| OPTION 2 ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| PARAGARD INTRAUTERINE COPPER INTRAUTERINE INTRAUTERINE DEVICE (<i>copper</i>) | CE | N7 (NPB); QL (1 INTRAUTERINE DEVICE per 300 days) |
| <i>norethindrone-eth estradiol</i> (Philith Oral Tablet 0.4-35 Mg-Mcg) | CE | N7 (G) |
| <i>desogestrel-ethinyl estradiol</i> (Pimtrea Oral Tablet 0.15-0.02/0.01 Mg (21/5)) | CE | N7 (G) |
| <i>levonorgestrel-ethinyl estrad</i> (Portia-28 Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| REACT ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| <i>desogestrel-ethinyl estradiol</i> (Reclipsen Oral Tablet 0.15-30 Mg-Mcg) | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day</i> (Rivelsa Oral Tablet 42-21-21-7 Days) | CE | N7 (G) |
| SAFYRAL ORAL TABLET 3-0.03-0.451 MG (<i>drosipren-eth estrad-levomefol</i>) | NPB | |
| <i>levonorgest-eth estrad 91-day</i> (Setlakin Oral Tablet 0.15-0.03 Mg) | CE | N7 (G) |
| <i>norethindrone</i> (Sharobel Oral Tablet 0.35 Mg) | CE | N7 (G) |
| <i>desogestrel-ethinyl estradiol</i> (Simliya Oral Tablet 0.15-0.02/0.01 Mg (21/5)) | CE | N7 (G) |
| <i>levonorgest-eth estrad 91-day</i> (Simpesse Oral Tablet 0.15-0.03 &0.01 Mg) | CE | N7 (G) |
| SKYLA INTRAUTERINE INTRAUTERINE DEVICE 13.5 MG (<i>levonorgestrel</i>) | CE | N7 (PB); QL (1 INTRAUTERINE DEVICE per 300 DAYs) |
| SLYND ORAL TABLET 4 MG (<i>drosiprenone</i>) | CE | N7 (NF) |
| <i>norgestimate-eth estradiol</i> (Sprintec 28 Oral Tablet 0.25-35 Mg-Mcg) | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>levonorgestrel-ethinyl estrad</i> (Sronyx Oral Tablet 0.1-20 Mg-Mcg) | CE | N7 (G) |
| <i>drosipренone-ethinyl estradiol</i> (Syeda Oral Tablet 3-0.03 Mg) | CE | N7 (G) |
| TAKE ACTION ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | CE | N7 (Not Covered) |
| <i>norethin ace-eth estrad-fe</i> (Tarina 24 Fe Oral Tablet 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Tarina Fe 1/20 Eq Oral Tablet 1-20 Mg-Mcg) | CE | N7 (G) |
| <i>norethin ace-eth estrad-fe</i> (Taysofy Oral Capsule 1-20 Mg-Mcg(24)) | CE | N7 (G) |
| TAYTULLA ORAL CAPSULE 1-20 MG-MCG(24) (<i>norethin ace-eth estrad-fe</i>) | NF | |
| <i>norethindron-ethinyl estrad-fe</i> (Tilia Fe Oral Tablet 1-20/1-30/1-35 Mg-Mcg) | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic</i> (Tri-Estarrylla Oral Tablet 0.18/0.215/0.25 Mg-35 Mcg) | CE | N7 (G) |
| <i>norethindron-ethinyl estrad-fe</i> (Tri-Legest Fe Oral Tablet 1-20/1-30/1-35 Mg-Mcg) | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic</i> (Tri-Linyah Oral Tablet 0.18/0.215/0.25 Mg-35 Mcg) | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic</i> (Tri-Lo-Estarrylla Oral Tablet 0.18/0.215/0.25 Mg-25 Mcg) | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic</i> (Tri-Lo-Marzia Oral Tablet 0.18/0.215/0.25 Mg-25 Mcg) | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic</i> (Tri-Lo-Mili Oral Tablet 0.18/0.215/0.25 Mg-25 Mcg) | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic</i> (Tri-Lo-Sprintec Oral Tablet 0.18/0.215/0.25 Mg-25 Mcg) | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic</i> (Tri-Mili Oral Tablet 0.18/0.215/0.25 Mg-35 Mcg) | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>norgestim-eth estrad triphasic</i> (Tri-Nymyo Oral Tablet 0.18/0.215/0.25 Mg-35 Mcg) | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic</i> (Tri-Sprintec Oral Tablet 0.18/0.215/0.25 Mg-35 Mcg) | CE | N7 (G) |
| <i>levonorg-eth estrad triphasic</i> (Trivora (28) Oral Tablet 50-30/75-40/ 125-30 Mcg) | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic</i> (Tri-Vylibra Lo Oral Tablet 0.18/0.215/0.25 Mg-25 Mcg) | CE | N7 (G) |
| <i>norgestim-eth estrad triphasic</i> (Tri-Vylibra Oral Tablet 0.18/0.215/0.25 Mg-35 Mcg) | CE | N7 (G) |
| <i>norgestrel-ethynodiolide</i> (Turqoz Oral Tablet 0.3-30 Mg-Mcg) | CE | N7 (G) |
| TWIRLA TRANSDERMAL PATCH WEEKLY 120-30 MCG/24HR (<i>levonorgestrel-ethynodiolide</i>) | CE | N7 (NF) |
| TYBLUME ORAL TABLET CHEWABLE 0.1-20 MG-MCG (<i>levonorgestrel-ethynodiolide</i>) | CE | N7 (NF) |
| <i>drospirenone-ethynodiolide</i> (Tydemy Oral Tablet 3-0.03-0.451 Mg) | CE | N7 (G) |
| VELIVET ORAL TABLET 0.1/0.125/0.15 -0.025 MG (<i>desogestrel-ethynodiolide</i>) | CE | N7 (G) |
| <i>drospirenone-ethynodiolide</i> (Vestura Oral Tablet 3-0.02 Mg) | CE | N7 (G) |
| <i>levonorgestrel-ethynodiolide</i> (Vienna Oral Tablet 0.1-20 Mg-Mcg) | CE | N7 (G) |
| <i>viorele oral tablet 0.15-0.02/0.01 mg (21/5)</i> | CE | N7 (G) |
| <i>desogestrel-ethynodiolide</i> (Volnea Oral Tablet 0.15-0.02/0.01 Mg (21/5)) | CE | N7 (G) |
| <i>norethindrone-ethynodiolide</i> (Vyfemla Oral Tablet 0.4-35 Mg-Mcg) | CE | N7 (G) |
| <i>norgestimate-ethynodiolide</i> (Vylibra Oral Tablet 0.25-35 Mg-Mcg) | CE | N7 (G) |
| <i>norethindrone-ethynodiolide</i> (Wera Oral Tablet 0.5-35 Mg-Mcg) | CE | N7 (G) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>norethin-eth estradiol-fe</i> (Wymzya Fe Oral Tablet Chewable 0.4-35 Mg-Mcg) | CE | N7 (G) |
| <i>norelgestromin-eth estradiol</i> (Xulane Transdermal Patch Weekly 150-35 Mcg/24Hr) | CE | N7 (G) |
| YASMIN 28 ORAL TABLET 3-0.03 MG (<i>drosipренон-этинил эстрадиол</i>) | NF | N7 (NF) |
| YAZ ORAL TABLET 3-0.02 MG (<i>drosipренон-этинил эстрадиол</i>) | NF | |
| <i>norelgestromin-eth estradiol</i> (Zafemy Transdermal Patch Weekly 150-35 Mcg/24Hr) | CE | N7 (G) |
| <i>ethynodiol diac-eth estradiol</i> (Zovia 1/35 (28) Oral Tablet 1-35 Mg-Mcg) | CE | N7 (G) |
| <i>drosipренон-этинил эстрадиол</i> (Zumandimine Oral Tablet 3-0.03 Mg) | CE | N7 (G) |
| CORTISOL SYNTHESIS INHIBITORS | | |
| RECORLEV ORAL TABLET 150 MG (<i>levoketoconazole</i>) | NF | |
| DIABETIC SUPPLIES | | |
| ACCU-CHEK AVIVA PLUS IN VITRO STRIP (<i>glucose blood</i>) | PB | QL (150 TEST STRIPS per 25 days) |
| ACCU-CHEK FASTCLIX LANCET KIT (<i>lancets misc.</i>) | PB | |
| ACCU-CHEK FASTCLIX LANCETS (<i>lancets</i>) | PB | |
| ACCU-CHEK GUIDE IN VITRO STRIP (<i>glucose blood</i>) | PB | QL (150 TEST STRIPS per 25 days) |
| ACCU-CHEK SAFE-T PRO LANCETS (<i>lancets</i>) | PB | |
| ACCU-CHEK SMARTVIEW IN VITRO STRIP (<i>glucose blood</i>) | PB | QL (150 TEST STRIPS per 25 days) |
| ACCU-CHEK SOFTCLIX LANCET DEV KIT (<i>lancets misc.</i>) | PB | |
| ACCU-CHEK SOFTCLIX LANCETS (<i>lancets</i>) | PB | |
| DEXCOM G6 RECEIVER DEVICE (<i>continuous glucose receiver</i>) | PB | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| DEXCOM G6 SENSOR (<i>continuous glucose sensor</i>) | PB | QL (3 SENSORS per 25 days) |
| DEXCOM G6 TRANSMITTER (<i>continuous glucose transmitter</i>) | PB | |
| DEXCOM G7 RECEIVER DEVICE (<i>continuous glucose receiver</i>) | PB | |
| DEXCOM G7 SENSOR (<i>continuous glucose sensor</i>) | PB | QL (3 SENSORS per 25 DAYs) |
| DIASTIX REAGENT IN VITRO STRIP (<i>glucose urine test-glucose ox</i>) | NF | |
| EMBRACE WAVE BLOOD GLUCOSE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| EVERSENSE E3 SENSOR/HOLDER (<i>continuous glucose sensor</i>) | NF | |
| EVERSENSE E3 SMART TRANSMITTER (<i>continuous glucose transmitter</i>) | NF | |
| FORA 6 CONNECT/GTEL TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| FREESTYLE LIBRE 14 DAY SENSOR (<i>continuous glucose sensor</i>) | NF | |
| FREESTYLE LIBRE 2 SENSOR (<i>continuous glucose sensor</i>) | NF | |
| FREESTYLE LIBRE 3 READER DEVICE (<i>continuous glucose receiver</i>) | NF | |
| FREESTYLE LIBRE 3 SENSOR (<i>continuous glucose sensor</i>) | NF | |
| GUARDIAN 4 GLUCOSE SENSOR (<i>continuous glucose sensor</i>) | NF | |
| GUARDIAN 4 TRANSMITTER (<i>continuous glucose transmitter</i>) | NF | |
| GUARDIAN LINK 3 TRANSMITTER (<i>continuous glucose transmitter</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| LIBERTY GLUCOSE CONTROL IN VITRO SOLUTION HIGH (<i>blood glucose calibration</i>) | NPB | N8 (Listing does not include certain NDCs) |
| OMNIPOD 5 G6 INTRO (GEN 5) KIT (<i>insulin disposable pump</i>) | PB | |
| OMNIPOD 5 G6 PODS (GEN 5) (<i>insulin disposable pump</i>) | PB | |
| OMNIPOD 5 G7 INTRO (GEN 5) KIT (<i>insulin disposable pump</i>) | PB | |
| OMNIPOD 5 G7 PODS (GEN 5) (<i>insulin disposable pump</i>) | PB | |
| OMNIPOD DASH INTRO (GEN 4) KIT (<i>insulin disposable pump</i>) | PB | |
| OMNIPOD DASH PDM (GEN 4) KIT (<i>insulin disposable pump</i>) | PB | |
| OMNIPOD DASH PODS (GEN 4) (<i>insulin disposable pump</i>) | PB | |
| OMNIPOD GO KIT 10 UNIT/24HR, 15 UNIT/24HR, 20 UNIT/24HR, 25 UNIT/24HR, 30 UNIT/24HR, 35 UNIT/24HR, 40 UNIT/24HR (<i>insulin disposable pump</i>) | NF | |
| ONETOUCH DELICA PLUS LANCET33G (<i>lancets</i>) | PB | |
| ONETOUCH DELICA PLUS LANCING (<i>lancet devices</i>) | PB | |
| ONETOUCH ULTRA IN VITRO STRIP (<i>glucose blood</i>) | PB | QL (150 TEST STRIPS per 25 days) |
| ONETOUCH ULTRASOFT 2 LANCETS (<i>lancets</i>) | PB | |
| ONETOUCH VERIO IN VITRO STRIP (<i>glucose blood</i>) | PB | QL (150 TEST STRIPS per 25 days) |
| PTS PANELS EGLU TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| V-GO 20 KIT 20 UNIT/24HR (<i>insulin disposable pump</i>) | PB | |
| V-GO 30 KIT 30 UNIT/24HR (<i>insulin disposable pump</i>) | PB | |
| V-GO 40 KIT 40 UNIT/24HR (<i>insulin disposable pump</i>) | PB | |
| VIVAGUARD INO TEST STRIPS IN VITRO STRIP (<i>glucose blood</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ENDOMETRIOSIS | | |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | G | N8 (Listing does not include certain NDCs) |
| ORILISSA ORAL TABLET 150 MG, 200 MG (<i>elagolix sodium</i>) | PB | PA |
| SYNAREL NASAL SOLUTION 2 MG/ML (<i>nafarelin acetate</i>) | NPB | PA |
| ENZYME REPLACEMENTS - DRUGS FOR REPLACEMENT, MODIFICATION, TREATMENT | | |
| <i>betaine oral powder</i> | SP | PA |
| CARBAGLU ORAL TABLET SOLUBLE 200 MG (<i>carglumic acid</i>) | NF | |
| <i>carglumic acid oral tablet soluble 200 mg</i> | SP | PA |
| CYSTADANE ORAL POWDER (<i>betaine</i>) | NF | |
| GALAFOLD ORAL CAPSULE 123 MG (<i>migalastat hcl</i>) | SP | PA |
| OLPRUVA (2 GM DOSE) ORAL THERAPY PACK 2 GM (<i>sodium phenylbutyrate</i>) | NF | |
| OLPRUVA (3 GM DOSE) ORAL THERAPY PACK 3 GM (<i>sodium phenylbutyrate</i>) | NF | |
| OLPRUVA (4 GM DOSE) ORAL THERAPY PACK 2 & 2 GM (<i>sodium phenylbutyrate</i>) | NF | |
| OLPRUVA (5 GM DOSE) ORAL THERAPY PACK 2 & 3 GM (<i>sodium phenylbutyrate</i>) | NF | |
| OLPRUVA (6 GM DOSE) ORAL THERAPY PACK 3 & 3 GM (<i>sodium phenylbutyrate</i>) | NF | |
| OLPRUVA (6.67 GM DOSE) ORAL THERAPY PACK 3 & 3.67 GM (<i>sodium phenylbutyrate</i>) | NF | |
| OPFOLDA ORAL CAPSULE 65 MG (<i>miglustat (gaa deficiency)</i>) | NF | |
| PHEBURANE ORAL PELLET 483 MG/GM (<i>sodium phenylbutyrate</i>) | SP | PA; QL (672 G per 30 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| sodium phenylbutyrate oral powder 3 gm/tsp | SP | PA; QL (798 G per 30 days) |
| STRENSIQ SUBCUTANEOUS SOLUTION 18 MG/0.45ML, 28 MG/0.7ML, 40 MG/ML, 80 MG/0.8ML (asfotase alfa) | SP | PA |
| ENZYME REPLACEMENTS - DRUGS TO TREAT ENZYME DEFICIENCIES | | |
| ALDURAZYME INTRAVENOUS SOLUTION 2.9 MG/5ML (<i>laronidase</i>) | SP | PA |
| BUPHENYL ORAL POWDER 3 GM/TSP (<i>sodium phenylbutyrate</i>) | NF | |
| BUPHENYL ORAL TABLET 500 MG (<i>sodium phenylbutyrate</i>) | NF | |
| ELAPRASE INTRAVENOUS SOLUTION 6 MG/3ML (<i>idursulfase</i>) | SP | PA |
| FABRAZYME INTRAVENOUS SOLUTION RECONSTITUTED 35 MG, 5 MG (<i>agalsidase beta</i>) | SP | PA |
| KANUMA INTRAVENOUS SOLUTION 20 MG/10ML (<i>sebelipase alfa</i>) | SP | PA |
| KUVAN ORAL PACKET 100 MG, 500 MG (<i>sapropterin dihydrochloride</i>) | NF | |
| KUVAN ORAL TABLET 100 MG (<i>sapropterin dihydrochloride</i>) | NF | |
| LUMIZYME INTRAVENOUS SOLUTION RECONSTITUTED 50 MG (<i>alglucosidase alfa</i>) | SP | PA |
| MYALEPT SUBCUTANEOUS SOLUTION RECONSTITUTED 11.3 MG (<i>metreleptin</i>) | SP | PA; QL (30 VIALS per 30 DAYs) |
| NAGLAZYME INTRAVENOUS SOLUTION 1 MG/ML (<i>galsulfase</i>) | SP | PA |
| PALYNZIQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.5ML, 2.5 MG/0.5ML, 20 MG/ML (<i>pegvaliase-pqpz</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-----------------------------------|
| RAVICTI ORAL LIQUID 1.1 GM/ML (<i>glycerol phenylbutyrate</i>) | NF | |
| <i>sapropterin dihydrochloride oral packet 100 mg, 500 mg</i> | SP | PA |
| <i>sapropterin dihydrochloride oral tablet 100 mg</i> | SP | PA |
| <i>sodium phenylbutyrate oral tablet 500 mg</i> | SP | PA; QL (1200 TABLETS per 30 DAYs) |
| VIMIZIM INTRAVENOUS SOLUTION 5 MG/5ML (<i>elosulfase alfa</i>) | SP | PA |
| ESTROGENS - DRUGS TO REGULATE FEMALE HORMONES | | |
| ALORA TRANSDERMAL PATCH TWICE WEEKLY 0.025 MG/24HR, 0.075 MG/24HR, 0.1 MG/24HR (<i>estradiol</i>) | NF | |
| <i>estradiol-norethindrone acet</i> (Amabelz Oral Tablet 0.5-0.1 Mg) | G | |
| ANGELIQ ORAL TABLET 0.25-0.5 MG, 0.5-1 MG (<i>drospirenone-estradiol</i>) | NF | |
| BIJUVA ORAL CAPSULE 0.5-100 MG, 1-100 MG (<i>estradiol-progesterone</i>) | PB | |
| CLIMARA PRO TRANSDERMAL PATCH WEEKLY 0.045-0.015 MG/DAY (<i>estradiol-levonorgestrel</i>) | PB | |
| CLIMARA TRANSDERMAL PATCH WEEKLY 0.025 MG/24HR, 0.0375 MG/24HR, 0.05 MG/24HR, 0.06 MG/24HR, 0.075 MG/24HR, 0.1 MG/24HR (<i>estradiol</i>) | NF | |
| COMBIPATCH TRANSDERMAL PATCH TWICE WEEKLY 0.05-0.14 MG/DAY, 0.05-0.25 MG/DAY (<i>estradiol-norethindrone acet</i>) | PB | |
| DUAVEE ORAL TABLET 0.45-20 MG (<i>conj estrogens-bazedoxifene</i>) | NPB | PA |
| ELESTRIN TRANSDERMAL GEL 0.52 MG/0.87 GM (0.06%) (<i>estradiol</i>) | NF | |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| estradiol transdermal gel 0.25 mg/0.25gm, 0.5 mg/0.5gm, 0.75 mg/0.75gm, 1 mg/gm, 1.25 mg/1.25gm | G | |
| estradiol transdermal gel 0.75 mg/1.25 gm (0.06%) | NF | |
| estradiol transdermal patch twice weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr | G | |
| estradiol transdermal patch weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.06 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr | G | |
| estradiol vaginal cream 0.1 mg/gm | G | |
| estradiol vaginal tablet 10 mcg | NF | |
| estradiol valerate intramuscular oil 20 mg/ml, 40 mg/ml | G | |
| estradiol-norethindrone acet oral tablet 0.5-0.1 mg, 1-0.5 mg | G | |
| ESTRING VAGINAL RING 7.5 MCG/24HR (estradiol) | NF | |
| ESTROGEL TRANSDERMAL GEL 0.75 MG/1.25 GM (0.06%) (estradiol) | NF | |
| FEMRING VAGINAL RING 0.05 MG/24HR, 0.1 MG/24HR (estradiol acetate) | NF | |
| norethindrone-eth estradiol (Fyavolv Oral Tablet 0.5-2.5 Mg-Mcg, 1-5 Mg-Mcg) | G | |
| IMVEXXY MAINTENANCE PACK VAGINAL INSERT 10 MCG, 4 MCG (estradiol) | PB | |
| IMVEXXY STARTER PACK VAGINAL INSERT 10 MCG, 4 MCG (estradiol) | PB | |
| norethindrone-eth estradiol (Jinteli Oral Tablet 1-5 Mg-Mcg) | G | |
| MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG, 2.5 MG (esterified estrogens) | NF | |
| MENOSTAR TRANSDERMAL PATCH WEEKLY 14 MCG/24HR (estradiol) | NF | |
| estradiol-norethindrone acet (Mimvey Oral Tablet 1-0.5 Mg) | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| MINIVELLE TRANSDERMAL PATCH TWICE WEEKLY 0.025 MG/24HR, 0.0375 MG/24HR, 0.05 MG/24HR, 0.075 MG/24HR, 0.1 MG/24HR (<i>estradiol</i>) | NF | |
| PREFEST ORAL TABLET 1/1-0.09 MG (15/15) (<i>estradiol-norgestimate</i>) | NF | |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG (<i>estrogens conjugated</i>) | NF | |
| PREMARIN VAGINAL CREAM 0.625 MG/GM (<i>estrogens, conjugated</i>) | NF | |
| PREMPHASE ORAL TABLET 0.625-5 MG (<i>conj estrog-medroxyprogesterone acetate</i>) | NF | |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG (<i>conj estrog-medroxyprogesterone acetate</i>) | NF | |
| VAGIFEM VAGINAL TABLET 10 MCG (<i>estradiol</i>) | PB | |
| VIVELLE-DOT TRANSDERMAL PATCH TWICE WEEKLY 0.025 MG/24HR, 0.0375 MG/24HR, 0.05 MG/24HR, 0.075 MG/24HR, 0.1 MG/24HR (<i>estradiol estradiol</i> (Yuvafem Vaginal Tablet 10 Mcg)) | NF | |
| FERTILITY REGULATORS | | |
| <i>cetrorelix acetate subcutaneous kit 0.25 mg</i> | SP | PA; SPC |
| CETROTIDE SUBCUTANEOUS KIT 0.25 MG (<i>cetrorelix acetate</i>) | NF | |
| <i>chorionic gonadotropin intramuscular solution reconstituted 10000 unit</i> | NF | |
| CLOMID ORAL TABLET 50 MG (<i>clomiphene citrate</i>) | G | SPC |
| FOLLISTIM AQ SUBCUTANEOUS SOLUTION 300 UNT/0.36ML, 600 UNT/0.72ML, 900 UNT/1.08ML (<i>follitropin beta</i>) | SP | PA; SPC |
| <i>ganirelix acetate</i> (Fyremadel Subcutaneous Solution Prefilled Syringe 250 Mcg/0.5ML) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| ganirelix acetate solution prefilled syringe 250 mcg/0.5ml subcutaneous | NF | |
| ganirelix acetate solution prefilled syringe 250 mcg/0.5ml subcutaneous | SP | PA; SPC |
| GONAL-F INJECTION SOLUTION RECONSTITUTED 1050 UNIT, 450 UNIT (<i>follitropin alfa</i>) | NF | |
| GONAL-F RFF REDIRECT SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/0.5ML, 450 UNT/0.75ML, 900 UNIT/1.5ML (<i>follitropin alfa</i>) | NF | |
| GONAL-F RFF SUBCUTANEOUS SOLUTION RECONSTITUTED 75 UNIT (<i>follitropin alfa</i>) | NF | |
| MENOPUR SUBCUTANEOUS SOLUTION RECONSTITUTED 75 UNIT (<i>menotropins</i>) | SP | PA; SPC |
| NOVAREL INTRAMUSCULAR SOLUTION RECONSTITUTED 10000 UNIT, 5000 UNIT (<i>chorionic gonadotropin</i>) | NF | |
| OVIDREL SUBCUTANEOUS INJECTABLE 250 MCG/0.5ML (<i>choriogonadotropin alfa</i>) | SP | PA; SPC |
| PREGNYL INTRAMUSCULAR SOLUTION RECONSTITUTED 10000 UNIT (<i>chorionic gonadotropin</i>) | NF | |
| GAUCHER DISEASE - DRUGS TO TREAT GAUCHER DISEASE | | |
| CERDELGA ORAL CAPSULE 84 MG (<i>eliglustat tartrate</i>) | SP | PA; QL (56 CAPSULES per 28 days) |
| CEREZYME INTRAVENOUS SOLUTION RECONSTITUTED 400 UNIT (<i>imiglucerase</i>) | SP | PA; QL (15 VIALS per 14 days) |
| ELELYSO INTRAVENOUS SOLUTION RECONSTITUTED 200 UNIT (<i>taliglucerase alfa</i>) | NF | |
| <i>miglustat oral capsule 100 mg</i> | SP | PA; QL (90 CAPSULES per 30 days) |
| VPRIIV INTRAVENOUS SOLUTION RECONSTITUTED 400 UNIT (<i>velaglucerase alfa</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| ZAVESCA ORAL CAPSULE 100 MG (<i>miglustat</i>) | SP | PA; QL (90 CAPSULES per 30 days) |
| GLUCOCORTICOIDS - DRUGS TO TREAT INFLAMMATORY RESPONSE | | |
| AGAMREE ORAL SUSPENSION 40 MG/ML (<i>vamorolone</i>) | NF | |
| ALKINDI SPRINKLE ORAL CAPSULE SPRINKLE 0.5 MG, 1 MG, 2 MG, 5 MG (<i>hydrocortisone</i>) | NF | |
| <i>cortisone acetate oral tablet 25 mg</i> | NF | |
| <i>deflazacort oral tablet 18 mg, 30 mg, 36 mg, 6 mg</i> | NF | |
| <i>dexabliss oral tablet therapy pack 1.5 mg (39)</i> | NF | |
| <i>dexamethasone oral elixir 0.5 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>dexamethasone oral solution 0.5 mg/5ml</i> | G | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 2 mg, 4 mg, 6 mg</i> | G | |
| <i>dexamethasone oral tablet 1.5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>dexamethasone oral tablet therapy pack 1.5 mg (21), 1.5 mg (35), 1.5 mg (51)</i> | G | |
| EMFLAZA ORAL SUSPENSION 22.75 MG/ML (<i>deflazacort</i>) | NF | |
| EMFLAZA ORAL TABLET 18 MG, 30 MG, 36 MG, 6 MG (<i>deflazacort</i>) | NF | |
| <i>fudrocortisone acetate oral tablet 0.1 mg</i> | G | |
| HEMADY ORAL TABLET 20 MG (<i>dexamethasone</i>) | NF | |
| <i>dexamethasone (Hidex 6-Day Oral Tablet Therapy Pack 1.5 Mg (21))</i> | G | |
| <i>hydrocortisone oral tablet 10 mg, 5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>hydrocortisone oral tablet 20 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | G | |
| <i>methylprednisolone oral tablet therapy pack 4 mg</i> | G | |
| <i>prednisolone oral solution 15 mg/5ml</i> | G | |
| <i>prednisolone oral tablet 5 mg</i> | NF | |
| <i>prednisolone sodium phosphate oral solution 10 mg/5ml, 20 mg/5ml</i> | NF | |
| <i>prednisolone sodium phosphate oral solution 15 mg/5ml, 6.7 (5 base) mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>prednisolone sodium phosphate oral solution 25 mg/5ml</i> | G | |
| <i>prednisolone sodium phosphate oral tablet dispersible 10 mg, 15 mg, 30 mg</i> | G | |
| <i>prednisone oral solution 5 mg/5ml</i> | G | |
| <i>prednisone oral tablet 1 mg, 20 mg, 5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>prednisone oral tablet 10 mg, 2.5 mg, 50 mg</i> | G | |
| <i>prednisone oral tablet therapy pack 10 mg (21), 10 mg (48), 5 mg (21), 5 mg (48)</i> | G | |
| RAYOS ORAL TABLET DELAYED RELEASE 1 MG, 2 MG, 5 MG (prednisone) | NF | |
| TAPERDEX 12-DAY ORAL TABLET THERAPY PACK 1.5 MG (49) (dexamethasone) | NF | |
| <i>dexamethasone (Taperdex 6-Day Oral Tablet Therapy Pack 1.5 Mg (21))</i> | NF | |
| TAPERDEX 7-DAY ORAL TABLET THERAPY PACK 1.5 MG (27) (dexamethasone) | NF | |
| GLUCOSE ELEVATING AGENTS - DRUGS TO TREAT LOW BLOOD SUGAR | | |
| BAQSIMI ONE PACK NASAL POWDER 3 MG/DOSE (glucagon) | PB | |
| BAQSIMI TWO PACK NASAL POWDER 3 MG/DOSE (glucagon) | PB | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| BD GLUCOSE ORAL TABLET CHEWABLE 5 GM (dextrose (diabetic use)) | NPB | |
| diazoxide oral suspension 50 mg/ml | G | |
| GLUCAGEN HYPOKIT INJECTION SOLUTION RECONSTITUTED 1 MG (glucagon hcl (rdna)) | NF | |
| glucagon emergency injection kit 1 mg | G | |
| glucagon emergency injection solution reconstituted 1 mg/ml | NF | |
| glucose oral tablet chewable 4 gm | NPB | |
| gnp glucose gummies oral tablet chewable 2 gm | G | |
| GVOKE HYPOOPEN 1-PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 0.5 MG/0.1ML, 1 MG/0.2ML (glucagon) | PB | |
| GVOKE KIT SUBCUTANEOUS SOLUTION 1 MG/0.2ML (glucagon) | PB | |
| GVOKE PFS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 0.5 MG/0.1ML, 1 MG/0.2ML (glucagon) | PB | |
| ZEGALOGUE SUBCUTANEOUS SOLUTION AUTO-INJECTOR 0.6 MG/0.6ML (dasiglucagon hcl) | PB | |
| ZEGALOGUE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 0.6 MG/0.6ML (dasiglucagon hcl) | PB | |
| GROWTH IMPROVEMENT AGENTS - DRUGS TO PROMOTE GROWTH | | |
| VOXZOGO SUBCUTANEOUS SOLUTION RECONSTITUTED 0.4 MG, 0.56 MG, 1.2 MG (vosoritide) | SP | PA; QL (30 VIALS per 30 DAYs) |
| HEREDITARY TYROSINEMIA TYPE 1 AGENTS - DRUGS FOR REPLACEMENT, MODIFICATION, TREATMENT | | |
| nitisinone oral capsule 10 mg, 2 mg, 20 mg, 5 mg | SP | PA |
| NITYR ORAL TABLET 10 MG, 2 MG, 5 MG (nitisinone) | NF | |
| ORFADIN ORAL CAPSULE 10 MG, 2 MG, 20 MG, 5 MG (nitisinone) | SP | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| ORFADIN ORAL SUSPENSION 4 MG/ML (<i>nitisinone</i>) | SP | PA |
| HUMAN GROWTH HORMONES - DRUGS TO REGULATE PITUITARY HORMONES | | |
| GENOTROPIN MINIQUICK SUBCUTANEOUS PREFILLED SYRINGE 0.2 MG, 0.4 MG, 0.6 MG, 0.8 MG, 1 MG, 1.2 MG, 1.4 MG, 1.6 MG, 1.8 MG, 2 MG (<i>somatropin</i>) | NF | |
| GENOTROPIN SUBCUTANEOUS CARTRIDGE 12 MG, 5 MG (<i>somatropin</i>) | NF | |
| HUMATROPE INJECTION CARTRIDGE 12 MG, 24 MG, 6 MG (<i>somatropin</i>) | SP | PA |
| NGENLA SUBCUTANEOUS SOLUTION PEN-INJECTOR 24 MG/1.2ML, 60 MG/1.2ML (<i>somatrogon-ghla</i>) | NF | |
| SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 5 MG, 6 MG (<i>somatropin (non-refrigerated)</i>) | SP | PA |
| SKYTROFA SUBCUTANEOUS CARTRIDGE 11 MG, 13.3 MG, 3 MG, 3.6 MG, 4.3 MG, 5.2 MG, 6.3 MG, 7.6 MG, 9.1 MG (<i>lonapegsomatropin-tcgd</i>) | NF | |
| SOGROYA SUBCUTANEOUS SOLUTION PEN-INJECTOR 10 MG/1.5ML, 15 MG/1.5ML, 5 MG/1.5ML (<i>somapacitan-beco</i>) | SP | PA; QL (4 PENS per 28 DAYS) |
| HUMAN GROWTH HORMONES - DRUGS TO REGULATE PITUITARYHORMONES | | |
| NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN-INJECTOR 10 MG/1.5ML, 15 MG/1.5ML, 30 MG/3ML, 5 MG/1.5ML (<i>somatropin</i>) | SP | PA |
| NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR 10 MG/2ML (<i>somatropin</i>) | NF | |
| NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR 20 MG/2ML (<i>somatropin</i>) | NF | |
| NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR 5 MG/2ML (<i>somatropin</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE 10 MG/1.5ML, 5 MG/1.5ML (<i>somatropin</i>) | NF | |
| OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED 5.8 MG (<i>somatropin</i>) | NF | |
| SAIZEN INJECTION SOLUTION RECONSTITUTED 5 MG, 8.8 MG (<i>somatropin (non-refrigerated)</i>) | NF | |
| SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG (<i>somatropin (non-refrigerated)</i>) | SP | PA |
| ZOMACTON SUBCUTANEOUS SOLUTION RECONSTITUTED 10 MG, 5 MG (<i>somatropin</i>) | NF | |
| ZORBTIVE SUBCUTANEOUS SOLUTION RECONSTITUTED 8.8 MG (<i>somatropin (non-refrigerated)</i>) | SP | PA |
| MINERALOCORTICOID RECEPTOR ANTAGONISTS - DRUGS TO TREAT CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES | | |
| KERENDIA ORAL TABLET 10 MG, 20 MG (<i>finerenone</i>) | PB | |
| MISCELLANEOUS | | |
| ACTHAR INJECTION GEL 80 UNIT/ML (<i>corticotropin</i>) | SP | PA; QL (35 ML per 21 DAYS) |
| <i>cabergoline oral tablet 0.5 mg</i> | G | |
| CORTROPHIN INJECTION GEL 80 UNIT/ML (<i>corticotropin</i>) | SP | PA; QL (35 ML per 21 days) |
| CYSTAGON ORAL CAPSULE 150 MG, 50 MG (<i>cysteamine bitartrate</i>) | SP | PA |
| EVENITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 105 MG/1.17ML (<i>romosozumab-aqqg</i>) | NF | |
| IMCIVREE SUBCUTANEOUS SOLUTION 10 MG/ML (<i>setmelanotide acetate</i>) | NF | |
| INCRELEX SUBCUTANEOUS SOLUTION 40 MG/4ML (<i>mecasermin</i>) | SP | PA |
| INTRAROSA VAGINAL INSERT 6.5 MG (<i>prasterone</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-------------------------------------|
| ISTURISA ORAL TABLET 1 MG, 5 MG (<i>osilodrostat phosphate</i>) | NF | |
| JYNARQUE ORAL TABLET 15 MG, 30 MG (<i>tolvaptan</i>) | NF | |
| JYNARQUE ORAL TABLET THERAPY PACK 15 MG, 30 & 15 MG, 45 & 15 MG, 60 & 30 MG, 90 & 30 MG (<i>tolvaptan</i>) | NF | |
| <i>methylergonovine maleate</i> (Methergine Oral Tablet 0.2 Mg) | G | QL (4 TABLETS per 1 DAY) |
| <i>methylergonovine maleate oral tablet 0.2 mg</i> | G | QL (4 TABLETS per 1 DAY) |
| <i>mifepristone oral tablet 200 mg</i> | CE | N7 (G); N8 (Available at \$0 copay) |
| OSPHENA ORAL TABLET 60 MG (<i>ospemifene</i>) | NPB | PA |
| <i>raloxifene hcl oral tablet 60 mg</i> | CE | N7 (G); AL (Min 35 Years) |
| REZDIFRA ORAL TABLET 100 MG, 60 MG, 80 MG (<i>resmetrirom</i>) | NF | |
| SAMSCA ORAL TABLET 15 MG, 30 MG (<i>tolvaptan</i>) | SP | PA |
| SIGNIFOR LAR INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 10 MG, 20 MG, 30 MG, 40 MG, 60 MG (<i>pasireotide pamoate</i>) | NF | |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML, 0.6 MG/ML, 0.9 MG/ML (<i>pasireotide diaspartate</i>) | SP | PA; QL (60 AMPULES per 30 DAYS) |
| <i>tolvaptan oral tablet 15 mg, 30 mg</i> | SP | PA |
| VEOZAH ORAL TABLET 45 MG (<i>fezolinetant</i>) | NF | |
| VIJOICE ORAL TABLET THERAPY PACK 125 MG, 200 & 50 MG, 50 MG (<i>alpelisib</i>) | NF | |
| XURIDEN ORAL PACKET 2 GM (<i>uridine triacetate</i>) | SP | QL (4 PACKETS per 1 DAY) |
| ZOKINVY ORAL CAPSULE 50 MG, 75 MG (<i>lonafarnib</i>) | SP | PA; QL (120 CAPSULES per 30 DAYS) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| PHOSPHATE BINDER AGENTS - DRUGS TO REGULATE CALCIUM AND PHOSPHORUS LEVELS | | |
| AURYXIA ORAL TABLET 1 GM 210 MG(FE) (<i>ferric citrate</i>) | PB | |
| <i>calcium acetate (phos binder) oral capsule 667 mg</i> | G | |
| FOSRENOL ORAL PACKET 1000 MG, 750 MG (<i>lanthanum carbonate</i>) | NF | |
| FOSRENOL ORAL TABLET CHEWABLE 1000 MG, 500 MG, 750 MG (<i>lanthanum carbonate</i>) | NF | |
| RENELA ORAL PACKET 0.8 GM, 2.4 GM (<i>sevelamer carbonate</i>) | NF | |
| RENELA ORAL TABLET 800 MG (<i>sevelamer carbonate</i>) | NF | |
| <i>sevelamer carbonate oral packet 0.8 gm, 2.4 gm</i> | G | |
| <i>sevelamer carbonate oral tablet 800 mg</i> | G | |
| <i>sevelamer hcl oral tablet 400 mg, 800 mg</i> | G | |
| VELPHORO ORAL TABLET CHEWABLE 500 MG (<i>sucroferric oxyhydroxide</i>) | NF | |
| XPHOZAH ORAL TABLET 20 MG, 30 MG (<i>tenapanor hcl (ckd)</i>) | NF | |
| POLYNEUROPATHY | | |
| TEGSEDI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 284 MG/1.5ML (<i>inotersen sodium</i>) | SP | PA; QL (4 SYRINGES per 28 days) |
| WAINUA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 45 MG/0.8ML (<i>eplontersen sodium</i>) | NF | |
| POTASSIUM-REMOVING AGENTS - DRUGS TO REGULATE POTASSIUM LEVELS | | |
| LOKELMA ORAL PACKET 10 GM, 5 GM (<i>sodium zirconium cyclosilicate</i>) | NF | |
| <i>sodium polystyrene sulfonate oral powder</i> | G | |
| SPS ORAL SUSPENSION 15 GM/60ML (<i>sodium polystyrene sulfonate</i>) | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| VELTASSA ORAL PACKET 16.8 GM, 25.2 GM, 8.4 GM <i>(patiromer sorbitex calcium)</i> | PB | |
| PROGESTINS - DRUGS TO REGULATE FEMALE HORMONES | | |
| CRINONE VAGINAL GEL 4 %, 8 % (<i>progesterone</i>) | NF | |
| <i>medroxyprogesterone acetate oral tablet 10 mg, 2.5 mg, 5 mg</i> | G | |
| <i>megestrol acetate oral suspension 625 mg/5ml</i> | CE | N7 (G) |
| <i>norethindrone acetate oral tablet 5 mg</i> | G | |
| PROGESTINS - DRUGS TO REGULATE PROGESTIN | | |
| ENDOMETRIN VAGINAL INSERT 100 MG <i>(progesterone)</i> | PB | |
| <i>megestrol acetate oral suspension 40 mg/ml</i> | CE | N7 (G) |
| <i>progesterone oral capsule 100 mg, 200 mg</i> | G | |
| PROMETRIUM ORAL CAPSULE 100 MG, 200 MG <i>(progesterone)</i> | NF | |
| THYROID AGENTS - DRUGS TO REGULATE THYROID LEVELS | | |
| ADTHYZA ORAL TABLET 120 MG, 130 MG, 15 MG, 16.25 MG, 30 MG, 32.5 MG, 60 MG, 65 MG, 90 MG, 97.5 MG (<i>thyroid</i>) | NF | |
| CYTOMEL ORAL TABLET 25 MCG, 5 MCG, 50 MCG <i>(liothyronine sodium)</i> | NF | |
| ERMEZA ORAL SOLUTION 150 MCG/5ML (<i>levothyroxine sodium</i>) | NF | |
| <i>levothyroxine sodium oral capsule 100 mcg, 112 mcg, 125 mcg, 13 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg</i> | NF | |
| <i>levothyroxine sodium oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | G | |
| <i>liothyronine sodium oral tablet 25 mcg, 5 mcg, 50 mcg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>methimazole oral tablet 10 mg, 5 mg</i> | G | |
| <i>niva thyroid oral tablet 120 mg, 15 mg, 30 mg, 60 mg, 90 mg</i> | NF | |
| <i>propylthiouracil oral tablet 50 mg</i> | G | |
| THYQUIDITY ORAL SOLUTION 100 MCG/5ML (levothyroxine sodium) | NF | |
| <i>thyroid oral tablet 120 mg, 15 mg, 30 mg, 60 mg, 90 mg</i> | NF | |
| TIROSINT ORAL CAPSULE 100 MCG, 112 MCG, 125 MCG, 13 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 37.5 MCG, 44 MCG, 50 MCG, 62.5 MCG, 75 MCG, 88 MCG (levothyroxine sodium) | NF | |
| TIROSINT-SOL ORAL SOLUTION 100 MCG/ML, 112 MCG/ML, 125 MCG/ML, 13 MCG/ML, 137 MCG/ML, 150 MCG/ML, 175 MCG/ML, 200 MCG/ML, 25 MCG/ML, 37.5 MCG/ML, 44 MCG/ML, 50 MCG/ML, 62.5 MCG/ML, 75 MCG/ML, 88 MCG/ML (levothyroxine sodium) | NF | |
| UTERINE FIBROIDS - DRUGS TO TREAT UTERINE FIBROIDS | | |
| MYFEMBREE ORAL TABLET 40-1-0.5 MG (relugolix-estradiol-norethind) | PB | PA |
| ORIAHNN ORAL CAPSULE THERAPY PACK 300-1-0.5 & 300 MG (elagolix-estradiol-norethind) | PB | PA |
| VASOPRESSINS - DRUGS TO REGULATE PITUITARY HORMONES | | |
| DDAVP ORAL TABLET 0.1 MG, 0.2 MG (desmopressin acetate) | NPB | |
| <i>desmopressin ace spray refrig nasal solution 0.01 %</i> | G | |
| <i>desmopressin acetate nasal solution 1.5 mg/ml</i> | SP | PA |
| <i>desmopressin acetate oral tablet 0.1 mg, 0.2 mg</i> | G | |
| <i>desmopressin acetate spray nasal solution 0.01 %</i> | G | |
| NOCDURNA SUBLINGUAL TABLET SUBLINGUAL 27.7 MCG, 55.3 MCG (desmopressin acetate) | NPB | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| GASTROINTESTINAL - DRUGS TO TREAT STOMACH AND INTESTINAL DISORDERS | | |
| ANTICHOLINERGICS | | |
| CUVPOSA ORAL SOLUTION 1 MG/5ML (<i>glycopyrrolate</i>) | NPB | |
| <i>dicyclomine hcl oral capsule 10 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>dicyclomine hcl oral tablet 20 mg</i> | G | N8 (Listing does not include certain NDCs) |
| GLYCATE ORAL TABLET 1.5 MG (<i>glycopyrrolate</i>) | NF | |
| <i>glycopyrrolate oral solution 1 mg/5ml</i> | G | |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>glycopyrrolate oral tablet 1.5 mg</i> | NF | |
| LIBRAX ORAL CAPSULE 5-2.5 MG (<i>chlordiazepoxide-clidinium</i>) | NF | |
| <i>methscopolamine bromide oral tablet 2.5 mg, 5 mg</i> | G | |
| ROBINUL ORAL TABLET 1 MG (<i>glycopyrrolate</i>) | NF | |
| ROBINUL-FORTE ORAL TABLET 2 MG (<i>glycopyrrolate</i>) | NF | |
| ANTIDIARRHEALS | | |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5ml</i> | G | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | G | |
| MOTOFEN ORAL TABLET 1-0.025 MG (<i>difenoxin-atropine</i>) | NF | |
| MYTESI ORAL TABLET DELAYED RELEASE 125 MG (<i>crofelemer</i>) | NF | |
| ANTIEMETICS - DRUGS FOR NAUSEA AND VOMITING | | |
| AKYNZEO ORAL CAPSULE 300-0.5 MG (<i>netupitant-palonosetron</i>) | NF | |
| ANTIVERT ORAL TABLET 50 MG (<i>meclizine hcl</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ANZEMET ORAL TABLET 50 MG (<i>dolasetron mesylate</i>) | NF | |
| <i>aprepitant oral capsule 125 mg</i> | G | QL (2 CAPSULES per 21 DAYs) |
| <i>aprepitant oral capsule 40 mg</i> | G | QL (3 CAPSULES per 180 DAYs) |
| <i>aprepitant oral capsule 80 & 125 mg</i> | G | QL (2 PACKS per 21 DAYs) |
| <i>aprepitant oral capsule 80 mg</i> | G | QL (4 CAPSULES per 21 DAYs) |
| <i>prochlorperazine (Compro Rectal Suppository 25 Mg)</i> | G | |
| <i>doxylamine-pyridoxine oral tablet delayed release 10-10 mg</i> | G | |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> | G | PA; QL (120 CAPSULES per 25 DAYs) |
| EMEND ORAL CAPSULE 80 MG (<i>aprepitant</i>) | NF | |
| EMEND ORAL SUSPENSION RECONSTITUTED 125 MG/5ML (<i>aprepitant</i>) | NF | |
| EMEND TRI-PACK ORAL CAPSULE 80 & 125 MG (<i>aprepitant</i>) | NF | |
| GIMOTI NASAL SOLUTION 15 MG/ACT (<i>metoclopramide hcl</i>) | NF | |
| <i>granisetron hcl oral tablet 1 mg</i> | G | QL (12 TABLETS per 21 days) |
| MARINOL ORAL CAPSULE 2.5 MG (<i>dronabinol</i>) | NPB | PA; QL (120 CAPSULES per 25 days) |
| <i>metoclopramide hcl oral solution 10 mg/10ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | G | |
| <i>metoclopramide hcl oral tablet dispersible 5 mg</i> | G | |
| <i>ondansetron hcl oral solution 4 mg/5ml</i> | G | QL (200 ML per 21 DAYs) |
| <i>ondansetron hcl oral tablet 24 mg</i> | G | QL (2 TABLETS per 21 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | G | QL (18 TABLETS per 21 DAYs) |
| <i>ondansetron oral tablet dispersible 4 mg, 8 mg</i> | G | QL (18 TABLETS per 21 DAYs) |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>promethazine hcl oral solution 6.25 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>promethazine hcl oral tablet 12.5 mg, 25 mg, 50 mg</i> | G | |
| <i>promethazine hcl rectal suppository 12.5 mg, 25 mg</i> | G | |
| PROMETHEGAN RECTAL SUPPOSITORY 50 MG (<i>promethazine hcl</i>) | G | |
| SANCUSO TRANSDERMAL PATCH 3.1 MG/24HR (<i>granisetron</i>) | PB | QL (2 PATCHES per 21 DAYs) |
| <i>scopolamine transdermal patch 72 hour 1 mg/3days</i> | G | |
| SYNDROS ORAL SOLUTION 5 MG/ML (<i>dronabinol</i>) | NF | |
| TRANSDERM-SCOP TRANSDERMAL PATCH 72 HOUR 1 MG/3DAYS (<i>scopolamine base</i>) | NF | |
| <i>trimethobenzamide hcl oral capsule 300 mg</i> | G | N8 (Listing does not include certain NDCs) |
| VARUBI (180 MG DOSE) ORAL TABLET THERAPY PACK 2 X 90 MG (<i>rolapitant hcl</i>) | NF | |
| H2-RECEPTOR ANTAGONISTS - DRUGS FOR ULCERS AND STOMACH ACID | | |
| <i>cimetidine oral tablet 300 mg, 400 mg, 800 mg</i> | G | |
| <i>famotidine oral tablet 40 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | G | |
| INFLAMMATORY BOWEL DISEASE - BOWEL, INTESTINE, AND STOMACH CONDITION DRUGS | | |
| <i>budesonide er oral tablet extended release 24 hour 9 mg</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>budesonide oral capsule delayed release particles 3 mg</i> | G | |
| <i>budesonide rectal foam 2 mg</i> | NF | |
| <i>mesalamine er oral capsule extended release 500 mg</i> | G | |
| <i>mesalamine oral tablet delayed release 1.2 gm, 800 mg</i> | G | |
| <i>mesalamine rectal suppository 1000 mg</i> | G | N8 (Listing does not include certain NDCs) |
| PENTASA ORAL CAPSULE EXTENDED RELEASE 250 MG, 500 MG (mesalamine) | NF | |
| ROWASA RECTAL KIT 4 GM (mesalamine-cleanser) | NF | |
| <i>sulfasalazine oral tablet 500 mg</i> | G | |
| UCERIS ORAL TABLET EXTENDED RELEASE 24 HOUR 9 MG (budesonide) | PB | |
| INFLAMMATORY BOWEL DISEASE - BOWEL, INTESTINE, AND STOMACH CONDITION DRUGS | | |
| APRISO ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.375 GM (mesalamine) | NPB | |
| <i>balsalazide disodium oral capsule 750 mg</i> | G | |
| CANASA RECTAL SUPPOSITORY 1000 MG (mesalamine) | NF | |
| COLAZAL ORAL CAPSULE 750 MG (balsalazide disodium) | NF | |
| CORTIFOAM EXTERNAL FOAM 10 % (hydrocortisone acetate) | PB | |
| DELZICOL ORAL CAPSULE DELAYED RELEASE 400 MG (mesalamine) | NF | |
| DIPENTUM ORAL CAPSULE 250 MG (olsalazine sodium) | NPB | PA |
| LIALDA ORAL TABLET DELAYED RELEASE 1.2 GM (mesalamine) | NF | |
| <i>mesalamine er oral capsule extended release 24 hour 0.375 gm</i> | G | |
| <i>mesalamine oral capsule delayed release 400 mg</i> | G | |
| <i>mesalamine rectal enema 4 gm</i> | G | |
| SFROWASA RECTAL ENEMA 4 GM/60ML (mesalamine) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| sulfasalazine oral tablet delayed release 500 mg | G | |
| UCERIS RECTAL FOAM 2 MG/ACT (budesonide) | NF | |
| IRRITABLE BOWEL SYNDROME WITH CONSTIPATION | | |
| AMITIZA ORAL CAPSULE 24 MCG, 8 MCG (lubiprostone) | NF | |
| IBSRELA ORAL TABLET 50 MG (tenapanor hcl) | NF | |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG (linaclotide) | PB | |
| <i>lubiprostone oral capsule 24 mcg, 8 mcg</i> | G | N8 (Listing does not include certain NDCs) |
| IRRITABLE BOWEL SYNDROME WITH DIARRHEA | | |
| alosetron hcl oral tablet 0.5 mg, 1 mg | G | PA |
| LOTRONEX ORAL TABLET 0.5 MG, 1 MG (alosetron hcl) | NPB | PA |
| VIBERZI ORAL TABLET 100 MG, 75 MG (eluxadoline) | PB | PA |
| LAXATIVES - DRUGS FOR CONSTIPATION | | |
| CLENPIQ ORAL SOLUTION 10-3.5-12 MG-GM - GM/175ML (sod picosulfate-mag ox-cit acd) | CE | N7 (PB); N8 (\$0 copay for members age 45 through 75); AL (Min 45 Years and Max 75 Years) |
| <i>enulose oral solution 10 gm/15ml</i> | G | |
| GAVILYTE-C ORAL SOLUTION RECONSTITUTED 240 GM (peg 3350-kcl-nabcb-nacl-nasulf) | G | |
| <i>peg 3350-kcl-nabcb-nacl-nasulf</i> (Gavilyte-G Oral Solution Reconstituted 236 Gm) | G | |
| GOLYTELY ORAL SOLUTION RECONSTITUTED 236 GM (peg 3350-kcl-nabcb-nacl-nasulf) | NF | |
| KRISTALOSE ORAL PACKET 10 GM (lactulose) | NPB | |
| <i>lactulose oral packet 10 gm</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>lactulose oral solution 10 gm/15ml</i> | G | N8 (Listing does not include certain NDCs) |
| MOVIPREP ORAL SOLUTION RECONSTITUTED 100 GM (<i>peg-kcl-nacl-nasulf-na asc-c</i>) | NF | |
| <i>na sulfate-k sulfate-mg sulf oral solution 17.5-3.13-1.6 gm/177ml</i> | CE | N7 (G); N8 (\$0 copay for members age 45 through 75); AL (Min 45 Years and Max 75 Years) |
| <i>peg 3350-kcl-na bicarb-nacl oral solution reconstituted 420 gm</i> | G | |
| <i>peg-3350/electrolytes oral solution reconstituted 236 gm</i> | G | |
| <i>peg-kcl-nacl-nasulf-na asc-c oral solution reconstituted 100 gm</i> | CE | N7 (NF) |
| PEG-PREP ORAL KIT 5-210 MG-GM (<i>bisacodyl-peg-kcl-nabicar-nacl</i>) | CE | N7 (NPB); N8 (\$0 copay for members age 45 through 75); AL (Min 45 Years and Max 75 Years) |
| PLENUV ORAL SOLUTION RECONSTITUTED 140 GM (<i>peg-kcl-nacl-nasulf-na asc-c</i>) | CE | N7 (NF); N8 (\$0 copay for members age 45 through 75, otherwise not covered); AL (Min 45 Years and Max 75 Years) |
| SUFLAVE ORAL SOLUTION RECONSTITUTED 178.7 GM (<i>peg 3350-kcl-nacl-nasulf-mgsul</i>) | CE | N7 (Not Covered); AL (Min 45 Years and Max 75 Years) |
| SUPREP BOWEL PREP KIT ORAL SOLUTION 17.5-3.13-1.6 GM/177ML (<i>na sulfate-k sulfate-mg sulf</i>) | NF | |
| SUTAB ORAL TABLET 1479-225-188 MG (<i>sodium sulfate-mag sulfate-kcl</i>) | CE | N7 (NF); N8 (\$0 copay for members age 45 through 75, otherwise not covered) |
| MISCELLANEOUS | | |
| BYLVAY (PELLETS) ORAL CAPSULE SPRINKLE 200 MCG, 600 MCG (<i>odevixibat</i>) | NF | |
| BYLVAY ORAL CAPSULE 1200 MCG, 400 MCG (<i>odevixibat</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| CARAFATE ORAL SUSPENSION 1 GM/10ML (<i>sucralfate</i>) | NF | |
| CARAFATE ORAL TABLET 1 GM (<i>sucralfate</i>) | NF | |
| CHENODAL ORAL TABLET 250 MG (<i>chenodiol</i>) | SP | PA |
| <i>chlordiazepoxide-clidinium oral capsule 5-2.5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| CHOLBAM ORAL CAPSULE 250 MG, 50 MG (<i>cholic acid</i>) | SP | PA |
| EOHILIA ORAL SUSPENSION 2 MG/10ML (<i>budesonide</i>) | NF | |
| <i>flavoxate hcl oral tablet 100 mg</i> | G | |
| GATTEX SUBCUTANEOUS KIT 5 MG (<i>teduglutide (rdna)</i>) | SP | PA; QL (1 KIT per 30 DAYS) |
| LIVMARLI ORAL SOLUTION 9.5 MG/ML (<i>maralixibat chloride</i>) | SP | PA; QL (90 ML per 30 DAYS) |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> | G | N7 (G); N8 (Available at \$0 copay) |
| MOTEGRITY ORAL TABLET 1 MG, 2 MG (<i>prucalopride succinate</i>) | NF | |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG (<i>naloxegol oxalate</i>) | NF | |
| OCALIVA ORAL TABLET 10 MG, 5 MG (<i>obeticholic acid</i>) | SP | PA; QL (30 TABLETS per 30 DAYS) |
| RELISTOR ORAL TABLET 150 MG (<i>methylnaltrexone bromide</i>) | NF | |
| RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6ML, 8 MG/0.4ML (<i>methylnaltrexone bromide</i>) | NF | |
| RELTONE ORAL CAPSULE 200 MG, 400 MG (<i>ursodiol</i>) | NF | |
| SUCRAID ORAL SOLUTION 8500 UNIT/ML (<i>sacrosidase</i>) | SP | PA; QL (3 BOTTLES per 25 days) |
| <i>sucralfate oral suspension 1 gm/10ml</i> | NF | |
| <i>sucralfate oral tablet 1 gm</i> | G | N8 (Listing does not include certain NDCs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| SYMPROIC ORAL TABLET 0.2 MG (<i>naldemedine tosylate</i>) | PB | PA |
| <i>ursodiol oral capsule 200 mg, 400 mg</i> | NF | |
| <i>ursodiol oral capsule 300 mg</i> | G | |
| <i>ursodiol oral tablet 250 mg, 500 mg</i> | G | |
| VOQUEZNA ORAL TABLET 10 MG, 20 MG (<i>vonoprazan fumarate</i>) | NF | |
| VOWST ORAL CAPSULE (<i>fecal microb spores, live-brpk</i>) | SP | PA; QL (12 CAPSULES per 30 DAYS) |
| XERMELO ORAL TABLET 250 MG (<i>telotristat etiprate</i>) | SP | PA; QL (84 TABLETS per 28 days) |
| PANCREATIC ENZYMES | | |
| CREON ORAL CAPSULE DELAYED RELEASE PARTICLES 12000-38000 UNIT, 24000-76000 UNIT, 3000-9500 UNIT, 36000-114000 UNIT, 6000-19000 UNIT (<i>pancrelipase (lip-prot-amyl)</i>) | PB | |
| PANCREAZE ORAL CAPSULE DELAYED RELEASE PARTICLES 10500-35500 UNIT, 16800-56800 UNIT, 21000-54700 UNIT, 2600-8800 UNIT, 37000-97300 UNIT, 4200-14200 UNIT (<i>pancrelipase (lip-prot-amyl)</i>) | NF | |
| PERTZYE ORAL CAPSULE DELAYED RELEASE PARTICLES 16000-57500 UNIT, 24000-86250 UNIT, 4000-14375 UNIT, 8000-28750 UNIT (<i>pancrelipase (lip-prot-amyl)</i>) | NF | |
| VIOKACE ORAL TABLET 10440-39150 UNIT, 20880-78300 UNIT (<i>pancrelipase (lip-prot-amyl)</i>) | PB | |
| ZENPEP ORAL CAPSULE DELAYED RELEASE PARTICLES 10000-32000 UNIT, 15000-47000 UNIT, 20000-63000 UNIT, 25000-79000 UNIT, 3000-10000 UNIT, 40000-126000 UNIT, 5000-24000 UNIT, 60000-189600 UNIT (<i>pancrelipase (lip-prot-amyl)</i>) | PB | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| PROTON PUMP INHIBITORS - DRUGS FOR ULCERS AND STOMACH ACID | | |
| ACIPHEX ORAL TABLET DELAYED RELEASE 20 MG <i>(rabeprazole sodium)</i> | NF | |
| DEXILANT ORAL CAPSULE DELAYED RELEASE 30 MG, 60 MG <i>(dexlansoprazole)</i> | NF | |
| <i>dexlansoprazole oral capsule delayed release 30 mg, 60 mg</i> | NF | |
| <i>esomeprazole magnesium oral capsule delayed release 20 mg</i> | G | Select OTC; QL (90 CAPSULES per 365 DAYs) |
| <i>esomeprazole magnesium oral capsule delayed release 40 mg</i> | G | QL (90 CAPSULES per 365 DAYs) |
| <i>esomeprazole magnesium oral packet 10 mg, 20 mg, 40 mg</i> | G | QL (90 PACKETS per 365 DAYs) |
| <i>esomeprazole magnesium oral tablet delayed release 20 mg</i> | G | Select OTC; QL (90 TABLETS per 365 DAYs) |
| KONVOMEП ORAL SUSPENSION RECONSTITUTED 2-84 MG/ML <i>(omeprazole-sodium bicarbonate)</i> | NF | |
| <i>lansoprazole oral capsule delayed release 30 mg</i> | G | QL (90 CAPSULES per 365 DAYs) |
| <i>lansoprazole oral tablet delayed release dispersible 30 mg</i> | NF | |
| NEXIUM 24HR ORAL TABLET DELAYED RELEASE 20 MG <i>(esomeprazole magnesium)</i> | G | Select OTC; QL (90 TABLETS per 365 DAYs) |
| NEXIUM ORAL CAPSULE DELAYED RELEASE 40 MG <i>(esomeprazole magnesium)</i> | NF | |
| NEXIUM ORAL PACKET 10 MG, 2.5 MG, 20 MG, 40 MG, 5 MG <i>(esomeprazole magnesium)</i> | NF | |
| <i>omeprazole magnesium oral capsule delayed release 20.6 (20 base) mg</i> | G | Select OTC; QL (90 CAPSULES per 365 DAYs) |
| <i>omeprazole magnesium oral tablet delayed release 20 mg</i> | G | Select OTC; QL (90 TABLETS per 365 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>omeprazole oral capsule delayed release 10 mg, 40 mg</i> | G | QL (90 CAPSULES per 365 DAYs) |
| <i>omeprazole oral capsule delayed release 20 mg</i> | G | Select OTC; QL (90 CAPSULES per 365 days) |
| <i>omeprazole-sodium bicarbonate oral capsule 20-1100 mg</i> | G | Select OTC; QL (90 CAPSULES per 365 DAYs) |
| <i>omeprazole-sodium bicarbonate oral capsule 40-1100 mg</i> | NF | |
| <i>omeprazole-sodium bicarbonate oral packet 20-1680 mg, 40-1680 mg</i> | NF | |
| <i>pantoprazole sodium oral packet 40 mg</i> | NF | |
| <i>pantoprazole sodium oral tablet delayed release 20 mg</i> | G | N8 (Listing does not include certain NDCs); QL (90 TABLETS per 365 days) |
| <i>pantoprazole sodium oral tablet delayed release 40 mg</i> | G | N8 (Listing does not include certain NDCs); QL (90 TABLETS per 365 DAYs) |
| PREVACID ORAL CAPSULE DELAYED RELEASE 30 MG (<i>lansoprazole</i>) | NF | |
| PREVACID SOLUTAB ORAL TABLET DELAYED RELEASE DISPERSIBLE 30 MG (<i>lansoprazole</i>) | NF | |
| PRILOSEC ORAL PACKET 10 MG, 2.5 MG (<i>omeprazole magnesium</i>) | NF | |
| PRILOSEC OTC ORAL TABLET DELAYED RELEASE 20 MG (<i>omeprazole magnesium</i>) | G | Select OTC; QL (90 TABLETS per 365 DAYs) |
| PROTONIX ORAL PACKET 40 MG (<i>pantoprazole sodium</i>) | NF | |
| PROTONIX ORAL TABLET DELAYED RELEASE 20 MG, 40 MG (<i>pantoprazole sodium</i>) | NF | |
| <i>qc lansoprazole oral capsule delayed release 15 mg</i> | G | Select OTC; QL (90 CAPSULES per 365 DAYs) |
| <i>ra omeprazole oral tablet delayed release 20 mg</i> | G | Select OTC; QL (90 TABLETS per 365 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| rabeprazole sodium oral capsule sprinkle 10 mg | NPB | QL (90 CAPSULES per 365 DAYS) |
| rabeprazole sodium oral tablet delayed release 20 mg | G | QL (90 TABLETS per 365 days) |
| ZEGERID ORAL CAPSULE 40-1100 MG (<i>omeprazole-sodium bicarbonate</i>) | NF | |
| ZEGERID ORAL PACKET 20-1680 MG, 40-1680 MG (<i>omeprazole-sodium bicarbonate</i>) | NF | |
| RECTAL, CORTICOSTEROIDS | | |
| hydrocortisone (<i>perianal</i>) external cream 2.5 % | G | |
| PROCTOFOAM HC EXTERNAL FOAM 1-1 % (<i>hydrocortisone ace-pramoxine</i>) | PB | |
| hydrocortisone (<i>Proctozone-Hc External Cream 2.5 %</i>) | G | |
| ULCER THERAPY COMBINATIONS | | |
| <i>amoxicill-clarithro-lansopraz oral therapy pack 500 & 500 & 30 mg</i> | G | |
| <i>bismuth/metronidaz/tetracyclin oral capsule 140-125-125 mg</i> | G | |
| HELIDAC THERAPY ORAL (<i>metronid-tetracyc-bis subsal</i>) | NF | |
| TALICIA ORAL CAPSULE DELAYED RELEASE 250-12.5-10 MG (<i>amoxicill-rifabutin-omeprazole</i>) | PB | |
| GENITOURINARY - DRUGS TO TREAT GENITAL AND URINARY TRACT CONDITIONS | | |
| BENIGN PROSTATIC HYPERPLASIA - DRUGS TO TREAT ENLARGED PROSTATE | | |
| <i>alfuzosin hcl er oral tablet extended release 24 hour 10 mg</i> | G | |
| <i>doxazosin mesylate oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>dutasteride oral capsule 0.5 mg</i> | G | |
| <i>dutasteride-tamsulosin hcl oral capsule 0.5-0.4 mg</i> | G | |
| ENTADFI ORAL CAPSULE 5-5 MG (<i>finasteride-tadalafil</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>finasteride oral tablet 5 mg</i> | G | |
| JALYN ORAL CAPSULE 0.5-0.4 MG (<i>dutasteride-tamsulosin hcl</i>) | NF | |
| PROSCAR ORAL TABLET 5 MG (<i>finasteride</i>) | NPB | |
| RAPAFLO ORAL CAPSULE 4 MG, 8 MG (<i>silodosin</i>) | NF | |
| <i>silodosin oral capsule 4 mg, 8 mg</i> | G | |
| <i>tamsulosin hcl oral capsule 0.4 mg</i> | G | |
| <i>terazosin hcl oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | G | LGC; N8 (Listing does not include certain NDCs) |
| UROXATRAL ORAL TABLET EXTENDED RELEASE 24 HOUR 10 MG (<i>alfuzosin hcl</i>) | NF | |
| CONTRACEPTIVES - PRODUCTS FOR BIRTH CONTROL | | |
| ENCARE VAGINAL SUPPOSITORY 100 MG (<i>nonoxynol-9</i>) | CE | N7 (Not Covered) |
| OPTIONS GYNOL II CONTRACEPTIVE VAGINAL GEL 3 % (<i>nonoxynol-9</i>) | CE | N7 (Not Covered) |
| PHEXXI VAGINAL GEL 1.8-1-0.4 % (<i>lactic ac-citric ac-pot bitart</i>) | CE | N7 (NPB) |
| TODAY SPONGE VAGINAL 1000 MG (<i>nonoxynol-9</i>) | CE | N7 (Not Covered) |
| VCF VAGINAL CONTRACEPTIVE VAGINAL FILM 28 % (<i>nonoxynol-9</i>) | CE | N7 (Not Covered) |
| VCF VAGINAL CONTRACEPTIVE VAGINAL GEL 4 % (<i>nonoxynol-9</i>) | CE | N7 (Not Covered) |
| ERECTILE DYSFUNCTION | | |
| CAVERJECT IMPULSE INTRACAVERNOSAL KIT 10 MCG, 20 MCG (<i>alprostadil (vasodilator)</i>) | NPB | SPC; QL (6 KIT per 25 DAYs) |
| CAVERJECT INTRACAVERNOSAL SOLUTION RECONSTITUTED 40 MCG (<i>alprostadil (vasodilator)</i>) | NPB | SPC; QL (6 SOLUTION RECONSTITUTED per 25 DAYs) |
| CIALIS ORAL TABLET 10 MG, 20 MG, 5 MG (<i>tadalafil</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| EDEX INTRACAVERNOSAL KIT 10 MCG, 20 MCG, 40 MCG (<i>alprostadil (vasodilator)</i>) | NPB | SPC; QL (6 KIT per 25 DAYs) |
| MUSE URETHRAL PELLET 1000 MCG, 250 MCG, 500 MCG (<i>alprostadil (vasodilator)</i>) | PB | SPC; QL (6 PELLET per 25 DAYs) |
| <i>phenylephrine hcl intracavernosal solution 2 mg/2ml</i> | NF | |
| <i>quad-mix intracavernosal solution reconstituted 150-10-0.1-1 mg</i> | NF | |
| <i>sildenafil citrate oral tablet 100 mg, 25 mg, 50 mg</i> | G | SPC; QL (6 TABLETS per 25 days) |
| STENDRA ORAL TABLET 100 MG, 200 MG, 50 MG (<i>avanafil</i>) | NF | |
| <i>super quad-mix intracavernosal solution reconstituted 150-20-0.2-2 mg</i> | NF | |
| <i>tadalafil oral tablet 10 mg</i> | G | SPC; QL (6 TABLETS per 25 days) |
| <i>tadalafil oral tablet 2.5 mg</i> | G | SPC; QL (30 TABLETS per 25 days) |
| <i>tadalafil oral tablet 20 mg</i> | G | SPC; N8 (Listing does not include certain NDCs); QL (6 TABLETS per 25 days) |
| <i>tadalafil oral tablet 5 mg</i> | G | SPC; N8 (Listing does not include certain NDCs. Only available for select plans); QL (30 TABLETS per 25 days) |
| <i>vardenafil hcl oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | G | SPC; QL (6 TABLETS per 25 DAYs) |
| <i>vardenafil hcl oral tablet dispersible 10 mg</i> | G | |
| VIAGRA ORAL TABLET 100 MG, 25 MG, 50 MG (<i>sildenafil citrate</i>) | NF | |
| MISCELLANEOUS | | |
| <i>acetic acid irrigation solution 0.25 %</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg | G | N8 (Listing does not include certain NDCs) |
| ELMIRON ORAL CAPSULE 100 MG (<i>pentosan polysulfate sodium</i>) | NF | |
| FILSPARI ORAL TABLET 200 MG, 400 MG (<i>sparsentan</i>) | NF | |
| LITHOSTAT ORAL TABLET 250 MG (<i>acetohydroxamic acid</i>) | NF | |
| oral citrate oral solution 490-640 mg/5ml | NF | |
| pot & sod cit-cit ac oral solution 550-500-334 mg/5ml | G | N8 (Listing does not include certain NDCs) |
| potassium citrate er oral tablet extended release 10 meq (1080 mg), 15 meq (1620 mg), 5 meq (540 mg) | G | |
| PROCYSBI ORAL CAPSULE DELAYED RELEASE 25 MG, 75 MG (<i>cysteamine bitartrate</i>) | NF | |
| PROCYSBI ORAL PACKET 300 MG, 75 MG (<i>cysteamine bitartrate</i>) | NF | |
| RIVFLOZA SUBCUTANEOUS SOLUTION 80 MG/0.5ML (<i>nedosiran sodium</i>) | NF | |
| RIVFLOZA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 128 MG/0.8ML, 160 MG/ML (<i>nedosiran sodium</i>) | NF | |
| TARPEYO ORAL CAPSULE DELAYED RELEASE 4 MG (<i>budesonide</i>) | NF | |
| THIOLA EC ORAL TABLET DELAYED RELEASE 100 MG, 300 MG (<i>tiopronin</i>) | NF | |
| THIOLA ORAL TABLET 100 MG (<i>tiopronin</i>) | NF | |
| tiopronin oral tablet 100 mg | SP | PA |
| tiopronin oral tablet delayed release 100 mg, 300 mg | NF | |
| URINARY ANTISPASMODICS - DRUGS TO TREAT URINARY INCONTINENCE | | |
| darifenacin hydrobromide er oral tablet extended release 24 hour 15 mg, 7.5 mg | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| DETROL LA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 2 MG, 4 MG (<i>tolterodine tartrate</i>) | NF | |
| <i>fesoterodine fumarate er oral tablet extended release 24 hour 4 mg, 8 mg</i> | G | |
| GELNIQUE TRANSDERMAL GEL 10 % (<i>oxybutynin chloride</i>) | NF | |
| GEMTESA ORAL TABLET 75 MG (<i>vibegron</i>) | PB | ST; QL (30 TABLETS per 25 days) |
| MYRBETRIQ ORAL SUSPENSION RECONSTITUTED ER 8 MG/ML (<i>mirabegron</i>) | NF | |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HOUR 25 MG, 50 MG (<i>mirabegron</i>) | NF | |
| <i>oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg, 5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>oxybutynin chloride oral solution 5 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>oxybutynin chloride oral tablet 2.5 mg</i> | NF | |
| <i>oxybutynin chloride oral tablet 5 mg</i> | G | |
| <i>solifenacin succinate oral tablet 10 mg, 5 mg</i> | G | |
| <i>tolterodine tartrate er oral capsule extended release 24 hour 2 mg, 4 mg</i> | G | |
| <i>tolterodine tartrate oral tablet 1 mg, 2 mg</i> | G | |
| TOVIAZ ORAL TABLET EXTENDED RELEASE 24 HOUR 4 MG, 8 MG (<i>fesoterodine fumarate</i>) | NF | |
| <i>trospium chloride er oral capsule extended release 24 hour 60 mg</i> | G | |
| <i>trospium chloride oral tablet 20 mg</i> | G | N8 (Listing does not include certain NDCs) |
| VESICARE ORAL TABLET 10 MG, 5 MG (<i>solifenacin succinate</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| VAGINAL ANTI-INFECTIVES - DRUGS TO TREAT VAGINAL INFECTIONS | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> | G | |
| <i>metronidazole vaginal gel 0.75 %</i> | G | |
| <i>miconazole 3 vaginal suppository 200 mg</i> | G | |
| NUVESSA VAGINAL GEL 1.3 % (metronidazole) | NF | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | G | |
| <i>terconazole vaginal suppository 80 mg</i> | G | |
| HEMATOLOGIC - DRUGS TO TREAT BLOOD DISORDERS | | |
| ANTICOAGULANTS - BLOOD THINNERS | | |
| <i>dabigatran etexilate mesylate oral capsule 110 mg, 150 mg, 75 mg</i> | NF | |
| ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5 MG (apixaban) | PB | |
| ELIQUIS ORAL TABLET 2.5 MG, 5 MG (apixaban) | PB | |
| <i>enoxaparin sodium injection solution 300 mg/3ml</i> | G | |
| <i>enoxaparin sodium injection solution prefilled syringe 100 mg/ml, 120 mg/0.8ml, 150 mg/ml, 30 mg/0.3ml, 40 mg/0.4ml, 60 mg/0.6ml, 80 mg/0.8ml</i> | G | |
| <i>fondaparinux sodium subcutaneous solution 10 mg/0.8ml, 2.5 mg/0.5ml, 5 mg/0.4ml, 7.5 mg/0.6ml</i> | G | |
| FRAGMIN SUBCUTANEOUS SOLUTION 10000 UNIT/4ML, 95000 UNIT/3.8ML (dalteparin sodium) | NF | |
| FRAGMIN SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10000 UNIT/ML, 12500 UNIT/0.5ML, 15000 UNIT/0.6ML, 18000 UNT/0.72ML, 2500 UNIT/0.2ML, 5000 UNIT/0.2ML, 7500 UNIT/0.3ML (dalteparin sodium) | NF | |
| <i>heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 20000 unit/ml, 5000 unit/ml</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>heparin sodium (porcine) pf injection solution 1000 unit/ml, 5000 unit/0.5ml</i> | G | |
| PRADAXA ORAL CAPSULE 110 MG, 150 MG, 75 MG (<i>dabigatran etexilate mesylate</i>) | NF | |
| PRADAXA ORAL PACKET 110 MG, 150 MG, 20 MG, 30 MG, 40 MG, 50 MG (<i>dabigatran etexilate mesylate</i>) | NF | |
| SAVAYSA ORAL TABLET 15 MG, 30 MG, 60 MG (<i>edoxaban tosylate</i>) | NF | |
| <i>warfarin sodium oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | G | LGC |
| XARELTO ORAL SUSPENSION RECONSTITUTED 1 MG/ML (<i>rivaroxaban</i>) | PB | |
| XARELTO ORAL TABLET 10 MG, 15 MG, 2.5 MG, 20 MG (<i>rivaroxaban</i>) | PB | |
| XARELTO STARTER PACK ORAL TABLET THERAPY PACK 15 & 20 MG (<i>rivaroxaban</i>) | PB | |
| BLEEDING DISORDERS AGENTS | | |
| ALPHANATE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 500 UNIT (<i>antihemophilic factor-vwf</i>) | SP | PA |
| CABLIVI INJECTION KIT 11 MG (<i>caplacizumab-yhdp</i>) | NF | |
| CORIFACT INTRAVENOUS KIT 1000-1600 UNIT (<i>factor xiii concentrate human</i>) | SP | PA |
| FEIBA INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2500 UNIT, 500 UNIT (<i>antiinhibitor coagulant cmplx</i>) | NF | |
| FIBRYGA INTRAVENOUS SOLUTION RECONSTITUTED (<i>fibrinogen concentrate (human)</i>) | SP | PA |
| HUMATE-P INTRAVENOUS SOLUTION RECONSTITUTED 1000-2400 UNIT, 250-600 UNIT, 500-1200 UNIT (<i>antihemophilic factor-vwf</i>) | SP | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| KCENTRA INTRAVENOUS KIT 1000 UNIT, 500 UNIT (<i>prothrombin complex conc human</i>) | SP | PA |
| NOVOSEVEN RT INTRAVENOUS SOLUTION RECONSTITUTED 1 MG, 2 MG, 5 MG, 8 MG (<i>coagulation factor viia recomb</i>) | SP | PA |
| RIASTAP INTRAVENOUS SOLUTION RECONSTITUTED (<i>fibrinogen concentrate (human)</i>) | SP | PA |
| SEVENFACT INTRAVENOUS SOLUTION RECONSTITUTED 1 MG, 5 MG (<i>coagulation factor viia-jncw</i>) | SP | PA |
| TRETEN INTRAVENOUS SOLUTION RECONSTITUTED 2500 UNIT (<i>coagulation factor xiii a-sub</i>) | SP | PA |
| WILATE INTRAVENOUS KIT 1000-1000 UNIT, 500-500 UNIT (<i>antihemophilic factor-vwf</i>) | SP | PA |
| HEMATOPOIETIC GROWTH FACTORS | | |
| ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML (<i>darbepoetin alfa</i>) | SP | PA |
| ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE 10 MCG/0.4ML, 100 MCG/0.5ML, 150 MCG/0.3ML, 200 MCG/0.4ML, 25 MCG/0.42ML, 300 MCG/0.6ML, 40 MCG/0.4ML, 500 MCG/ML, 60 MCG/0.3ML (<i>darbepoetin alfa</i>) | SP | PA |
| EPOGEN INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML (<i>epoetin alfa</i>) | NF | |
| FULPHILA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML (<i>pegfilgrastim-jmdb</i>) | NF | |
| FYLNTRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML (<i>pegfilgrastim-pbbk</i>) | SP | PA; QL (2 SYRINGES per 28 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| GRANIX SUBCUTANEOUS SOLUTION 300 MCG/ML, 480 MCG/1.6ML (<i>tbo-filgrastim</i>) | NF | |
| GRANIX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML (<i>tbo-filgrastim</i>) | NF | |
| JESDUVROQ ORAL TABLET 1 MG, 2 MG, 4 MG, 6 MG, 8 MG (<i>daprodustat</i>) | NF | |
| LEUKINE INJECTION SOLUTION RECONSTITUTED 250 MCG (<i>sargramostim</i>) | NF | |
| MIRCERA INJECTION SOLUTION PREFILLED SYRINGE 100 MCG/0.3ML, 120 MCG/0.3ML, 150 MCG/0.3ML, 200 MCG/0.3ML, 30 MCG/0.3ML, 50 MCG/0.3ML, 75 MCG/0.3ML (<i>methoxy peg-epoetin beta</i>) | NF | |
| NEULASTA ONPRO SUBCUTANEOUS PREFILLED SYRINGE KIT 6 MG/0.6ML (<i>pegfilgrastim</i>) | NF | |
| NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML (<i>pegfilgrastim</i>) | NF | |
| NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML (<i>filgrastim</i>) | NF | |
| NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML (<i>filgrastim</i>) | NF | |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML (<i>filgrastim-aafi</i>) | SP | PA |
| NIVESTYM INJECTION SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML (<i>filgrastim-aafi</i>) | SP | PA |
| NYVEPRIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML (<i>pegfilgrastim-apgf</i>) | SP | PA; QL (2 SYRINGES per 28 days) |
| PROCIT INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML (<i>epoetin alfa</i>) | SP | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| releuko subcutaneous solution prefilled syringe 300 mcg/0.5ml, 480 mcg/0.8ml | NF | |
| RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML (<i>epoetin alfa-epbx</i>) | SP | PA |
| ROLVEDON SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 13.2 MG/0.6ML (<i>eflapegrastim-xnst</i>) | NF | |
| STIMUFEND SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML (<i>pegfilgrastim-fpgk</i>) | NF | |
| UDENYCA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 6 MG/0.6ML (<i>pegfilgrastim-cbqv</i>) | NF | |
| UDENYCA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML (<i>pegfilgrastim-cbqv</i>) | NF | |
| ZARXIO INJECTION SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML (<i>filgrastim-sndz</i>) | NF | |
| ZIEXTENZO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML (<i>pegfilgrastim-bmez</i>) | NF | |
| HEMOPHILIA A AGENTS | | |
| ADVATE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT (<i>antihemophil factor (rahf-pfm)</i>) | SP | PA |
| adynovate intravenous solution reconstituted 1000 unit, 1500 unit, 2000 unit, 250 unit, 3000 unit, 500 unit, 750 unit | SP | PA |
| AFSTYLA INTRAVENOUS KIT 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 2500 UNIT, 3000 UNIT, 500 UNIT (<i>antihemophil fact single chain</i>) | SP | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| ALTUVIPIO INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT, 750 UNIT (<i>antihem fact fc-vwf-xten-ehtl</i>) | NF | |
| ELOCTATE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT, 5000 UNIT, 6000 UNIT, 750 UNIT (<i>antihem fact (bdd-rfviiifc)</i>) | SP | PA |
| ESPEROCT INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 3000 UNIT, 500 UNIT (<i>antihemoph fact rcmb gpeg-exei</i>) | SP | PA |
| HEMLIBRA SUBCUTANEOUS SOLUTION 105 MG/0.7ML, 12 MG/0.4ML, 150 MG/ML, 30 MG/ML, 300 MG/2ML, 60 MG/0.4ML (<i>emicizumab-kxwh</i>) | SP | PA |
| HEMOFIL M INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1700 UNIT, 250 UNIT, 500 UNIT (<i>antihemophilic factor</i>) | SP | PA |
| JIVI INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 3000 UNIT, 500 UNIT (<i>ahf (bdd-rfviii peg-auc1)</i>) | SP | PA |
| KOATE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 250 UNIT, 500 UNIT (<i>antihemophilic factor</i>) | SP | PA |
| KOATE-DVI INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 500 UNIT (<i>antihemophilic factor</i>) | SP | PA |
| KOGENATE FS INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT (<i>antihem factor recomb (rfviii)</i>) | SP | PA |
| KOVALTRY INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT (<i>antihemophil factor (rahf-pfm)</i>) | SP | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| NOVOEIGHT INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT (<i>antihemophilic factor bd truncated</i>) | SP | PA |
| NUWIQ INTRAVENOUS KIT 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 2500 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT (<i>antihem fact (bdd-rfviii,sim)</i>) | SP | PA |
| NUWIQ INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 2500 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT (<i>antihem fact (bdd-rfviii,sim)</i>) | SP | PA |
| <i>obizur intravenous solution reconstituted 500 unit</i> | SP | PA |
| RECOMBINATE INTRAVENOUS SOLUTION RECONSTITUTED 1241-1800 UNIT, 1801-2400 UNIT, 220-400 UNIT, 401-800 UNIT, 801-1240 UNIT (<i>antihem factor recomb (rfviii)</i>) | SP | PA |
| XYNTHA INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 500 UNIT (<i>antihem fact (bdd-rfviii,mor)</i>) | SP | PA |
| XYNTHA SOLOFUSE INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT (<i>antihem fact (bdd-rfviii,mor)</i>) | SP | PA |
| HEMOPHILIA B AGENTS | | |
| ALPHANINE SD INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 500 UNIT (<i>coagulation factor ix</i>) | SP | PA |
| ALPROLIX INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT (<i>coagulation factor ix (rfixfc)</i>) | SP | PA |
| BENEFIX INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT (<i>coagulation factor ix (recomb)</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| COAGADEX INTRAVENOUS SOLUTION RECONSTITUTED 250 UNIT, 500 UNIT (<i>coagulation factor x (human)</i>) | SP | PA |
| IDELVION INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 250 UNIT, 3500 UNIT, 500 UNIT (<i>coagulation factor ix (rix-fp)</i>) | SP | PA |
| IXINITY INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT (<i>coagulation factor ix (recomb)</i>) | NF | |
| PROFILNINE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 500 UNIT (<i>factor ix complex</i>) | SP | PA |
| REBINYN INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 3000 UNIT, 500 UNIT (<i>coagulation factor ix glycopeg</i>) | SP | PA |
| <i>rixubis intravenous solution reconstituted 1000 unit, 2000 unit, 250 unit, 3000 unit, 500 unit</i> | NF | |
| VONVENDI INTRAVENOUS SOLUTION RECONSTITUTED 1300 UNIT, 650 UNIT (<i>von willebrand factor (recomb)</i>) | NF | |
| MISCELLANEOUS | | |
| AGRYLIN ORAL CAPSULE 0.5 MG (<i>anagrelide hcl</i>) | NPB | QL (180 CAPSULES per 25 DAYs) |
| <i>aminocaproic acid oral solution 0.25 g/ml/ml</i> | G | |
| <i>aminocaproic acid oral tablet 1000 mg, 500 mg</i> | G | |
| <i>anagrelide hcl oral capsule 0.5 mg</i> | G | QL (180 CAPSULES per 25 DAYs) |
| <i>anagrelide hcl oral capsule 1 mg</i> | G | QL (90 CAPSULES per 25 DAYs) |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | G | QL (60 TABLETS per 25 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-----------------------------------|
| CYSTADROPS OPHTHALMIC SOLUTION 0.37 % (<i>cysteamine hcl</i>) | NF | |
| LACRISERT OPHTHALMIC INSERT 5 MG (<i>artificial tear insert</i>) | NF | |
| OXERVATE OPHTHALMIC SOLUTION 0.002 % (<i>cenegermin-bk bj</i>) | SP | PA; QL (2 CARTONS per 7 DAYs) |
| <i>pentoxifylline er oral tablet extended release 400 mg</i> | G | |
| PYRUKYND ORAL TABLET 20 MG, 5 MG, 50 MG (<i>mitapivat sulfate</i>) | NF | |
| PYRUKYND TAPER PACK ORAL TABLET THERAPY PACK 5 MG, 7 X 20 MG & 7 X 5 MG, 7 X 50 MG & 7 X 20 MG (<i>mitapivat sulfate</i>) | NF | |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2ML (<i>lanadelumab-fryo</i>) | SP | PA; QL (2 VIALS per 28 DAYs) |
| TAVNEOS ORAL CAPSULE 10 MG (<i>avacopan</i>) | SP | PA; QL (180 CAPSULES per 30 days) |
| <i>tranexamic acid oral tablet 650 mg</i> | G | |
| UPNEEQ OPHTHALMIC SOLUTION 0.1 % (<i>oxymetazoline hcl</i>) | NF | |
| VISUDYNE INTRAVENOUS SOLUTION RECONSTITUTED 15 MG (<i>verteporfin</i>) | SP | PA |
| PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AGENTS | | |
| EMPAVELI SUBCUTANEOUS SOLUTION 1080 MG/20ML (<i>pegcetacoplan</i>) | SP | PA; QL (10 VIALS per 30 days) |
| FABHALTA ORAL CAPSULE 200 MG (<i>iptacopan hcl</i>) | SP | PA; QL (60 CAPSULES per 30 DAYs) |
| VOYDEYA ORAL TABLET 100 MG (<i>danicopan</i>) | NF | |
| VOYDEYA ORAL TABLET THERAPY PACK 50 & 100 MG (<i>danicopan</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| PLATELET AGGREGATION INHIBITORS - BLOOD THINNERS | | |
| aspirin-dipyridamole er oral capsule extended release 12 hour 25-200 mg | G | QL (60 CAPSULES per 25 DAYs) |
| BRILINTA ORAL TABLET 60 MG, 90 MG (ticagrelor) | PB | QL (60 TABLETS per 25 DAYs) |
| clopidogrel bisulfate oral tablet 300 mg, 75 mg | G | |
| dipyridamole oral tablet 25 mg, 75 mg | G | QL (120 TABLETS per 25 DAYs) |
| dipyridamole oral tablet 50 mg | G | QL (240 TABLETS per 25 DAYs) |
| EFFIENT ORAL TABLET 10 MG, 5 MG (prasugrel hcl) | NPB | QL (30 TABLETS per 25 days) |
| PLAVIX ORAL TABLET 75 MG (clopidogrel bisulfate) | NF | |
| prasugrel hcl oral tablet 10 mg, 5 mg | G | QL (30 TABLETS per 25 DAYs) |
| YOSPRALA ORAL TABLET DELAYED RELEASE 325-40 MG, 81-40 MG (aspirin-omeprazole) | NF | |
| ZONTIVITY ORAL TABLET 2.08 MG (vorapaxar sulfate) | NF | |
| SICKLE CELL DISEASE | | |
| ENDARI ORAL PACKET 5 GM (glutamine (sickle cell)) | SP | PA; QL (180 PACKETS per 30 days) |
| OXBRYTA ORAL TABLET 300 MG, 500 MG (voxelotor) | NF | |
| OXBRYTA ORAL TABLET SOLUBLE 300 MG (voxelotor) | NF | |
| SIKLOS ORAL TABLET 100 MG, 1000 MG (hydroxyurea) | PB | |
| THROMBOCYTOPENIA AGENTS - DRUGS TO TREAT PLATELET DISORDERS | | |
| ALVAIZ ORAL TABLET 18 MG, 36 MG, 54 MG, 9 MG (eltrombopag choline) | NF | |
| DOPTELET ORAL TABLET 20 MG (avatrombopag maleate) | SP | PA; QL (60 TABLETS per 30 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| MULPLETA ORAL TABLET 3 MG (<i>lusutrombopag</i>) | SP | PA; QL (7 TABLETS per 14 days) |
| NPLATE SUBCUTANEOUS SOLUTION RECONSTITUTED 125 MCG, 250 MCG, 500 MCG (<i>romiplostim</i>) | NF | |
| PROMACTA ORAL PACKET 12.5 MG (<i>eltrombopag olamine</i>) | SP | PA; QL (120 PACKETS per 30 days) |
| PROMACTA ORAL PACKET 25 MG (<i>eltrombopag olamine</i>) | SP | PA; QL (180 PACKETS per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG, 75 MG (<i>eltrombopag olamine</i>) | SP | PA; QL (60 TABLETS per 30 days) |
| PROMACTA ORAL TABLET 25 MG, 50 MG (<i>eltrombopag olamine</i>) | SP | PA; QL (90 TABLETS per 30 days) |
| TAVALISSE ORAL TABLET 100 MG, 150 MG (<i>fostamatinib disodium</i>) | SP | PA; QL (60 TABLETS per 30 days) |
| VITAMINS - VITAMINS AND SUPPLEMENTS | | |
| <i>cyanocobalamin nasal solution 500 mcg/0.1ml</i> | NF | |
| IMMUNOLOGIC AGENTS - DRUGS TO TREAT DISORDERS OF THE IMMUNE SYSTEM | | |
| ALLERGENIC EXTRACTS | | |
| GRASTEK SUBLINGUAL TABLET SUBLINGUAL 2800 BAU (<i>timothy grass pollen allergen</i>) | PB | PA |
| ODACTRA SUBLINGUAL TABLET SUBLINGUAL 12 SQ-HDM (<i>dust mite mixed allergen ext</i>) | NPB | PA |
| ORALAIR SUBLINGUAL TABLET SUBLINGUAL 300 IR (<i>grass mix pollens allergen ext</i>) | SP | PA |
| PALFORZIA (12 MG DAILY DOSE) ORAL 2 X 1 MG & 10 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA (120 MG DAILY DOSE) ORAL 20 MG & 100 MG (<i>peanut powder-dnfp</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| PALFORZIA (160 MG DAILY DOSE) ORAL 3 X 20 MG & 100 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA (20 MG DAILY DOSE) ORAL 20 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA (200 MG DAILY DOSE) ORAL 2 X 100 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA (240 MG DAILY DOSE) ORAL 2 X 20 MG & 2 X 100 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA (3 MG DAILY DOSE) ORAL 3 X 1 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA (300 MG MAINTENANCE) ORAL PACKET 300 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA (300 MG TITRATION) ORAL PACKET 300 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA (40 MG DAILY DOSE) ORAL 2 X 20 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA (6 MG DAILY DOSE) ORAL 6 X 1 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA (80 MG DAILY DOSE) ORAL 4 X 20 MG (<i>peanut powder-dnfp</i>) | NF | |
| PALFORZIA INITIAL ESCALATION ORAL 0.5 & 1 & 1.5 & 3 & 6 MG (<i>peanut powder-dnfp</i>) | NF | |
| RAGWITEK SUBLINGUAL TABLET SUBLINGUAL 12 AMB A 1-U (<i>short ragweed pollen ext</i>) | PB | PA |
| AUTOIMMUNE AGENTS (PHYSICIAN-ADMINISTERED) | | |
| ACTEMRA INTRAVENOUS SOLUTION 200 MG/10ML, 400 MG/20ML, 80 MG/4ML (<i>tocilizumab</i>) | NF | |
| AVSOLA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG (<i>infliximab-axxq</i>) | SP | PA; ST; QL (5 VIALS per 42 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| ENTYVIO INTRAVENOUS SOLUTION RECONSTITUTED 300 MG (<i>vedolizumab</i>) | NF | IBC (Available as NPSP with PA for Ulcerative Colitis) |
| ILUMYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML (<i>tildrakizumab-asmn</i>) | SP | PA; QL (1 SYRINGE per 90 days) |
| INFLECTRA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG (<i>infliximab-dyyb</i>) | NF | |
| <i>infliximab intravenous solution reconstituted 100 mg</i> | NF | |
| ORENCIA INTRAVENOUS SOLUTION RECONSTITUTED 250 MG (<i>abatacept</i>) | NF | |
| REMICADE INTRAVENOUS SOLUTION RECONSTITUTED 100 MG (<i>infliximab</i>) | SP | PA; QL (5 VIALS per 42 days) |
| RENFLEXIS INTRAVENOUS SOLUTION RECONSTITUTED 100 MG (<i>infliximab-abda</i>) | NF | |
| SIMPONI ARIA INTRAVENOUS SOLUTION 50 MG/4ML (<i>golimumab</i>) | SP | PA; QL (4 VIALS per 56 days) |
| TOFIDENCE INTRAVENOUS SOLUTION 200 MG/10ML, 400 MG/20ML, 80 MG/4ML (<i>tocilizumab-bavi</i>) | NF | |
| TYENNE INTRAVENOUS SOLUTION 200 MG/10ML, 400 MG/20ML, 80 MG/4ML (<i>tocilizumab-aazg</i>) | NF | |
| AUTOIMMUNE AGENTS (SELF-ADMINISTERED) | | |
| ABRILADA (1 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.8ML (<i>adalimumab-afzb</i>) | NF | |
| ABRILADA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 20 MG/0.4ML, 40 MG/0.8ML (<i>adalimumab-afzb</i>) | NF | |
| ACTEMRA ACTPEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 162 MG/0.9ML (<i>tocilizumab</i>) | NF | |
| ACTEMRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 162 MG/0.9ML (<i>tocilizumab</i>) | NF | |
| <i>adalimumab-aacf (2 pen) subcutaneous auto-injector kit 40 mg/0.8ml</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-------------------------------------|
| adalimumab-aaty (1 pen) subcutaneous auto-injector kit 40 mg/0.4ml, 80 mg/0.8ml | NF | |
| adalimumab-aaty (2 syringe) subcutaneous prefilled syringe kit 20 mg/0.2ml, 40 mg/0.4ml | NF | |
| adalimumab-adaz subcutaneous solution auto-injector 40 mg/0.4ml | SP | PA; ST; QL (4 PENS per 28 DAYs) |
| adalimumab-adaz subcutaneous solution prefilled syringe 40 mg/0.4ml | SP | PA; ST; QL (4 SYRINGES per 28 DAYs) |
| adalimumab-adbm (2 pen) subcutaneous auto-injector kit 40 mg/0.8ml | NF | |
| adalimumab-adbm (2 syringe) subcutaneous prefilled syringe kit 10 mg/0.2ml, 20 mg/0.4ml, 40 mg/0.8ml | NF | |
| adalimumab-fkjp subcutaneous auto-injector kit 40 mg/0.8ml | NF | |
| adalimumab-fkjp subcutaneous prefilled syringe kit 20 mg/0.4ml, 40 mg/0.8ml | NF | |
| adalimumab-ryvk (2 pen) subcutaneous auto-injector kit 40 mg/0.4ml | NF | |
| AMJEVITA SUBCUTANEOUS SOLUTION AUTO-Injector 40 MG/0.4ML, 40 MG/0.8ML, 80 MG/0.8ML (adalimumab-atto) | NF | |
| AMJEVITA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML, 40 MG/0.8ML (adalimumab-atto) | NF | |
| AMJEVITA-PED 10KG TO <15KG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.2ML (adalimumab-atto) | NF | |
| AMJEVITA-PED 15KG TO <30KG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/0.2ML, 20 MG/0.4ML (adalimumab-atto) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| BIMZELX SUBCUTANEOUS SOLUTION AUTO-INJECTOR 160 MG/ML (<i>bimekizumab-bkzx</i>) | SP | PA; IBC (Preferred agent for Psoriasis after the failure of two preferred agents); QL (2 INJECTIONS per 56 DAYS) |
| BIMZELX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 160 MG/ML (<i>bimekizumab-bkzx</i>) | SP | PA; IBC (Preferred agent for Psoriasis after the failure of two preferred agents); QL (2 INJECTIONS per 56 DAYS) |
| CIMZIA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 200 MG/ML (<i>certolizumab pegol</i>) | SP | PA; ST; IBC (Preferred agent for Non-radiographical Axial Spondyloarthritis and preferred agent for Ankylosing Spondylitis, Crohn's, Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis after the failure of two preferred agents.); QL (2 KITS per 28 Days) |
| CIMZIA STARTER KIT SUBCUTANEOUS PREFILLED SYRINGE KIT 6 X 200 MG/ML (<i>certolizumab pegol</i>) | SP | PA; ST; IBC (Preferred agent for Non-radiographical Axial Spondyloarthritis and preferred agent for Ankylosing Spondylitis, Crohn's, Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis after the failure of two preferred agents.); QL (1 KIT per 28 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| COSENTYX (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML (<i>secukinumab</i>) | SP | PA; ST; IBC (Preferred agent for Ankylosing Spondylitis, Psoriatic Arthritis and Non-radiographical Axial Spondyloarthritis. Not covered for Psoriasis); QL (2 SYRINGES per 28 days) |
| COSENTYX SENSOREADY (300 MG) SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML (<i>secukinumab</i>) | SP | PA; ST; IBC (Preferred agent for Ankylosing Spondylitis, Psoriatic Arthritis and Non-radiographical Axial Spondyloarthritis. Not covered for Psoriasis); QL (2 PENS per 28 days) |
| COSENTYX SENSOREADY PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML (<i>secukinumab</i>) | SP | PA; ST; IBC (Preferred agent for Ankylosing Spondylitis, Psoriatic Arthritis and Non-radiographical Axial Spondyloarthritis. Not covered for Psoriasis); QL (1 PEN per 28 days) |
| COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML (<i>secukinumab</i>) | SP | PA; ST; IBC (Preferred agent for Ankylosing Spondylitis, Psoriatic Arthritis and Non-radiographical Axial Spondyloarthritis. Not covered for Psoriasis); QL (1 SYRINGE per 28 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML (<i>secukinumab</i>) | SP | PA; ST; IBC (Preferred agent for Ankylosing Spondylitis, Psoriatic Arthritis and Non-radiographical Axial Spondyloarthritis. Not covered for Psoriasis); QL (1 SYRINGE per 28 DAYS) |
| COSENTYX UNOREADY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 300 MG/2ML (<i>secukinumab</i>) | SP | PA; ST; IBC (Preferred agent for Ankylosing Spondylitis, Psoriatic Arthritis and Non-radiographical Axial Spondyloarthritis. Not covered for Psoriasis); QL (1 PEN per 28 DAYS) |
| CYLTEZO (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.8ML (<i>adalimumab-adbm</i>) | NF | |
| CYLTEZO (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.2ML, 20 MG/0.4ML, 40 MG/0.8ML (<i>adalimumab-adbm</i>) | NF | |
| ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML (<i>etanercept</i>) | SP | PA; ST; IBC (Preferred agent for all conditions except Psoriasis); QL (4 CARTRIDGES per 28 days) |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML (<i>etanercept</i>) | SP | PA; ST; IBC (Preferred agent for all conditions except Psoriasis); QL (8 VIALS per 28 days) |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML (<i>etanercept</i>) | SP | PA; ST; IBC (Preferred agent for all conditions except Psoriasis); QL (8 SYRINGES per 28 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 50 MG/ML (<i>etanercept</i>) | SP | PA; ST; IBC (Preferred agent for all conditions except Psoriasis); QL (4 SYRINGES per 28 days) |
| ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML (<i>etanercept</i>) | SP | PA; ST; IBC (Preferred agent for all conditions except Psoriasis); QL (4 SYRINGES per 28 days) |
| ENTYVIO SUBCUTANEOUS SOLUTION PEN-INJECTOR 108 MG/0.68ML (<i>vedolizumab</i>) | NF | |
| HADLIMA PUSHTOUCH SUBCUTANEOUS SOLUTION AUTO-INJECTOR 40 MG/0.4ML, 40 MG/0.8ML (<i>adalimumab-bwwd</i>) | NF | |
| HADLIMA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML, 40 MG/0.8ML (<i>adalimumab-bwwd</i>) | NF | |
| HULIO (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.8ML (<i>adalimumab-fkjp</i>) | NF | |
| HULIO (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 20 MG/0.4ML, 40 MG/0.8ML (<i>adalimumab-fkjp</i>) | NF | |
| HUMIRA (2 PEN) SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML (<i>adalimumab</i>) | NF | |
| HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML (<i>adalimumab</i>) | NF | |
| HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML, 80 MG/0.8ML (<i>adalimumab</i>) | NF | |
| HUMIRA-PED<40KG CROHNS STARTER SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML & 40MG/0.4ML (<i>adalimumab</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-------------------------------------|
| HUMIRA-PED>/=40KG CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML (<i>adalimumab</i>) | NF | |
| HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML (<i>adalimumab</i>) | NF | |
| HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML & 40MG/0.4ML (<i>adalimumab</i>) | NF | |
| HYRIMOZ SUBCUTANEOUS SOLUTION AUTO-INJECTOR 40 MG/0.4ML, 40 MG/0.8ML (<i>adalimumab-adaz</i>) | SP | PA; ST; QL (4 PENS per 28 DAYS) |
| HYRIMOZ SUBCUTANEOUS SOLUTION AUTO-INJECTOR 80 MG/0.8ML (<i>adalimumab-adaz</i>) | SP | PA; ST; QL (2 PENS per 28 DAYS) |
| HYRIMOZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.1 ML (<i>adalimumab-adaz</i>) | SP | PA; ST; QL (2 SYRINGES per 28 DAYS) |
| HYRIMOZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML (<i>adalimumab-adaz</i>) | SP | PA; ST; QL (4 SYRINGES per 28 DAYS) |
| HYRIMOZ-PED<40KG CROHN STARTER SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 80 MG/0.8ML & 40MG/0.4ML (<i>adalimumab-adaz</i>) | SP | PA; ST; QL (1 KIT per 28 DAYS) |
| HYRIMOZ-PED>/=40KG CROHN START SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 80 MG/0.8ML (<i>adalimumab-adaz</i>) | SP | PA; ST; QL (1 KIT per 28 DAYS) |
| HYRIMOZ-PLAQUE PSORIASIS START SUBCUTANEOUS SOLUTION AUTO-INJECTOR 80 MG/0.8ML & 40MG/0.4ML (<i>adalimumab-adaz</i>) | SP | PA; ST; QL (1 KIT per 28 DAYS) |
| IDACIO (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.8ML (<i>adalimumab-aacf</i>) | NF | |
| IDACIO (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 40 MG/0.8ML (<i>adalimumab-aacf</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| KEVZARA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/1.14ML, 200 MG/1.14ML (<i>sarilumab</i>) | SP | PA; ST; IBC (Preferred agent for Rheumatoid Arthritis); QL (2 PENS per 28 days) |
| KEVZARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/1.14ML, 200 MG/1.14ML (<i>sarilumab</i>) | SP | PA; ST; IBC (Preferred agent for Rheumatoid Arthritis); QL (2 SYRINGES per 28 days) |
| KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.67ML (<i>anakinra</i>) | NF | |
| LITFULO ORAL CAPSULE 50 MG (<i>ritlecitinib tosylate</i>) | SP | PA; QL (28 CAPSULES per 28 DAYS) |
| OLUMIANT ORAL TABLET 1 MG, 2 MG, 4 MG (<i>baricitinib</i>) | NF | |
| OMVOH SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML (<i>mirikizumab-mrkz</i>) | NF | |
| ORENCIA CLICKJECT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 125 MG/ML (<i>abatacept</i>) | SP | PA; ST; IBC (Preferred agent for Rheumatoid Arthritis. Not covered for other conditions); QL (4 SYRINGES per 28 days) |
| ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MG/ML, 50 MG/0.4ML, 87.5 MG/0.7ML (<i>abatacept</i>) | SP | PA; ST; IBC (Preferred agent for Rheumatoid Arthritis. Not covered for other conditions); QL (4 SYRINGES per 28 days) |
| OTEZLA ORAL TABLET 30 MG (<i>apremilast</i>) | SP | PA; IBC (Preferred agent for Psoriasis and Psoriatic Arthritis); QL (60 TABLETS per 30 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| OTEZLA ORAL TABLET THERAPY PACK 10 & 20 & 30 MG (<i>apremilast</i>) | SP | PA; IBC (Preferred agent for Psoriasis and Psoriatic Arthritis); QL (55 TABLETS per 28 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 15 MG (<i>upadacitinib</i>) | SP | PA; IBC (Preferred agent for Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ankylosing Spondylitis, Ulcerative Colitis, Non-radiographical Axial Spondyloarthritis, and Crohn's Disease); QL (30 TABLETS per 30 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 30 MG (<i>upadacitinib</i>) | SP | PA; IBC (Preferred agent for Atopic Dermatitis, Ulcerative Colitis, and Crohn's Disease); QL (30 TABLETS per 30 DAYS) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 45 MG (<i>upadacitinib</i>) | SP | PA; IBC (Preferred agent for Ulcerative Colitis and Crohn's Disease); QL (1 FILL per 1 INDUCTION PERIOD) |
| SILIQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 210 MG/1.5ML (<i>brodalumab</i>) | NF | |
| SIMLANDI (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.4ML (<i>adalimumab-ryvk</i>) | NF | |
| SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML, 50 MG/0.5ML (<i>golimumab</i>) | NF | |
| SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 50 MG/0.5ML (<i>golimumab</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| SKYRIZI PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML (<i>risankizumab-rzaa</i>) | SP | PA; IBC (Preferred agent for Psoriasis and Psoriatic Arthritis); QL (1 SYRINGE per 84 days) |
| SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 180 MG/1.2ML, 360 MG/2.4ML (<i>risankizumab-rzaa</i>) | SP | PA; IBC (Preferred agent for Crohn's Disease); QL (1 CARTRIDGE per 56 DAYS) |
| SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML (<i>risankizumab-rzaa</i>) | SP | PA; IBC (Preferred agent for Psoriasis and Psoriatic Arthritis); QL (1 SYRINGE per 84 days) |
| SOTYKTU ORAL TABLET 6 MG (<i>deucravacitinib</i>) | SP | PA; IBC (Preferred agent for Psoriasis); QL (30 TABLETS per 30 days) |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML (<i>ustekinumab</i>) | SP | PA; IBC (Preferred agent for Crohn's Disease, Psoriasis, Psoriatic Arthritis, Ulcerative Colitis); QL (1 SYRINGE per 84 days) |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML (<i>ustekinumab</i>) | SP | PA; IBC (Preferred agent for Crohn's Disease, Psoriasis, Psoriatic Arthritis, Ulcerative Colitis); QL (1 SYRINGE per 84 days) |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 90 MG/ML (<i>ustekinumab</i>) | SP | PA; IBC (Preferred agent for Crohn's Disease, Psoriasis, Psoriatic Arthritis, Ulcerative Colitis); QL (1 SYRINGE per 56 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| TALTZ SUBCUTANEOUS SOLUTION AUTO-INJECTOR 80 MG/ML (<i>ixekizumab</i>) | SP | PA; ST; IBC (Preferred agent for Psoriasis. Not covered for Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis); QL (1 INJECTION per 28 days) |
| TALTZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 80 MG/ML (<i>ixekizumab</i>) | SP | PA; ST; IBC (Preferred agent for Psoriasis. Not covered for Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis); QL (1 INJECTION per 28 days) |
| TREMFYA SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 MG/ML (<i>guselkumab</i>) | SP | PA; IBC (Preferred agent for Psoriasis and Psoriatic Arthritis); QL (1 SYRINGE per 56 days) |
| TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML (<i>guselkumab</i>) | SP | PA; IBC (Preferred agent for Psoriasis and Psoriatic Arthritis); QL (1 SYRINGE per 56 days) |
| VELSIPITY ORAL TABLET 2 MG (<i>etrasimod arginine</i>) | NF | |
| XELJANZ ORAL SOLUTION 1 MG/ML (<i>tofacitinib citrate</i>) | SP | PA; ST; IBC (Preferred agent for Rheumatoid Arthritis, Ulcerative Colitis. Not covered for Psoriatic Arthritis, Ankylosing Spondylitis); QL (240 ML per 24 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| XELJANZ ORAL TABLET 10 MG, 5 MG (<i>tofacitinib citrate</i>) | SP | PA; ST; IBC (Preferred agent for Rheumatoid Arthritis, Ulcerative Colitis. Not covered for Psoriatic Arthritis, Ankylosing Spondylitis); QL (60 TABLETS per 30 days) |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HOUR 11 MG, 22 MG (<i>tofacitinib citrate</i>) | SP | PA; ST; IBC (Preferred agent for Rheumatoid Arthritis, Ulcerative Colitis. Not covered for Psoriatic Arthritis, Ankylosing Spondylitis); QL (30 TABLETS per 30 days) |
| YUFLYMA (1 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.4ML, 80 MG/0.8ML (<i>adalimumab-aaty</i>) | NF | |
| YUFLYMA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 20 MG/0.2ML, 40 MG/0.4ML (<i>adalimumab-aaty</i>) | NF | |
| YUSIMRY SUBCUTANEOUS SOLUTION PEN-INJECTOR 40 MG/0.8ML (<i>adalimumab-aqvh</i>) | NF | |
| ZYMFENTRA (1 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 120 MG/ML (<i>infliximab-dyyb</i>) | NF | |
| ZYMFENTRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 120 MG/ML (<i>infliximab-dyyb</i>) | NF | |
| BIOLOGIC DISEASE-MODIFYING AGENTS | | |
| ILARIS SUBCUTANEOUS SOLUTION 150 MG/ML (<i>canakinumab</i>) | SP | PA |
| DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDs) - DRUGS TO TREAT RHEUMATOID ARTHRITIS | | |
| <i>hydroxychloroquine sulfate oral tablet 200 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| leflunomide oral tablet 10 mg, 20 mg | G | |
| methotrexate sodium oral tablet 2.5 mg | CE | N7 (G); N8 (Listing does not include certain NDCs) |
| OTREXUP SUBCUTANEOUS SOLUTION AUTO- INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML (<i>methotrexate (anti-rheumatic)</i>) | NF | |
| RASUVO SUBCUTANEOUS SOLUTION AUTO- INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML (<i>methotrexate (anti-rheumatic)</i>) | SP | PA; QL (4 INJECTIONS per 28 days) |
| SOVUNA ORAL TABLET 200 MG (<i>hydroxychloroquine sulfate</i>) | NF | |
| HEREDITARY ANGIOEDEMA | | |
| BERINERT INTRAVENOUS KIT 500 UNIT (<i>c1 esterase inhibitor (human)</i>) | NF | |
| CINRYZE INTRAVENOUS SOLUTION RECONSTITUTED 500 UNIT (<i>c1 esterase inhibitor (human)</i>) | NF | |
| FIRAZYR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 30 MG/3ML (<i>icatibant acetate</i>) | NF | |
| HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT (<i>c1 esterase inhibitor (human)</i>) | SP | PA; QL (20 VIALS per 30 days) |
| <i>icatibant acetate subcutaneous solution prefilled syringe 30 mg/3ml</i> | SP | PA; QL (45 SYRINGES per 90 days) |
| KALBITOR SUBCUTANEOUS SOLUTION 10 MG/ML (<i>ecallantide</i>) | SP | PA; QL (30 CARTONS per 90 days) |
| ORLADEYO ORAL CAPSULE 110 MG, 150 MG (<i>berotralstat hcl</i>) | SP | PA; QL (28 CAPSULES per 28 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| RUCONEST INTRAVENOUS SOLUTION RECONSTITUTED 2100 UNIT (<i>c1 esterase inhibitor (recomb.)</i>) | SP | PA; QL (60 VIALS per 90 days) |
| TAKHYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 300 MG/2ML (<i>lanadelumab-flyo</i>) | SP | PA; QL (2 SYRINGES per 28 DAYs) |
| IMMUNOGLOBULIN | | |
| ALYGLO INTRAVENOUS SOLUTION 10 GM/100ML, 20 GM/200ML, 5 GM/50ML (<i>immune globulin (human)-stwk</i>) | NF | |
| ASCENIV INTRAVENOUS SOLUTION 5 GM/50ML (<i>immune globulin (human)-slra</i>) | NF | |
| BIVIGAM INTRAVENOUS SOLUTION 10 GM/100ML, 5 GM/50ML (<i>immune globulin (human)</i>) | SP | PA |
| CUTAQUIG SUBCUTANEOUS SOLUTION 1 GM/6ML, 1.65 GM/10ML, 2 GM/12ML, 3.3 GM/20ML, 4 GM/24ML, 8 GM/48ML (<i>immune globulin (human)-hipp</i>) | SP | PA |
| CUVITRU SUBCUTANEOUS SOLUTION 1 GM/5ML, 10 GM/50ML, 2 GM/10ML, 4 GM/20ML, 8 GM/40ML (<i>immune globulin (human)</i>) | NF | |
| FLEBOGAMMA DIF INTRAVENOUS SOLUTION 0.5 GM/10ML, 10 GM/100ML, 10 GM/200ML, 2.5 GM/50ML, 20 GM/200ML, 20 GM/400ML, 5 GM/100ML, 5 GM/50ML (<i>immune globulin (human)</i>) | SP | PA |
| GAMMAGARD INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML (<i>immune globulin (human)</i>) | SP | PA |
| GAMMAGARD S/D LESS IGA INTRAVENOUS SOLUTION RECONSTITUTED 10 GM, 5 GM (<i>immune globulin (human)</i>) | SP | PA |
| GAMMAKED INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 20 GM/200ML, 5 GM/50ML (<i>immune globulin (human)</i>) | SP | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 20 GM/400ML, 5 GM/100ML, 5 GM/50ML (<i>immune globulin (human)</i>) | SP | PA |
| GAMUNEX-C INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 40 GM/400ML, 5 GM/50ML (<i>immune globulin (human)</i>) | SP | PA |
| HIZENTRA SUBCUTANEOUS SOLUTION 1 GM/5ML, 10 GM/50ML, 2 GM/10ML, 4 GM/20ML (<i>immune globulin (human)</i>) | SP | PA |
| HIZENTRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 1 GM/5ML, 2 GM/10ML, 4 GM/20ML (<i>immune globulin (human)</i>) | SP | PA |
| HYPERRHO S/D INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 1500 UNIT, 250 UNIT (<i>rho d immune globulin</i>) | SP | |
| HYPERTET INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 250 UNIT/ML (<i>tetanus immune globulin</i>) | SP | |
| HYQVIA SUBCUTANEOUS KIT 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML (<i>immune globulin-hyaluronidase</i>) | NF | |
| IMOGLAM RABIES-HT INJECTION SOLUTION 300 UNIT/2ML (<i>rabies immune globulin</i>) | SP | |
| <i>kedrab injection solution 1500 unit/10ml, 300 unit/2ml</i> | SP | |
| MICRHOGAM ULTRA-FILTERED PLUS INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 250 UNIT (<i>rho d immune globulin</i>) | SP | |
| OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 10 GM/100ML, 10 GM/200ML, 2 GM/20ML, 2.5 GM/50ML, 20 GM/200ML, 30 GM/300ML, 5 GM/100ML, 5 GM/50ML (<i>immune globulin (human)</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| PANZYGA INTRAVENOUS SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML (<i>immune globulin (human)-ifas</i>) | NF | |
| PRIVIGEN INTRAVENOUS SOLUTION 10 GM/100ML, 20 GM/200ML, 40 GM/400ML, 5 GM/50ML (<i>immune globulin (human)</i>) | SP | PA |
| RHOGAM ULTRA-FILTERED PLUS INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 1500 UNIT (<i>rho d immune globulin</i>) | SP | |
| RHOPHYLAC INJECTION SOLUTION PREFILLED SYRINGE 1500 UNIT/2ML (<i>rho d immune globulin</i>) | SP | |
| VARIZIG INTRAMUSCULAR SOLUTION 125 UNIT/1.2ML (<i>varicella-zoster immune glob</i>) | SP | |
| WINRHO SDF INJECTION SOLUTION 1500 UNIT/1.3ML, 15000 UNIT/13ML, 2500 UNIT/2.2ML, 5000 UNIT/4.4ML (<i>rho d immune globulin</i>) | SP | |
| XEMBIFY SUBCUTANEOUS SOLUTION 1 GM/5ML, 10 GM/50ML, 2 GM/10ML, 4 GM/20ML (<i>immune globulin (human)-klhw</i>) | SP | PA |
| IMMUNOMODULATORS | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5ML (<i>interferon gamma-1b</i>) | SP | PA |
| ARCALYST SUBCUTANEOUS SOLUTION RECONSTITUTED 220 MG (<i>rilonacept</i>) | NF | |
| JOENJA ORAL TABLET 70 MG (<i>leniolisib phosphate</i>) | NF | |
| IMMUNOSUPPRESSANTS | | |
| ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG, 1 MG, 5 MG (<i>tacrolimus</i>) | NPB | |
| ATGAM INTRAVENOUS INJECTABLE 50 MG/ML (<i>lymphocyte, anti-thymo imm glob</i>) | NPB | |
| <i>azathioprine oral tablet 100 mg, 50 mg, 75 mg</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|-----------------------------------|
| BENLYSTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML (<i>belimumab</i>) | SP | PA; QL (4 INJECTIONS per 28 DAYS) |
| BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML (<i>belimumab</i>) | SP | PA; QL (4 INJECTIONS per 28 DAYS) |
| <i>cyclosporine intravenous solution 50 mg/ml</i> | G | |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | G | |
| <i>cyclosporine modified oral solution 100 mg/ml</i> | G | |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | G | |
| ENSPRYNG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120 MG/ML (<i>satralizumab-mwge</i>) | SP | PA; QL (1 SYRINGE per 28 days) |
| <i>everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg</i> | G | |
| <i>cyclosporine modified (Gengraf Oral Capsule 100 Mg, 25 Mg)</i> | G | |
| <i>cyclosporine modified (Gengraf Oral Solution 100 Mg/Ml)</i> | G | |
| IMURAN ORAL TABLET 50 MG (<i>azathioprine</i>) | NPB | |
| LUPKYNIS ORAL CAPSULE 7.9 MG (<i>voclosporin</i>) | NF | |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | G | |
| <i>mycophenolate mofetil oral suspension reconstituted 200 mg/ml</i> | G | |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | G | |
| <i>mycophenolate sodium oral tablet delayed release 180 mg, 360 mg</i> | G | |
| NEORAL ORAL CAPSULE 100 MG, 25 MG (<i>cyclosporine modified</i>) | SP | |
| NEORAL ORAL SOLUTION 100 MG/ML (<i>cyclosporine modified</i>) | SP | |
| PROGRAF INTRAVENOUS SOLUTION 5 MG/ML (<i>tacrolimus</i>) | SP | |
| REZUROCK ORAL TABLET 200 MG (<i>belumosudil mesylate</i>) | NF | |
| SANDIMMUNE INTRAVENOUS SOLUTION 50 MG/ML (<i>cyclosporine</i>) | SP | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| SANDIMMUNE ORAL CAPSULE 100 MG, 25 MG (<i>cyclosporine</i>) | SP | |
| SANDIMMUNE ORAL SOLUTION 100 MG/ML (<i>cyclosporine</i>) | SP | |
| SIMULECT INTRAVENOUS SOLUTION RECONSTITUTED 10 MG, 20 MG (<i>basiliximab</i>) | NPB | |
| <i>sirolimus oral solution 1 mg/ml</i> | G | |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | G | |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> | G | |
| THYMOGLOBULIN INTRAVENOUS SOLUTION RECONSTITUTED 25 MG (<i>anti-thymocyte glob (rabbit)</i>) | NPB | |
| MISCELLANEOUS | | |
| SYNAGIS INTRAMUSCULAR SOLUTION 100 MG/ML, 50 MG/0.5ML (<i>palivizumab</i>) | SP | PA |
| MEDICAL DEVICES | | |
| CONTRACEPTIVES - PRODUCTS FOR BIRTH CONTROL | | |
| CAYA VAGINAL DIAPHRAGM (<i>diaphragm arc-spring</i>) | CE | N7 (NPB); QL (1 DIAPHRAGM per 300 DAYs) |
| FEMCAP VAGINAL DEVICE 22 MM, 26 MM, 30 MM (<i>cervical caps</i>) | CE | N7 (NPB); QL (1 DEVICE per 300 DAYs) |
| OMNIFLEX DIAPHRAGM VAGINAL DIAPHRAGM (<i>diaphragms</i>) | CE | N7 (NPB); QL (1 DIAPHRAGM per 300 DAYs) |
| WIDE-SEAL DIAPHRAGM 60 VAGINAL DIAPHRAGM 2 % (<i>diaphragm wide seal</i>) | CE | N7 (NPB); QL (1 DIAPHRAGM per 300 DAYs) |
| WIDE-SEAL DIAPHRAGM 65 VAGINAL DIAPHRAGM 2 % (<i>diaphragm wide seal</i>) | CE | N7 (NPB); QL (1 DIAPHRAGM per 300 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| WIDE-SEAL DIAPHRAGM 70 VAGINAL DIAPHRAGM 2 % (<i>diaphragm wide seal</i>) | CE | N7 (NPB); QL (1 DIAPHRAGM per 300 DAYs) |
| WIDE-SEAL DIAPHRAGM 75 VAGINAL DIAPHRAGM 2 % (<i>diaphragm wide seal</i>) | CE | N7 (NPB); QL (1 DIAPHRAGM per 300 DAYs) |
| WIDE-SEAL DIAPHRAGM 80 VAGINAL DIAPHRAGM 2 % (<i>diaphragm wide seal</i>) | CE | N7 (NPB); QL (1 DIAPHRAGM per 300 DAYs) |
| WIDE-SEAL DIAPHRAGM 85 VAGINAL DIAPHRAGM 2 % (<i>diaphragm wide seal</i>) | CE | N7 (NPB); QL (1 DIAPHRAGM per 300 DAYs) |
| WIDE-SEAL DIAPHRAGM 90 VAGINAL DIAPHRAGM 2 % (<i>diaphragm wide seal</i>) | CE | N7 (NPB); QL (1 DIAPHRAGM per 300 DAYs) |
| WIDE-SEAL DIAPHRAGM 95 VAGINAL DIAPHRAGM 2 % (<i>diaphragm wide seal</i>) | CE | N7 (NPB); QL (1 DIAPHRAGM per 300 DAYs) |
| DIABETIC SUPPLIES | | |
| ACCUTREND GLUCOSE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ADVANCE INTUITION TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ADVOCATE REDI-CODE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ADVOCATE REDI-CODE+ TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ADVOCATE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| AGAMATRIX AMP TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| AGAMATRIX JAZZ TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| AGAMATRIX KEYNOTE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| AGAMATRIX PRESTO TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>alcohol swabs pad</i> | NPB | |
| ASSURE 3 TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ASSURE 4 TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ASSURE II CHECK IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ASSURE II IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ASSURE PLATINUM IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ASSURE PRISM MULTI TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ASSURE PRO TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| BD INSULIN SYRINGE U-500 31G X 6MM 0.5 ML (<i>insulin syringe/needle u-500</i>) | PB | N8 (BD syringes and needles are the only preferred options) |
| BD PEN NEEDLE MICRO U/F 32G X 6 MM (<i>insulin pen needle</i>) | PB | N8 (BD syringes and needles are the only preferred options) |
| BD PEN NEEDLE MINI U/F 31G X 5 MM (<i>insulin pen needle</i>) | PB | N8 (BD syringes and needles are the only preferred options) |
| BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM (<i>insulin pen needle</i>) | PB | N8 (BD syringes and needles are the only preferred options) |
| BD PEN NEEDLE NANO U/F 32G X 4 MM (<i>insulin pen needle</i>) | PB | N8 (BD syringes and needles are the only preferred options) |
| BD PEN NEEDLE ORIGINAL U/F 29G X 12.7MM (<i>insulin pen needle</i>) | PB | N8 (BD syringes and needles are the only preferred options) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| BD PEN NEEDLE SHORT U/F 31G X 8 MM (<i>insulin pen needle</i>) | PB | N8 (BD syringes and needles are the only preferred options) |
| <i>blood glucose test in vitro strip</i> | NF | |
| CARESENS N GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CARETOUCH TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CLEVER CHEK AUTO-CODE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CLEVER CHEK AUTO-CODE VOICE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CLEVER CHEK TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CLEVER CHOICE AUTO-CODE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CLEVER CHOICE MICRO TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CLEVER CHOICE NO CODING IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CLEVER CHOICE TALK SYSTEM IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CONTOUR NEXT TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CONTOUR TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| COOL BLOOD GLUCOSE TEST STRIPS IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| CVS ADVANCED GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| D-CARE BLOOD GLUCOSE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| DIATHRIVE GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>diatru plus test in vitro strip</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| DUO-CARE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>easy plus ii glucose test in vitro strip</i> | NF | |
| EASY STEP TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>easy talk blood glucose test in vitro strip</i> | NF | |
| <i>easy trak blood glucose test in vitro strip</i> | NF | |
| EASYGLUCO IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| EASYMAX 15 TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| EASYMAX TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| EASYPROM BLOOD GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| EASYPROM PLUS IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>element compact test in vitro strip</i> | NF | |
| ELEMENT TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| EMBRACE EVO BLOOD GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| EMBRACE PRO GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| EMBRACE TALK GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| ENLITE GLUCOSE SENSOR (<i>continuous glucose sensor</i>) | NF | |
| <i>eq blood glucose test in vitro strip</i> | NF | |
| EVERSENSE SENSOR/HOLDER (<i>continuous glucose sensor</i>) | NF | |
| EVERSENSE SMART TRANSMITTER (<i>continuous glucose transmitter</i>) | NF | |
| EVOLUTION AUTOCODE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| FIFTY50 GLUCOSE TEST 2.0 IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| FORA 6 CONNECT IN VITRO STRIP (<i>glucose blood</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| FORA D15G BLOOD GLUCOSE TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA D20 BLOOD GLUCOSE TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA D40/G31 BLOOD GLUCOSE IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA G20 BLOOD GLUCOSE TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA GD20 TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA GD50 BLOOD GLUCOSE TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA GTTEL BLOOD GLUCOSE TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA TN'G ADVANCE PRO IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA TN'G/TN'G VOICE IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA V10 BLOOD GLUCOSE TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA V12 BLOOD GLUCOSE TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA V20 BLOOD GLUCOSE TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORA V30A BLOOD GLUCOSE TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORACARE GD40 TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORACARE PREMIUM V10 TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORACARE TEST N GO TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |
| FORTISCARE TEST IN VITRO STRIP <i>(glucose blood)</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| FREESTYLE INSULINX TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| FREESTYLE LIBRE READER DEVICE (<i>continuous glucose receiver</i>) | NF | |
| FREESTYLE LITE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| FREESTYLE PRECISION NEO TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| FREESTYLE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>ge100 blood glucose test in vitro strip</i> | NF | |
| GENULTIMATE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>ght test in vitro strip</i> | NF | |
| GLUCO PERFECT 3 TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| GLUCOCARD 01 SENSOR PLUS IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| GLUCOCARD EXPRESSION TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| GLUCOCARD SHINE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| GLUCOCARD VITAL TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| GLUCOCARD X-SENSOR IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| GLUCOCOM TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| GLUCONAVII BLOOD GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>glucose control in vitro solution</i> | NPB | N8 (Listing does not include certain NDCs) |
| <i>glucose meter test in vitro strip</i> | NF | |
| <i>gnp easy touch glucose test in vitro strip</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| GOJJI BLOOD TEST STRIP/LANCETS IN VITRO STRIP (glucose blood) | NF | |
| <i>goodsense blood glucose in vitro strip</i> | NF | |
| GUARDIAN REAL-TIME REPLACE PED DEVICE (continuous glucose receiver) | NF | |
| GUARDIAN SENSOR (3) (continuous glucose sensor) | NF | |
| <i>guardian sensor 3</i> | NF | |
| HW EMBRACE PRO GLUCOSE TEST IN VITRO STRIP (glucose blood) | NF | |
| HW EMBRACE TALK GLUCOSE TEST IN VITRO STRIP (glucose blood) | NF | |
| IGLUCOSE TEST STRIPS IN VITRO STRIP (glucose blood) | NF | |
| IN TOUCH BLOOD GLUCOSE TEST IN VITRO STRIP (glucose blood) | NF | |
| INFINITY BLOOD GLUCOSE TEST IN VITRO STRIP (glucose blood) | NF | |
| INFINITY VOICE IN VITRO STRIP (glucose blood) | NF | |
| KROGER HEALTHPRO GLUCOSE TEST IN VITRO STRIP (glucose blood) | NF | |
| LIBERTY NEXT GENERATION TEST IN VITRO STRIP (glucose blood) | NF | |
| <i>liberty test in vitro strip</i> | NF | |
| <i>meijer essential glucose test in vitro strip</i> | NF | |
| MEIJER TRUETEST TEST IN VITRO STRIP (glucose blood) | NF | |
| MEIJER TRUETRACK TEST IN VITRO STRIP (glucose blood) | NF | |
| MICRODOT TEST IN VITRO STRIP (glucose blood) | NF | |
| MYGLUCOHEALTH TEST IN VITRO STRIP (glucose blood) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| NEUTEK 2TEK TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| NOVA MAX GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| OMNIPOD CLASSIC PODS (GEN 3) (<i>insulin disposable pump</i>) | PB | |
| <i>one drop test in vitro strip</i> | NF | |
| ONETOUCH DELICA PLUS LANCET30G (<i>lancets</i>) | PB | |
| OPTIUMEZ TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| PHARMACIST CHOICE AUTOCODE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>pharmacist choice no coding in vitro strip</i> | NF | |
| POCKETCHEM EZ TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| POGO AUTOMATIC TEST CARTRIDGES IN VITRO DIAGNOSTIC TEST (<i>glucose blood</i>) | NF | |
| PRECISION XTRA BLOOD GLUCOSE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>premium blood glucose test in vitro strip</i> | NF | |
| <i>pro voice v8/v9 glucose in vitro strip</i> | NF | |
| PRODIGY NO CODING BLOOD GLUC IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| QUICKTEK TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| QUINTET AC BLOOD GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| QUINTET BLOOD GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| REFUAH PLUS BLOOD GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| RELION BLOOD GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| RELION PRIME TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| RELION ULTIMA TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| RIGHTEST GS100 BLOOD GLUCOSE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| RIGHTEST GS300 BLOOD GLUCOSE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| RIGHTEST GS550 BLOOD GLUCOSE IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| SMART SENSE PREMIUM TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| SMARTEST BLOOD GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| SOLUS V2 TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| TRUE METRIX BLOOD GLUCOSE TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| TRUETEST TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| TRUETRACK TEST IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| UNISTRIP1 GENERIC IN VITRO STRIP (<i>glucose blood</i>) | NF | |
| <i>verasens blood glucose test in vitro strip</i> | NF | |
| NUTRITIONAL/SUPPLEMENTS - VITAMINS AND SUPPLEMENTS | | |
| ELECTROLYTES | | |
| <i>potassium chloride</i> (Klor-Con 10 Oral Tablet Extended Release 10 Meq) | G | |
| <i>potassium chloride crys er</i> (Klor-Con M10 Oral Tablet Extended Release 10 Meq) | G | |
| <i>potassium chloride crys er</i> (Klor-Con M15 Oral Tablet Extended Release 15 Meq) | G | |
| <i>potassium chloride crys er</i> (Klor-Con M20 Oral Tablet Extended Release 20 Meq) | G | |
| <i>potassium chloride</i> (Klor-Con Oral Packet 20 Meq) | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>potassium chloride (Klor-Con Oral Tablet Extended Release 8 Meq)</i> | G | |
| POKONZA ORAL PACKET 10 MEQ (potassium chloride) | NF | |
| <i>potassium chloride crys er oral tablet extended release 10 meq, 20 meq</i> | G | |
| <i>potassium chloride er oral capsule extended release 10 meq, 8 meq</i> | G | |
| <i>potassium chloride er oral tablet extended release 10 meq, 20 meq, 8 meq</i> | G | |
| <i>potassium chloride oral solution 20 meq/15ml (10%)</i> | G | N8 (Listing does not include certain NDCs) |
| <i>potassium chloride oral solution 40 meq/15ml (20%)</i> | G | |
| <i>sodium fluoride oral tablet chewable 0.55 (0.25 f) mg</i> | CE | N7 (Not Covered); AL (Max 5 Years) |
| PRENATAL VITAMINS | | |
| ATABEX EC ORAL TABLET DELAYED RELEASE 29-1 MG (prenatal vit-dss-fe cbn-fa) | NF | |
| <i>azesco oral tablet 13-1 mg</i> | NF | |
| CITRANATAL 90 DHA ORAL 90-1 & 300 MG (prenat w/o a-fecbgl-dss-fa-dha) | NF | |
| CITRANATAL ASSURE ORAL 35-1 & 300 MG (prenat w/o a-fecbgl-dss-fa-dha) | NF | |
| CITRANATAL B-CALM ORAL 20-1 MG & 2 X 25 MG (prenat w/o a fecbnseglu-fa &b6) | NF | |
| CITRANATAL HARMONY ORAL CAPSULE 27-1-260 MG (prenat-fefmcb-dss-fa-dha w/o a) | NF | |
| CITRANATAL MEDLEY ORAL CAPSULE 27-1-200 MG (prenat-fecb-fefum-fa-dha w/o a) | NF | |
| <i>complete natal dha oral 29-1-200 & 200 mg</i> | NF | |
| <i>completenate oral tablet chewable 29-1 mg</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| CONCEPT OB ORAL CAPSULE 130-92.4-1 MG (<i>prenat w/o a vit-fefum-fepo-fa</i>) | NF | |
| DUET DHA 400 ORAL 25-1 & 400 MG (<i>prenat-sepoly-fered-fa-omega 3</i>) | NF | |
| ENBRACE HR ORAL CAPSULE (<i>prenat vit-fe gly cys-fa-omega</i>) | NF | |
| FOLIVANE-OB ORAL CAPSULE 85-1 MG (<i>prenat w/o a vit-fefum-fepo-fa</i>) | NF | |
| INATAL GT ORAL TABLET (<i>prenatal vit-dss-fe cbn-fa</i>) | G | |
| <i>jenliva prenatal/postnatal oral capsule 1 mg</i> | NF | |
| <i>kosher prenatal plus iron oral tablet 30-1 mg</i> | NF | |
| NATACHEW ORAL TABLET CHEWABLE 28-1 MG (<i>prenatal vit-fe fum-fe bisg-fa</i>) | NF | |
| <i>natal pnv oral tablet 6-0.5 mg</i> | NF | |
| NATALVIT ORAL TABLET (<i>prenatal vit-fe fumarate-fa</i>) | NF | |
| NEEVO DHA ORAL CAPSULE 27-1.13 MG (<i>prenat w/o a-fefum-methf-omegas</i>) | NF | |
| <i>neonatal + dha oral 29-1 & 200 mg</i> | NF | |
| <i>neonatal 19 oral tablet 1 mg</i> | NF | |
| <i>neonatal fe oral tablet 90-1 mg</i> | NF | |
| NESTABS DHA ORAL 32-1 MG (<i>prenat-w/oa-fe bisgly-fa-omega</i>) | NF | |
| NESTABS ONE ORAL CAPSULE 38-1-225 MG (<i>prenat-fe-methylfol-dha w/o a</i>) | NF | |
| NESTABS ORAL TABLET 32-1 MG (<i>prenat-fe bisgly-fa-w/o vit a</i>) | NF | |
| OB COMPLETE ONE ORAL CAPSULE 50-1-476 MG (<i>prenat-fecbn-feaspgl-fa-fish</i>) | NF | |
| OB COMPLETE ORAL TABLET 50-1.25 MG (<i>prenatal vit-iron carbonyl-fa</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| OB COMPLETE PETITE ORAL CAPSULE 35-5-1-200 MG (<i>prenat-fecbn-feaspgl-fa-omega</i>) | NF | |
| OB COMPLETE PREMIER ORAL TABLET 30-20-1 MG (<i>prenatal-fe cbn-fe asp gly-fa</i>) | NF | |
| OB COMPLETE/DHA ORAL CAPSULE 30-10-1-200 MG (<i>prenat-fecbn-feaspgl-fa-omega</i>) | NF | |
| <i>pnv prenatal plus multivit+dha oral 27-1 & 312 mg</i> | NF | |
| <i>pnv tabs 20-1 oral tablet 20-1 mg</i> | NF | |
| <i>pnv-dha oral capsule 27-0.6-0.4-300 mg</i> | G | |
| <i>pnv-dha+docusate oral capsule 27-1.25-300 mg</i> | NF | |
| <i>pnv-omega oral capsule 28-0.6-0.4-340 mg</i> | NF | |
| <i>pregen dha oral capsule 28-1-35 mg</i> | NF | |
| <i>pregenna oral tablet 20-1 mg</i> | NF | |
| <i>prena 1 true oral 30-1.4 & 300 mg</i> | NF | |
| <i>prenaissance oral capsule 29-1.25-325 mg</i> | NF | |
| <i>prenaissance plus oral capsule 28-1-250 mg</i> | NF | |
| PRENATAL-U ORAL CAPSULE 106.5-1 MG (<i>prenatal w/o a vit-fe fum-fa</i>) | NF | |
| PRENATE AM ORAL TABLET 1 MG (<i>prenatal ca-b6-b12-fa-ginger</i>) | NF | |
| PRENATE DHA ORAL CAPSULE 18-0.6-0.4-300 MG (<i>prenat-feasp-meth-fa-dha w/o a</i>) | NF | |
| PRENATE ELITE ORAL TABLET 20-0.6-0.4 MG (<i>prenatal-feaspgly-methylfol-fa</i>) | NF | |
| PRENATE ENHANCE ORAL CAPSULE 28-0.6-0.4-400 MG (<i>prenat w/o a-fe-methfol-fa-dha</i>) | NF | |
| PRENATE MINI ORAL CAPSULE 18-0.6-0.4-350 MG (<i>prenat-fecbn-feasp-meth-fa-dha</i>) | NF | |
| PRENATE ORAL TABLET CHEWABLE 0.6-0.4 MG (<i>prenat mv-min-methylfolate-fa</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| PRENATE PIXIE ORAL CAPSULE 10-0.6-0.4-200 MG (<i>prenat-feasp-meth-fa-dha w/o a</i>) | NF | |
| PRENATE RESTORE ORAL CAPSULE 27-0.6-0.4-400 MG (<i>prenat w/o a-fe-methfol-fa-dha</i>) | NF | |
| <i>prenatvite plus oral tablet 1 mg</i> | NF | |
| PRIMACARE ORAL CAPSULE 30-1-470 MG (<i>pren-fe-meth-fa-omeg w/o a</i>) | NF | |
| PROVIDA OB ORAL CAPSULE 20-20-1.25 MG (<i>prenat w/o a vit-fefum-fepo-fa</i>) | NF | |
| SELECT-OB ORAL TABLET CHEWABLE 29-0.6-0.4 MG (<i>prenat vit-fepoly-methylfol-fa</i>) | NF | |
| SELECT-OB ORAL TABLET CHEWABLE 29-1 MG (<i>prenatal vit-fe psac cmplx-fa</i>) | NF | |
| SELECT-OB+DHA ORAL 29-1 & 250 MG (<i>prenatal vit-fepoly-fa-dha</i>) | NF | |
| TARON-C DHA ORAL CAPSULE 35-1 MG (<i>prenat-fefum-fepo-fa-omega 3</i>) | NF | |
| TRINATE ORAL TABLET (<i>prenatal vit-fe fumarate-fa</i>) | G | |
| <i>tristar dha oral capsule 31-0.6-0.4-200 mg</i> | NF | |
| VINATE II ORAL TABLET 29-1 MG (<i>prenatal vit wl fe bisg-fa</i>) | NF | |
| VINATE ONE ORAL TABLET 60-1 MG (<i>prenatal vit-fe fumarate-fa</i>) | NF | |
| VITAFOL FE+ ORAL CAPSULE 90-0.6-0.4-200 MG (<i>prenat-fe poly-methfol-fa-dha</i>) | NF | |
| VITAFOL GUMMIES ORAL TABLET CHEWABLE 3.33-0.333-34.8 MG (<i>prenatal vit-fe phos-fa-omega</i>) | NF | |
| VITAFOL STRIPS ORAL FILM 1 MG (<i>prenatal-b6-b12-d3-folic acid</i>) | NF | |
| VITAFOL ULTRA ORAL CAPSULE 29-0.6-0.4-200 MG (<i>prenat-fe poly-methfol-fa-dha</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| VITAFOL-NANO ORAL TABLET 18-0.6-0.4 MG (<i>prenatal-fe fum-methf-fa w/o a</i>) | NF | |
| VITAFOL-OB ORAL TABLET (<i>prenatal vit-fe fumarate-fa</i>) | NF | |
| VITAFOL-OB+DHA ORAL 65-1 & 250 MG (<i>prenatal mv-min-fe fum-fa-dha</i>) | NF | |
| VITAFOL-ONE ORAL CAPSULE 29-1-200 MG (<i>prenatal vit-fepoly-fa-dha</i>) | NF | |
| VITAMEDMD REDICHEW RX ORAL TABLET CHEWABLE 1.4 MG (<i>prenat-b2-b6-b12-d3-fa</i>) | NF | |
| VITAPEarl ORAL CAPSULE EXTENDED RELEASE 30-1.4-200 MG (<i>prenat-fefum-fered-fa-dha w/oa</i>) | NF | |
| VIVA DHA ORAL CAPSULE 28-1-200 MG (<i>prenatal vit-fe fum-fa-omega</i>) | NF | |
| wescap-c dha oral capsule 53.5-38-1 mg | NF | |
| wescap-pn dha oral capsule 27-0.6-0.4-300 mg | NF | |
| westgel dha oral capsule 31-0.6-0.4-200 mg | NF | |
| zalvit oral tablet 13-1 mg | NF | |
| VITAMINS - VITAMINS AND SUPPLEMENTS | | |
| ACCRUFER ORAL CAPSULE 30 MG (<i>ferric maltol</i>) | NF | |
| ASCOR INTRAVENOUS SOLUTION 25000 MG/50ML (<i>ascorbic acid</i>) | NF | |
| cyanocobalamin injection solution 1000 mcg/ml | G | |
| b complex-c-folic acid (Dexifol Oral Tablet 5 Mg) | NF | |
| doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg | G | N8 (Listing does not include certain NDCs) |
| FA-8 ORAL CAPSULE 0.8 MG (<i>folic acid</i>) | CE | N7 (Not Covered); QL (100 CAPSULES per 30 DAYs); AL (Max 55 Years) |
| FERRO-PLEX ORAL TABLET 115-1 MG (<i>fe fum-fa-c-e-b12-intrins fact</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| FLORIVA ORAL LIQUID 0.25-400 MG-UNIT/ML (<i>sodium fluoride-vitamin d</i>) | NF | |
| FLORIVA ORAL TABLET CHEWABLE 0.25 MG, 0.5 MG, 1 MG (<i>ped multiple vit-minerals-fl</i>) | NF | |
| <i>folbee plus oral tablet</i> | G | |
| FOLGARD OS ORAL TABLET 500-1.1 MG (<i>multiple vit-min-calcium-fa</i>) | NF | |
| <i>folic acid oral tablet 400 mcg, 800 mcg</i> | CE | N7 (Not Covered); QL (100 TABLETS per 30 DAYS); AL (Max 55 Years) |
| <i>na ferric gluc cplx in sucrose intravenous solution 12.5 mg/ml</i> | G | |
| NASCOBAL NASAL SOLUTION 500 MCG/0.1ML (<i>cyanocobalamin</i>) | NF | |
| NEPHPLEX RX ORAL TABLET (<i>b complex-c-zn-folic acid</i>) | NF | |
| NICOMIDE ORAL TABLET 750-27-2-0.5 MG (<i>niacinamide-zn-cu-methfo-se-cr</i>) | NF | |
| <i>nicotinamide oral tablet 750-27-2-0.5 mg</i> | NF | |
| <i>phytonadione oral tablet 5 mg</i> | G | QL (25 TABLETS per 25 days) |
| POLY-VI-FLOR ORAL SUSPENSION 0.25 MG/ML (<i>pediatric multivitamins-fl</i>) | NF | |
| POLY-VI-FLOR/IRON ORAL TABLET CHEWABLE 0.5-10 MG (<i>ped multivitamins-fl-iron</i>) | NF | |
| QUFLORA FE ORAL TABLET CHEWABLE 0.25 MG (<i>multi vit-min-fluoride-fe-fa</i>) | NF | |
| QUFLORA FE PEDIATRIC ORAL LIQUID 0.25-9.5 MG/ML (<i>ped multivitamins-fl-iron</i>) | NF | |
| RENATABS WITH IRON ORAL 1 & 100 MG (<i>b complex-c-biotin-e-fa-fe cbn</i>) | NF | |
| <i>reno caps oral capsule 1 mg</i> | G | Select OTC |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|------------------------------------|
| sodium fluoride oral solution 1.1 (0.5 f) mg/ml | CE | N7 (Not Covered); AL (Max 5 Years) |
| sodium fluoride oral tablet 1.1 (0.5 f) mg | CE | N7 (Not Covered); AL (Max 5 Years) |
| sodium fluoride oral tablet 2.2 (1 f) mg | G | |
| sodium fluoride oral tablet chewable 1.1 (0.5 f) mg | CE | N7 (Not Covered); AL (Max 5 Years) |
| sodium fluoride oral tablet chewable 2.2 (1 f) mg | G | |
| tri-vi-floro oral suspension 0.25 mg/ml | NF | |
| VENOFER INTRAVENOUS SOLUTION 20 MG/ML (iron sucrose) | SP | |
| vitamin d (ergocalciferol) oral capsule 1.25 mg (50000 ut) | G | |
| OPHTHALMIC - DRUGS TO TREAT EYE CONDITIONS | | |
| ANTIALLERGICS - DRUGS TO TREAT ALLERGIES | | |
| azelastine hcl ophthalmic solution 0.05 % | G | |
| bepotastine besilate ophthalmic solution 1.5 % | NF | |
| BEPREVE OPHTHALMIC SOLUTION 1.5 % (bepotastine besilate) | NF | |
| cromolyn sodium ophthalmic solution 4 % | G | |
| epinastine hcl ophthalmic solution 0.05 % | G | |
| ketotifen fumarate ophthalmic solution 0.035 % | G | Select OTC |
| ZADITOR OPHTHALMIC SOLUTION 0.035 % (ketotifen fumarate) | G | Select OTC |
| ZERVIATE OPHTHALMIC SOLUTION 0.24 % (cetirizine hcl) | NF | |
| ANTIGLAUCOMA - DRUGS TO TREAT GLAUCOMA | | |
| ALPHAGAN P OPHTHALMIC SOLUTION 0.1 %, 0.15 % (brimonidine tartrate) | PB | |
| AZOPT OPHTHALMIC SUSPENSION 1 % (brinzolamide) | NF | |
| betaxolol hcl ophthalmic solution 0.5 % | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| BETIMOL OPHTHALMIC SOLUTION 0.25 %, 0.5 % (timolol hemihydrate) | NF | |
| BETOPTIC-S OPHTHALMIC SUSPENSION 0.25 % (betaxolol hcl) | NF | |
| <i>bimatoprost ophthalmic solution 0.03 %</i> | G | |
| <i>brimonidine tartrate ophthalmic solution 0.1 %, 0.15 %, 0.2 %</i> | G | |
| <i>brimonidine tartrate-timolol ophthalmic solution 0.2-0.5 %</i> | G | |
| <i>brinzolamide ophthalmic suspension 1 %</i> | G | |
| <i>carteolol hcl ophthalmic solution 1 %</i> | G | |
| COMBIGAN OPHTHALMIC SOLUTION 0.2-0.5 % (brimonidine tartrate-timolol) | NF | |
| COSOPT PF OPHTHALMIC SOLUTION 2-0.5 % (dorzolamide hcl-timolol mal) | NF | |
| <i>dorzolamide hcl ophthalmic solution 2 %</i> | G | |
| <i>dorzolamide hcl-timolol mal ophthalmic solution 2-0.5 %</i> | G | |
| <i>dorzolamide hcl-timolol mal pf ophthalmic solution 2-0.5 %</i> | G | |
| ISTALOL OPHTHALMIC SOLUTION 0.5 % (timolol maleate) | NF | |
| IFYUZEH OPHTHALMIC SOLUTION 0.005 % (latanoprost) | NF | |
| <i>latanoprost ophthalmic solution 0.005 %</i> | G | |
| <i>levobunolol hcl ophthalmic solution 0.5 %</i> | G | |
| LUMIGAN OPHTHALMIC SOLUTION 0.01 % (bimatoprost) | NF | |
| <i>pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 %</i> | G | |
| RHOPRESSA OPHTHALMIC SOLUTION 0.02 % (netarsudil dimesylate) | NF | |
| ROCKLATAN OPHTHALMIC SOLUTION 0.02-0.005 % (netarsudil-latanoprost) | NF | |
| SIMBRINZA OPHTHALMIC SUSPENSION 1-0.2 % (brinzolamide-brimonidine) | PB | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>tafluprost (pf) ophthalmic solution 0.0015 %</i> | G | |
| <i>timolol maleate (once-daily) ophthalmic solution 0.5 %</i> | G | |
| <i>timolol maleate (Timolol Maleate Ocudose Ophthalmic Solution 0.5 %)</i> | NF | |
| <i>timolol maleate ophthalmic gel forming solution 0.25 %, 0.5 %</i> | G | |
| <i>timolol maleate ophthalmic solution 0.25 %, 0.5 %</i> | G | |
| <i>timolol maleate pf ophthalmic solution 0.25 %</i> | NF | |
| TIMOPTIC OCUDOSE OPHTHALMIC SOLUTION 0.25 %, 0.5 % (timolol maleate) | NF | |
| TRAVATAN Z OPHTHALMIC SOLUTION 0.004 % (travoprost) | NF | |
| <i>travoprost (bak free) ophthalmic solution 0.004 %</i> | G | |
| VYZULTA OPHTHALMIC SOLUTION 0.024 % (latanoprostene bunod) | NF | |
| XELPROS OPHTHALMIC EMULSION 0.005 % (latanoprost) | NF | |
| ANTI-INFECTIVE/ANTI-INFLAMMATORY - DRUGS TO TREAT INFECTION | | |
| <i>erythromycin ointment 5 mg/gm ophthalmic</i> | G | N8 (Listing does not include certain NDCs) |
| ANTI-INFECTIVE/ANTI-INFLAMMATORY - DRUGS TO TREAT INFECTIONS AND INFLAMMATION | | |
| <i>neomycin-polymyxin-dexameth ophthalmic ointment 3.5-10000-0.1</i> | G | |
| <i>neomycin-polymyxin-dexameth ophthalmic suspension 3.5-10000-0.1</i> | G | |
| <i>sulfacetamide-prednisolone ophthalmic solution 10-0.23 %</i> | G | |
| TOBRADEX OPHTHALMIC OINTMENT 0.3-0.1 % (tobramycin-dexamethasone) | NF | |
| TOBRADEX ST OPHTHALMIC SUSPENSION 0.3-0.05 % (tobramycin-dexamethasone) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>tobramycin-dexamethasone ophthalmic suspension 0.3-0.1 %</i> | G | |
| ZYLET OPHTHALMIC SUSPENSION 0.5-0.3 % (<i>loteprednol-tobramycin</i>) | NPB | |
| ANTI-INFECTIVES - DRUGS TO TREAT INFECTIONS | | |
| <i>bacitracin ophthalmic ointment 500 unit/gm</i> | G | |
| <i>bacitracin-polymyxin b ophthalmic ointment 500-10000 unit/gm</i> | G | |
| CILOXAN OPHTHALMIC OINTMENT 0.3 % (<i>ciprofloxacin hcl</i>) | NF | |
| <i>ciprofloxacin hcl ophthalmic solution 0.3 %</i> | G | |
| <i>erythromycin ointment 5 mg/gm ophthalmic</i> | NF | |
| <i>gatifloxacin ophthalmic solution 0.5 %</i> | G | |
| <i>gentamicin sulfate ophthalmic solution 0.3 %</i> | G | QL (20 ML per 25 days) |
| KLARITY-A OPHTHALMIC SOLUTION 1 % (<i>azithromycin</i>) | NF | |
| <i>levofloxacin ophthalmic solution 1.5 %</i> | NF | |
| <i>moxifloxacin hcl (2x day) ophthalmic solution 0.5 %</i> | G | |
| <i>moxifloxacin hcl ophthalmic solution 0.5 %</i> | G | |
| <i>ofloxacin ophthalmic solution 0.3 %</i> | G | N8 (Listing does not include certain NDCs) |
| <i>polymyxin b-trimethoprim ophthalmic solution 10000-0.1 unit/ml-%</i> | G | |
| <i>sulfacetamide sodium ophthalmic ointment 10 %</i> | G | |
| <i>sulfacetamide sodium ophthalmic solution 10 %</i> | G | |
| <i>tobramycin ophthalmic solution 0.3 %</i> | G | |
| <i>trifluridine ophthalmic solution 1 %</i> | G | |
| XDEMVY OPHTHALMIC SOLUTION 0.25 % (<i>lotilaner</i>) | NF | |
| ZYMAXID OPHTHALMIC SOLUTION 0.5 % (<i>gatifloxacin</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| ANTI-INFLAMMATORIES - DRUGS TO TREAT INFLAMMATION | | |
| ACUVAIL OPHTHALMIC SOLUTION 0.45 % (<i>ketorolac tromethamine</i>) | NF | |
| ALREX OPHTHALMIC SUSPENSION 0.2 % (<i>loteprednol etabonate</i>) | NF | |
| <i>bromfenac sodium (once-daily) ophthalmic solution 0.09 %</i> | G | |
| <i>bromfenac sodium ophthalmic solution 0.07 %, 0.075 %</i> | NF | |
| BROMSITE OPHTHALMIC SOLUTION 0.075 % (<i>bromfenac sodium</i>) | NF | |
| <i>dexamethasone sodium phosphate ophthalmic solution 0.1 %</i> | G | |
| <i>diclofenac sodium ophthalmic solution 0.1 %</i> | G | |
| <i>difluprednate ophthalmic emulsion 0.05 %</i> | G | |
| EYSUVIS OPHTHALMIC SUSPENSION 0.25 % (<i>loteprednol etabonate</i>) | NPB | PA; QL (2 BOTTLES per 90 days) |
| FLAREX OPHTHALMIC SUSPENSION 0.1 % (<i>fluorometholone acetate</i>) | NF | |
| <i>fluorometholone ophthalmic suspension 0.1 %</i> | G | |
| <i>flurbiprofen sodium ophthalmic solution 0.03 %</i> | G | |
| FML FORTE OPHTHALMIC SUSPENSION 0.25 % (<i>fluorometholone</i>) | NF | |
| FML LIQUIFILM OPHTHALMIC SUSPENSION 0.1 % (<i>fluorometholone</i>) | NF | |
| ILEVRO OPHTHALMIC SUSPENSION 0.3 % (<i>nepafenac</i>) | NF | |
| INVELTYS OPHTHALMIC SUSPENSION 1 % (<i>loteprednol etabonate</i>) | NF | |
| <i>ketorolac tromethamine ophthalmic solution 0.4 %, 0.5 %</i> | G | |
| LOTEMAX OPHTHALMIC GEL 0.5 % (<i>loteprednol etabonate</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| LOTEMAX OPHTHALMIC OINTMENT 0.5 % (<i>loteprednol etabonate</i>) | NF | |
| LOTEMAX OPHTHALMIC SUSPENSION 0.5 % (<i>loteprednol etabonate</i>) | NF | |
| LOTEMAX SM OPHTHALMIC GEL 0.38 % (<i>loteprednol etabonate</i>) | NF | |
| <i>loteprednol etabonate ophthalmic gel 0.5 %</i> | NF | |
| <i>loteprednol etabonate ophthalmic suspension 0.2 %</i> | NF | |
| <i>loteprednol etabonate ophthalmic suspension 0.5 %</i> | G | |
| MAXIDEX OPHTHALMIC SUSPENSION 0.1 % (<i>dexamethasone</i>) | NF | |
| NEVANAC OPHTHALMIC SUSPENSION 0.1 % (<i>nepafenac</i>) | NF | |
| PRED FORTE OPHTHALMIC SUSPENSION 1 % (<i>prednisolone acetate</i>) | NF | |
| PRED MILD OPHTHALMIC SUSPENSION 0.12 % (<i>prednisolone acetate</i>) | NF | |
| <i>prednisolone acetate ophthalmic suspension 1 %</i> | G | |
| PROLENSA OPHTHALMIC SOLUTION 0.07 % (<i>bromfenac sodium</i>) | NF | |
| DRY EYE DISEASE | | |
| CEQUA OPHTHALMIC SOLUTION 0.09 % (<i>cyclosporine</i>) | NF | |
| <i>cyclosporine ophthalmic emulsion 0.05 %</i> | NF | |
| MIEBO OPHTHALMIC SOLUTION 1.338 GM/ML (<i>perfluorohexyloctane</i>) | NF | |
| RESTASIS MULTIDOSE OPHTHALMIC EMULSION 0.05 % (<i>cyclosporine</i>) | PB | |
| RESTASIS OPHTHALMIC EMULSION 0.05 % (<i>cyclosporine</i>) | PB | |
| VEVYE OPHTHALMIC SOLUTION 0.1 % (<i>cyclosporine</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| XIIDRA OPHTHALMIC SOLUTION 5 % (<i>lifitegrast</i>) | PB | |
| MISCELLANEOUS | | |
| <i>atropine sulfate ophthalmic solution 1 %</i> | G | |
| CYSTARAN OPHTHALMIC SOLUTION 0.44 % (<i>cysteamine hcl</i>) | SP | PA; QL (4 BOTTLES per 28 days) |
| <i>tropicamide ophthalmic solution 0.5 %, 1 %</i> | G | |
| TYRVAYA NASAL SOLUTION 0.03 MG/ACT (<i>varenicline tartrate</i>) | NF | |
| VERKAZIA OPHTHALMIC EMULSION 0.1 % (<i>cyclosporine</i>) | NF | |
| RETINAL DISORDERS | | |
| BYOOVIZ INTRAVITREAL SOLUTION 0.5 MG/0.05ML (<i>ranibizumab-nuna</i>) | SP | PA |
| CIMERLI INTRAVITREAL SOLUTION 0.3 MG/0.05ML, 0.5 MG/0.05ML (<i>ranibizumab-eqrn</i>) | SP | PA |
| EYLEA INTRAVITREAL SOLUTION 2 MG/0.05ML (<i>aflibercept</i>) | NF | |
| EYLEA INTRAVITREAL SOLUTION PREFILLED SYRINGE 2 MG/0.05ML (<i>aflibercept</i>) | NF | |
| LUCENTIS INTRAVITREAL SOLUTION PREFILLED SYRINGE 0.3 MG/0.05ML, 0.5 MG/0.05ML (<i>ranibizumab</i>) | NF | |
| OTHER | | |
| IRRIGATION SOLUTIONS | | |
| <i>sterile water for irrigation irrigation solution</i> | G | STX |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| RESPIRATORY - DRUGS TO TREAT BREATHING DISORDERS | | |
| ALPHA-1 ANTITRYPSIN DEFICIENCY AGENTS - DRUGS FOR REPLACEMENT, MODIFICATION, TREATMENT | | |
| ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG (<i>alpha1-proteinase inhibitor</i>) | NF | |
| GLASSIA INTRAVENOUS SOLUTION 1000 MG/50ML (<i>alpha1-proteinase inhibitor</i>) | NF | |
| PROLASTIN-C INTRAVENOUS SOLUTION 1000 MG/20ML (<i>alpha1-proteinase inhibitor</i>) | SP | PA |
| PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG (<i>alpha1-proteinase inhibitor</i>) | SP | PA |
| ZEMAIRA INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 4000 MG, 5000 MG (<i>alpha1-proteinase inhibitor</i>) | SP | PA |
| ANAPHYLAXIS TREATMENT AGENTS | | |
| AUVI-Q INJECTION SOLUTION AUTO-INJECTOR 0.1 MG/0.1ML, 0.15 MG/0.15ML, 0.3 MG/0.3ML (<i>epinephrine</i>) | PB | QL (4 INJ per 25 days) |
| <i>epinephrine injection solution auto-injector 0.15 mg/0.15ml</i> | G | QL (4 INJ per 25 DAYs) |
| <i>epinephrine injection solution auto-injector 0.15 mg/0.3ml</i> | NF | |
| <i>epinephrine injection solution auto-injector 0.3 mg/0.3ml</i> | G | N8 (Listing does not include certain NDCs); QL (4 INJ per 25 days) |
| EPINEPHRINESNAP-V INJECTION KIT 1 MG/ML (<i>epinephrine</i>) | NF | |
| EPIPEN 2-PAK INJECTION SOLUTION AUTO-INJECTOR 0.3 MG/0.3ML (<i>epinephrine</i>) | NF | |
| EPIPEN JR 2-PAK INJECTION SOLUTION AUTO-INJECTOR 0.15 MG/0.3ML (<i>epinephrine</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| ANTIALLERGICS - DRUGS TO TREAT ALLERGIES | | |
| <i>acetylcysteine inhalation solution 10 %</i> | G | |
| ANTICHOLINERGIC/BETA AGONIST COMBINATIONS - DRUGS TO TREAT COPD | | |
| ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25 MCG/ACT (<i>umeclidinium-vilanterol</i>) | PB | QL (1 PACKAGE per 25 days) |
| BEVESPI AEROSPHERE INHALATION AEROSOL 9-4.8 MCG/ACT (<i>glycopyrrolate-formoterol</i>) | NF | |
| COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION 20-100 MCG/ACT (<i>ipratropium-albuterol</i>) | NPB | QL (2 PACKAGES per 25 DAYs) |
| <i>ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml</i> | G | QL (6 BOXES per 25 DAYs) |
| STIOLTO RESPIMAT INHALATION AEROSOL SOLUTION 2.5-2.5 MCG/ACT (<i>tiotropium bromide-olodaterol</i>) | PB | QL (1 PACKAGE per 25 days) |
| ANTICHOLINERGIC/BETA AGONIST/STEROID COMBINATIONS - DRUGS TO TREAT ASTHMA AND COPD | | |
| BREZTRI AEROSPHERE INHALATION AEROSOL 160-9-4.8 MCG/ACT (<i>budeson-glycopyrrol-formoterol</i>) | PB | QL (1 PACKAGE per 25 days) |
| TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/ACT, 200-62.5-25 MCG/ACT (<i>fluticasone-umeclidin-vilant</i>) | PB | QL (1 PACKAGE per 25 Days) |
| ANTICHOLINERGICS | | |
| <i>tiotropium bromide monohydrate inhalation capsule 18 mcg</i> | G | QL (1 PACKAGE per 25 DAYs) |
| TUDORZA PRESSAIR INHALATION AEROSOL POWDER BREATH ACTIVATED 400 MCG/ACT (<i>aclidinium bromide</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| ANTICHOLINERGICS - DRUGS TO TREAT COPD | | |
| ATROVENT HFA INHALATION AEROSOL SOLUTION 17 MCG/ACT (<i>ipratropium bromide hfa</i>) | NF | |
| INCRUSE ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5 MCG/ACT (<i>umeclidinium bromide</i>) | NF | |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | G | N8 (Listing does not include certain NDCs); QL (5 BOXES per 25 DAYs) |
| <i>ipratropium bromide nasal solution 0.03 %, 0.06 %</i> | G | |
| SPIRIVA HANDIHALER INHALATION CAPSULE 18 MCG (<i>tiotropium bromide monohydrate</i>) | PB | QL (1 PACKAGE per 25 DAYs) |
| SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25 MCG/ACT, 2.5 MCG/ACT (<i>tiotropium bromide monohydrate</i>) | PB | QL (1 PACKAGE per 25 DAYs) |
| YUPELRI INHALATION SOLUTION 175 MCG/3ML (<i>revefenacin</i>) | PB | QL (30 VIALS per 25 DAYs) |
| ANTIHISTAMINE COMBINATIONS | | |
| <i>azelastine-fluticasone nasal suspension 137-50 mcg/act</i> | G | QL (1 PACKAGE per 25 DAYs) |
| DYMISTA NASAL SUSPENSION 137-50 MCG/ACT (<i>azelastine-fluticasone</i>) | NF | |
| RYALTRIS NASAL SUSPENSION 665-25 MCG/ACT (<i>olopatadine-mometasone</i>) | NF | |
| ANTIHISTAMINES - DRUGS TO TREAT ALLERGIES | | |
| ALLEGRA ALLERGY CHILDRENS ORAL SUSPENSION 30 MG/5ML (<i>fexofenadine hcl</i>) | G | Select OTC |
| ALLEGRA ALLERGY CHILDRENS ORAL TABLET DISPERSIBLE 30 MG (<i>fexofenadine hcl</i>) | G | Select OTC |
| ALLEGRA ALLERGY ORAL TABLET 180 MG, 60 MG (<i>fexofenadine hcl</i>) | G | Select OTC |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| allergy rel child (cetirizine) oral tablet dispersible 10 mg | G | |
| allergy relief (cetirizine) oral capsule 10 mg | G | Select OTC |
| azelastine hcl nasal solution 137 mcg/spray | G | QL (2 BOTTLES per 25 DAYs) |
| carbinoxamine maleate oral tablet 4 mg | G | |
| carbinoxamine maleate oral tablet 6 mg | NF | |
| cetirizine hcl allergy child oral solution 5 mg/5ml | G | Select OTC |
| cetirizine hcl oral tablet 10 mg, 5 mg | G | Select OTC |
| cetirizine hcl oral tablet chewable 10 mg, 5 mg | G | Select OTC |
| CLARITIN ALLERGY CHILDRENS ORAL SOLUTION 5 MG/5ML (loratadine) | G | Select OTC |
| CLARITIN ORAL CAPSULE 10 MG (loratadine) | G | Select OTC |
| CLARITIN ORAL TABLET 10 MG (loratadine) | G | Select OTC |
| CLARITIN ORAL TABLET CHEWABLE 10 MG (loratadine) | G | LGC; Select OTC |
| CLARITIN REDITABS ORAL TABLET DISPERSIBLE 10 MG, 5 MG (loratadine) | G | Select OTC |
| clemastine fumarate oral syrup 0.67 mg/5ml | G | N8 (Listing does not include certain NDCs) |
| cvs allergy relief childrens oral suspension 30 mg/5ml | G | Select OTC |
| cyproheptadine hcl oral syrup 2 mg/5ml | G | |
| cyproheptadine hcl oral tablet 4 mg | G | N8 (Listing does not include certain NDCs) |
| desloratadine oral tablet 5 mg | G | |
| desloratadine oral tablet dispersible 2.5 mg, 5 mg | G | |
| eq loratadine childrens oral tablet chewable 5 mg | G | Select OTC |
| fexofenadine hcl oral tablet 180 mg | G | Select OTC |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| hydroxyzine hcl oral syrup 10 mg/5ml | G | |
| hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg | G | N8 (Listing does not include certain NDCs) |
| hydroxyzine pamoate oral capsule 100 mg | G | |
| hydroxyzine pamoate oral capsule 25 mg, 50 mg | G | N8 (Listing does not include certain NDCs) |
| KARBINAL ER ORAL SUSPENSION EXTENDED RELEASE 4 MG/5ML (<i>carbinoxamine maleate</i>) | NPB | ST |
| kp fexofenadine hcl oral tablet 60 mg | G | Select OTC |
| levocetirizine dihydrochloride oral tablet 5 mg | G | Select OTC |
| loratadine oral capsule 10 mg | G | Select OTC |
| loratadine oral tablet 10 mg | G | Select OTC |
| olopatadine hcl nasal solution 0.6 % | G | QL (1 SOLUTION per 25 DAYS) |
| RYVENT ORAL TABLET 6 MG (<i>carbinoxamine maleate</i>) | NF | |
| sm loratadine allergy relief oral tablet dispersible 10 mg | G | Select OTC |
| sm loratadine oral solution 5 mg/5ml | G | Select OTC |
| XYZAL ALLERGY 24HR ORAL TABLET 5 MG (<i>levocetirizine dihydrochloride</i>) | G | Select OTC |
| ZYRTEC ALLERGY CHILDRENS ORAL TABLET DISPERSIBLE 10 MG (<i>cetirizine hcl</i>) | G | Select OTC |
| ZYRTEC ALLERGY ORAL CAPSULE 10 MG (<i>cetirizine hcl</i>) | G | Select OTC |
| ZYRTEC ALLERGY ORAL TABLET 10 MG (<i>cetirizine hcl</i>) | G | Select OTC |
| ZYRTEC CHILDRENS ALLERGY ORAL SOLUTION 1 MG/ML (<i>cetirizine hcl</i>) | G | Select OTC |
| ZYRTEC CHILDRENS ALLERGY ORAL TABLET CHEWABLE 10 MG (<i>cetirizine hcl</i>) | G | Select OTC |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| ZYRTEC CHILDRENS ALLERGY ORAL TABLET CHEWABLE 2.5 MG (<i>cetirizine hcl</i>) | G | LGC; Select OTC |
| ZYRTEC ORAL TABLET CHEWABLE 10 MG (<i>cetirizine hcl</i>) | G | Select OTC |
| BETA AGONISTS - DRUGS TO TREAT ASTHMA AND COPD | | |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act</i> | G | N8 (Listing does not include certain NDCs); QL (2 INHALERS per 25 days) |
| <i>albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%</i> | G | N8 (Listing does not include certain NDCs); QL (5 BOXES per 25 DAYs) |
| <i>albuterol sulfate inhalation nebulization solution 0.63 mg/3ml, 1.25 mg/3ml</i> | G | N8 (Listing does not include certain NDCs); QL (5 BOXES per 25 days) |
| <i>albuterol sulfate inhalation nebulization solution 2.5 mg/0.5ml</i> | G | N8 (Listing does not include certain NDCs); QL (60 ML per 25 DAYs) |
| <i>albuterol sulfate oral syrup 2 mg/5ml</i> | G | |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | G | N8 (Listing does not include certain NDCs) |
| <i>arformoterol tartrate inhalation nebulization solution 15 mcg/2ml</i> | NF | |
| BROVANA INHALATION NEBULIZATION SOLUTION 15 MCG/2ML (<i>arformoterol tartrate</i>) | NF | |
| <i>formoterol fumarate inhalation nebulization solution 20 mcg/2ml</i> | G | QL (2 BOXES per 25 DAYs) |
| <i>levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/3ml</i> | G | QL (300 ML per 25 DAYs) |
| <i>levalbuterol hcl inhalation nebulization solution 1.25 mg/0.5ml</i> | G | QL (45 ML per 25 DAYs) |
| <i>levalbuterol tartrate inhalation aerosol 45 mcg/act</i> | G | QL (2 INHALERS per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| PERFOROMIST INHALATION NEBULIZATION SOLUTION 20 MCG/2ML (<i>formoterol fumarate</i>) | NPB | QL (60 VIALS per 25 days) |
| PROAIR DIGIHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 108 (90 BASE) MCG/ACT (<i>albuterol sulfate (sensor)</i>) | NF | |
| PROAIR RESPICLICK INHALATION AEROSOL POWDER BREATH ACTIVATED 108 (90 BASE) MCG/ACT (<i>albuterol sulfate</i>) | NF | |
| PROVENTIL HFA INHALATION AEROSOL SOLUTION 108 (90 BASE) MCG/ACT (<i>albuterol sulfate</i>) | NF | |
| STRIVERDI RESPIMAT INHALATION AEROSOL SOLUTION 2.5 MCG/ACT (<i>olodaterol hcl</i>) | PB | QL (1 PACKAGE per 25 DAYS) |
| <i>terbutaline sulfate oral tablet 2.5 mg, 5 mg</i> | G | N8 (Listing does not include certain NDCs) |
| VENTOLIN HFA INHALATION AEROSOL SOLUTION 108 (90 BASE) MCG/ACT (<i>albuterol sulfate</i>) | NF | |
| XOPENEX HFA INHALATION AEROSOL 45 MCG/ACT (<i>levalbuterol tartrate</i>) | NF | |
| COLD/COUGH | | |
| ALLEGRA-D ALLERGY & CONGESTION ORAL TABLET EXTENDED RELEASE 12 HOUR 60-120 MG (<i>fexofenadine-pseudoephedrine</i>) | G | Select OTC |
| ALLEGRA-D ALLERGY & CONGESTION ORAL TABLET EXTENDED RELEASE 24 HOUR 180-240 MG (<i>fexofenadine-pseudoephedrine</i>) | G | Select OTC |
| <i>benzonatate oral capsule 100 mg, 150 mg, 200 mg</i> | G | |
| <i>cetirizine-pseudoephedrine er oral tablet extended release 12 hour 5-120 mg</i> | G | Select OTC |
| CLARITIN-D 12 HOUR ORAL TABLET EXTENDED RELEASE 12 HOUR 5-120 MG (<i>loratadine-pseudoephedrine</i>) | G | Select OTC |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| CLARITIN-D 24 HOUR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-240 MG (<i>loratadine-pseudoephedrine</i>) | G | Select OTC |
| <i>coditussin ac oral liquid 200-10 mg/5ml</i> | G | Select OTC; QL (60 ML per 1 DAY) |
| <i>fexofenadine-pseudoephed er oral tablet extended release 12 hour 60-120 mg</i> | G | Select OTC |
| <i>fexofenadine-pseudoephed er oral tablet extended release 24 hour 180-240 mg</i> | G | Select OTC |
| HYCODAN ORAL SOLUTION 5-1.5 MG/5ML (<i>hydrocodone bit-homatrop mbr</i>) | NF | |
| HYCODAN ORAL TABLET 5-1.5 MG (<i>hydrocodone bit-homatrop mbr</i>) | NF | |
| <i>hydrocod poli-chlorphe poli er oral suspension extended release 10-8 mg/5ml</i> | G | |
| <i>hydrocodone bit-homatrop mbr oral solution 5-1.5 mg/5ml</i> | G | QL (30 ML per 1 DAY) |
| <i>hydrocodone bit-homatrop mbr oral tablet 5-1.5 mg</i> | G | QL (6 TABLETS per 1 DAY) |
| <i>loratadine-d 24hr oral tablet extended release 24 hour 10-240 mg</i> | G | Select OTC |
| <i>promethazine vc oral syrup 6.25-5 mg/5ml</i> | G | |
| <i>promethazine vc/codeine oral syrup 6.25-5-10 mg/5ml</i> | G | QL (30 ML per 1 DAY) |
| <i>promethazine-codeine oral solution 6.25-10 mg/5ml</i> | G | QL (30 ML per 1 DAY) |
| <i>promethazine-dm oral syrup 6.25-15 mg/5ml</i> | G | |
| <i>pseudoeph-bromphen-dm oral syrup 30-2-10 mg/5ml</i> | G | N8 (Listing does not include certain NDCs) |
| <i>sm loratadine d 12hr oral tablet extended release 12 hour 5-120 mg</i> | G | Select OTC |
| TUXARIN ER ORAL TABLET EXTENDED RELEASE 12 HOUR 54.3-8 MG (<i>chlorpheniramine-codeine</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| ZYRTEC-D ALLERGY & CONGESTION ORAL TABLET EXTENDED RELEASE 12 HOUR 5-120 MG (<i>cetirizine-pseudoephedrine</i>) | G | Select OTC |
| CYSTIC FIBROSIS | | |
| BETHKIS INHALATION NEBULIZATION SOLUTION 300 MG/4ML (<i>tobramycin</i>) | NF | |
| BRONCHITOL INHALATION CAPSULE 40 MG (<i>mannitol (cystic fibrosis)</i>) | NF | |
| CAYSTON INHALATION SOLUTION RECONSTITUTED 75 MG (<i>aztreonam lysine</i>) | NF | |
| KALYDECO ORAL PACKET 13.4 MG, 5.8 MG (<i>ivacaftor</i>) | SP | PA; QL (56 PACKETS per 28 DAYS) |
| KALYDECO ORAL PACKET 25 MG, 50 MG, 75 MG (<i>ivacaftor</i>) | SP | PA; QL (56 PACKETS per 28 days) |
| KALYDECO ORAL TABLET 150 MG (<i>ivacaftor</i>) | SP | PA; QL (1 CARTON per 28 days) |
| KITABIS PAK INHALATION NEBULIZATION SOLUTION 300 MG/5ML (<i>tobramycin</i>) | NF | |
| ORKAMBI ORAL PACKET 100-125 MG, 150-188 MG (<i>lumacaftor-ivacaftor</i>) | SP | PA; QL (56 PACKETS per 28 days) |
| ORKAMBI ORAL PACKET 75-94 MG (<i>lumacaftor-ivacaftor</i>) | SP | PA; QL (56 PACKETS per 28 DAYS) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG (<i>lumacaftor-ivacaftor</i>) | SP | PA; QL (112 TABLETS per 28 days) |
| PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML (<i>dornase alfa</i>) | SP | PA; QL (150 ML per 30 days) |
| SYMDEKO ORAL TABLET THERAPY PACK 100-150 & 150 MG, 50-75 & 75 MG (<i>tezacaftor-ivacaftor</i>) | SP | PA; QL (56 TABLETS per 28 days) |
| TOBI INHALATION NEBULIZATION SOLUTION 300 MG/5ML (<i>tobramycin</i>) | NF | |
| TOBI PODHALER INHALATION CAPSULE 28 MG (<i>tobramycin</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>tobramycin inhalation nebulization solution 300 mg/4ml</i> | G | PA; QL (224 ML per 28 days) |
| <i>tobramycin inhalation nebulization solution 300 mg/5ml</i> | G | PA; QL (280 ML per 28 days) |
| TRIKAFTA ORAL TABLET THERAPY PACK 100-50-75 & 150 MG (<i>elexacaftor-tezacaftor-ivacift</i>) | SP | PA; QL (84 TABLETS per 28 days) |
| TRIKAFTA ORAL TABLET THERAPY PACK 50-25-37.5 & 75 MG (<i>elexacaftor-tezacaftor-ivacift</i>) | SP | PA; QL (84 TABLETS per 28 DAYs) |
| TRIKAFTA ORAL THERAPY PACK 100-50-75 & 75 MG, 80-40-60 & 59.5 MG (<i>elexacaftor-tezacaftor-ivacift</i>) | SP | PA; QL (56 PACKETS per 28 days) |
| LEUKOTRIENE MODIFIERS | | |
| ZYFLO ORAL TABLET 600 MG (<i>zileuton</i>) | NF | |
| LEUKOTRIENE RECEPTOR ANTAGONISTS - DRUGS TO TREAT ASTHMA AND ALLERGIES | | |
| <i>montelukast sodium oral packet 4 mg</i> | G | |
| <i>montelukast sodium oral tablet 10 mg</i> | G | |
| <i>montelukast sodium oral tablet chewable 4 mg, 5 mg</i> | G | |
| SINGULAIR ORAL PACKET 4 MG (<i>montelukast sodium</i>) | NF | |
| SINGULAIR ORAL TABLET 10 MG (<i>montelukast sodium</i>) | NF | |
| SINGULAIR ORAL TABLET CHEWABLE 4 MG, 5 MG (<i>montelukast sodium</i>) | NF | |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> | G | |
| MAST CELL STABILIZERS - DRUGS TO TREAT ALLERGIES | | |
| <i>cromolyn sodium inhalation nebulization solution 20 mg/2ml</i> | G | QL (2 BOXES per 25 DAYs) |
| MISCELLANEOUS | | |
| <i>acetylcysteine inhalation solution 20 %</i> | G | |
| DALIRESP ORAL TABLET 250 MCG, 500 MCG (<i>roflumilast</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>roflumilast oral tablet 250 mcg, 500 mcg</i> | G | |
| <i>sodium chloride inhalation nebulization solution 10 %, 3 %</i> | G | |
| NASAL STEROIDS - DRUGS TO TREAT ALLERGIES | | |
| <i>budesonide nasal suspension 32 mcg/act</i> | G | Select OTC; QL (2 PACKAGES per 25 days) |
| <i>FLONASE ALLERGY RELIEF NASAL SUSPENSION 50 MCG/ACT (fluticasone propionate)</i> | G | Select OTC; QL (1 PACKAGE per 25 DAYs) |
| <i>flunisolide nasal solution 25 mcg/act (0.025%)</i> | G | QL (3 CONTAINERS per 25 DAYs) |
| <i>fluticasone propionate nasal suspension 50 mcg/act</i> | G | Select OTC; QL (1 PACKAGE per 25 DAYs) |
| <i>NASACORT ALLERGY 24HR NASAL AEROSOL 55 MCG/ACT (triamcinolone acetonide)</i> | G | Select OTC; QL (1 PACKAGE per 25 DAYs) |
| <i>OMNARIS NASAL SUSPENSION 50 MCG/ACT (ciclesonide)</i> | NF | |
| <i>QNASL CHILDRENS NASAL AEROSOL SOLUTION 40 MCG/ACT (beclomethasone diprop (nasal))</i> | NF | |
| <i>QNASL NASAL AEROSOL SOLUTION 80 MCG/ACT (beclomethasone diprop (nasal))</i> | NF | |
| <i>triamcinolone acetonide nasal aerosol 55 mcg/act</i> | G | Select OTC; QL (1 PACKAGE per 25 DAYs) |
| <i>XHANCE NASAL EXHALER SUSPENSION 93 MCG/ACT (fluticasone propionate)</i> | NPB | PA; QL (2 PACKAGES per 25 days) |
| <i>ZETONNA NASAL AEROSOL SOLUTION 37 MCG/ACT (ciclesonide)</i> | NF | |
| PULMONARY FIBROSIS AGENTS | | |
| <i>ESBRIET ORAL CAPSULE 267 MG (pirfenidone)</i> | NF | |
| <i>ESBRIET ORAL TABLET 267 MG, 801 MG (pirfenidone)</i> | NF | |
| <i>OFEV ORAL CAPSULE 100 MG, 150 MG (nintedanib esylate)</i> | SP | PA; QL (60 CAPSULES per 30 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|-----------------------------------|
| <i>pirfenidone oral capsule 267 mg</i> | SP | PA; QL (270 CAPSULES per 30 DAYs) |
| <i>pirfenidone oral tablet 267 mg</i> | SP | PA; QL (270 TABLETS per 30 DAYs) |
| <i>pirfenidone oral tablet 534 mg</i> | NF | |
| <i>pirfenidone oral tablet 801 mg</i> | SP | PA; QL (90 TABLETS per 30 DAYs) |
| SEVERE ASTHMA AGENTS | | |
| FASENRA PEN SUBCUTANEOUS SOLUTION AUTO- INJECTOR 30 MG/ML (<i>benralizumab</i>) | SP | PA; QL (1 SYRINGE per 56 days) |
| NUCALA SUBCUTANEOUS SOLUTION AUTO- INJECTOR 100 MG/ML (<i>mepolizumab</i>) | SP | PA; QL (3 INJECTIONS per 28 days) |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML (<i>mepolizumab</i>) | SP | PA; QL (3 INJECTIONS per 28 days) |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML (<i>mepolizumab</i>) | SP | PA; QL (1 SYRINGE per 28 DAYs) |
| NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED 100 MG (<i>mepolizumab</i>) | NF | |
| TEZSPIRE SUBCUTANEOUS SOLUTION AUTO- INJECTOR 210 MG/1.91ML (<i>tezepelumab-ekko</i>) | SP | PA; QL (1 PEN per 28 DAYs) |
| XOLAIR SUBCUTANEOUS SOLUTION AUTO- INJECTOR 150 MG/ML (<i>omalizumab</i>) | SP | PA; QL (8 INJECTIONS per 28 DAYs) |
| XOLAIR SUBCUTANEOUS SOLUTION AUTO- INJECTOR 300 MG/2ML (<i>omalizumab</i>) | SP | PA |
| XOLAIR SUBCUTANEOUS SOLUTION AUTO- INJECTOR 75 MG/0.5ML (<i>omalizumab</i>) | SP | PA; QL (2 INJECTIONS per 28 DAYs) |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML (<i>omalizumab</i>) | SP | PA; QL (8 SYRINGES per 28 days) |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MG/2ML (<i>omalizumab</i>) | SP | PA |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML (<i>omalizumab</i>) | SP | PA; QL (2 SYRINGES per 28 days) |
| XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED 150 MG (<i>omalizumab</i>) | SP | PA; QL (8 VIALS per 28 days) |
| STEROID INHALANTS - DRUGS TO TREAT ASTHMA | | |
| ARMONAIR DIGIHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 113 MCG/ACT, 232 MCG/ACT, 55 MCG/ACT (<i>fluticasone propionate(sensor)</i>) | NF | |
| ARNUITY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT (<i>fluticasone furoate</i>) | NF | |
| ASMANEX (120 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220 MCG/ACT (<i>mometasone furoate</i>) | NF | |
| ASMANEX (30 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 110 MCG/ACT, 220 MCG/ACT (<i>mometasone furoate</i>) | NF | |
| ASMANEX (60 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220 MCG/ACT (<i>mometasone furoate</i>) | NF | |
| ASMANEX HFA INHALATION AEROSOL 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT (<i>mometasone furoate</i>) | NF | |
| <i>budesonide inhalation suspension 0.25 mg/2ml</i> | G | QL (3 BOXES per 25 DAYS) |
| <i>budesonide inhalation suspension 0.5 mg/2ml</i> | G | QL (2 BOXES per 25 DAYS) |
| <i>budesonide inhalation suspension 1 mg/2ml</i> | G | QL (1 BOX per 25 DAYS) |
| <i>fluticasone propionate diskus inhalation aerosol powder breath activated 100 mcg/act, 250 mcg/act, 50 mcg/act</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>fluticasone propionate hfa inhalation aerosol 110 mcg/act, 220 mcg/act, 44 mcg/act</i> | NF | N8 (Covered for members age 6 years and younger); AL (Max 6 Years) |
| PULMICORT FLEXHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 180 MCG/ACT (<i>budesonide</i>) | PB | QL (2 PACKAGES per 25 DAYs) |
| PULMICORT FLEXHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 90 MCG/ACT (<i>budesonide</i>) | PB | QL (3 PACKAGES per 25 DAYs) |
| PULMICORT INHALATION SUSPENSION 0.25 MG/2ML, 0.5 MG/2ML, 1 MG/2ML (<i>budesonide</i>) | NF | |
| QVAR REDIHALER INHALATION AEROSOL BREATH ACTIVATED 40 MCG/ACT, 80 MCG/ACT (<i>beclomethasone diprop hfa</i>) | NF | N8 (Covered for members age 6 years and younger); AL (Max 6 Years) |
| STEROID/BETA-AGONIST COMBINATIONS - DRUGS TO TREAT ASTHMA AND COPD | | |
| ADVAIR DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50 MCG/ACT, 250-50 MCG/ACT, 500-50 MCG/ACT (<i>fluticasone-salmeterol</i>) | NF | |
| ADVAIR HFA INHALATION AEROSOL 115-21 MCG/ACT, 230-21 MCG/ACT, 45-21 MCG/ACT (<i>fluticasone-salmeterol</i>) | NF | |
| AIRDUO DIGIHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 113-14 MCG/ACT, 232-14 MCG/ACT, 55-14 MCG/ACT (<i>fluticasone-salmeterol sensor</i>) | NF | |
| AIRDUO RESPICLICK 113/14 INHALATION AEROSOL POWDER BREATH ACTIVATED 113-14 MCG/ACT (<i>fluticasone-salmeterol</i>) | NF | |
| AIRDUO RESPICLICK 232/14 INHALATION AEROSOL POWDER BREATH ACTIVATED 232-14 MCG/ACT (<i>fluticasone-salmeterol</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| AIRDUO RESPICLICK 55/14 INHALATION AEROSOL POWDER BREATH ACTIVATED 55-14 MCG/ACT <i>(fluticasone-salmeterol)</i> | NF | |
| AIRSUPRA INHALATION AEROSOL 90-80 MCG/ACT <i>(albuterol-budesonide)</i> | PB | QL (3 PACKAGES per 25 DAYs) |
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25 MCG/ACT, 200-25 MCG/ACT <i>(fluticasone furoate-vilanterol)</i> | PB | N8 (Listing does not include certain NDCs); QL (1 PACKAGE per 25 days) |
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 50-25 MCG/INH <i>(fluticasone furoate-vilanterol)</i> | PB | QL (1 PACKAGE per 25 DAYs) |
| <i>budesonide-formoterol fumarate inhalation aerosol 160-4.5 mcg/act, 80-4.5 mcg/act</i> | NF | |
| DUAKLIR PRESSAIR INHALATION AEROSOL POWDER BREATH ACTIVATED 400-12 MCG/ACT <i>(aclidinium br-formoterol fum)</i> | NF | |
| DULERA INHALATION AEROSOL 100-5 MCG/ACT, 200-5 MCG/ACT, 50-5 MCG/ACT <i>(mometasone furo-formoterol fum)</i> | NPB | QL (3 PACKAGES per 25 days) |
| <i>fluticasone furoate-vilanterol inhalation aerosol powder breath activated 100-25 mcg/act, 200-25 mcg/act</i> | NF | |
| <i>fluticasone-salmeterol inhalation aerosol 115-21 mcg/act, 230-21 mcg/act, 45-21 mcg/act</i> | NF | |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act</i> | G | N8 (Listing does not include certain NDCs); QL (1 PACKAGE per 25 days) |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 113-14 mcg/act, 232-14 mcg/act, 55-14 mcg/act</i> | NF | |
| SYMBICORT INHALATION AEROSOL 160-4.5 MCG/ACT, 80-4.5 MCG/ACT <i>(budesonide-formoterol fumarate)</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>fluticasone-salmeterol</i> (Wixela Inhub Inhalation Aerosol Powder Breath Activated 100-50 Mcg/Act, 250-50 Mcg/Act, 500-50 Mcg/Act) | G | N8 (Listing does not include certain NDCs); QL (1 PACKAGE per 25 days) |
| XANTHINES - DRUGS TO TREAT COPD | | |
| THEO-24 ORAL CAPSULE EXTENDED RELEASE 24 HOUR 100 MG, 200 MG, 300 MG, 400 MG (<i>theophylline</i>) | NF | |
| <i>theophylline er oral tablet extended release 12 hour 100 mg, 200 mg, 300 mg, 450 mg</i> | G | |
| <i>theophylline er oral tablet extended release 24 hour 400 mg, 600 mg</i> | G | |
| <i>theophylline oral elixir 80 mg/15ml</i> | G | |
| <i>theophylline oral solution 80 mg/15ml</i> | G | |
| TOPICAL - DRUGS TO TREAT EAR AND SKIN CONDITIONS | | |
| DERMATOLOGY, ACNE | | |
| ABSORICA LD ORAL CAPSULE 16 MG, 24 MG, 32 MG, 8 MG (<i>isotretinoin micronized</i>) | NF | |
| ABSORICA ORAL CAPSULE 10 MG, 20 MG, 25 MG, 30 MG, 35 MG, 40 MG (<i>isotretinoin</i>) | NF | |
| ACANYA EXTERNAL GEL 1.2-2.5 % (<i>clindamycin phosphbenzoyl perox</i>) | NF | |
| <i>isotretinoin</i> (Accutane Oral Capsule 20 Mg, 30 Mg, 40 Mg) | G | PA |
| ACZONE EXTERNAL GEL 5 %, 7.5 % (<i>dapsone</i>) | NF | |
| <i>adapalene external cream 0.1 %</i> | G | PA; QL (45 G per 25 days); AL (Max 35 Years) |
| <i>adapalene external gel 0.1 %</i> | G | PA; Select OTC; QL (45 G per 25 days); AL (Max 35 Years) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>adapalene external gel 0.3 %</i> | G | PA; N8 (Listing does not include certain NDCs. PA applies to members 35 and older); QL (45 G per 25 days); AL (Max 35 Years) |
| <i>adapalene external pad 0.1 %</i> | NF | |
| <i>adapalene external solution 0.1 %</i> | NF | |
| <i>adapalene-benzoyl peroxide external gel 0.1-2.5 %, 0.3-2.5 %</i> | G | PA; AL (Max 35 Years) |
| AKLIEF EXTERNAL CREAM 0.005 % (<i>trifarotene</i>) | PB | PA |
| ALTRENO EXTERNAL LOTION 0.05 % (<i>tretinoin</i>) | NF | |
| <i>isotretinoin</i> (Amnesteem Oral Capsule 10 Mg, 20 Mg, 40 Mg) | G | PA |
| AMZEEQ EXTERNAL FOAM 4 % (<i>minocycline hcl micronized</i>) | NF | |
| ARAZLO EXTERNAL LOTION 0.045 % (<i>tazarotene</i>) | NF | |
| ATRALIN EXTERNAL GEL 0.05 % (<i>tretinoin</i>) | NF | |
| AZELEX EXTERNAL CREAM 20 % (<i>azelaic acid</i>) | NF | |
| <i>benzoyl peroxide-erythromycin external gel 5-3 %</i> | G | |
| CABTREO EXTERNAL GEL 0.15-3.1-1.2 % (<i>adapalene-benzoyl per-clindamycin</i>) | NF | |
| <i>isotretinoin</i> (Claravis Oral Capsule 10 Mg, 20 Mg, 30 Mg, 40 Mg) | G | PA |
| CLEOCIN-T EXTERNAL LOTION 1 % (<i>clindamycin phosphate</i>) | NPB | QL (60 ML per 25 DAYs) |
| <i>clindamycin phosphate</i> (Clindacin-P External Swab 1 %) | G | |
| CLINDAGEL EXTERNAL GEL 1 % (<i>clindamycin phosphate</i>) | NF | |
| <i>clindamycin phos-benzoyl perox external gel 1.2-3.75 %</i> | G | N8 (Listing does not include certain NDCs) |
| <i>clindamycin phos-benzoyl perox external gel 1-5 %, 1.2-2.5 %, 1.2-5 %</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>clindamycin phosphate external foam 1 %</i> | G | N8 (Listing does not include certain NDCs) |
| <i>clindamycin phosphate external gel 1 %</i> | G | N8 (Listing does not include certain NDCs); QL (75 G per 25 DAYs) |
| <i>clindamycin phosphate external lotion 1 %</i> | G | QL (60 ML per 25 DAYs) |
| <i>clindamycin phosphate external solution 1 %</i> | G | QL (60 ML per 25 DAYs) |
| <i>clindamycin-tretinooin external gel 1.2-0.025 %</i> | G | PA; AL (Max 35 Years) |
| <i>dapsone external gel 5 %</i> | G | N8 (Listing does not include certain NDCs) |
| <i>dapsone external gel 7.5 %</i> | G | |
| DIFFERIN EXTERNAL CREAM 0.1 % (<i>adapalene</i>) | NPB | PA; QL (45 G per 25 days); AL (Max 35 Years) |
| DIFFERIN EXTERNAL GEL 0.1 % (<i>adapalene</i>) | G | PA; Select OTC; QL (45 G per 25 days); AL (Max 35 Years) |
| DIFFERIN EXTERNAL GEL 0.3 % (<i>adapalene</i>) | NPB | PA; QL (45 G per 25 days); AL (Max 35 Years) |
| DIFFERIN EXTERNAL LOTION 0.1 % (<i>adapalene</i>) | NF | |
| EPIDUO EXTERNAL GEL 0.1-2.5 % (<i>adapalene-benzoyl peroxide</i>) | PB | PA; AL (Max 35 Years) |
| EPIDUO FORTE EXTERNAL GEL 0.3-2.5 % (<i>adapalene-benzoyl peroxide</i>) | PB | PA; AL (Max 35 Years) |
| <i>ery external pad 2 %</i> | G | |
| ERYGEL EXTERNAL GEL 2 % (<i>erythromycin</i>) | NPB | QL (60 G per 25 DAYs) |
| <i>erythromycin external gel 2 %</i> | G | QL (60 G per 25 days) |
| <i>erythromycin external solution 2 %</i> | G | QL (60 ML per 25 DAYs) |
| FABIOR EXTERNAL FOAM 0.1 % (<i>tazarotene</i>) | NF | |
| <i>isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | G | PA |
| <i>isotretinoin oral capsule 25 mg, 35 mg</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| KLARON EXTERNAL LOTION 10 % (<i>sulfacetamide sodium (acne)</i>) | NPB | ST |
| ONEXTON EXTERNAL GEL 1.2-3.75 % (<i>clindamycin phosphbenzoyl perox</i>) | PB | |
| RETIN-A EXTERNAL CREAM 0.025 %, 0.05 %, 0.1 % (<i>tretinooin</i>) | NPB | PA; AL (Max 35 Years) |
| RETIN-A EXTERNAL GEL 0.01 %, 0.025 % (<i>tretinooin</i>) | NPB | PA; AL (Max 35 Years) |
| RETIN-A MICRO EXTERNAL GEL 0.04 %, 0.1 % (<i>tretinooin microsphere</i>) | NF | |
| RETIN-A MICRO PUMP EXTERNAL GEL 0.04 %, 0.06 %, 0.08 %, 0.1 % (<i>tretinooin microsphere</i>) | NF | |
| <i>sulfacetamide sodium (acne) external lotion 10 %</i> | G | |
| <i>tazarotene external foam 0.1 %</i> | NF | |
| <i>tretinooin external cream 0.025 %, 0.05 %, 0.1 %</i> | G | PA; AL (Max 35 Years) |
| <i>tretinooin external gel 0.01 %, 0.025 %, 0.05 %</i> | G | PA; AL (Max 35 Years) |
| <i>tretinooin microsphere external gel 0.04 %, 0.1 %</i> | G | PA; AL (Max 35 Years) |
| <i>tretinooin microsphere pump external gel 0.08 %</i> | NF | |
| TWYNEO EXTERNAL CREAM 0.1-3 % (<i>tretinoin-benzoyl peroxide</i>) | PB | |
| VELTIN EXTERNAL GEL 1.2-0.025 % (<i>clindamycin-tretinooin</i>) | NF | |
| WINLEVI EXTERNAL CREAM 1 % (<i>clascoterone</i>) | PB | PA |
| <i>isotretinoin (Zenatane Oral Capsule 10 Mg, 20 Mg, 30 Mg, 40 Mg)</i> | G | PA |
| ZIANA EXTERNAL GEL 1.2-0.025 % (<i>clindamycin-tretinooin</i>) | NF | |
| DERMATOLOGY, ACTINIC KERATOSIS | | |
| CARAC EXTERNAL CREAM 0.5 % (<i>fluorouracil</i>) | NF | |
| <i>fluorouracil external cream 0.5 %</i> | NF | |
| <i>fluorouracil external cream 5 %</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>fluorouracil external solution 2 %, 5 %</i> | G | |
| <i>imiquimod external cream 5 %</i> | G | QL (24 packets per 21 days) |
| <i>imiquimod pump external cream 3.75 %</i> | G | PA |
| KLISYRI EXTERNAL OINTMENT 1 % (<i>tirbanibulin</i>) | NF | |
| TOLAK EXTERNAL CREAM 4 % (<i>fluorouracil</i>) | NF | |
| ZYCLARA EXTERNAL CREAM 3.75 % (<i>imiquimod</i>) | NF | |
| ZYCLARA PUMP EXTERNAL CREAM 2.5 % (<i>imiquimod</i>) | NF | |
| DERMATOLOGY, ANTIBIOTICS | | |
| <i>gentamicin sulfate external cream 0.1 %</i> | G | QL (120 G per 25 days) |
| <i>gentamicin sulfate external ointment 0.1 %</i> | G | QL (120 G per 25 days) |
| <i>mafenide acetate external packet 5 %</i> | G | |
| <i>mupirocin calcium external cream 2 %</i> | NF | |
| <i>mupirocin external ointment 2 %</i> | G | QL (30 G per 25 DAYs) |
| NEO-SYNALAR EXTERNAL CREAM 0.5-0.025 % (<i>neomycin-fluocinolone</i>) | NF | |
| <i>silver sulfadiazine external cream 1 %</i> | G | |
| <i>silver sulfadiazine (Ssd External Cream 1 %)</i> | G | |
| XEPI EXTERNAL CREAM 1 % (<i>ozenoxacin</i>) | NPB | PA; QL (30 G per 25 DAYs) |
| DERMATOLOGY, ANTIFUNGALS | | |
| <i>butenafine hcl external cream 1 %</i> | G | QL (60 G per 25 days) |
| <i>ciclopirox external gel 0.77 %</i> | G | |
| <i>ciclopirox external shampoo 1 %</i> | G | |
| <i>ciclopirox external solution 8 %</i> | G | PA; STX; QL (6.6 ML per 21 days) |
| <i>ciclopirox olamine external cream 0.77 %</i> | G | |
| <i>ciclopirox olamine external suspension 0.77 %</i> | G | |
| <i>clotrimazole-betamethasone external cream 1-0.05 %</i> | G | STX; QL (60 G per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>clotrimazole-betamethasone external lotion 1-0.05 %</i> | G | STX; QL (60 ML per 25 DAYs) |
| <i>econazole nitrate external cream 1 %</i> | G | QL (85 G per 25 DAYs) |
| ECOZA EXTERNAL FOAM 1 % (econazole nitrate) | NF | |
| ERTACZO EXTERNAL CREAM 2 % (sertaconazole nitrate) | NF | |
| EXELDERM EXTERNAL CREAM 1 % (sulconazole nitrate) | NPB | ST; QL (60 G per 25 DAYs) |
| EXELDERM EXTERNAL SOLUTION 1 % (sulconazole nitrate) | NPB | ST; QL (60 ML per 25 DAYs) |
| JUBLIA EXTERNAL SOLUTION 10 % (efinaconazole) | NPB | PA; QL (4 ML per 21 days) |
| <i>ketoconazole external cream 2 %</i> | G | |
| <i>ketoconazole external foam 2 %</i> | NF | |
| <i>luliconazole external cream 1 %</i> | NF | |
| LUZU EXTERNAL CREAM 1 % (luliconazole) | NF | |
| <i>miconazole-zinc oxide-petrolat external ointment 0.25-15-81.35 %</i> | G | |
| <i>naftifine hcl external cream 1 %, 2 %</i> | G | |
| <i>naftifine hcl external gel 2 %</i> | NF | |
| NAFTIN EXTERNAL GEL 1 %, 2 % (naftifine hcl) | NF | |
| <i>nystatin external cream 100000 unit/gm</i> | G | |
| <i>nystatin external ointment 100000 unit/gm</i> | G | |
| <i>nystatin-triamcinolone external cream 100000-0.1 unit/gm-%</i> | G | STX; QL (60 G per 25 DAYs) |
| <i>nystatin-triamcinolone external ointment 100000-0.1 unit/gm-%</i> | G | STX; QL (60 G per 25 DAYs) |
| <i>oxiconazole nitrate external cream 1 %</i> | G | N8 (Listing does not include certain NDCs); QL (60 G per 25 DAYs) |
| OXISTAT EXTERNAL CREAM 1 % (oxiconazole nitrate) | NF | |
| OXISTAT EXTERNAL LOTION 1 % (oxiconazole nitrate) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| sulconazole nitrate external cream 1 % | G | QL (60 G per 25 DAYs) |
| sulconazole nitrate external solution 1 % | G | QL (60 ML per 25 DAYs) |
| tavaborole external solution 5 % | NF | |
| VUSION EXTERNAL OINTMENT 0.25-15-81.35 % (miconazole-zinc oxide-petrolat) | NF | |
| DERMATOLOGY, ANTIPRURITIC | | |
| doxepin hcl external cream 5 % | NF | |
| PRUDOXIN EXTERNAL CREAM 5 % (doxepin hcl (antipruritic)) | NPB | ST; QL (45 G per 25 DAYs) |
| ZONALON EXTERNAL CREAM 5 % (doxepin hcl (antipruritic)) | NPB | ST; QL (45 G per 25 DAYs) |
| DERMATOLOGY, ANTIPSORIATICS | | |
| acitretin oral capsule 10 mg, 17.5 mg, 25 mg | G | PA; QL (60 CAPSULES per 25 DAYs) |
| calcipotriene external cream 0.005 % | NF | |
| calcipotriene external ointment 0.005 % | G | ST; QL (60 G per 25 DAYs) |
| calcipotriene external solution 0.005 % | G | ST; QL (60 ML per 25 DAYs) |
| calcipotriene-betameth diprop external ointment 0.005-0.064 % | NF | |
| calcipotriene-betameth diprop external suspension 0.005-0.064 % | NF | |
| calcitriol external ointment 3 mcg/gm | NF | |
| ENSTILAR EXTERNAL FOAM 0.005-0.064 % (calcipotriene-betameth diprop) | PB | |
| methoxsalen rapid oral capsule 10 mg | G | |
| SORILUX EXTERNAL FOAM 0.005 % (calcipotriene) | NF | |
| SPEVIGO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML (spesolimab-sbzo) | SP | PA |
| TACLONEX EXTERNAL OINTMENT 0.005-0.064 % (calcipotriene-betameth diprop) | PB | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| TACLONEX EXTERNAL SUSPENSION 0.005-0.064 % <i>(calcipotriene-betameth diprop)</i> | PB | |
| tazarotene external cream 0.1 % | G | PA; AL (Max 35 Years) |
| tazarotene external gel 0.05 %, 0.1 % | NF | |
| TAZORAC EXTERNAL CREAM 0.05 %, 0.1 % (<i>tazarotene</i>) | NF | |
| TAZORAC EXTERNAL GEL 0.05 %, 0.1 % (<i>tazarotene</i>) | NF | |
| VECTICAL EXTERNAL OINTMENT 3 MCG/GM <i>(calcitriol)</i> | NF | |
| VTAMA EXTERNAL CREAM 1 % (<i>tapinarof</i>) | PB | |
| WYNZORA EXTERNAL CREAM 0.005-0.064 % <i>(calcipotriene-betameth diprop)</i> | NF | |
| ZORYVE EXTERNAL CREAM 0.3 % (<i>roflumilast</i>) | PB | |
| DERMATOLOGY, ANTISEBORRHEICS | | |
| ketoconazole external shampoo 2 % | G | |
| ZORYVE EXTERNAL FOAM 0.3 % (<i>roflumilast</i> <i>(antiseborrheic)</i>) | PB | |
| DERMATOLOGY, ATOPIC DERMATITIS | | |
| ADBRY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML (<i>tralokinumab-ldrm</i>) | SP | PA; QL (4 SYRINGES per 28 days) |
| CIBINQO ORAL TABLET 100 MG, 200 MG, 50 MG <i>(abrocitinib)</i> | SP | PA; QL (30 TABLETS per 30 days) |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 200 MG/1.14ML (<i>dupilumab</i>) | SP | PA; QL (2 PENS per 28 days) |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 MG/2ML (<i>dupilumab</i>) | SP | PA; QL (4 PENS per 28 days) |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML (<i>dupilumab</i>) | SP | PA; QL (2 SYRINGES per 28 days) |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MG/2ML (<i>dupilumab</i>) | SP | PA; QL (4 SYRINGES per 28 days) |
| ELIDEL EXTERNAL CREAM 1 % (<i>pimecrolimus</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| EUCRISA EXTERNAL OINTMENT 2 % (<i>crisaborole</i>) | PB | |
| OPZELURA EXTERNAL CREAM 1.5 % (<i>ruxolitinib phosphate</i>) | PB | PA; QL (60 G per 28 days) |
| <i>pimecrolimus external cream 1 %</i> | G | PA |
| <i>tacrolimus external ointment 0.03 %, 0.1 %</i> | G | PA |
| DERMATOLOGY, CORTICOSTEROIDS | | |
| <i>alclometasone dipropionate external cream 0.05 %</i> | G | QL (120 G per 25 DAYS) |
| <i>alclometasone dipropionate external ointment 0.05 %</i> | G | QL (120 G per 25 DAYS) |
| <i>amcinonide external lotion 0.1 %</i> | G | QL (120 ML per 25 DAYS) |
| <i>amcinonide external ointment 0.1 %</i> | NF | |
| APEXICON E EXTERNAL CREAM 0.05 % (<i>diflorasone diacet emoll base</i>) | NF | |
| <i>betamethasone dipropionate aug external cream 0.05 %</i> | G | QL (120 G per 25 DAYS) |
| <i>betamethasone dipropionate aug external gel 0.05 %</i> | G | QL (120 G per 25 DAYS) |
| <i>betamethasone dipropionate aug external lotion 0.05 %</i> | G | QL (120 ML per 25 DAYS) |
| <i>betamethasone dipropionate aug external ointment 0.05 %</i> | G | QL (120 G per 25 DAYS) |
| <i>betamethasone dipropionate external cream 0.05 %</i> | G | QL (120 G per 25 DAYS) |
| <i>betamethasone dipropionate external lotion 0.05 %</i> | G | QL (120 ML per 25 DAYS) |
| <i>betamethasone dipropionate external ointment 0.05 %</i> | NF | |
| <i>betamethasone valerate external cream 0.1 %</i> | G | QL (120 G per 25 DAYS) |
| <i>betamethasone valerate external foam 0.12 %</i> | G | QL (120 G per 25 days) |
| <i>betamethasone valerate external lotion 0.1 %</i> | G | QL (120 ML per 25 DAYS) |
| <i>betamethasone valerate external ointment 0.1 %</i> | G | QL (120 G per 25 DAYS) |
| BRYHALI EXTERNAL LOTION 0.01 % (<i>halobetasol propionate</i>) | PB | QL (120 G per 25 DAYS) |
| CAPEX EXTERNAL SHAMPOO 0.01 % (<i>fluocinolone acetonide</i>) | NF | |
| <i>clobetasol propionate e external cream 0.05 %</i> | G | QL (120 G per 25 DAYS) |
| <i>clobetasol propionate emulsion external foam 0.05 %</i> | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>clobetasol propionate external cream 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>clobetasol propionate external foam 0.05 %</i> | G | QL (120 G per 25 days) |
| <i>clobetasol propionate external gel 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>clobetasol propionate external liquid 0.05 %</i> | NF | |
| <i>clobetasol propionate external lotion 0.05 %</i> | G | QL (120 ML per 25 DAYs) |
| <i>clobetasol propionate external ointment 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>clobetasol propionate external shampoo 0.05 %</i> | G | QL (120 ML per 25 DAYs) |
| <i>clobetasol propionate external solution 0.05 %</i> | G | QL (120 ML per 25 DAYs) |
| CLOBEX EXTERNAL LOTION 0.05 % (<i>clobetasol propionate</i>) | NPB | PA; QL (180 ML per 25 DAYs) |
| CLOBEX EXTERNAL SHAMPOO 0.05 % (<i>clobetasol propionate</i>) | NPB | PA; QL (180 ML per 25 DAYs) |
| CLOBEX SPRAY EXTERNAL LIQUID 0.05 % (<i>clobetasol propionate</i>) | NF | |
| <i>clorcortolone pivalate external cream 0.1 %</i> | NF | |
| CLODERM EXTERNAL CREAM 0.1 % (<i>clorcortolone pivalate</i>) | NPB | PA; QL (180 G per 25 DAYs) |
| CORDRAN EXTERNAL CREAM 0.05 % (<i>flurandrenolide</i>) | NF | |
| CORDRAN EXTERNAL LOTION 0.05 % (<i>flurandrenolide</i>) | NF | |
| CORDRAN EXTERNAL TAPE 4 MCG/SQCM (<i>flurandrenolide</i>) | NF | |
| DERMA-SMOOTH/FS BODY EXTERNAL OIL 0.01 % (<i>fluocinolone acetonide</i>) | NPB | PA; QL (120 ML per 25 days) |
| DERMA-SMOOTH/FS SCALP EXTERNAL OIL 0.01 % (<i>fluocinolone acetonide</i>) | NPB | PA; QL (120 ML per 25 days) |
| <i>desonide external cream 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>desonide external gel 0.05 %</i> | NF | |
| <i>desonide external lotion 0.05 %</i> | G | QL (120 ML per 25 days) |
| <i>desonide external ointment 0.05 %</i> | G | QL (120 G per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| DESOWEN EXTERNAL CREAM 0.05 % (<i>desonide</i>) | NPB | PA; QL (180 G per 25 DAYs) |
| <i>desoximetasone external cream 0.05 %, 0.25 %</i> | G | QL (120 G per 25 DAYs) |
| <i>desoximetasone external gel 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>desoximetasone external liquid 0.25 %</i> | G | QL (120 ML per 25 DAYs) |
| <i>desoximetasone external ointment 0.05 %</i> | NF | |
| <i>desoximetasone external ointment 0.25 %</i> | G | QL (120 G per 25 DAYs) |
| <i>diflorasone diacetate external cream 0.05 %</i> | NF | |
| <i>diflorasone diacetate external ointment 0.05 %</i> | NF | |
| DIPROLENE EXTERNAL OINTMENT 0.05 % (<i>betamethasone dipropionate aug</i>) | NPB | PA; QL (180 G per 25 days) |
| DUOBRII EXTERNAL LOTION 0.01-0.045 % (<i>halobetasol prop-tazarotene</i>) | NF | |
| <i>fluocinolone acetonide body external oil 0.01 %</i> | G | QL (120 ML per 25 DAYs) |
| <i>fluocinolone acetonide external cream 0.01 %, 0.025 %</i> | G | QL (120 G per 25 days) |
| <i>fluocinolone acetonide external ointment 0.025 %</i> | G | QL (120 G per 25 DAYs) |
| <i>fluocinolone acetonide external solution 0.01 %</i> | G | QL (120 ML per 25 DAYs) |
| <i>fluocinolone acetonide scalp external oil 0.01 %</i> | G | QL (120 ML per 25 DAYs) |
| <i>fluocinonide emulsified base external cream 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>fluocinonide external cream 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>fluocinonide external cream 0.1 %</i> | NF | |
| <i>fluocinonide external gel 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>fluocinonide external ointment 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>fluocinonide external solution 0.05 %</i> | G | QL (120 ML per 25 days) |
| <i>flurandrenolide external cream 0.05 %</i> | NF | |
| <i>flurandrenolide external lotion 0.05 %</i> | NF | |
| <i>fluticasone propionate external cream 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>fluticasone propionate external lotion 0.05 %</i> | G | QL (120 ML per 25 days) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>fluticasone propionate external ointment 0.005 %</i> | G | QL (120 G per 25 DAYs) |
| <i>halcinonide external cream 0.1 %</i> | NF | |
| <i>halobetasol propionate external cream 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| <i>halobetasol propionate external foam 0.05 %</i> | NF | |
| <i>halobetasol propionate external ointment 0.05 %</i> | G | QL (120 G per 25 DAYs) |
| HALOG EXTERNAL CREAM 0.1 % (halcinonide) | NF | |
| HALOG EXTERNAL OINTMENT 0.1 % (halcinonide) | NF | |
| HALOG EXTERNAL SOLUTION 0.1 % (halcinonide) | NF | |
| <i>hydrocortisone butyr lipo base external cream 0.1 %</i> | NF | |
| <i>hydrocortisone butyrate external cream 0.1 %</i> | G | QL (120 G per 25 DAYs) |
| <i>hydrocortisone butyrate external lotion 0.1 %</i> | NF | |
| <i>hydrocortisone butyrate external ointment 0.1 %</i> | G | QL (120 G per 25 DAYs) |
| <i>hydrocortisone butyrate external solution 0.1 %</i> | G | QL (120 ML per 25 DAYs) |
| <i>hydrocortisone external cream 2.5 %</i> | G | QL (120 G per 25 DAYs) |
| <i>hydrocortisone external lotion 2.5 %</i> | G | QL (120 ML per 25 DAYs) |
| <i>hydrocortisone external ointment 2.5 %</i> | G | QL (120 G per 25 DAYs) |
| <i>hydrocortisone valerate external cream 0.2 %</i> | G | QL (120 G per 25 days) |
| <i>hydrocortisone valerate external ointment 0.2 %</i> | G | QL (120 G per 25 days) |
| IMPOYZ EXTERNAL CREAM 0.025 % (clobetasol propionate) | NF | |
| KENALOG EXTERNAL AEROSOL SOLUTION 0.147 MG/GM (triamcinolone acetonide) | NF | |
| LEXETTE EXTERNAL FOAM 0.05 % (halobetasol propionate) | NF | |
| LOCOID EXTERNAL LOTION 0.1 % (hydrocortisone butyrate) | NPB | PA; QL (180 ML per 25 DAYs) |
| LOCOID LIPOCREAM EXTERNAL CREAM 0.1 % (hydrocortisone butyr lipo base) | NPB | PA; QL (180 G per 25 DAYs) |
| <i>mometasone furoate external cream 0.1 %</i> | G | QL (120 G per 25 DAYs) |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>mometasone furoate external ointment 0.1 %</i> | G | QL (120 G per 25 DAYs) |
| <i>mometasone furoate external solution 0.1 %</i> | G | QL (120 ML per 25 DAYs) |
| PANDEL EXTERNAL CREAM 0.1 % (<i>hydrocortisone probutate</i>) | NPB | PA; QL (180 G per 25 days) |
| SERNIVO EXTERNAL EMULSION 0.05 % (<i>betamethasone dipropionate</i>) | NPB | PA; STX; QL (120 ML per 25 days) |
| SYNALAR EXTERNAL CREAM 0.025 % (<i>fluocinolone acetonide</i>) | NPB | PA; QL (180 G per 25 DAYs) |
| SYNALAR EXTERNAL OINTMENT 0.025 % (<i>fluocinolone acetonide</i>) | NPB | PA; QL (180 G per 25 DAYs) |
| SYNALAR EXTERNAL SOLUTION 0.01 % (<i>fluocinolone acetonide</i>) | NPB | PA; QL (180 ML per 25 DAYs) |
| TEXACORT EXTERNAL SOLUTION 2.5 % (<i>hydrocortisone</i>) | NPB | PA; QL (120 ML per 25 days) |
| TOPICORT EXTERNAL CREAM 0.05 %, 0.25 % (<i>desoximetasone</i>) | NPB | PA; QL (180 G per 25 DAYs) |
| TOPICORT EXTERNAL GEL 0.05 % (<i>desoximetasone</i>) | NPB | PA; QL (180 G per 25 DAYs) |
| TOPICORT EXTERNAL OINTMENT 0.05 %, 0.25 % (<i>desoximetasone</i>) | NPB | PA; QL (180 G per 25 DAYs) |
| TOPICORT SPRAY EXTERNAL LIQUID 0.25 % (<i>desoximetasone</i>) | NPB | PA; QL (180 ML per 25 DAYs) |
| <i>clobetasol propionate emulsion (Tovet External Foam 0.05 %)</i> | NF | |
| <i>triamcinolone acetonide external aerosol solution 0.147 mg/gm</i> | NF | |
| <i>triamcinolone acetonide external cream 0.025 %, 0.1 %, 0.5 %</i> | G | QL (120 G per 25 DAYs) |
| <i>triamcinolone acetonide external lotion 0.025 %, 0.1 %</i> | G | QL (120 ML per 25 DAYs) |
| <i>triamcinolone acetonide external ointment 0.025 %, 0.1 %</i> | G | QL (120 G per 25 DAYs) |
| <i>triamcinolone acetonide external ointment 0.5 %</i> | G | QL (120 G per 25 days) |
| ULTRAVATE EXTERNAL LOTION 0.05 % (<i>halobetasol propionate</i>) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| VANOS EXTERNAL CREAM 0.1 % (<i>fluocinonide</i>) | NF | |
| VERDESO EXTERNAL FOAM 0.05 % (<i>desonide</i>) | NF | |
| DERMATOLOGY, LOCAL ANESTHETICS | | |
| <i>lidocaine external ointment 5 %</i> | G | QL (50 G per 25 DAYs) |
| <i>lidocaine external patch 5 %</i> | G | PA; N8 (Listing does not include certain NDCs); QL (90 PATCHES per 25 DAYs) |
| <i>lidocaine hcl external solution 4 %</i> | G | QL (50 ML per 25 DAYs) |
| <i>lidocaine-prilocaine external cream 2.5-2.5 %</i> | G | QL (30 G per 25 DAYs) |
| LIDODERM EXTERNAL PATCH 5 % (<i>lidocaine</i>) | NPB | PA; QL (90 PATCHES per 25 DAYs) |
| PLIAGLIS EXTERNAL CREAM 7-7 % (<i>lidocaine-tetracaine</i>) | NF | |
| DERMATOLOGY, MISCELLANEOUS SKIN AND MUCOUS MEMBRANE | | |
| ABREVA EXTERNAL CREAM 10 % (<i>docosanol</i>) | G | Select OTC |
| <i>acyclovir external cream 5 %</i> | NF | |
| <i>acyclovir external ointment 5 %</i> | G | |
| ALFERON N INJECTION SOLUTION 5000000 UNIT/ML (<i>interferon alfa-n3</i>) | SP | |
| AMELUZ EXTERNAL GEL 10 % (<i>aminolevulinic acid hcl</i>) | NF | |
| <i>bexarotene external gel 1 %</i> | SP | PA |
| DENAVIR EXTERNAL CREAM 1 % (<i>penciclovir</i>) | NPB | PA |
| <i>docosanol external cream 10 %</i> | G | Select OTC |
| HYFTOR EXTERNAL GEL 0.2 % (<i>sirolimus</i>) | NF | |
| LEVULAN KERASTICK EXTERNAL SOLUTION RECONSTITUTED 20 % (<i>aminolevulinic acid hcl</i>) | SP | QL (1 STICK per 25 DAYs) |
| <i>penciclovir external cream 1 %</i> | NF | |
| <i>podofilox external gel 0.5 %</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>podofilox external solution 0.5 %</i> | G | |
| SANTYL EXTERNAL OINTMENT 250 UNIT/GM (collagenase) | NPB | PA |
| TARGRETIN EXTERNAL GEL 1 % (bexarotene) | NF | |
| VALCHLOR EXTERNAL GEL 0.016 % (mechlorethamine hcl (topical)) | SP | PA; QL (2 TUBES per 30 DAYs) |
| VEREGEN EXTERNAL OINTMENT 15 % (sinecatechins) | NF | |
| ZOVIRAX EXTERNAL CREAM 5 % (acyclovir) | NF | |
| ZOVIRAX EXTERNAL OINTMENT 5 % (acyclovir) | NF | |
| ZYCLARA PUMP EXTERNAL CREAM 3.75 % (imiquimod) | NF | |
| DERMATOLOGY, ROSACEA | | |
| <i>azelaic acid external gel 15 %</i> | G | |
| <i>brimonidine tartrate external gel 0.33 %</i> | NF | |
| <i>doxycycline oral capsule delayed release 40 mg</i> | NF | |
| EPSOLAY EXTERNAL CREAM 5 % (benzoyl peroxide) | NF | |
| FINACEA EXTERNAL FOAM 15 % (azelaic acid) | PB | PA |
| FINACEA EXTERNAL GEL 15 % (azelaic acid) | NF | |
| <i>ivermectin external cream 1 %</i> | NF | |
| METROCREAM EXTERNAL CREAM 0.75 % (metronidazole) | NPB | ST; QL (60 G per 25 days) |
| METROGEL EXTERNAL GEL 1 % (metronidazole) | NF | |
| METROLOTION EXTERNAL LOTION 0.75 % (metronidazole) | NPB | QL (60 ML per 25 DAYs) |
| <i>metronidazole external cream 0.75 %</i> | G | QL (60 G per 25 days) |
| <i>metronidazole external gel 0.75 %, 1 %</i> | G | QL (60 G per 25 days) |
| <i>metronidazole external lotion 0.75 %</i> | G | QL (60 ML per 25 days) |
| MIRVASO EXTERNAL GEL 0.33 % (brimonidine tartrate) | NF | |
| NORITATE EXTERNAL CREAM 1 % (metronidazole) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July
07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| ORACEA ORAL CAPSULE DELAYED RELEASE 40 MG <i>(doxycycline)</i> | PB | |
| RHOFADE EXTERNAL CREAM 1 % <i>(oxymetazoline hcl)</i> | NF | |
| SOOLANTRA EXTERNAL CREAM 1 % <i>(ivermectin)</i> | PB | |
| ZILXI EXTERNAL FOAM 1.5 % <i>(minocycline hcl micronized)</i> | NF | |
| DERMATOLOGY, SCABICIDES AND PEDICULICIDES | | |
| CROTAN EXTERNAL LOTION 10 % <i>(crotamiton)</i> | G | |
| <i>malathion external lotion 0.5 %</i> | G | |
| <i>permethrin external cream 5 %</i> | G | |
| <i>spinosad external suspension 0.9 %</i> | G | |
| DERMATOLOGY, WOUND CARE AGENTS | | |
| REGRANEX EXTERNAL GEL 0.01 % <i>(becaplermin)</i> | NPB | PA; QL (30 G per 25 DAYS) |
| MOUTH/THROAT/DENTAL AGENTS | | |
| <i>cevimeline hcl oral capsule 30 mg</i> | G | |
| <i>chlorhexidine gluconate mouth/throat solution 0.12 %</i> | G | N8 (Listing does not include certain NDCs) |
| <i>clotrimazole mouth/throat troche 10 mg</i> | G | QL (90 LOZENGES per 25 days) |
| <i>lidocaine viscous hcl mouth/throat solution 2 %</i> | G | N8 (Listing does not include certain NDCs) |
| <i>nystatin suspension 100000 unit/ml mouth/throat</i> | G | |
| <i>nystatin suspension 100000 unit/ml mouth/throat</i> | NF | |
| ORAVIG BUCCAL TABLET 50 MG <i>(miconazole)</i> | NPB | QL (14 TABLETS per 25 days) |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> | G | |
| <i>triamcinolone acetonide mouth/throat paste 0.1 %</i> | G | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| OTIC - DRUGS TO TREAT CONDITIONS OF THE EAR | | |
| <i>acetic acid otic solution 2 %</i> | G | N8 (Listing does not include certain NDCs) |
| <i>ciprofloxacin hcl otic solution 0.2 %</i> | G | |
| <i>ciprofloxacin-dexamethasone otic suspension 0.3-0.1 %</i> | G | |
| <i>fluocinolone acetonide otic oil 0.01 %</i> | G | |
| <i>hydrocortisone-acetic acid solution 1-2 % otic</i> | NF | |
| <i>hydrocortisone-acetic acid solution 1-2 % otic</i> | G | |
| <i>neomycin-polymyxin-hc otic solution 1 %</i> | G | |
| <i>neomycin-polymyxin-hc otic suspension 3.5-10000-1</i> | G | |
| <i>ofloxacin otic solution 0.3 %</i> | G | |
| OTOVEL OTIC SOLUTION 0.3-0.025 % (ciprofloxacin-fluocinolone) | NF | |

2024 Pharmacy Drug Guide - Advanced Control Plan - Aetna Student Health CA

The formulary is updated annually in July

07/01/2024

CE=Copay Exception | G=Generics | PB=Preferred Brands | NPB=Non-Preferred Brands | SP=Specialty | NF=Non-Formulary | PA=Prior Authorization | ST=Step Therapy | QL=Quantity Limits | AL=Age Limits | LGC=Lowest Generic Copay | N7=Drug tier when CE does not apply | Select OTC=You may have coverage for products noted with a doctor's prescription | SPC=Only available for select plans | IBC=Indication Based Coverage | QLR=Quantity Limit Restriction Based on Age | STX=Safer and/or more effective treatments are available | N8=Drug Specific Coverage

Index

| | | | | | |
|--|----------|--|----------|---|-----|
| <i>abacavir sulfate</i> | 34 | <i>adalimumab-aacf (2 pen)</i> | 206 | AIRDUO DIGIHALER | 259 |
| <i>abacavir sulfate-lamivudine</i> | 38 | <i>adalimumab-aaty (1 pen)</i> | 207 | AIRDUO RESPICLICK | |
| ABILIFY | 96 | <i>adalimumab-aaty (2 syringe)</i> | 207 | 113/14 | 259 |
| ABILIFY ASIMTUFII | 96 | <i>adalimumab-adaz</i> | 207 | AIRDUO RESPICLICK | |
| ABILIFY MAINTENA | 96 | <i>adalimumab-adbm (2 pen)</i> | 207 | 232/14 | 259 |
| <i>abiraterone acetate</i> | 52 | <i>adalimumab-adbm (2 syringe)</i> | 207 | AIRDUO RESPICLICK | |
| ABREVA | 274 | <i>adalimumab-fkjp</i> | 207 | 55/14 | 260 |
| ABRILADA (1 PEN) | 206 | <i>adalimumab-ryvk (2 pen)</i> | 207 | AIRSUPRA | 260 |
| ABRILADA (2 SYRINGE) | 206 | <i>adapalene</i> | 261, 262 | AJOVY | 115 |
| ABSORICA | 261 | <i>adapalene-benzoyl peroxide</i> | 262 | AKEEGA | 52 |
| ABSORICA LD | 261 | <i>ADBRY</i> | 268 | AKLIEF | 262 |
| <i>acamprosate calcium</i> | 83 | <i>ADCIRCA</i> | 81 | AKYNZEO | 179 |
| ACANYA | 261 | <i>ADDERALL</i> | 106 | <i>albendazole</i> | 32 |
| <i>acarbose</i> | 133 | <i>ADDERALL XR</i> | 107 | <i>albuterol sulfate</i> | 251 |
| ACCRUFER | 237 | <i>ADDYI</i> | 128 | <i>albuterol sulfate hfa</i> | 251 |
| ACCU-CHEK AVIVA PLUS | 161 | <i>adefovir dipivoxil</i> | 44 | <i>alclometasone dipropionate</i> | 269 |
| ACCU-CHEK FASTCLIX | 161 | <i>ADEMPAS</i> | 81 | <i>alcohol swabs</i> | 225 |
| LANCET | 161 | <i>ADIPEX-P</i> | 143 | ALDURAZYME | 165 |
| ACCU-CHEK FASTCLIX | 161 | <i>ADLARITY</i> | 85 | ALECENSA | 54 |
| LANCETS | 161 | <i>ADMELOG</i> | 136 | <i>alendronate sodium</i> | 145 |
| ACCU-CHEK GUIDE | 161 | <i>ADMELOG SOLOSTAR</i> | 136 | ALFERON N | 274 |
| ACCU-CHEK SAFE-T PRO | 161 | <i>ADTHYZA</i> | 177 | <i>alfuzosin hcl er</i> | 189 |
| LANCETS | 161 | <i>ADVAIR DISKUS</i> | 259 | ALINIA | 46 |
| ACCU-CHEK SMARTVIEW | 161 | <i>ADVAIR HFA</i> | 259 | <i>aliskiren fumarate</i> | 77 |
| ACCU-CHEK SOFTCLIX | 161 | <i>ADVANCE INTUITION TEST</i> | 224 | ALKINDI SPRINKLE | 170 |
| LANCET DEV | 161 | <i>ADVATE</i> | 198 | ALLEGRA ALLERGY | 248 |
| ACCU-CHEK SOFTCLIX | 161 | <i>ADVOCATE REDI-CODE</i> | 224 | ALLEGRA ALLERGY CHILDRENS | 248 |
| LANCETS | 161 | <i>ADVOCATE REDI-CODE+ TEST</i> | 224 | ALLEGRA-D ALLERGY & CONGESTION | 252 |
| Accutane | 261 | <i>adynovate</i> | 198 | <i>allergy rel child (cetirizine)</i> | 249 |
| ACCUTREND GLUCOSE | 224 | <i>ADZENYS XR-ODT</i> | 107 | <i>allergy relief (cetirizine)</i> | 249 |
| <i>acebutolol hcl</i> | 73 | <i>AFINITOR</i> | 54 | <i>allopurinol</i> | 17 |
| <i>acetaminophen-codeine</i> | 21, 22 | <i>AFINITOR DISPERZ</i> | 54 | ALLZITAL | 18 |
| <i>acetazolamide</i> | 77 | <i>Afirmelle</i> | 148 | <i>almotriptan malate</i> | 115 |
| <i>acetazolamide er</i> | 77 | <i>AFREZZA</i> | 136 | <i>alogliptin benzoate</i> | 135 |
| <i>acetic acid</i> | 191, 277 | <i>AFSTYLA</i> | 198 | <i>alogliptin-metformin hcl</i> | 134 |
| <i>acetylcysteine</i> | 247, 255 | <i>AFTERA</i> | 148 | <i>alogliptin-pioglitazone</i> | 134 |
| ACIPHEX | 187 | <i>AFTERPILL</i> | 148 | ALORA | 166 |
| <i>acitretin</i> | 267 | <i>AGAMATRIX AMP TEST</i> | 224 | <i>alosetron hcl</i> | 183 |
| ACTEMRA | 205, 206 | <i>AGAMATRIX JAZZ TEST</i> | 224 | ALPHAGAN P | 239 |
| ACTEMRA ACTPEN | 206 | <i>AGAMATRIX KEYNOTE TEST</i> | 225 | ALPHANATE | 195 |
| ACTHAR | 174 | <i>AGAMATRIX PRESTO TEST</i> | 225 | ALPHANINE SD | 200 |
| ACTIMMUNE | 221 | <i>AGAMREE</i> | 170 | <i>alprazolam</i> | 83 |
| ACTONEL | 145 | <i>AGRYLIN</i> | 201 | <i>alprazolam er</i> | 83 |
| ACTOS | 141 | <i>AIMOVIG</i> | 115 | ALPRAZOLAM INTENSOL | 83 |
| ACUVAIL | 243 | | | ALPROLIX | 200 |
| <i>acyclovir</i> | 40, 274 | | | ALREX | 243 |
| ACZONE | 261 | | | Altavera | 148 |

| | | | | | |
|---|--------|---------------------------------|-----|---------------------------------|----------|
| ALTOPREV | 70 | ANAFRANIL | 84 | ASMANEX HFA | 258 |
| ALTRENO | 262 | <i>anagrelide hcl</i> | 201 | <i>aspirin</i> | 30 |
| ALTUVIPIO | 199 | <i>anastrozole</i> | 52 | <i>aspirin childrens</i> | 30 |
| ALUNBRIG | 54 | ANDRODERM | 132 | <i>aspirin-dipyridamole er</i> | 203 |
| ALVAIZ | 203 | ANDROGEL PUMP | 132 | ASPRUZYO SPRINKLE | 79 |
| <i>alyacen 1/35</i> | 148 | ANGELIQ | 166 | ASSURE 3 TEST | 225 |
| <i>alyacen 7/7/7</i> | 148 | ANNOVERA | 149 | ASSURE 4 TEST | 225 |
| ALYGLO | 219 | ANORO ELLIPTA | 247 | ASSURE II | 225 |
| Alyq | 81 | ANTIVERT | 179 | ASSURE II CHECK | 225 |
| Amabelz | 166 | ANZEMET | 180 | ASSURE PLATINUM | 225 |
| <i>amantadine hcl</i> | 94 | APADAZ | 24 | ASSURE PRISM MULTI | |
| AMBIEN | 113 | <i>apap-caff-dihydrocodeine</i> | 25 | TEST | 225 |
| AMBIEN CR | 113 | APEXICON E | 269 | ASSURE PRO TEST | 225 |
| <i>ambrisentan</i> | 81 | APIDRA | 136 | ASTAGRAF XL | 221 |
| <i>amcinonide</i> | 269 | APIDRA SOLOSTAR | 136 | ATABEX EC | 233 |
| AMELUZ | 274 | APLENZIN | 87 | ATACAND | 67 |
| Amethyst | 149 | APOKYN | 94 | ATACAND HCT | 66 |
| <i>amiloride hcl</i> | 77 | <i>apomorphine hcl</i> | 94 | <i>atazanavir sulfate</i> | 34 |
| <i>amiloride-hydrochlorothiazide</i> | 77 | <i>aprepitant</i> | 180 | ATELVIA | 145 |
| <i>aminocaproic acid</i> | 201 | Apri | 149 | <i>atenolol</i> | 73 |
| <i>amiodarone hcl</i> | 68 | APRISO | 182 | <i>atenolol-chlorthalidone</i> | 73 |
| AMITIZA | 183 | APTENSIO XR | 107 | ATGAM | 221 |
| <i>amitriptyline hcl</i> | 86 | APTIOM | 99 | ATIVAN | 84 |
| AMJEVITA | 207 | APTIVUS | 34 | <i>atomoxetine hcl</i> | 107, 108 |
| AMJEVITA-PED 10KG TO <15KG | 207 | ARAKODA | 34 | ATORVALIQ | 71 |
| AMJEVITA-PED 15KG TO <30KG | 207 | ARALAST NP | 246 | <i>atorvastatin calcium</i> | 70 |
| <i>amlodipine besy-benazepril hcl</i> | 64 | Aranelle | 149 | <i>atovaquone</i> | 46 |
| <i>amlodipine besylate</i> | 75 | ARANESP (ALBUMIN FREE) | 196 | <i>atovaquone-proguanil hcl</i> | 34 |
| <i>amlodipine besylate-valsartan</i> | 66 | ARAZLO | 262 | ATRALIN | 262 |
| <i>amlodipine-atorvastatin</i> | 75 | ARCALYST | 221 | <i>atropine sulfate</i> | 245 |
| <i>amlodipine-olmesartan</i> | 66 | <i>arformoterol tartrate</i> | 251 | ATROVENT HFA | 248 |
| <i>amlodipine-valsartan-hctz</i> | 66 | ARIKAYCE | 32 | AUBAGIO | 120 |
| Amnesteem | 262 | <i>aripiprazole</i> | 96 | Aubra Eq | 149 |
| <i>amoxapine</i> | 86, 87 | ARISTADA | 96 | AUGTYRO | 54 |
| <i>amoxicill-clarithro-lansopraz</i> | 189 | ARISTADA INITIO | 96 | Aurovela 1.5/30 | 149 |
| <i>amoxicillin</i> | 47, 48 | <i>armodafinil</i> | 126 | Aurovela 1/20 | 149 |
| <i>amoxicillin-pot clavulanate</i> | 48 | ARMONAIR DIGIHALER | 258 | Aurovela 24 Fe | 149 |
| <i>amoxicillin-pot clavulanate er</i> | 48 | ARNUTITY ELLIPTA | 258 | Aurovela Fe 1.5/30 | 149 |
| <i>amphetamine sulfate</i> | 107 | ARTHROTEC | 21 | Aurovela Fe 1/20 | 149 |
| <i>amphetamine-dextroamphetamine er</i> | 107 | ASCENIV | 219 | AURYXIA | 176 |
| <i>amphetamine-dextroamphetamine</i> | 107 | ASCOR | 237 | AUSTEDO | 119, 120 |
| <i>amphet-dextroamphetamine 3-bead er</i> | 107 | <i>asenapine maleate</i> | 96 | AUSTEDO XR | 120 |
| <i>ampicillin</i> | 48 | Ashlynna | 149 | AUSTEDO XR PATIENT TITRATION | 120 |
| AMPYRA | 120 | ASMANEX (120 METERED DOSES) | 258 | AUVELITY | 87 |
| AMRIX | 125 | ASMANEX (30 METERED DOSES) | 258 | AUVI-Q | 246 |
| AMZEEQ | 262 | ASMANEX (60 METERED DOSES) | 258 | AVEED | 132 |
| | | | | Aviane | 149 |
| | | | | AVONEX PEN | 120 |
| | | | | AVONEX PREFILLED | 120 |

| | | | | | |
|---------------------------------------|----------|---------------------------------------|---------|---------------------------------------|---------------|
| AVSOLA | 205 | BENLYSTA | 222 | BREO ELLIPTA | 260 |
| Ayuna | 149 | <i>benzhydrocodone-acetaminophen</i> | 22 | BREXAFEMME | 32 |
| AYVAKIT | 54 | <i>benzonatate</i> | 252 | BREZTRI AEROSPHERE | 247 |
| <i>azathioprine</i> | 221 | <i>benzoyl peroxide-erythromycin</i> | 262 | <i>brielllyn</i> | 150 |
| <i>azelaic acid</i> | 275 | <i>benzphetamine hcl</i> | 144 | BRILINTA | 203 |
| <i>azelastine hcl</i> | 239, 249 | <i>benztropine mesylate</i> | 94 | <i>brimonidine tartrate</i> | 240, 275 |
| <i>azelastine-fluticasone</i> | 248 | <i>bepotastine besilate</i> | 239 | <i>brimonidine tartrate-timolol</i> | 240 |
| AZELEX | 262 | BEPREVE | 239 | <i>brinzolamide</i> | 240 |
| azesco | 233 | BERINERT | 218 | BRIVIACT | 100 |
| <i>azithromycin</i> | 43 | BESREMI | 51 | <i>bromfenac sodium</i> | 243 |
| AZOPT | 239 | <i>betaine</i> | 164 | <i>bromfenac sodium (once-daily)</i> | 243 |
| AZOR | 66 | <i>betamethasone dipropionate</i> | 269 | <i>bromocriptine mesylate</i> | 94 |
| AZSTARYS | 108 | <i>betamethasone dipropionate aug</i> | 269 | BROMSITE | 243 |
| Azurette | 149 | <i>betamethasone valerate</i> | 269 | BRONCHITOL | 254 |
| <i>bacitracin</i> | 242 | BETAPACE | 74 | BROVANA | 251 |
| <i>bacitracin-polymyxin b</i> | 242 | BETAPACE AF | 73 | BRUKINSA | 55 |
| <i>baclofen</i> | 124, 125 | BETASERON | 121 | BRYHALI | 269 |
| BAFIERTAM | 120 | <i>betaxolol hcl</i> | 74, 239 | <i>budesonide</i> | 182, 256, 258 |
| BALCOLTRA | 149 | <i>bethanechol chloride</i> | 192 | <i>budesonide er</i> | 181 |
| <i>balsalazide disodium</i> | 182 | BETHKIS | 254 | <i>budesonide-formoterol fumarate</i> | 260 |
| BALVERSA | 54, 55 | BETIMOL | 240 | <i>bumetanide</i> | 77 |
| Balziva | 149 | BETOPTIC-S | 240 | Bupap | 18 |
| BANZEL | 99 | BEVESPI AEROSPHERE | 247 | BUPHENYL | 165 |
| BAQSIMI ONE PACK | 171 | <i>bexagliflozin</i> | 143 | <i>buprenorphine</i> | 30 |
| BAQSIMI TWO PACK | 171 | <i>bexarotene</i> | 62, 274 | <i>buprenorphine hcl</i> | 127 |
| BARACLUDE | 44 | BEYAZ | 150 | <i>buprenorphine hcl-naloxone hcl</i> | 126 |
| BASAGLAR KWIKPEN | 136 | <i>bicalutamide</i> | 52 | <i>bupropion hcl</i> | 87 |
| BASAGLAR TEMPO PEN | 136 | BIJUVA | 166 | <i>bupropion hcl er (smoking det)</i> | 130 |
| BD GLUCOSE | 172 | BIKTARVY | 38 | <i>bupropion hcl er (sr)</i> | 87 |
| BD INSULIN SYRINGE U-500 | 225 | BILTRICIDE | 32 | <i>bupropion hcl er (xl)</i> | 87 |
| BD PEN NEEDLE MICRO U/F | 225 | <i>bimatoprost</i> | 240 | <i>buspirone hcl</i> | 84 |
| BD PEN NEEDLE MINI U/F | 225 | BIMZELX | 208 | <i>butalbital-acetaminophen</i> | 18 |
| BD PEN NEEDLE NANO 2ND GEN | 225 | BINOSTO | 146 | <i>butalbital-apap-caff-cod</i> | 25 |
| BD PEN NEEDLE NANO U/F | 225 | <i>bismuth/metronidaz/tetracyclin</i> | 189 | <i>butalbital-apap-caffeine</i> | 18 |
| BD PEN NEEDLE ORIGINAL U/F | 225 | <i>bisoprolol fumarate</i> | 74 | <i>butalbital-asa-caff-codeine</i> | 22 |
| BD PEN NEEDLE SHORT U/F | 226 | <i>bisoprolol-hydrochlorothiazide</i> | 73 | <i>butalbital-aspirin-caffeine</i> | 18 |
| BELBUCA | 29 | BIVIGAM | 219 | <i>butenafine hcl</i> | 265 |
| BELSOMRA | 113 | Blisovi 24 Fe | 150 | <i>butorphanol tartrate</i> | 25 |
| <i>benazepril hcl</i> | 64 | Blisovi Fe 1.5/30 | 150 | BUTRANS | 30 |
| <i>benazepril-hydrochlorothiazide</i> | 64 | Blisovi Fe 1/20 | 150 | BYDUREON BCISE | 135 |
| BENEFIX | 200 | <i>blood glucose test</i> | 226 | BYETTA 10 MCG PEN | 135 |
| BENICAR | 67 | <i>bosentan</i> | 81 | BYETTA 5 MCG PEN | 135 |
| BENICAR HCT | 66 | BOSULIF | 55 | BYLVAY | 184 |
| | | BOTOX | 112 | BYLVAY (PELLETS) | 184 |
| | | BRAFTOVI | 55 | BYOOVIZ | 245 |
| | | BRENZAVVY | 143 | BYSTOLIC | 74 |

| | | | | | |
|---------------------------------------|----------|---------------------------------------|-----|---------------------------------------|--------------|
| <i>cabergoline</i> | 174 | CAYA | 223 | <i>ciprofloxacin hcl</i> | 44, 242, 277 |
| CABLIVI | 195 | CAYSTON | 254 | <i>ciprofloxacin-dexamethasone</i> | 277 |
| CABOMETYX | 55 | <i>cefaclor</i> | 42 | <i>citalopram hydrobromide</i> | 87 |
| CABTREO | 262 | <i>cefadroxil</i> | 42 | CITRANATAL 90 DHA | 233 |
| <i>calcipotriene</i> | 267 | <i>cefdinir</i> | 42 | CITRANATAL ASSURE | 233 |
| <i>calcipotriene-betameth diprop.</i> | 267 | <i>cefixime</i> | 42 | CITRANATAL B-CALM | 233 |
| <i>calcitonin (salmon)</i> | 146 | <i>cefodoxime proxetil</i> | 42 | CITRANATAL HARMONY | |
| <i>calcitriol</i> | 145, 267 | <i>cefprozil</i> | 42 | | 233 |
| <i>calcium acetate (phos binder)</i> | 176 | <i>cefuroxime axetil</i> | 42 | CITRANATAL MEDLEY | 233 |
| CALQUENCE | 55 | CELEBREX | 17 | Claravis | 262 |
| CAMBIA | 19 | <i>celecoxib</i> | 17 | <i>clarithromycin</i> | 43 |
| Camila | 150 | <i>cephalexin</i> | 43 | <i>clarithromycin er</i> | 43 |
| Camrese | 150 | CEQUA | 244 | CLARITIN | 249 |
| Camrese Lo | 150 | CERDELGA | 169 | CLARITIN ALLERGY | |
| CAMZYOS | 79 | CEREZYME | 169 | CHILDRENS | 249 |
| CANASA | 182 | <i>cetirizine hcl</i> | 249 | CLARITIN REDITABS | 249 |
| <i>candesartan cilexetil</i> | 67 | <i>cetirizine hcl allergy child</i> | 249 | CLARITIN-D 12 HOUR | 252 |
| <i>candesartan cilexetil-hetz</i> | 66 | <i>cetirizine-pseudoephedrine er</i> | 252 | CLARITIN-D 24 HOUR | 253 |
| <i>capecitabine</i> | 50 | <i>cetrorelix acetate</i> | 168 | <i>clemastine fumarate</i> | 249 |
| CAPEX | 269 | CETROTIDE | 168 | CLENPIQ | 183 |
| CAPLYTA | 96 | <i>cevimeline hcl</i> | 276 | CLEOCIN-T | 262 |
| CAPRELSA | 55 | Charlotte 24 Fe | 150 | CLEVER CHEK AUTO- | |
| <i>captопril</i> | 64 | Chateal Eq | 150 | CODE TEST | 226 |
| <i>captопril-hydrochlorothiazide</i> | 64 | CHENODAL | 185 | CLEVER CHEK AUTO- | |
| CARAC | 264 | <i>chlordiazepoxide hcl</i> | 84 | CODE VOICE | 226 |
| CARAFATE | 185 | <i>chlordiazepoxide-amitriptyline</i> | 129 | CLEVER CHEK TEST | 226 |
| CARBAGLU | 164 | <i>chlordiazepoxide-clidinium</i> | 185 | CLEVER CHOICE AUTO- | |
| <i>carbamazepine</i> | 100 | <i>chlorhexidine gluconate</i> | 276 | CODE TEST | 226 |
| <i>carbamazepine er</i> | 100 | <i>chloroquine phosphate</i> | 34 | CLEVER CHOICE MICRO | |
| <i>carbidopa</i> | 94 | <i>chlorpromazine hcl</i> | 96 | TEST | 226 |
| <i>carbidopa-levodopa</i> | 94 | <i>chlorthalidone</i> | 77 | CLEVER CHOICE NO | |
| <i>carbidopa-levodopa er</i> | 94 | <i>chlorzoxazone</i> | 125 | CODING | 226 |
| <i>carbidopa-levodopa-entacapone</i> | 94 | CHOLBAM | 185 | CLEVER CHOICE TALK | |
| <i>carbinoxamine maleate</i> | 249 | <i>cholestyramine</i> | 69 | SYSTEM | 226 |
| CARDIZEM | 75 | <i>cholestyramine light</i> | 69 | CLIMARA | 166 |
| CARDIZEM CD | 75 | <i>chorionic gonadotropin</i> | 168 | CLIMARA PRO | 166 |
| CARDIZEM LA | 75 | CIALIS | 190 | Clindacin-P | 262 |
| CARESENS N GLUCOSE TEST | 226 | CIBINQO | 268 | CLINDAGEL | 262 |
| CARETOUCH TEST | 226 | <i>ciclopirox</i> | 265 | <i>clindamycin hcl</i> | 46 |
| <i>carglumic acid</i> | 164 | <i>ciclopirox olamine</i> | 265 | <i>clindamycin palmitate hcl</i> | 46 |
| <i>carisoprodol</i> | 124, 125 | <i>cidofovir</i> | 40 | <i>clindamycin phos-benzoyl</i> | |
| CARNITOR | 147 | <i>cilostazol</i> | 201 | <i>perox</i> | 262 |
| CARNITOR SF | 147 | CILOXAN | 242 | <i>clindamycin phosphate</i> | 194, 263 |
| CAROSPIR | 65 | CIMDUO | 38 | <i>clindamycin-tretinoin</i> | 263 |
| <i>carteolol hcl</i> | 240 | CIMERLI | 245 | <i>clobazam</i> | 100 |
| <i>carvedilol</i> | 74 | <i>cimetidine</i> | 181 | <i>clobetasol propionate</i> | 270 |
| <i>carvedilol phosphate er</i> | 74 | CIMZIA (2 SYRINGE) | 208 | <i>clobetasol propionate e</i> | 269 |
| CAVERJECT | 190 | CIMZIA STARTER KIT | 208 | <i>clobetasol propionate emulsion</i> | 269 |
| CAVERJECT IMPULSE | 190 | <i>cinacalcet hcl</i> | 145 | CLOBEX | 270 |
| | | CINRYZE | 218 | CLOBEX SPRAY | 270 |

| | | | | | |
|-----------------------------|----------|------------------------------|----------|--------------------------------|---------|
| clocortolone pivalate | 270 | CORDRAN | 270 | Cyred Eq | 150 |
| CLODERM | 270 | COREG CR | 74 | CYSTADANE | 164 |
| CLOMID | 168 | CORIFACT | 195 | CYSTADROPS | 202 |
| clomipramine hcl | 84 | CORLANOR | 78 | CYSTAGON | 174 |
| clonazepam | 100 | CORTIFOAM | 182 | CYSTARAN | 245 |
| clonidine | 79 | cortisone acetate | 170 | CYTOMEL | 177 |
| clonidine hcl | 79 | CORTROPHIN | 174 | dabigatran etexilate mesylate | 194 |
| clonidine hcl er | 79 | COSENTYX | 209, 210 | dalfampridine er | 121 |
| clopidogrel bisulfate | 203 | COSENTYX (300 MG | | DALIRESP | 255 |
| clorazepate dipotassium | 100 | DOSE) | 209 | danazol | 164 |
| clotrimazole | 276 | COSENTYX | | dantrolene sodium | 125 |
| clotrimazole-betamethasone | 265, 266 | SENSOREADY (300 MG) | 209 | dapagliflozin pro-metformin er | 142 |
| clozapine | 97 | COSENTYX | | dapagliflozin propanediol | 143 |
| COAGADEX | 201 | SENSOREADY PEN | 209 | dapsone | 46, 263 |
| codeine sulfate | 25 | COSENTYX UNOREADY | 210 | DARAPRIM | 46 |
| coditussin ac | 253 | COSOPT PF | 240 | darifenacin hydrobromide er | 192 |
| COLAZAL | 182 | COTELLIC | 56 | darunavir | 34 |
| colchicine | 17 | COTEMPLA XR-ODT | 108 | Dasetta 1/35 | 150 |
| colchicine-probenecid | 17 | COXANTO | 18 | Dasetta 7/7/7 | 150 |
| COLCRYS | 17 | COZAAR | 67 | DAURISMO | 51 |
| colesevelam hcl | 69 | CREON | 186 | DAYBUE | 118 |
| colestipol hcl | 69 | CRESEMBA | 32 | Daysee | 150 |
| colistimethate sodium (cba) | 46 | CRESTOR | 71 | DAYTRANA | 108 |
| COMBIGAN | 240 | CRINONE | 177 | DAYVIGO | 113 |
| COMBIPATCH | 166 | cromolyn sodium | 239, 255 | D-CARE BLOOD | |
| COMBIVENT RESPIMAT | 247 | CROTAN | 276 | GLUCOSE | 226 |
| COMBIVIR | 38 | Cryselle-28 | 150 | DDAVP | 178 |
| COMETRIQ (100 MG | | CUPRIMINE | 147 | Deblitane | 151 |
| DAILY DOSE) | 55 | CURAE | 150 | deferasirox | 147 |
| COMETRIQ (140 MG | | CUTAQUIG | 219 | deferasirox granules | 147 |
| DAILY DOSE) | 55 | CUVITRU | 219 | deferiprone | 147 |
| COMETRIQ (60 MG DAILY | | CUVPOSA | 179 | deferoxamine mesylate | 147 |
| DOSE) | 55 | CUVRIOR | 147 | deflazacort | 170 |
| COMPLERA | 38 | CVS ADVANCED | | DELSTRIGO | 38 |
| complete natal dha | 233 | GLUCOSE TEST | 226 | Delyla | 151 |
| completenate | 233 | cvs allergy relief childrens | 249 | DELZICOL | 182 |
| Compro | 180 | cvs nicotine | 128, 130 | demeclocycline hcl | 48 |
| CONCEPT OB | 234 | cvs nicotine polacrilex | 128, 130 | DEMSER | 79 |
| CONCERTA | 108 | cyanocobalamin | 204, 237 | DENAVIR | 274 |
| condoms | 150 | cyclobenzaprine hcl | 124, 125 | DEPAKOTE | 100 |
| CONJUPRI | 75 | cyclobenzaprine hcl er | 125 | DEPAKOTE ER | 100 |
| CONTOUR NEXT TEST | 226 | cyclophosphamide | 50 | DEPAKOTE SPRINKLES | 100 |
| CONTOUR TEST | 226 | cycloserine | 40 | DEPEN TITRATABS | 148 |
| CONTRAVE | 144 | CYCLOSET | 135 | DEPO-SUBQ PROVERA | |
| CONZIP | 25 | cyclosporine | 222, 244 | 104 | 151 |
| COOL BLOOD GLUCOSE | | cyclosporine modified | 222 | DERMA-SMOOTH/FS | |
| TEST STRIPS | 226 | CYLTEZO (2 PEN) | 210 | BODY | 270 |
| COPAXONE | 121 | CYLTEZO (2 SYRINGE) | 210 | DERMA-SMOOTH/FS | |
| COPIKTRA | 55 | CYMBALTA | 87 | SCALP | 270 |
| | | cyproheptadine hcl | 249 | DESCOVY | 38 |

| | | | | | |
|--------------------------------|-------------|--------------------------------|------------------|---------------------------------|----------|
| DESFERAL | 148 | diclofenac-misoprostol | 21 | doxycycline monohydrate | 49 |
| desipramine hcl | 87, 88 | dicloxacillin sodium | 48 | doxylamine-pyridoxine | 180 |
| desloratadine | 249 | dicyclomine hcl | 179 | dronabinol | 180 |
| desmopressin ace spray refrig. | 178 | diethylpropion hcl | 144 | drospirene-eth estrad-levomefol | 151 |
| desmopressin acetate | 178 | diethylpropion hcl er | 144 | drospirenone-ethinyl estradiol | 151 |
| desmopressin acetate spray | 178 | DIFFERIN | 263 | droxidopa | 79 |
| desogestrel-ethinyl estradiol | 151 | DIFICID | 43 | DUAKLIR PRESSAIR | 260 |
| desonide | 270 | diflorasone diacetate | 271 | DUAVEE | 166 |
| DESOWEN | 271 | dilfunisal | 30 | DUET DHA 400 | 234 |
| desoximetasone | 271 | dilfluprednate | 243 | DUEXIS | 21 |
| DESOXYN | 108 | digoxin | 77 | DULERA | 260 |
| desvenlafaxine er | 88 | dihydroergotamine mesylate | 115 | duloxetine hcl | 89 |
| desvenlafaxine succinate er | 88 | DILANTIN | 101 | DUOBRII | 271 |
| DETROL LA | 193 | DILANTIN INFATABS | 101 | DUO-CARE TEST | 227 |
| dexabliss | 170 | DILAUDID | 22, 25 | DUOPA | 95 |
| dexamethasone | 170 | diltiazem hcl | 76 | DUPIXENT | 268 |
| dexamethasone sodium | | diltiazem hcl er | 76 | DUROLANE | 30 |
| phosphate | 243 | diltiazem hcl er beads | 76 | dutasteride | 189 |
| DEXCOM G6 RECEIVER | 161 | diltiazem hcl er coated beads | 76 | dutasteride-tamsulosin hcl | 189 |
| DEXCOM G6 SENSOR | 162 | dilt-xr | 76 | DYANAVEL XR | 108, 109 |
| DEXCOM G6 | | dimethyl fumarate | 121 | DYMISTA | 248 |
| TRANSMITTER | 162 | dimethyl fumarate starter pack | 121 | DYRENIUM | 78 |
| DEXCOM G7 RECEIVER | 162 | DIOVAN | 68 | DYSPORT | 113 |
| DEXCOM G7 SENSOR | 162 | DIOVAN HCT | 66 | E.E.S. GRANULES | 43 |
| DEXEDRINE | 108 | DIPENTUM | 182 | easy plus ii glucose test | 227 |
| Dexifol | 237 | diphenoxylate-atropine | 179 | EASY STEP TEST | 227 |
| DEXILANT | 187 | DIPROLENE | 271 | easy talk blood glucose test | 227 |
| dexlansoprazole | 187 | dipyridamole | 203 | easy trak blood glucose test | 227 |
| dexamethylphenidate hcl | 108 | disopyramide phosphate | 68 | EASYGLUCO | 227 |
| dexamethylphenidate hcl er | 108 | disulfiram | 83 | EASYMAX 15 TEST | 227 |
| dextroamphetamine sulfate | 108 | divalproex sodium | 101 | EASYMAX TEST | 227 |
| dextroamphetamine sulfate er | 108 | divalproex sodium er | 101 | EASYPRO BLOOD | |
| DHIVY | 94 | docosanol | 274 | GLUCOSE TEST | 227 |
| DIACOMIT | 100 | dofetilide | 68 | EASYPRO PLUS | 227 |
| DIASTAT ACUDIAL | 100 | Dolishale | 151 | econazole nitrate | 266 |
| DIASTIX REAGENT | 162 | donepezil hcl | 85 | ECONTRA ONE-STEP | 151 |
| DIATHRIVE GLUCOSE | | DOPTELET | 203 | ECOZA | 266 |
| TEST | 226 | DORAL | 113 | EDARBI | 68 |
| diatruel plus test | 226 | DORYX | 48 | EDARBYCLOR | 66 |
| diazepam | 101 | DORYX MPC | 48 | EDEX | 191 |
| Diazepam Intensol | 101 | dorzolamide hcl | 240 | EDLUAR | 113 |
| diazoxide | 172 | dorzolamide hcl-timolol mal | 240 | EDURANT | 34 |
| DIBENZYLINE | 79 | dorzolamide hcl-timolol mal pf | 240 | efavirenz | 34, 35 |
| dichlorphenamide | 77 | DOVATO | 38 | efavirenz-emtricitab-tenofo df | 38 |
| diclofenac epolamine | 18 | doxazosin mesylate | 189 | efavirenz-lamivudine-tenofovir | 38 |
| diclofenac potassium | 18, 19 | doxepin hcl | 88, 89, 113, 267 | EFFEXOR XR | 89 |
| diclofenac | | doxercalciferol | 237 | EFFIENT | 203 |
| potassium(migraine) | 18 | doxycycline | 275 | ELAPRASE | 165 |
| diclofenac sodium | 18, 20, 243 | doxycycline hydiate | 48, 49 | EELYSO | 169 |
| diclofenac sodium er | 20 | | | element compact test | 227 |

| | | | | | |
|--------------------------------------|----------|------------------------------------|---------------|---------------------------------------|---------|
| ELEMENT TEST | 227 | ENTADFI | 189 | estradiol-norethindrone acet... | 167 |
| ELEPSIA XR | 101 | entecavir | 44 | ESTRING | 167 |
| ELESTRIN | 166 | ENTRESTO | 79 | ESTROGEL | 167 |
| <i>eletriptan hydrobromide</i> | 115 | ENTYVIO | 206, 211 | <i>eszopiclone</i> | 113 |
| ELIDEEL | 268 | enulose | 183 | <i>ethacrynic acid</i> | 78 |
| ELIGARD | 52 | EOHILIA | 185 | <i>ethambutol hcl</i> | 40 |
| Elinest | 151 | EPANED | 65 | <i>ethosuximide</i> | 101 |
| ELIQUIS | 194 | EPCLUSA | 44 | <i>ethynodiol diac-eth estradiol</i> | 151 |
| ELIQUIS DVT/PE STARTER PACK | 194 | EPIDIOLEX | 101 | <i>etodolac</i> | 20 |
| ELLA | 151 | EPIDUO | 263 | <i>etodolac er</i> | 20 |
| ELMIRON | 192 | EPIDUO FORTE | 263 | <i>etonogestrel-ethinyl estradiol</i> | 151 |
| ELOCTATE | 199 | <i>epinastine hcl</i> | 239 | <i>etoposide</i> | 63 |
| ELYXYB | 17 | <i>epinephrine</i> | 246 | <i>etravirine</i> | 35 |
| EMBRACE EVO BLOOD GLUCOSE TEST | 227 | EPINEPHRINESNAP-V | 246 | EUCRISA | 269 |
| EMBRACE PRO GLUCOSE TEST | 227 | EPIPEN 2-PAK | 246 | EUFLICXXA | 30 |
| EMBRACE TALK GLUCOSE TEST | 227 | EPIPEN JR 2-PAK | 246 | EULEXIN | 52 |
| EMBRACE WAVE BLOOD GLUCOSE | 162 | EPIVIR | 35 | EVEKEO | 109 |
| EMEND | 180 | <i>eplerenone</i> | 65 | EVEKEO ODT | 109 |
| EMEND TRI-PACK | 180 | EPOGEN | 196 | EVENITY | 174 |
| EMFLAZA | 170 | <i>epoprostenol sodium</i> | 81 | <i>everolimus</i> | 56, 222 |
| EMGALITY | 115 | EPRONTIA | 101 | EVERSENSE E3 | |
| EMGALITY (300 MG DOSE) | 115 | EPSOLAY | 275 | SENSOR/HOLDER | 162 |
| EMPAVELI | 202 | EPZICOM | 39 | EVERSENSE E3 SMART | |
| <i>emtricitabine</i> | 35 | <i>eq blood glucose test</i> | 227 | TRANSMITTER | 162 |
| <i>emtricitabine-tenofovir df</i> | 38, 39 | <i>eq loratadine childrens</i> | 249 | EVERSENSE | |
| EMTRIVA | 35 | <i>ergoloid mesylates</i> | 85 | SENSOR/HOLDER | 227 |
| EMVERM | 32 | ERIVEDGE | 51 | EVERSENSE SMART | |
| <i>enalapril maleate</i> | 64, 65 | ERLEADA | 52 | TRANSMITTER | 227 |
| <i>enalapril-hydrochlorothiazide</i> | 64 | <i>erlotinib hcl</i> | 56 | EVOLUTION AUTOCODE | 227 |
| ENBRACE HR | 234 | ERMEZA | 177 | EVOTAZ | 39 |
| ENBREL | 210, 211 | Errin | 151 | EVRYSDI | 118 |
| ENBREL MINI | 210 | ERTACZO | 266 | EXELDERM | 266 |
| ENBREL SURECLICK | 211 | ery | 263 | <i>exemestane</i> | 52 |
| ENCARE | 190 | ERYGEL | 263 | EXFORGE | 67 |
| ENDARI | 203 | ERYPED 200 | 43 | EXFORGE HCT | 67 |
| ENDOMETRIN | 177 | ERYPED 400 | 43 | EXJADE | 148 |
| ENLITE GLUCOSE SENSOR | 227 | Ery-Tab | 43 | EXKIVITY | 56 |
| <i>enoxaparin sodium</i> | 194 | ERYTHROCIN STEARATE | 43 | EXSERVAN | 118 |
| Enpresse-28 | 151 | <i>erythromycin</i> | 241, 242, 263 | EXTAVIA | 121 |
| Enskyce | 151 | <i>erythromycin base</i> | 43, 44 | EYLEA | 245 |
| ENSPRYNG | 222 | <i>erythromycin ethylsuccinate</i> | 44 | EYSUVIS | 243 |
| ENSTILAR | 267 | ESBRIET | 256 | EZALLOR SPRINKLE | 70 |
| <i>entacapone</i> | 95 | <i>escitalopram oxalate</i> | 89 | <i>ezetimibe</i> | 69 |
| | | ESGIC | 18 | <i>ezetimibe-rosuvastatin</i> | 72 |
| | | <i>esomeprazole magnesium</i> | 187 | <i>ezetimibe-simvastatin</i> | 72 |
| | | ESPEROCT | 199 | FA-8 | 237 |
| | | Estarrylla | 151 | FABHALTA | 202 |
| | | <i>estazolam</i> | 113 | FABIOR | 263 |
| | | <i>estradiol</i> | 166, 167 | FABRAZYME | 165 |
| | | <i>estradiol valerate</i> | 167 | Falmina | 151 |

| | | | | | |
|-----------------------------|--------|--------------------------------|---------------|------------------------|-----|
| famciclovir | 41 | FIRMAGON | 53 | FOLIVANE-OB | 234 |
| famotidine | 181 | FIRMAGON (240 MG | | FOLLISTIM AQ | 168 |
| FANAPT | 97 | DOSE) | 52 | fondaparinux sodium | 194 |
| FANAPT TITRATION | | FIRVANQ | 46 | FORA 6 CONNECT | 227 |
| PACK | 97 | FLAREX | 243 | FORA 6 CONNECT/GTEL | |
| FARXIGA | 143 | flavoxate hcl | 185 | TEST | 162 |
| FASENRA PEN | 257 | FLEBOGAMMA DIF | 219 | FORA D15G BLOOD | |
| FASLODEX | 52 | flecainide acetate | 68 | GLUCOSE TEST | 228 |
| FC2 FEMALE CONDOM | 152 | FLECTOR | 19 | FORA D20 BLOOD | |
| febuxostat | 17 | FLEQSUVY | 124 | GLUCOSE TEST | 228 |
| FEIBA | 195 | FLOLAN | 81 | FORA D40/G31 BLOOD | |
| felbamate | 101 | flolipid | 70 | GLUCOSE | 228 |
| felodipine er | 76 | FLONASE ALLERGY | | FORA G20 BLOOD | |
| FEMCAP | 223 | RELIEF | 256 | GLUCOSE TEST | 228 |
| FEMRING | 167 | FLORIVA | 238 | FORA GD20 TEST | 228 |
| fenofibrate | 69, 70 | fluconazole | 33 | FORA GD50 BLOOD | |
| fenofibrate micronized | 69, 70 | flucytosine | 33 | GLUCOSE TEST | 228 |
| fenofibric acid | 70 | fludrocortisone acetate | 170 | FORA GTEL BLOOD | |
| FENOGLIDE | 70 | flunisolide | 256 | GLUCOSE TEST | 228 |
| fenoprofen calcium | 20 | fluocinolone acetonide | 271, 277 | FORA TN'G ADVANCE | |
| fentanyl | 26 | fluocinolone acetonide body | 271 | PRO | 228 |
| fentanyl citrate | 25 | fluocinolone acetonide scalp | 271 | FORA TN'G/TN'G VOICE | 228 |
| FENTORA | 26 | fluocinonide | 271 | FORA V10 BLOOD | |
| FERRIPROX | 148 | fluocinonide emulsified base | 271 | GLUCOSE TEST | 228 |
| FERRIPROX TWICE-A- | | fluorometholone | 243 | FORA V12 BLOOD | |
| DAY | 148 | fluorouracil | 264, 265 | GLUCOSE TEST | 228 |
| FERRO-PLEX | 237 | fluoxetine hcl | 89 | FORA V20 BLOOD | |
| fesoterodine fumarate er | 193 | fluoxetine hcl (pmdd) | 89 | GLUCOSE TEST | 228 |
| FETZIMA | 89 | fluphenazine hcl | 97 | FORA V30A BLOOD | |
| FETZIMA TITRATION | 89 | flurandrenolide | 271 | GLUCOSE TEST | 228 |
| sexofenadine hcl | 249 | flurazepam hcl | 113 | FORACARE GD40 TEST | 228 |
| sexofenadine-pseudoephed er | 253 | flurbiprofen | 20 | FORACARE PREMIUM | |
| FIASP | 137 | flurbiprofen sodium | 243 | V10 TEST | 228 |
| FIASP FLEXTOUCH | 137 | fluticasone furoate-vilanterol | 260 | FORACARE TEST N GO | |
| FIASP PENFILL | 137 | fluticasone propionate | | TEST | 228 |
| FIASP PUMPCART | 137 | | 256, 271, 272 | formoterol fumarate | 251 |
| FIBRICOR | 70 | fluticasone propionate diskus | 258 | FORTEO | 146 |
| FIBRYGA | 195 | fluticasone propionate hfa | 259 | FORTESTA | 132 |
| FIFTY50 GLUCOSE TEST | | fluticasone-salmeterol | 260 | FORTISCARE TEST | 228 |
| 2.0 | 227 | fluvastatin sodium | 71 | FOSAMAX | 146 |
| FILSPARI | 192 | fluvastatin sodium er | 70 | FOSAMAX PLUS D | 146 |
| FINACEA | 275 | fluvoxamine maleate | 84 | fosamprenavir calcium | 35 |
| finasteride | 190 | fluvoxamine maleate er | 84 | fosinopril sodium | 65 |
| fingolimod hcl | 121 | FML FORTE | 243 | fosinopril sodium-hctz | 64 |
| FINTEPLA | 101 | FML LIQUIFILM | 243 | FOSRENOL | 176 |
| Finzala | 152 | FOCALIN | 109 | FOTIVDA | 56 |
| FIORICET | 18 | FOCALIN XR | 109 | FRAGMIN | 194 |
| FIORICET/CODEINE | 26 | folbee plus | 238 | FREESTYLE INSULINX | |
| FIRAZYR | 218 | FOLGARD OS | 238 | TEST | 229 |
| FIRDAPSE | 118 | folic acid | 238 | | |

| | | | | | |
|-------------------------------------|----------|------------------------------------|----------|------------------------------------|-----|
| FREESTYLE LIBRE | 14 | Gemmily | 152 | GOJJI BLOOD TEST | |
| DAY SENSOR | 162 | GEMTESA | 193 | STRIP/LANCETS | 230 |
| FREESTYLE LIBRE 2 | | Gengraf | 222 | GOLYTELY | 183 |
| SENSOR | 162 | GENOTROPIN | 173 | GONAL-F | 169 |
| FREESTYLE LIBRE 3 | | GENOTROPIN | | GONAL-F RFF | 169 |
| READER | 162 | MINIQUICK | 173 | GONAL-F RFF REDIRECT | 169 |
| FREESTYLE LIBRE 3 | | <i>gentamicin sulfate</i> | 242, 265 | goodsense blood glucose | 230 |
| SENSOR | 162 | GENULTIMATE TEST | 229 | GRALISE | 128 |
| FREESTYLE LIBRE | | GENVISC 850 | 31 | granisetron hcl | 180 |
| READER | 229 | GENVOYA | 39 | GRANIX | 197 |
| FREESTYLE LITE TEST | 229 | GEODON | 97 | GRASTEK | 204 |
| FREESTYLE PRECISION | | <i>ght test</i> | 229 | <i>griseofulvin microsize</i> | 33 |
| NEO TEST | 229 | GILENYA | 121 | <i>griseofulvin ultramicrosize</i> | 33 |
| FREESTYLE TEST | 229 | GILOTrif | 56 | <i>guanfacine hcl</i> | 79 |
| FROVA | 115 | GIMOTI | 180 | <i>guanfacine hcl er</i> | 109 |
| <i>frovatriptan succinate</i> | 116 | GLASSIA | 246 | GUARDIAN 4 GLUCOSE | |
| FRUZAQLA | 56 | <i>glatiramer acetate</i> | 121 | SENSOR | 162 |
| FULPHILA | 196 | Glatopa | 121 | GUARDIAN 4 | |
| <i>fulvestrant</i> | 53 | GLEEVEC | 56 | TRANSMITTER | 162 |
| <i>furosemide</i> | 78 | GLEOSTINE | 50 | GUARDIAN LINK 3 | |
| FUZEON | 35 | <i>glimepiride</i> | 143 | TRANSMITTER | 162 |
| Fyavolv | 167 | <i>glipizide</i> | 143 | GUARDIAN REAL-TIME | |
| FYCOMPA | 101 | <i>glipizide er</i> | 143 | REPLACE PED | 230 |
| FYLNETRA | 196 | <i>glipizide-metformin hcl</i> | 134 | GUARDIAN SENSOR (3) | 230 |
| Fyremadel | 168 | GLOPERBA | 17 | <i>guardian sensor 3</i> | 230 |
| <i> gabapentin</i> | 102 | GLUCAGEN HYPOKIT | 172 | GVOKE HYPOPEN 1- | |
| <i> gabapentin (once-daily)</i> | 127, 128 | <i>glucagon emergency</i> | 172 | PACK | 172 |
| GALAFOLD | 164 | GLUCO PERFECT 3 TEST | 229 | GVOKE KIT | 172 |
| <i> galantamine hydrobromide</i> | 85 | GLUCOCARD 01 SENSOR | | GVOKE PFS | 172 |
| <i> galantamine hydrobromide er</i> | 85 | PLUS | 229 | HADLIMA | 211 |
| GAMMAGARD | 219 | GLUCOCARD | | HADLIMA PUSHTOUCH | 211 |
| GAMMAGARD S/D LESS | | EXPRESSION TEST | 229 | HAEGARDA | 218 |
| IGA | 219 | GLUCOCARD SHINE | | Hailey 1.5/30 | 152 |
| GAMMAKED | 219 | TEST | 229 | Hailey 24 Fe | 152 |
| GAMMAPLEX | 220 | GLUCOCARD VITAL | | Hailey Fe 1.5/30 | 152 |
| GAMUNEX-C | 220 | TEST | 229 | Hailey Fe 1/20 | 152 |
| <i> ganciclovir</i> | 41 | GLUCOCARD X-SENSOR | 229 | <i>halcinonide</i> | 272 |
| <i> ganciclovir sodium</i> | 41 | GLUCOCOM TEST | 229 | HALCION | 114 |
| <i> ganirelix acetate</i> | 169 | GLUCONAVII BLOOD | | <i>halobetasol propionate</i> | 272 |
| <i> gatifloxacin</i> | 242 | GLUCOSE TEST | 229 | HALOG | 272 |
| GATTEX | 185 | <i>glucose</i> | 172 | <i>haloperidol</i> | 97 |
| GAVILYTE-C | 183 | <i>glucose control</i> | 229 | <i>haloperidol lactate</i> | 97 |
| Gavilyte-G | 183 | <i>glucose meter test</i> | 229 | HARVONI | 45 |
| GAVRETO | 56 | GLUMETZA | 133 | Heather | 152 |
| <i> ge100 blood glucose test</i> | 229 | GLYCATE | 179 | HELIDAC THERAPY | 189 |
| <i> gefitinib</i> | 56 | <i>glycopyrrolate</i> | 179 | HEMADY | 170 |
| GELNIQUE | 193 | GLYXAMBI | 143 | HEMLIBRA | 199 |
| GEL-ONE | 30 | <i>gnp easy touch glucose test</i> | 229 | HEMOFIL M | 199 |
| GELSYN-3 | 30 | <i>gnp glucose gummies</i> | 172 | <i>heparin sodium (porcine)</i> | 194 |
| <i> gemfibrozil</i> | 70 | GOCOVRI | 95 | <i>heparin sodium (porcine) pf</i> | 195 |

| | | | | | |
|--------------------------|-----|--|------------|---|-----|
| HER STYLE | 152 | HYCAMTIN | 64 | IGLUCOSE TEST STRIPS .. | 230 |
| HETLIOZ | 114 | HYCODAN | 253 | ILARIS | 217 |
| HETLIOZ LQ | 114 | <i>hydralazine hcl</i> | 79 | ILEVRO | 243 |
| Hidex 6-Day | 170 | <i>hydrochlorothiazide</i> | 78 | ILUMYA | 206 |
| HIZENTRA | 220 | <i>hydrocod poli-chlorphe poli er.</i> | 253 | <i>imatinib mesylate</i> | 57 |
| HORIZANT | 128 | <i>hydrocodone bitartrate er</i> | 22, 26 | IMBRUVICA | 57 |
| HULIO (2 PEN) | 211 | <i>hydrocodone bit-homatrop mbr</i> | 253 | IMCIVREE | 174 |
| HULIO (2 SYRINGE) | 211 | <i>hydrocodone-acetaminophen</i> | 22, 26 | <i>imipramine hcl</i> | 90 |
| HUMALOG | 137 | <i>hydrocodone-ibuprofen</i> | 22, 26 | <i>imipramine pamoate</i> | 90 |
| HUMALOG JUNIOR | | <i>hydrocortisone</i> | 170, 272 | <i>imiquimod</i> | 265 |
| KWIKPEN | 137 | <i>hydrocortisone (perianal)</i> | 189 | <i>imiquimod pump</i> | 265 |
| HUMALOG KWIKPEN | 137 | <i>hydrocortisone butyr lipo base</i> | 272 | IMITREX | 116 |
| HUMALOG MIX 50/50 | 137 | <i>hydrocortisone butyrate</i> | 272 | IMITREX STATDOSE | |
| HUMALOG MIX 50/50 | | <i>hydrocortisone valerate</i> | 272 | REFILL | 116 |
| KWIKPEN | 137 | <i>hydrocortisone-acetic acid</i> | 277 | IMITREX STATDOSE | |
| HUMALOG MIX 75/25 | 137 | <i>hydromorphone hcl</i> | 22, 23, 26 | SYSTEM | 116 |
| HUMALOG MIX 75/25 | | <i>hydromorphone hcl er</i> | 26 | IMO GAM RABIES-HT | 220 |
| KWIKPEN | 137 | <i>hydroxychloroquine sulfate</i> | 34, 217 | IMPOYZ | 272 |
| HUMALOG TEMPO PEN | 137 | <i>hydroxyurea</i> | 62 | IMURAN | 222 |
| HUMATE-P | 195 | <i>hydroxyzine hcl</i> | 250 | IMVEXXY | |
| HUMATIN | 32 | <i>hydroxyzine pamoate</i> | 250 | MAINTENANCE PACK | 167 |
| HUMATROPE | 173 | HYFTOR | 274 | IMVEXXY STARTER | |
| HUMIRA (2 PEN) | 211 | HYMOVIS | 31 | PACK | 167 |
| HUMIRA (2 SYRINGE) | 211 | HYPERRHO S/D | 220 | IN TOUCH BLOOD | |
| HUMIRA-CD/UC/HS | | HYPERTET | 220 | GLUCOSE TEST | 230 |
| STARTER | 211 | HYQVIA | 220 | INATAL GT | 234 |
| HUMIRA-PED<40KG | | HYRIMOZ | 212 | INBRIJA | 95 |
| CROHNS STARTER | 211 | HYRIMOZ-PED<40KG | | Incassia | 152 |
| HUMIRA-PED>/=40KG | | CROHN STARTER | 212 | INCRELEX | 174 |
| CROHNS START | 212 | HYRIMOZ-PED>/=40KG | | INCRUSE ELLIPTA | 248 |
| HUMIRA-PS/UV/ADOL HS | | CROHN START | 212 | <i>indapamide</i> | 78 |
| STARTER | 212 | HYRIMOZ-PLAQUE | | INDERAL LA | 74 |
| HUMIRA- | | PSORIASIS START | 212 | INDERAL XL | 74 |
| PSORIASIS/UVEIT | | HYSINGLA ER | 26 | INDOCIN | 20 |
| STARTER | 212 | HYZAAR | 66 | <i>indomethacin</i> | 19 |
| HUMULIN 70/30 | 138 | <i>ibandronate sodium</i> | 146 | INFINITY BLOOD | |
| HUMULIN 70/30 | | IBRANCE | 56 | GLUCOSE TEST | 230 |
| KWIKPEN | 138 | IBSRELA | 183 | INFINITY VOICE | 230 |
| HUMULIN N | 138 | <i>ibuprofen</i> | 20 | INFLECTRA | 206 |
| HUMULIN N KWIKPEN | 138 | <i>ibuprofen-famotidine</i> | 21 | <i>infliximab</i> | 206 |
| HUMULIN R | 138 | <i>icatibant acetate</i> | 218 | INGREZZA | 120 |
| HUMULIN R U-500 | | Iclevia | 152 | INLYTA | 57 |
| (CONCENTRATED) | 138 | ICLUSIG | 56 | INNOPRAN XL | 74 |
| HUMULIN R U-500 | | <i>icosapent ethyl</i> | 72 | INPEFA | 79 |
| KWIKPEN | 138 | IDACIO (2 PEN) | 212 | INQOVI | 50 |
| HW EMBRACE PRO | | IDACIO (2 SYRINGE) | 212 | INREBIC | 57 |
| GLUCOSE TEST | 230 | IDELEVION | 201 | <i>insulin asp prot & asp flexpen</i> | 138 |
| HW EMBRACE TALK | | IDHIFA | 62 | <i>insulin aspart</i> | 138 |
| GLUCOSE TEST | 230 | | | <i>insulin aspart flexpen</i> | 138 |
| HYALGAN | 31 | | | <i>insulin aspart penfill</i> | 138 |

| | | | | | |
|---|---------|-----------------------------------|-----|----------------------------------|--------------|
| <i>insulin aspart prot & aspart</i> | 138 | JANUMET XR | 134 | <i>ketoconazole</i> | 33, 266, 268 |
| <i>insulin degludec</i> | 138 | JANUVIA | 135 | <i>ketoprofen</i> | 19 |
| <i>insulin degludec flextouch</i> | 138 | JARDIANCE | 143 | <i>ketoprofen er</i> | 20 |
| <i>insulin glargin max solostar</i> | 138 | Jasmiel | 152 | <i>ketorolac tromethamine</i> | 20, 243 |
| <i>insulin glargin solostar</i> | 139 | JATENZO | 132 | <i>ketotifen fumarate</i> | 239 |
| <i>insulin glargin-yfgn</i> | 139 | JAYPIRCA | 57 | KEVEYIS | 78 |
| <i>insulin lispro</i> | 139 | Jencycla | 152 | KEVZARA | 213 |
| <i>insulin lispro (1 unit dial)</i> | 139 | <i>jenliva prenatal/postnatal</i> | 234 | KINERET | 213 |
| <i>insulin lispro junior kwikpen</i> | 139 | JENTADUETO | 134 | KISQALI (200 MG DOSE) | 57 |
| <i>insulin lispro prot & lispro</i> | 139 | JENTADUETO XR | 134 | KISQALI (400 MG DOSE) | 57 |
| INTELENCE | 35 | JESDUVROQ | 197 | KISQALI (600 MG DOSE) | 57 |
| INTRAROSA | 174 | Jinteli | 167 | KISQALI FEMARA (200 | |
| Introvale | 152 | JIVI | 199 | MG DOSE) | 57 |
| INTUNIV | 109 | JOENJA | 221 | KISQALI FEMARA (400 | |
| INVEGA | 97 | Jolessa | 152 | MG DOSE) | 57 |
| INVEGA HAFYERA | 97 | JORNAY PM | 109 | KISQALI FEMARA (600 | |
| INVEGA TRINZA | 97 | Joyeaux | 152 | MG DOSE) | 57 |
| INVELTYS | 243 | JUBLIA | 266 | KITABIS PAK | 254 |
| INVOKAMET | 142 | Juleber | 153 | KLARITY-A | 242 |
| INVOKAMET XR | 142 | JULUCA | 39 | KLARON | 264 |
| INVOKANA | 143 | Junel 1.5/30 | 153 | KLISYRI | 265 |
| <i>ipratropium bromide</i> | 248 | Junel 1/20 | 153 | KLONOPIN | 102 |
| <i>ipratropium-albuterol</i> | 247 | Junel Fe 1.5/30 | 153 | Klor-Con | 232, 233 |
| <i>irbesartan</i> | 68 | Junel Fe 1/20 | 153 | Klor-Con 10 | 232 |
| <i>irbesartan-hydrochlorothiazide</i> | 67 | Junel Fe 24 | 153 | Klor-Con M10 | 232 |
| IRESSA | 57 | JUXTAPID | 72 | Klor-Con M15 | 232 |
| ISENTRESS | 35 | JYlamvo | 50 | Klor-Con M20 | 232 |
| ISENTRESS HD | 35 | JYNARQUE | 175 | KLOXXADO | 127 |
| Isibloom | 152 | Kaitlib Fe | 153 | KOATE | 199 |
| <i>isoniazid</i> | 40 | KALBITOR | 218 | KOATE-DVI | 199 |
| ISORDIL TITRADOSE | 80 | KALETRA | 39 | KOGENATE FS | 199 |
| <i>isosorb dinitrate-hydralazine</i> | 79 | Kalliga | 153 | KOMBIGLYZE XR | 134 |
| <i>isosorbide dinitrate</i> | 80 | KALYDECO | 254 | KONVOMEП | 187 |
| <i>isosorbide mononitrate</i> | 80 | KANUMA | 165 | KORLYM | 142 |
| <i>isosorbide mononitrate er</i> | 80 | KAPSPARGO SPRINKLE | 74 | KOSELUGO | 58 |
| <i>isotretinoin</i> | 263 | KAPVAY | 109 | <i>kosher prenatal plus iron</i> | 234 |
| <i>isradipine</i> | 76 | KARBINAL ER | 250 | KOVALTRY | 199 |
| ISTALOL | 240 | Kariva | 153 | <i>kp fexofenadine hcl</i> | 250 |
| ISTURISA | 175 | KATERZIA | 76 | KRAZATI | 62 |
| <i>itraconazole</i> | 33 | KAZANO | 134 | KRINTAFEL | 34 |
| <i>ivermectin</i> | 32, 275 | KCENTRA | 196 | KRISTALOSE | 183 |
| IWILFIN | 62 | <i>kedrab</i> | 220 | KROGER HEALTHPRO | |
| IXINITY | 201 | Kelnor 1/35 | 153 | GLUCOSE TEST | 230 |
| IYUZEH | 240 | Kelnor 1/50 | 153 | KRYSTEXXA | 17 |
| JADENU | 148 | KENALOG | 272 | Kurvelo | 153 |
| JADENU SPRINKLE | 148 | KEPPRA | 102 | KUVAN | 165 |
| Jaimiess | 152 | KEPPRA XR | 102 | KYLEENA | 153 |
| JAKAFI | 57 | KERENDIA | 174 | KYZATREX | 132 |
| JALYN | 190 | KERYDIN | 33 | <i>labetalol hcl</i> | 74 |
| JANUMET | 134 | KESIMPTA | 121 | <i>lacosamide</i> | 102 |

| | | | | | |
|---|------------|---|---------|--|----------|
| LACRISERT | 202 | leucovorin calcium | 63 | lisinopril | 65 |
| <i>lactulose</i> | 183, 184 | LEUKERAN | 50 | <i>lisinopril-hydrochlorothiazide</i> .. | 64 |
| LAMICTAL | 102 | LEUKINE | 197 | LITFULO | 213 |
| LAMICTAL ODT | 102 | <i>leuprolide acetate</i> | 53 | <i>lithium</i> | 119 |
| LAMICTAL STARTER | 102 | <i>levalbuterol hcl</i> | 251 | <i>lithium carbonate</i> | 119 |
| LAMICTAL XR | 102 | <i>levalbuterol tartrate</i> | 251 | <i>lithium carbonate er</i> | 119 |
| <i>lamivudine</i> | 35, 36, 44 | <i>levamlodipine maleate</i> | 76 | LITHOSTAT | 192 |
| <i>lamivudine-zidovudine</i> | 39 | LEVEMIR | 139 | LIVALO | 71 |
| <i>lamotrigine</i> | 103 | LEVEMIR FLEXPEN | 139 | LIVMARLI | 185 |
| <i>lamotrigine er</i> | 103 | <i>levetiracetam</i> | 103 | LIVTENCITY | 41 |
| <i>lamotrigine starter kit-blue</i> | 103 | <i>levetiracetam er</i> | 103 | LO LOESTRIN FE | 154 |
| <i>lamotrigine starter kit-green</i> | 103 | <i>levobunolol hcl</i> | 240 | LOCOID | 272 |
| <i>lamotrigine starter kit-orange</i> | 103 | <i>levocarnitine</i> | 147 | LOCOID LIPOCREAM | 272 |
| LANOXIN | 77 | <i>levocetirizine dihydrochloride</i> .. | 250 | LODINE | 20 |
| <i>lanreotide acetate</i> | 131 | <i>levofloxacin</i> | 44, 242 | LODOCOCO | 79 |
| <i>lansoprazole</i> | 187 | Levonest | 154 | Loestrin 1.5/30 (21) | 154 |
| LANTUS | 139 | <i>levonorgest-eth est & eth est</i> .. | 154 | Loestrin 1/20 (21) | 155 |
| LANTUS SOLOSTAR | 139 | <i>levonorgest-eth estrad 91-day</i> .. | 154 | Loestrin Fe 1.5/30 | 155 |
| <i>lapatinib ditosylate</i> | 58 | <i>levonorgestrel</i> | 154 | Loestrin Fe 1/20 | 155 |
| Larin 1.5/30 | 153 | <i>levonorgestrel-ethinyl estrad</i> .. | 154 | Lofena | 19 |
| Larin 1/20 | 153 | <i>levonorg-eth estrad triphasic</i> .. | 154 | Lojaimiess | 155 |
| Larin 24 Fe | 154 | Levora 0.15/30 (28) | 154 | LOKELMA | 176 |
| Larin Fe 1.5/30 | 154 | <i>levorphanol tartrate</i> | 23 | LOMAIRA | 144 |
| Larin Fe 1/20 | 154 | <i>levothyroxine sodium</i> | 177 | LONSURF | 50 |
| <i>latanoprost</i> | 240 | LEVULAN KERASTICK | 274 | <i>lopinavir-ritonavir</i> | 39 |
| LATUDA | 97 | LEXAPRO | 90 | <i>loratadine</i> | 250 |
| Layolis Fe | 154 | LEXETTE | 272 | <i>loratadine-d 24hr</i> | 253 |
| <i>ledipasvir-sofosbuvir</i> | 45 | LEXIVA | 36 | <i>lorazepam</i> | 84 |
| Leena | 154 | LIALDA | 182 | Lorazepam Intensol | 84 |
| <i>leflunomide</i> | 218 | LIBERTY GLUCOSE | | LORBRENA | 58 |
| LENVIMA (10 MG DAILY DOSE) | 58 | CONTROL | 163 | LOREEV XR | 85 |
| LENVIMA (12 MG DAILY DOSE) | 58 | LIBERTY NEXT | | Loryna | 155 |
| LENVIMA (14 MG DAILY DOSE) | 58 | GENERATION TEST | 230 | <i>losartan potassium</i> | 67 |
| LENVIMA (18 MG DAILY DOSE) | 58 | <i>liberty test</i> | 230 | <i>losartan potassium-hctz</i> | 67 |
| LENVIMA (20 MG DAILY DOSE) | 58 | LIBERVANT | 103 | LOTEMAX | 243, 244 |
| LENVIMA (24 MG DAILY DOSE) | 58 | LIBRAX | 179 | LOTEMAX SM | 244 |
| LENVIMA (4 MG DAILY DOSE) | 58 | LICART | 19 | <i>loteprednol etabonate</i> | 244 |
| LENVIMA (8 MG DAILY DOSE) | 58 | <i>lidocaine</i> | 274 | LOTRONEX | 183 |
| LESCOL XL | 71 | <i>lidocaine hcl</i> | 274 | <i>lovastatin</i> | 71 |
| Lessina | 154 | <i>lidocaine viscous hcl</i> | 276 | LOVAZA | 72 |
| LETAIRIS | 81 | <i>lidocaine-prilocaine</i> | 274 | Low-Ogestrel | 155 |
| <i>letrozole</i> | 53 | LIDODERM | 274 | <i>loxapine succinate</i> | 97 |
| | | LIKMEZ | 46 | Lo-Zumandimine | 155 |
| | | LILETTA (52 MG) | 154 | <i>lubiprostone</i> | 183 |
| | | <i>linezolid</i> | 46 | LUCEMYRA | 129 |
| | | LINZESS | 183 | LUCENTIS | 245 |
| | | <i>liothyronine sodium</i> | 177 | <i>luliconazole</i> | 266 |
| | | LIPITOR | 71 | LUMAKRAS | 62 |
| | | LIQREV | 81 | LUMIGAN | 240 |
| | | <i>lisdexamphetamine dimesylate</i> .. | 109 | LUMIZYME | 165 |

| | | | | | |
|---------------------------------|-----|-----------------------------------|------------|------------------------------------|--------------|
| LUMRYZ..... | 126 | MAVYRET..... | 45 | methitest..... | 132 |
| LUNESTA..... | 114 | MAXALT..... | 116 | methocarbamol..... | 125 |
| LUPKYNIS..... | 222 | MAXALT-MLT..... | 116 | methotrexate sodium..... | 51, 218 |
| LUPRON DEPOT (1-MONTH)..... | 53 | MAXIDEX..... | 244 | methotrexate sodium (pf)..... | 51 |
| LUPRON DEPOT (3-MONTH)..... | 53 | MAYZENT..... | 122 | methoxsalen rapid..... | 267 |
| LUPRON DEPOT (4-MONTH)..... | 53 | MAYZENT STARTER | | methscopolamine bromide..... | 179 |
| LUPRON DEPOT (6-MONTH)..... | 53 | PACK..... | 122 | methyldopa..... | 79 |
| LUPRON DEPOT-PED (1-MONTH)..... | 147 | meclofenamate sodium..... | 20 | methylergonovine maleate..... | 175 |
| LUPRON DEPOT-PED (3-MONTH)..... | 147 | medroxyprogesterone acetate..... | 155, 177 | METHYLIN..... | 110 |
| lurasidone hcl..... | 98 | mefenamic acid..... | 20 | methylphenidate..... | 111 |
| Lutera..... | 155 | mefloquine hcl..... | 34 | methylphenidate hcl..... | 111 |
| LUZU..... | 266 | megestrol acetate..... | 53, 177 | methylphenidate hcl er.... | 110, 111 |
| LYBALVI..... | 98 | meijer essential glucose test.... | 230 | methylphenidate hcl er (cd).... | 110 |
| Lyleq..... | 155 | MEIJER TRUETEST TEST | 230 | methylphenidate hcl er (la).... | 110 |
| LYNPARZA..... | 62 | MEIJER TRUETRACK | | methylphenidate hcl er (osm).... | 110 |
| LYRICA..... | 103 | TEST..... | 230 | methylphenidate hcl er (xr).... | 110 |
| LYRICA CR..... | 128 | MEKINIST..... | 58, 59 | methylprednisolone..... | 171 |
| LYSODREN..... | 53 | MEKTOVI..... | 59 | methyltestosterone..... | 132 |
| LYTGOBI (12 MG DAILY DOSE)..... | 58 | meloxicam..... | 19, 20 | metoclopramide hcl..... | 180 |
| LYTGOBI (16 MG DAILY DOSE)..... | 58 | melphalan..... | 50 | metolazone..... | 78 |
| LYTGOBI (20 MG DAILY DOSE)..... | 58 | memantine hcl..... | 85 | metoprolol succinate er..... | 74 |
| LYUMJEV..... | 139 | memantine hcl er..... | 85 | metoprolol tartrate..... | 74 |
| LYUMJEV KWIKPEN..... | 139 | MENEST..... | 167 | metoprolol-hydrochlorothiazide | 73 |
| LYUMJEV TEMPO PEN.... | 139 | MENOPUR..... | 169 | METROCREAM..... | 275 |
| LYVISPAH..... | 124 | MENOSTAR..... | 167 | METROGEL..... | 275 |
| Lyza..... | 155 | meperidine hcl..... | 26 | METROLOTION..... | 275 |
| MACRODANTIN..... | 46 | MEPRON..... | 46 | metronidazole..... | 46, 194, 275 |
| mafенide acetate..... | 265 | mercaptopurine..... | 50 | metyrosine..... | 80 |
| malathion..... | 276 | Merzee..... | 155 | Mibelas 24 Fe..... | 155 |
| maraviroc..... | 36 | mesalamine..... | 182 | MICARDIS..... | 68 |
| MARINOL..... | 180 | mesalamine er..... | 182 | MICARDIS HCT..... | 67 |
| marlissa..... | 155 | MESTINON..... | 119 | miconazole 3..... | 194 |
| MATULANE..... | 50 | METADATE CD..... | 110 | miconazole-zinc oxide-petrolat | 266 |
| Matzim La..... | 76 | metaxalone..... | 124, 125 | MICRHOGAM ULTRA-FILTERED PLUS..... | 220 |
| MAVENCLAD (10 TABS).... | 122 | metformin hcl..... | 133 | MICRODOT TEST..... | 230 |
| MAVENCLAD (4 TABS).... | 122 | metformin hcl er..... | 133 | Microgestin 1.5/30..... | 155 |
| MAVENCLAD (5 TABS).... | 122 | metformin hcl er (mod).... | 133 | Microgestin 1/20..... | 155 |
| MAVENCLAD (6 TABS).... | 122 | metformin hcl er (osm).... | 133 | Microgestin 24 Fe..... | 156 |
| MAVENCLAD (7 TABS).... | 122 | methadone hcl..... | 23, 26, 27 | Microgestin Fe 1.5/30..... | 156 |
| MAVENCLAD (8 TABS).... | 122 | Methadone Hcl Intensol..... | 23 | Microgestin Fe 1/20..... | 156 |
| MAVENCLAD (9 TABS).... | 122 | METHADOSE..... | 27 | midazolam hcl..... | 114 |
| | | METHADOSE SUGAR-FREE..... | 27 | midodrine hcl..... | 80 |
| | | methamphetamine hcl..... | 110 | MIEBO..... | 244 |
| | | methazolamide..... | 78 | mifepristone..... | 142, 175 |
| | | methenamine hippurate..... | 46 | MIGERGOT..... | 116 |
| | | methenamine mandelate..... | 46 | miglitol..... | 133 |
| | | Methergine..... | 175 | miglustat..... | 169 |
| | | methimazole..... | 178 | MIGRANAL..... | 116 |
| | | | | Mili..... | 156 |

| | | | | | |
|--|----------|---|--------|--|----------|
| Mimvey..... | 167 | MYXREDLIN | 139 | NEULASTA | 197 |
| MINASTRIN 24 FE..... | 156 | <i>na ferric gluc cplx in sucrose</i> ... | 238 | NEULASTA ONPRO | 197 |
| MINIVELLE..... | 168 | <i>na sulfate-k sulfate-mg sulf</i> | 184 | NEUPOGEN | 197 |
| <i>minocycline hcl</i> | 49 | <i>nabumetone</i> | 19, 20 | NEUPRO | 95 |
| <i>minocycline hcl er</i> | 49 | <i>nadolol</i> | 74 | NEURONTIN | 103 |
| MINOLIRA..... | 49 | <i>naftifine hcl</i> | 266 | NEUTEK 2TEK TEST | 231 |
| <i>minoxidil</i> | 80 | NAFTIN | 266 | NEVANAC | 244 |
| MIRCERA..... | 197 | NAGLAZYME | 165 | <i>nevirapine</i> | 36 |
| MIRENA (52 MG)..... | 156 | <i>nalocet</i> | 27 | <i>nevirapine er</i> | 36 |
| <i>mirtazapine</i> | 90 | <i>naloxone hcl</i> | 127 | NEW DAY | 156 |
| MIRVASO..... | 275 | <i>naltrexone hcl</i> | 127 | NEXAVAR | 59 |
| <i>misoprostol</i> | 185 | NAMENDA XR | 85 | NEXICLON XR | 80 |
| MITIGARE..... | 17 | NAMZARIC | 86 | NEXIUM | 187 |
| <i>modafinil</i> | 126 | NAPRELAN | 20 | NEXIUM 24HR | 187 |
| <i>moexipril hcl</i> | 65 | NAPROSYN | 20 | NEXLETOL | 69 |
| <i>mometasone furoate</i> | 272, 273 | <i>naproxen</i> | 19, 21 | NEXLIZET | 69 |
| Mono-Linyah..... | 156 | <i>naproxen sodium</i> | 19, 21 | NEXPLANON | 156 |
| MONOVISC..... | 31 | <i>naproxen sodium er</i> | 21 | NEXTSTELLIS | 156 |
| <i>montelukast sodium</i> | 255 | <i>naproxen-esomeprazole mg</i> | 21 | NGENLA | 173 |
| <i>morphine sulfate</i> | 27 | <i>naratriptan hcl</i> | 116 | <i>niacin er (antihyperlipidemic)</i> .. | 72 |
| <i>morphine sulfate (concentrate)</i> .. | 23 | NARCAN | 127 | NIACOR | 72 |
| <i>morphine sulfate er</i> | 23, 27 | NASACORT ALLERGY | | <i>nicardipine hcl</i> | 76 |
| <i>morphine sulfate er beads</i> | 27 | 24HR | 256 | NICOMIDE | 238 |
| MOTEGRITY | 185 | NASCOBAL | 238 | <i>nicotinamide</i> | 238 |
| MOTOFEN..... | 179 | NATACHEW | 234 | NICOTROL | 130 |
| MOTPOLY XR..... | 103 | <i>natal pnv</i> | 234 | NICOTROL NS | 130 |
| MOUNJARO..... | 135 | NATALVIT | 234 | <i>nifedipine</i> | 76 |
| MOVANTIK..... | 185 | NATAZIA | 156 | <i>nifedipine er</i> | 76 |
| MOVIPREP | 184 | <i>nateglinide</i> | 142 | <i>nifedipine er osmotic release</i> .. | 76 |
| <i>moxifloxacin hcl</i> | 44, 242 | NATESTO | 132 | Nikki | 156 |
| <i>moxifloxacin hcl (2x day)</i> | 242 | NAYZILAM | 103 | NILANDRON | 53 |
| MS CONTIN | 27 | <i>nebivolol hcl</i> | 74 | <i>nilutamide</i> | 53 |
| MULPLETA..... | 204 | Necon 0.5/35 (28) | 156 | <i>nimodipine</i> | 76 |
| MULTAQ..... | 68 | NEEVO DHA | 234 | NINLARO | 63 |
| <i>mupirocin</i> | 265 | <i>nefazodone hcl</i> | 90 | <i>nisoldipine er</i> | 76 |
| <i>mupirocin calcium</i> | 265 | <i>neomycin sulfate</i> | 32 | <i>nitazoxanide</i> | 47 |
| MUSE..... | 191 | <i>neomycin-polymyxin-dexameth</i> | | <i>nitisinone</i> | 172 |
| MY CHOICE..... | 156 | | 241 | <i>nitrofurantoin</i> | 47 |
| MY WAY | 156 | <i>neomycin-polymyxin-hc</i> | 277 | <i>nitrofurantoin macrocrystal</i> | 47 |
| MYALEPT | 165 | <i>neonatal + dha</i> | 234 | <i>nitrofurantoin monohyd macro.</i> .. | 47 |
| MYCAPSSA..... | 131 | <i>neonatal 19</i> | 234 | <i>nitroglycerin</i> | 80 |
| <i>mycophenolate mofetil</i> | 222 | <i>neonatal fe</i> | 234 | NITYR | 172 |
| <i>mycophenolate sodium</i> | 222 | NEORAL | 222 | <i>niva thyroid</i> | 178 |
| MYDAYIS..... | 111 | NEO-SYNALAR | 265 | NIVESTYM | 197 |
| MYFEMBREE..... | 178 | NEPHPLEX RX | 238 | <i>nizatidine</i> | 181 |
| MYGLUCOHEALTH TEST | 230 | NERLYNX | 59 | NOCDURNA | 178 |
| MYLERAN | 50 | NESINA | 135 | Nora-Be | 156 |
| MYRBETRIQ | 193 | NESTABS | 234 | NORDITROPIN FLEXPRO173 | |
| MYTESI..... | 179 | NESTABS DHA | 234 | <i>norethin ace-eth estrad-fe</i> .. | 156, 157 |
| | | NESTABS ONE | 234 | <i>norethindrone</i> | 157 |

| | | | | | |
|--|--------|-----------------------------------|--------------|--------------------------------------|----------|
| <i>norethindrone acetate</i> | 177 | NPLATE | 204 | OLPRUVA (4 GM DOSE)... | 164 |
| <i>norethindrone acet-ethinyl est.</i> | 157 | NUBEQA | 53 | OLPRUVA (5 GM DOSE)... | 164 |
| <i>norethindron-ethinyl estrad-fe.</i> | 157 | NUCALA | 257 | OLPRUVA (6 GM DOSE)... | 164 |
| <i>norethin-eth estradiol-fe</i> | 157 | NUCYNTA | 23 | OLPRUVA (6.67 GM DOSE) | |
| Norgesic | 124 | NUCYNTA ER | 23 | | 164 |
| <i>norgesic forte</i> | 125 | NUEDEXTA | 129 | OLUMIANT | 213 |
| <i>norgestimate-eth estradiol</i> | 157 | NUPLAZID | 98 | <i>omega-3-acid ethyl esters</i> | 72 |
| <i>norgestim-eth estrad triphasic.</i> | 157 | NURTEC | 116 | <i>omeprazole</i> | 188 |
| NORITATE | 275 | NUTROPIN AQ NUSPIN 10 | | <i>omeprazole magnesium</i> | 187 |
| NORLIQVA | 76 | | 173 | <i>omeprazole-sodium bicarbonate</i> | 188 |
| Norlyroc | 157 | NUTROPIN AQ NUSPIN 20 | | OMNARIS | 256 |
| NORPACE | 68 | | 173 | OMNIFLEX DIAPHRAGM | 223 |
| NORPRAMIN | 90 | NUTROPIN AQ NUSPIN 5 | 173 | OMNIPOD 5 G6 INTRO | |
| NORTHERA | 80 | NUVARING | 157 | (GEN 5)..... | 163 |
| Nortrel 0.5/35 (28) | 157 | NUVESSA | 194 | OMNIPOD 5 G6 PODS | |
| Nortrel 1/35 (21) | 157 | NUVIGIL | 126 | (GEN 5)..... | 163 |
| Nortrel 7/7/7 | 157 | NUWIQ | 200 | OMNIPOD 5 G7 INTRO | |
| <i>nortriptyline hcl</i> | 90, 91 | NUZYRA | 49 | (GEN 5)..... | 163 |
| NORVASC | 77 | Nylia 1/35 | 157 | OMNIPOD 5 G7 PODS | |
| NORVIR | 36 | Nylia 7/7/7 | 157 | (GEN 5)..... | 163 |
| NOURIANZ | 95 | Nymyo | 157 | OMNIPOD CLASSIC PODS | |
| NOVA MAX GLUCOSE TEST | 231 | <i>nystatin</i> | 33, 266, 276 | (GEN 3)..... | 231 |
| NOVAREL | 169 | <i>nystatin-triamcinolone</i> | 266 | OMNIPOD DASH INTRO | |
| NOVOEIGHT | 200 | NYVEPRIA | 197 | (GEN 4)..... | 163 |
| NOVOLIN 70/30 | 140 | OB COMPLETE | 234 | OMNIPOD DASH PDM | |
| NOVOLIN 70/30 FLEXPEN | 140 | OB COMPLETE ONE | 234 | (GEN 4)..... | 163 |
| NOVOLIN 70/30 FLEXPEN RELION | 139 | OB COMPLETE PETITE | 235 | OMNIPOD DASH PODS | |
| NOVOLIN 70/30 RELION | 140 | OB COMPLETE PREMIER | 235 | (GEN 4)..... | 163 |
| NOVOLIN N | 140 | OB COMPLETE/DHA | 235 | OMNIPOD GO | 163 |
| NOVOLIN N FLEXPEN | 140 | <i>obizur</i> | 200 | OMNITROPE | 174 |
| NOVOLIN N FLEXPEN RELION | 140 | OCALIVA | 185 | OMVOH | 213 |
| NOVOLIN R | 140 | Ocella | 157 | <i>ondansetron</i> | 181 |
| NOVOLIN R FLEXPEN | 140 | OCTAGAM | 220 | <i>ondansetron hcl</i> | 180, 181 |
| NOVOLIN R FLEXPEN RELION | 140 | <i>octreotide acetate</i> | 131 | <i>one drop test</i> | 231 |
| NOVOLIN R RELION | 140 | ODACTRA | 204 | ONETOUCH DELICA | |
| NOVOLOG | 141 | ODEFSEY | 39 | PLUS LANCET30G | 231 |
| NOVOLOG 70/30 FLEXPEN | | ODOMZO | 62 | ONETOUCH DELICA | |
| RELION | 140 | OFEV | 256 | PLUS LANCET33G | 163 |
| NOVOLIN R RELION | 140 | <i>ofloxacin</i> | 242, 277 | ONETOUCH DELICA | |
| NOVOLOG | 141 | OGSIVEO | 62 | PLUS LANCING | 163 |
| NOVOLOG 70/30 FLEXPEN RELION | 140 | OJEMDA | 59 | ONETOUCH ULTRA | 163 |
| NOVOLOG MIX 70/30 | 141 | OJJAARA | 59 | ONETOUCH ULTRASOFT | |
| NOVOLOG MIX 70/30 FLEXPEN | 141 | <i>olanzapine</i> | 98 | 2 LANCETS | 163 |
| NOVOLOG PENFILL | 141 | <i>olanzapine-fluoxetine hcl</i> | 129 | ONETOUCH VERIO | 163 |
| NOVOSEVEN RT | 196 | <i>olmesartan medoxomil</i> | 67 | ONEXTON | 264 |
| FLEXPEN | 141 | <i>olmesartan medoxomil-hctz</i> | 66 | ONFI | 103, 104 |
| NOVOLOG PENFILL | 141 | <i>olmesartan-amlodipine-hctz</i> | 67 | ONGENTYS | 95 |
| NOXAFIL | 33 | <i>olopatadine hcl</i> | 250 | ONGLYZA | 135 |
| | | OLPRUVA (2 GM DOSE)... | 164 | ONUREG | 50 |
| | | OLPRUVA (3 GM DOSE)... | 164 | | |

| | | | | | |
|--------------------------------------|----------|--------------------------------|--------|-------------------------------------|----------|
| ONZETRA XSAIL | 117 | <i>oxybutynin chloride</i> | 193 | <i>paricalcitol</i> | 145 |
| OPCICON ONE-STEP | 157 | <i>oxybutynin chloride er</i> | 193 | <i>paroxetine hcl</i> | 91 |
| OPFOLDA | 164 | <i>oxycodone hcl</i> | 23, 28 | <i>paroxetine hcl er</i> | 91 |
| OPILL | 157 | <i>oxycodone hcl er</i> | 23 | <i>paroxetine mesylate</i> | 92 |
| OPSUMIT | 81 | <i>oxycodone-acetaminophen</i> | 24, 28 | PARSABIV | 145 |
| OPSYNVI | 81 | OXYCONTIN | 28 | PAXIL | 92 |
| OPTION 2 | 158 | <i>oxymorphone hcl</i> | 29 | PAXIL CR | 92 |
| OPTIONS GYNOL II | | <i>oxymorphone hcl er</i> | 29 | PAXLOVID (150/100) | 41 |
| CONTRACEPTIVE | 190 | OZEMPIC (0.25 OR 0.5 | | PAXLOVID (300/100) | 41 |
| OPTIUMEZ TEST | 231 | MG/DOSE) | 135 | <i>pazopanib hcl</i> | 59 |
| OPVEE | 127 | OZEMPIC (1 MG/DOSE) | 135 | <i>peg 3350-kcl-na bicarb-nacl</i> | 184 |
| OPZELURA | 269 | OZEMPIC (2 MG/DOSE) | 135 | <i>peg-3350/electrolytes</i> | 184 |
| ORACEA | 276 | OZOBAX | 125 | PEGASYS | 45 |
| <i>oral citrate</i> | 192 | OZOBAX DS | 125 | <i>peg-kcl-nacl-nasulf-na asc-c</i> | 184 |
| ORALAIR | 204 | PALFORZIA (12 MG | | PEG-PREP | 184 |
| ORAVIG | 276 | DAILY DOSE) | 204 | PEMAZYRE | 59 |
| ORENCIA | 206, 213 | PALFORZIA (120 MG | | <i>penciclovir</i> | 274 |
| ORENCIA CLICKJECT | 213 | DAILY DOSE) | 204 | <i>penicillamine</i> | 148 |
| ORENITRAM | 82 | PALFORZIA (160 MG | | <i>penicillin v potassium</i> | 48 |
| ORENITRAM MONTH 1 | 81 | DAILY DOSE) | 205 | PENNSAID | 19 |
| ORENITRAM MONTH 2 | 81 | PALFORZIA (20 MG | | <i>pentamidine isethionate</i> | 47 |
| ORENITRAM MONTH 3 | 81 | DAILY DOSE) | 205 | PENTASA | 182 |
| ORFADIN | 172, 173 | PALFORZIA (200 MG | | <i>pentazocine-naloxone hcl</i> | 21 |
| ORGOVYX | 53 | DAILY DOSE) | 205 | <i>pentoxifylline er</i> | 202 |
| ORIAHNN | 178 | PALFORZIA (240 MG | | PERCOCET | 29 |
| ORILISSA | 164 | DAILY DOSE) | 205 | PERFOROMIST | 252 |
| ORKAMBI | 254 | PALFORZIA (3 MG DAILY | | <i>perindopril erbumine</i> | 65 |
| ORLADEYO | 218 | DOSE) | 205 | <i>permethrin</i> | 276 |
| <i>orlistat</i> | 144 | PALFORZIA (300 MG | | <i>perphenazine</i> | 98 |
| <i>orphenadrine-aspirin-caffeine</i> | 124 | MAINTENANCE) | 205 | <i>perphenazine-amitriptyline</i> | 129 |
| Orphengesic Forte | 125 | PALFORZIA (300 MG | | PERSERIS | 98 |
| ORSERDU | 53 | TITRATION) | 205 | PERTZYE | 186 |
| ORTHOVISC | 31 | PALFORZIA (40 MG | | PHARMACIST CHOICE | |
| <i>oseltamivir phosphate</i> | 41 | DAILY DOSE) | 205 | AUTOCODE | 231 |
| OSENI | 134 | PALFORZIA (6 MG DAILY | | <i>pharmacist choice no coding</i> | 231 |
| OSMOLEX ER | 95 | DOSE) | 205 | PHEBURANE | 164 |
| OSPHENA | 175 | PALFORZIA (80 MG | | <i>phendimetrazine tartrate</i> | 144 |
| OTEZLA | 213, 214 | DAILY DOSE) | 205 | <i>phendimetrazine tartrate er</i> | 144 |
| OTOVEL | 277 | PALFORZIA INITIAL | | <i>phenelzine sulfate</i> | 92 |
| OTREXUP | 218 | ESCALATION | 205 | <i>phenobarbital</i> | 104 |
| OVIDREL | 169 | <i>paliperidone er</i> | 98 | <i>phenoxybenzamine hcl</i> | 80 |
| <i>oxaprozin</i> | 19, 21 | PALYNZIQ | 165 | <i>phentermine hcl</i> | 144 |
| OXAYDO | 27 | PAMELOR | 91 | <i>phenylephrine hcl</i> | 191 |
| <i>oxazepam</i> | 85 | <i>pamidronate disodium</i> | 146 | <i>phenytoin</i> | 104 |
| OXBRYTA | 203 | PANCREAZE | 186 | <i>phenytoin sodium extended</i> | 104 |
| <i>oxcarbazepine</i> | 104 | PANDEL | 273 | PHEXXI | 190 |
| OXERVATE | 202 | <i>pantoprazole sodium</i> | 188 | Philith | 158 |
| <i>oxiconazole nitrate</i> | 266 | PANZYGA | 221 | <i>phytonadione</i> | 238 |
| OXISTAT | 266 | PARAGARD | | PIFELTRO | 36 |
| OXTELLAR XR | 104 | INTRAUTERINE COPPER 158 | | <i>pilocarpine hcl</i> | 240, 276 |

| | | | | | |
|---------------------------------------|----------|--------------------------------------|-----|----------------------------------|-----|
| <i>pimecrolimus</i> | 269 | <i>prasugrel hcl</i> | 203 | <i>pro voice v8/v9 glucose</i> | 231 |
| <i>pimozide</i> | 129 | <i>pravastatin sodium</i> | 71 | PROAIR DIGIHALER | 252 |
| PimtreA | 158 | <i>praziquantel</i> | 32 | PROAIR RESPICLICK | 252 |
| <i>pindolol</i> | 74 | <i>prazosin hcl</i> | 65 | <i>probeneclid</i> | 17 |
| <i>pioglitazone hcl</i> | 141 | PRECISION XTRA BLOOD | | Procentra | 111 |
| <i>pioglitazone hcl-glimepiride</i> | 142 | GLUCOSE | 231 | <i>procyclizine maleate</i> | 181 |
| <i>pioglitazone hcl-metformin hcl</i> | 141 | PRED FORTE | 244 | PROCRIT | 197 |
| PIQRAY (200 MG DAILY DOSE) | 59 | PRED MILD | 244 | PROCTOFOAM HC | 189 |
| PIQRAY (250 MG DAILY DOSE) | 59 | <i>prednisolone</i> | 171 | Proctozone-Hc | 189 |
| PIQRAY (300 MG DAILY DOSE) | 59 | <i>prednisolone acetate</i> | 244 | PROCYSBI | 192 |
| <i>pirfenidone</i> | 257 | <i>prednisolone sodium phosphate</i> | 171 | PRODIGY NO CODING | |
| <i>piroxicam</i> | 21 | <i>prednisone</i> | 171 | BLOOD GLUC | 231 |
| <i>pitavastatin calcium</i> | 71 | PREFEST | 168 | PROFILNINE | 201 |
| PLAVIX | 203 | <i>pregabalin</i> | 104 | <i>progesterone</i> | 177 |
| PLEGRIDY | 122, 123 | <i>pregabalin er</i> | 128 | PROGRAF | 222 |
| PLEGRIDY STARTER PACK | 122, 123 | <i>pregen dha</i> | 235 | PROLASTIN-C | 246 |
| PLENVU | 184 | <i>pregenna</i> | 235 | PROLATE | 29 |
| PLIAGLIS | 274 | PREGNYL | 169 | PROLENSA | 244 |
| <i>pnv prenatal plus multivit+dha</i> | 235 | PREMARIN | 168 | PROLIA | 146 |
| <i>pnv tabs 20-1</i> | 235 | <i>premium blood glucose test</i> | 231 | PROMACTA | 204 |
| <i>pnv-dha</i> | 235 | PREMPHASE | 168 | <i>promethazine hcl</i> | 181 |
| <i>pnv-dha+docusate</i> | 235 | PREMPRO | 168 | <i>promethazine vc</i> | 253 |
| <i>pnv-omega</i> | 235 | <i>prena 1 true</i> | 235 | <i>promethazine vc/codeine</i> | 253 |
| POCKETCHEM EZ TEST | 231 | <i>prenaissance</i> | 235 | <i>promethazine-codeine</i> | 253 |
| <i>podofilox</i> | 274, 275 | <i>prenaissance plus</i> | 235 | <i>promethazine-dm</i> | 253 |
| POGO AUTOMATIC TEST CARTRIDGES | 231 | PRENATAL-U | 235 | PROMETHEGAN | 181 |
| POKONZA | 233 | PRENATE | 235 | PROMETRIUM | 177 |
| <i>polymyxin b-trimethoprim</i> | 242 | PRENATE AM | 235 | <i>propafenone hcl</i> | 68 |
| POLY-VI-FLOR | 238 | PRENATE DHA | 235 | <i>propafenone hcl er</i> | 68 |
| POLY-VI-FLOR/IRON | 238 | PRENATE ELITE | 235 | <i>propranolol hcl</i> | 75 |
| POMALYST | 51 | PRENATE ENHANCE | 235 | <i>propranolol hcl er</i> | 75 |
| PONVORY | 123 | PRENATE MINI | 235 | <i>propylthiouracil</i> | 178 |
| PONVORY STARTER PACK | 123 | PRENATE PIXIE | 236 | PROSCAR | 190 |
| <i>Portia-28</i> | 158 | PRENATE RESTORE | 236 | PROTONIX | 188 |
| <i>posaconazole</i> | 33 | <i>prenatvite plus</i> | 236 | <i>protriptyline hcl</i> | 92 |
| <i>pot & sod cit-cit ac</i> | 192 | PRESTALIA | 64 | PROVENTIL HFA | 252 |
| <i>potassium chloride</i> | 233 | <i>pretomanid</i> | 40 | PROVIDA OB | 236 |
| <i>potassium chloride crys er</i> | 233 | PREVACID | 188 | PROVIGIL | 126 |
| <i>potassium chloride er</i> | 233 | PREVACID SOLUTAB | 188 | PROZAC | 92 |
| <i>potassium citrate er</i> | 192 | PREVYMIS | 41 | PRUDOXIN | 267 |
| PRADAXA | 195 | PREZCOBIX | 39 | <i>pseudoeph-bromphen-dm</i> | 253 |
| PRALUENT | 73 | PREZISTA | 36 | PTS PANELS EGLU TEST | 163 |
| <i>pramipexole dihydrochloride</i> | 95 | PRIALT | 17 | PULMICORT | 259 |
| <i>pramipexole dihydrochloride er</i> | 95 | PRILOSEC | 188 | PULMICORT | |
| | | PRILOSEC OTC | 188 | FLEXHALER | 259 |
| | | PRIMACARE | 236 | PULMOZYME | 254 |
| | | <i>primaquine phosphate</i> | 34 | PURIXAN | 51 |
| | | <i>primidone</i> | 104 | <i>pyrazinamide</i> | 40 |
| | | PRISTIQ | 92 | <i>pyridostigmine bromide</i> | 119 |
| | | PRIVIGEN | 221 | <i>pyridostigmine bromide er</i> | 119 |

| | | | | | |
|--------------------------------------|-----|----------------------|-----|------------------------------------|----------|
| pyrimethamine | 47 | REACT | 158 | REYVOW | 117 |
| PYRUKYND | 202 | REBIF | 123 | REZDIFFRA | 175 |
| PYRUKYND TAPER | | REBIF REBIDOSE | 123 | REZLIDHIA | 62 |
| PACK | 202 | REBIF REBIDOSE | | REZUROCK | 222 |
| <i>qc lansoprazole</i> | 188 | TITRATION PACK | 123 | REZVOGLAR KWIKPEN | 141 |
| QDOLO | 29 | REBIF TITRATION PACK | 123 | RHOFADE | 276 |
| QELBREE | 111 | REBINYN | 201 | RHOGAM ULTRA- | |
| QINLOCK | 59 | RECLAST | 146 | FILTERED PLUS | 221 |
| QNDSL | 256 | Reclipsen | 158 | RHOPHYLAC | 221 |
| QNDSL CHILDRENS | 256 | RECOMBINATE | 200 | RHOPRESSA | 240 |
| QSYMIA | 144 | RECORLEV | 161 | RIASTAP | 196 |
| QTERN | 143 | REFUAH PLUS BLOOD | | <i>ribavirin</i> | 45 |
| <i>quad-mix</i> | 191 | GLUCOSE TEST | 231 | <i>rifabutin</i> | 40 |
| <i>quazepam</i> | 114 | REGRANEX | 276 | <i>rifampin</i> | 40 |
| QUDEXY XR | 104 | RELAFEN DS | 21 | RIGHTEST GS100 BLOOD | |
| <i>quetiapine fumarate</i> | 98 | RELENZA DISKHALER | 41 | GLUCOSE | 232 |
| <i>quetiapine fumarate er</i> | 98 | <i>releuko</i> | 198 | RIGHTEST GS300 BLOOD | |
| QUFLORA FE | 238 | RELEXXII | 111 | GLUCOSE | 232 |
| QUFLORA FE PEDIATRIC | | RELION BLOOD | | RIGHTEST GS550 BLOOD | |
| | 238 | GLUCOSE TEST | 231 | GLUCOSE | 232 |
| QUICKTEK TEST | 231 | RELION PRIME TEST | 231 | <i>riluzole</i> | 119 |
| QUILLICHEW ER | 111 | RELION ULTIMA TEST | 232 | <i>rimantadine hcl</i> | 41 |
| QUILLIVANT XR | 111 | RELISTOR | 185 | RINVOQ | 214 |
| <i>quinapril hcl</i> | 65 | RELPAX | 117 | RIOMET | 134 |
| <i>quinapril-hydrochlorothiazide</i> | 64 | RELTONE | 185 | <i>risedronate sodium</i> | 146 |
| <i>quinidine sulfate</i> | 68 | RELYVARIO | 119 | <i>risperidone</i> | 98 |
| <i>quinine sulfate</i> | 34 | REMICADE | 206 | <i>risperidone microspheres er</i> | 98 |
| QUINTET AC BLOOD | | REMODULIN | 82 | RITALIN | 112 |
| GLUCOSE TEST | 231 | RENATABS WITH IRON | 238 | RITALIN LA | 111, 112 |
| QUINTET BLOOD | | RENFLEXIS | 206 | <i>ritonavir</i> | 36 |
| GLUCOSE TEST | 231 | <i>reno caps</i> | 238 | <i>rivastigmine</i> | 86 |
| QULIPTA | 117 | RENVELA | 176 | <i>rivastigmine tartrate</i> | 86 |
| QUVIVIQ | 114 | <i>repaglinide</i> | 142 | Rivelsa | 158 |
| QVAR REDIHALER | 259 | REPATHA | 73 | RIVFLOZA | 192 |
| <i>ra omeprazole</i> | 188 | REPATHA PUSHTRONEX | | RIVIVE | 127 |
| <i>rabeprozole sodium</i> | 189 | SYSTEM | 73 | <i>rixubis</i> | 201 |
| RADICAVA ORS | 119 | REPATHA SURECLICK | 73 | <i>rizatriptan benzoate</i> | 117 |
| RADICAVA ORS | | RESTASIS | 244 | ROBINUL | 179 |
| STARTER KIT | 119 | RESTASIS MULTIDOSE | 244 | ROBINUL-FORTE | 179 |
| RAGWITEK | 205 | RESTORIL | 114 | ROCKLATAN | 240 |
| <i>raloxifene hcl</i> | 175 | RETACRIT | 198 | <i>roflumilast</i> | 256 |
| <i>ramelteon</i> | 114 | RETEVMO | 59 | ROLVEDON | 198 |
| <i>ramipril</i> | 65 | RETIN-A | 264 | <i>ropinirole hcl</i> | 95 |
| <i>ranolazine er</i> | 80 | RETIN-A MICRO | 264 | <i>ropinirole hcl er</i> | 95 |
| RAPAFLO | 190 | RETIN-A MICRO PUMP | 264 | <i>rosuvastatin calcium</i> | 71 |
| <i>rasagiline mesylate</i> | 95 | RETROVIR | 36 | ROSZET | 72 |
| RASUVO | 218 | REVATIO | 82 | ROWASA | 182 |
| RAVICTI | 166 | REVLIMID | 51 | ROXICODONE | 29 |
| RAYALDEE | 145 | REXULTI | 98 | ROXYBOND | 24 |
| RAYOS | 171 | REYATAZ | 36 | ROZEREM | 114 |

| | | | | | |
|------------------------------------|----------|-------------------------------------|----------|-------------------------------------|---------|
| ROZLYTREK | 59, 60 | SFROWASA | 182 | SOLOSEC | 47 |
| RUBRACA | 62 | Sharobel | 158 | SOLUS V2 TEST | 232 |
| RUCONEST | 219 | SIGNIFOR | 175 | SOMA | 125 |
| <i>rufinamide</i> | 104 | SIGNIFOR LAR | 175 | SOMATULINE DEPOT | 131 |
| RUKOBIA | 37 | SIKLOS | 203 | SOMAVERT | 131 |
| RYALTRIS | 248 | <i>sildenafil citrate</i> | 82, 191 | SOOLANTRA | 276 |
| RYBELSUS | 136 | SILENOR | 114 | <i>sorafenib tosylate</i> | 60 |
| RYDAPT | 60 | SILIQ | 214 | SORILUX | 267 |
| RYKINDO | 99 | <i>silodosin</i> | 190 | <i>sotalol hcl</i> | 68 |
| RYTARY | 95 | <i>silver sulfadiazine</i> | 265 | <i>sotalol hcl (af)</i> | 68 |
| RYVENT | 250 | SIMBRINZA | 240 | SOTYKTU | 215 |
| SABRIL | 104 | SIMLANDI (2 PEN) | 214 | SOVALDI | 45 |
| SAFYRAL | 158 | Simliya | 158 | SOVUNA | 34, 218 |
| SAIZEN | 174 | Simpesse | 158 | SPEVIGO | 267 |
| SAMSCA | 175 | SIMPONI | 214 | <i>spinosad</i> | 276 |
| SANCUSO | 181 | SIMPONI ARIA | 206 | SPIRIVA HANDIHALER | 248 |
| SANDIMMUNE | 222, 223 | SIMULECT | 223 | SPIRIVA RESPIMAT | 248 |
| SANDOSTATIN | 131 | <i>simvastatin</i> | 71 | <i>spironolactone</i> | 65 |
| SANDOSTATIN LAR | | SINEMET | 95 | <i>spironolactone-hctz</i> | 78 |
| DEPOT | 131 | SINGULAIR | 255 | SPORANOX | 33 |
| SANTYL | 275 | <i>sirolimus</i> | 223 | SPRAVATO (56 MG DOSE) | 92 |
| SAPHRIS | 99 | SIRTURO | 40 | SPRAVATO (84 MG DOSE) | 92 |
| <i>sapropterin dihydrochloride</i> | 166 | <i>sitagliptin</i> | 135 | Sprintec 28 | 158 |
| SAVAYSA | 195 | SITAVIG | 41 | SPRITAM | 105 |
| SAVELLA | 113 | SIVEXTRO | 47 | SPRIX | 21 |
| SAVELLA TITRATION | | SKYCLARYS | 119 | SPRYCEL | 60 |
| PACK | 113 | SKYLA | 158 | SPS | 176 |
| <i>saxagliptin hcl</i> | 135 | SKYRIZI | 215 | Sronyx | 159 |
| <i>saxagliptin-metformin er</i> | 134 | SKYRIZI PEN | 215 | Ssd | 265 |
| SAXENDA | 144 | SKYTROFA | 173 | STEGLATRO | 143 |
| SCEMBLIX | 60 | SLYND | 158 | STEGLUJAN | 143 |
| <i>scopolamine</i> | 181 | <i>sm loratadine</i> | 250 | STELARA | 215 |
| SECUADO | 99 | <i>sm loratadine allergy relief</i> | 250 | STENDRA | 191 |
| SEGLENTIS | 24 | <i>sm loratadine d 12hr</i> | 253 | <i>sterile water for irrigation</i> | 245 |
| SEGLUROMET | 142 | SMART SENSE PREMIUM | | STIMUFEND | 198 |
| SELECT-OB | 236 | TEST | 232 | STIOLTO RESPIMAT | 247 |
| SELECT-OB+DHA | 236 | SMARTEST BLOOD | | STIVARGA | 60 |
| <i>selegiline hcl</i> | 95 | GLUCOSE TEST | 232 | STRATTERA | 112 |
| SELZENTRY | 37 | SOAANZ | 78 | STRENSIQ | 165 |
| SEMGLEE (YFGN) | 141 | <i>sodium chloride</i> | 256 | STRIBILD | 39 |
| SENSIPAR | 145 | <i>sodium fluoride</i> | 233, 239 | STRIVERDI RESPIMAT | 252 |
| SERNIVO | 273 | <i>sodium oxybate</i> | 126 | SUBLOCADE | 30 |
| SEROQUEL XR | 99 | <i>sodium phenylbutyrate</i> | 165, 166 | SUBOXONE | 126 |
| SEROSTIM | 173, 174 | <i>sodium polystyrene sulfonate</i> | 176 | SUBSYS | 24 |
| <i>sertraline hcl</i> | 92 | <i>sofosbuvir-velpatasvir</i> | 45 | SUCRAID | 185 |
| Setlakin | 158 | SOGROYA | 173 | <i>sucralfate</i> | 185 |
| <i>sevelamer carbonate</i> | 176 | SOHONOS | 125 | SUFLAVE | 184 |
| <i>sevelamer hcl</i> | 176 | <i>solifenacin succinate</i> | 193 | <i>sulconazole nitrate</i> | 267 |
| SEVENFACT | 196 | SOLIQUA | 136 | <i>sulfacetamide sodium</i> | 242 |
| SEYSARA | 49 | SOLODYN | 49 | <i>sulfacetamide sodium (acne)</i> | 264 |

| | | | | | |
|------------------------------------|----------|-------------------------------------|----------|---------------------------------|----------|
| sulfacetamide-prednisolone | 241 | TALICIA | 189 | tetracycline hcl | 49 |
| sulfadiazine | 32 | TALTZ | 216 | TEXACORT | 273 |
| sulfamethoxazole-trimethoprim | 32 | TALZENNA | 62 | TEZSPIRE | 257 |
| sulfasalazine | 182, 183 | TAMIFLU | 41 | THALITONE | 78 |
| sulindac | 19 | tamoxifen citrate | 53 | THALOMID | 51, 52 |
| sumatriptan | 117 | tamsulosin hcl | 190 | THEO-24 | 261 |
| sumatriptan succinate | 117 | TAPERDEX 12-DAY | 171 | theophylline | 261 |
| sumatriptan succinate refill | 117 | Taperdex 6-Day | 171 | theophylline er | 261 |
| sumatriptan-naproxen sodium | 117 | TAPERDEX 7-DAY | 171 | THIOLA | 192 |
| sunitinib malate | 60 | TARCEVA | 60 | THIOLA EC | 192 |
| SUNLENCA | 37 | Targadox | 49 | thioridazine hcl | 99 |
| SUNOSI | 126 | TARGRETIN | 62, 275 | thiothixene | 99 |
| SUPARTZ FX | 31 | Tarina 24 Fe | 159 | THYMOGLOBULIN | 223 |
| super quad-mix | 191 | Tarina Fe 1/20 Eq | 159 | THYQUIDITY | 178 |
| SUPREP BOWEL PREP KIT | 184 | TARON-C DHA | 236 | thyroid | 178 |
| SUTAB | 184 | TARPEYO | 192 | tiagabine hcl | 105 |
| SUTENT | 60 | TASCENSO ODT | 123 | TIBSOVO | 63 |
| Syeda | 159 | TASIGNA | 60 | TIGLUTIK | 119 |
| SYMBICORT | 260 | tasimelteon | 114 | TIKOSYN | 68 |
| SYMDEKO | 254 | tavaborole | 267 | Tilia Fe | 159 |
| SYMFI | 40 | TAVALISSE | 204 | timolol maleate | 75, 241 |
| SYMFI LO | 39 | TAVNEOS | 202 | timolol maleate (once-daily) .. | 241 |
| SYMLINPEN 120 | 133 | Taysofy | 159 | Timolol Maleate Ocudose | 241 |
| SYMLINPEN 60 | 133 | TAYTULLA | 159 | timolol maleate pf | 241 |
| SYMPAZAN | 105 | tazarotene | 264, 268 | TIMOPTIC OCUDOSE | 241 |
| SYMPROIC | 186 | TAZORAC | 268 | tinidazole | 32 |
| SYMTUZA | 40 | TAZVERIK | 62 | tiopronin | 192 |
| SYNAGIS | 223 | TECFIDERA | 123 | tiotropium bromide | |
| SYNALAR | 273 | TEGRETOL | 105 | monohydrate | 247 |
| SYNAREL | 164 | TEGRETOL-XR | 105 | TIROSINT | 178 |
| SYNDROS | 181 | TEGSEDI | 176 | TIROSINT-SOL | 178 |
| SYNJARDY | 142 | telmisartan | 68 | TIVICAY | 37 |
| SYNJARDY XR | 142 | telmisartan-amlodipine | 67 | TIVICAY PD | 37 |
| SYNOJOYNT | 31 | telmisartan-hctz | 66 | tizanidine hcl | 125 |
| SYNVISC | 31 | temazepam | 114 | TLANDO | 132 |
| SYNVISC ONE | 31 | temozolomide | 50 | TOBI | 254 |
| SYPRINE | 148 | tenofovir disoproxil fumarate | 37 | TOBI PODHALER | 254 |
| TABLOID | 50 | TEPMETKO | 61 | TOBRADEX | 241 |
| TABRECTA | 60 | terazosin hcl | 190 | TOBRADEX ST | 241 |
| TACLONEX | 267, 268 | terbinafine hcl | 33 | tobramycin | 242, 255 |
| tacrolimus | 223, 269 | terbutaline sulfate | 252 | tobramycin-dexamethasone | 242 |
| tadalafil | 191 | terconazole | 194 | TODAY SPONGE | 190 |
| tadalafil (pah) | 82 | teriflunomide | 123 | TOFIDENCE | 206 |
| TADLIQ | 82 | teriparatide | 147 | TOLAK | 265 |
| TAFINLAR | 60 | teriparatide (recombinant) | 146 | tolcapone | 95 |
| tafluprost (pf) | 241 | TESTIM | 132 | TOLECTIN 600 | 19 |
| TAGRISSO | 60 | testosterone | 132 | tolmetin sodium | 19 |
| TAKE ACTION | 159 | testosterone cypionate | 132 | tolsura | 33 |
| TAKHZYRO | 202, 219 | testosterone enanthate | 132 | tolterodine tartrate | 193 |
| | | tetrabenazine | 120 | tolterodine tartrate er | 193 |

| | | | | | |
|-------------------------------|---------------|-----------------------|-----|--------------------------------|----------|
| tolvaptan | 175 | TRIJARDY XR | 134 | TYRVAYA | 245 |
| TOPICORT | 273 | TRIKAFTA | 255 | TYSABRI | 124 |
| TOPICORT SPRAY | 273 | Tri-Legest Fe | 159 | TYVASO | 82 |
| topiramate | 105 | TRILEPTAL | 105 | TYVASO DPI | |
| topiramate er | 105 | Tri-Linyah | 159 | MAINTENANCE KIT | 82 |
| TOPROL XL | 75 | Tri-Lo-Estarylla | 159 | TYVASO DPI TITRATION | |
| toremifene citrate | 53 | Tri-Lo-Marzia | 159 | KIT | 82 |
| torsemide | 78 | Tri-Lo-Mili | 159 | TYVASO REFILL | 82 |
| TOSYMRA | 118 | Tri-Lo-Sprintec | 159 | TYVASO STARTER | 82 |
| TOUJEO MAX SOLOSTAR | 141 | TRILURON | 31 | UBRELVY | 118 |
| TOUJEO SOLOSTAR | 141 | trimethobenzamide hcl | 181 | UCERIS | 182, 183 |
| Tovet | 273 | Tri-Mili | 159 | UDENYCA | 198 |
| TOVIAZ | 193 | trimipramine maleate | 93 | ULORIC | 17 |
| TRACLEER | 82 | TRINATE | 236 | ULTRAVATE | 273 |
| TRADJENTA | 135 | TRINTELLIX | 93 | UNISTRIP1 GENERIC | 232 |
| tramadol hcl | 24, 29 | Tri-Nymyo | 160 | UPNEEQ | 202 |
| tramadol hcl (er biphasic) | 24, 29 | TRIPTODUR | 147 | UPTRAVI | 83 |
| tramadol hcl er | 24 | Tri-Sprintec | 160 | UPTRAVI TITRATION | 83 |
| tramadol-acetaminophen | 24 | tristartr dha | 236 | UROXATRAL | 190 |
| trandolapril | 65 | TRIUMEQ | 40 | ursodiol | 186 |
| trandolapril-verapamil hcl er | 64 | TRIUMEQ PD | 40 | UZEDY | 99 |
| tranexamic acid | 202 | tri-vi-floro | 239 | VAGIFEM | 168 |
| TRANSDERM-SCOP | 181 | TRIVISC | 31 | valacyclovir hcl | 41 |
| tranylcypromine sulfate | 92 | Trivora (28) | 160 | VALCHLOR | 275 |
| TRAVATAN Z | 241 | Tri-Vylibra | 160 | VALCYTE | 41 |
| travoprost (bak free) | 241 | Tri-Vylibra Lo | 160 | valganciclovir hcl | 42 |
| trazodone hcl | 92 | tropicamide | 245 | VALIUM | 105 |
| TRELEGY ELLIPTA | 247 | trospium chloride | 193 | valproic acid | 105 |
| TRELSTAR MIXJECT | 54 | trospium chloride er | 193 | valsartan | 67, 68 |
| TREMFYA | 216 | TRUDHESA | 118 | valsartan-hydrochlorothiazide | |
| treprostinil | 82 | TRUE METRIX BLOOD | | | 66, 67 |
| TRESIBA | 141 | GLUCOSE TEST | 232 | VALTOCO 10 MG DOSE | 105 |
| TRESIBA FLEXTOUCH | 141 | TRUETEST TEST | 232 | VALTOCO 15 MG DOSE | 105 |
| tretinoin | 63, 264 | TRUETRACK TEST | 232 | VALTOCO 20 MG DOSE | 105 |
| tretinoin microsphere | 264 | TRULICITY | 136 | VALTOCO 5 MG DOSE | 106 |
| tretinoin microsphere pump | 264 | TRUQAP | 61 | VALTREX | 42 |
| TRETEN | 196 | TRUVADA | 40 | VANCOCIN | 47 |
| TREXALL | 51 | TUDORZA PRESSAIR | 247 | vancomycin hcl | 47 |
| TREXIMET | 118 | TUKYSA | 61 | VANFLYTA | 61 |
| triamicinolone acetonide | | TURALIO | 61 | VANOS | 274 |
| | 256, 273, 276 | Turqoz | 160 | vardenafil hcl | 191 |
| triamterene | 78 | TUXARIN ER | 253 | varenicline tartrate | 131 |
| triamterene-hctz | 78 | TWIRLA | 160 | varenicline tartrate (starter) | 131 |
| triazolam | 114 | TWYNEO | 264 | VARIZIG | 221 |
| TRICOR | 70 | TYBLUME | 160 | VARUBI (180 MG DOSE) | 181 |
| trientine hcl | 148 | TYBOST | 37 | VASCEPA | 72 |
| Tri-Estarylla | 159 | Tydemy | 160 | VCF VAGINAL | |
| trifluoperazine hcl | 99 | TYENNE | 206 | CONTRACEPTIVE | 190 |
| trifluridine | 242 | TYKERB | 61 | VECAMYL | 80 |
| trihexyphenidyl hcl | 96 | TYMLOS | 147 | VECTICAL | 268 |

| | | | | | |
|------------------------------------|-----|-----------------------------------|-----|-------------------------------|----------|
| VELETRI | 83 | VISCO-3 | 31 | WEGOVY | 144 |
| VELIVET | 160 | VISTOGARD | 63 | WELIREG | 63 |
| VELPHORO | 176 | VISUDYNE | 202 | WELLBUTRIN XL | 93 |
| VELSIPITY | 216 | VITAFOL FE+ | 236 | Wera | 160 |
| VELTASSA | 177 | VITAFOL GUMMIES | 236 | wescap-c dha | 237 |
| VELTIN | 264 | VITAFOL STRIPS | 236 | wescap-pn dha | 237 |
| VEMLIDY | 44 | VITAFOL ULTRA | 236 | westgel dha | 237 |
| VENCLEXTA | 51 | VITAFOL-NANO | 237 | WIDE-SEAL DIAPHRAGM | |
| VENCLEXTA STARTING PACK | 51 | VITAFOL-OB | 237 | 60 | 223 |
| <i>venlafaxine besylate er</i> | 93 | VITAFOL-OB+DHA | 237 | WIDE-SEAL DIAPHRAGM | |
| <i>venlafaxine hcl</i> | 93 | VITAFOL-ONE | 237 | 65 | 223 |
| <i>venlafaxine hcl er</i> | 93 | VITAMEDMD REDICHEW RX | 237 | WIDE-SEAL DIAPHRAGM | |
| VENOFER | 239 | <i>vitamin d (ergocalciferol)</i> | 239 | 70 | 224 |
| VENTAVIS | 83 | VITAPEARL | 237 | WIDE-SEAL DIAPHRAGM | |
| VENTOLIN HFA | 252 | VITRAKVI | 61 | 75 | 224 |
| VEOZAH | 175 | VIVA DHA | 237 | WIDE-SEAL DIAPHRAGM | |
| <i>verapamil hcl</i> | 77 | VIVAGUARD INO TEST STRIPS | 163 | 80 | 224 |
| <i>verapamil hcl er</i> | 77 | VIVELLE-DOT | 168 | WIDE-SEAL DIAPHRAGM | |
| <i>verasens blood glucose test</i> | 232 | VIVITROL | 127 | 85 | 224 |
| VERDESO | 274 | VIVJOA | 33 | WIDE-SEAL DIAPHRAGM | |
| VEREGEN | 275 | VIZIMPRO | 61 | 95 | 224 |
| VERKAZIA | 245 | VOGELXO | 133 | WILATE | 196 |
| VERQUVO | 79 | VOGELXO PUMP | 133 | WINLEVI | 264 |
| VERZENIO | 61 | Volnea | 160 | WINREVAIR | 83 |
| VESICARE | 193 | VONJO | 61 | WINRHO SDF | 221 |
| Vestura | 160 | VONVENDI | 201 | Wixela Inhub | 261 |
| VEVYE | 244 | VOQUEZNA | 186 | Wymzya Fe | 161 |
| V-GO 20 | 163 | <i>voriconazole</i> | 33 | WYNZORA | 268 |
| V-GO 30 | 163 | VOSEVI | 45 | XADAGO | 96 |
| V-GO 40 | 163 | VOTRIENT | 61 | XALKORI | 61 |
| VIAGRA | 191 | VOWST | 186 | XANAX | 85 |
| VIBERZI | 183 | VOXZOGO | 172 | XANAX XR | 85 |
| VIBRAMYCIN | 49 | VOYDEYA | 202 | XARELTO | 195 |
| VICTOZA | 136 | VPRI | 169 | XARELTO STARTER | |
| Vienna | 160 | VRAYLAR | 99 | PACK | 195 |
| vigabatrin | 106 | VTAMA | 268 | XATMEP | 51 |
| Vigadron | 106 | VUMERTY | 124 | XCOPRI | 106 |
| VIIBRYD | 93 | VUSION | 267 | XCOPRI (250 MG DAILY DOSE) | 106 |
| VIJOICE | 175 | Vyfemla | 160 | XCOPRI (350 MG DAILY DOSE) | 106 |
| <i>vilazodone hcl</i> | 93 | VYLEESI | 129 | XDEMVF | 242 |
| VIMIZIM | 166 | Vylibra | 160 | XELJANZ | 216, 217 |
| VIMOVO | 21 | VYNDAMAX | 80 | XELJANZ XR | 217 |
| VIMPAT | 106 | VYNDAQEL | 80 | XELODA | 50 |
| VINATE II | 236 | VYVANSE | 112 | XELPROS | 241 |
| VINATE ONE | 236 | VYZULTA | 241 | XELSTRYM | 112 |
| VIOKACE | 186 | WAINUA | 176 | XEMBIFY | 221 |
| <i>violele</i> | 160 | WAKIX | 126 | | |
| VIRACEPT | 37 | <i>warfarin sodium</i> | 195 | | |
| VIREAD | 37 | | | | |

| | | | | | |
|-----------------------------|----------|----------------------------|----------|--------------------------|----------|
| XENAZINE | 120 | YUSIMRY | 217 | ZONALON | 267 |
| XENICAL | 145 | Yuvalfem | 168 | ZONEGRAN | 106 |
| XEOMIN | 113 | ZADITOR | 239 | ZONISADE | 106 |
| XEPI | 265 | Zafemy | 161 | zonisamide | 106 |
| XERESE | 42 | zafirlukast | 255 | ZONTIVITY | 203 |
| XERMELO | 186 | zaleplon | 114 | ZORBTIVE | 174 |
| XGEVA | 146 | zalvit | 237 | ZORVOLEX | 21 |
| XHANCE | 256 | ZARXIO | 198 | ZORYVE | 268 |
| XIFAXAN | 47 | ZAVESCA | 170 | Zovia 1/35 (28) | 161 |
| XIGDUO XR | 142 | ZAVZPRET | 118 | ZOVIRAX | 275 |
| XiIDRA | 245 | ZEGALOGUE | 172 | ZTALMY | 106 |
| XIMINO | 50 | ZEGERID | 189 | ZUBSOLV | 127 |
| XOFLUZA (40 MG DOSE) | 42 | ZEJULA | 63 | Zumandimine | 161 |
| XOFLUZA (80 MG DOSE) | 42 | ZELAPAR | 96 | ZURZUVAE | 94 |
| XOLAIR | 257, 258 | ZELBORAF | 61 | ZYCLARA | 265 |
| XOPENEX HFA | 252 | ZEMAIRA | 246 | ZYCLARA PUMP | 265, 275 |
| XOSPATA | 61 | ZEMBRACE SYMTOUCH | 118 | ZYDELIG | 62 |
| XPHOZAH | 176 | Zenatane | 264 | ZYFLO | 255 |
| XPOVIO (100 MG ONCE WEEKLY) | 63 | ZENPEP | 186 | ZYKADIA | 62 |
| XPOVIO (40 MG ONCE WEEKLY) | 63 | Zenzedi | 112 | ZYLET | 242 |
| XPOVIO (40 MG TWICE WEEKLY) | 63 | ZEPATIER | 45 | ZYMAXID | 242 |
| XPOVIO (60 MG ONCE WEEKLY) | 63 | ZEPBOUND | 145 | ZYMFENTRA (1 PEN) | 217 |
| XPOVIO (60 MG TWICE WEEKLY) | 63 | ZEPOSIA | 124 | ZYMFENTRA (2 | |
| XPOVIO (80 MG ONCE WEEKLY) | 63 | ZEPOSIA 7-DAY STARTER PACK | 124 | SYRINGE) | 217 |
| XTAMPZA ER | 24 | ZEPOSIA STARTER KIT | 124 | ZYPITAMAG | 71 |
| XTANDI | 54 | ZERVIADE | 239 | ZYRTEC | 251 |
| Xulane | 161 | ZESTORETIC | 64 | ZYRTEC ALLERGY | 250 |
| XULTOPHY | 136 | ZETIA | 69 | ZYRTEC ALLERGY CHILDRENS | 250 |
| XURIDEN | 175 | ZETONNA | 256 | ZYRTEC CHILDRENS | |
| XYNTHA | 200 | ZIAGEN | 37 | ALLERGY | 250, 251 |
| XYNTHA SOLOFUSE | 200 | ZIANA | 264 | ZYRTEC-D ALLERGY & | |
| XYOSTED | 133 | zidovudine | 37 | CONGESTION | 254 |
| XYREM | 126 | ZIEXTENZO | 198 | ZYTIGA | 54 |
| XYWAV | 126 | ZILBRYSQ | 119 | ZYVOX | 47 |
| XYZAL ALLERGY 24HR | 250 | ZILXI | 276 | | |
| YASMIN 28 | 161 | ZIMHI | 127 | | |
| YAZ | 161 | ziprasidone hcl | 99 | | |
| YONSA | 54 | ziprasidone mesylate | 99 | | |
| YOSPRALA | 203 | ZIPSOR | 19 | | |
| YUFLYMA (1 PEN) | 217 | zituvio | 135 | | |
| YUFLYMA (2 SYRINGE) | 217 | ZOKINVY | 175 | | |
| YUPELRI | 248 | zoledronic acid | 146 | | |
| | | ZOLINZA | 63 | | |
| | | zolmitriptan | 118 | | |
| | | ZOLOFT | 93, 94 | | |
| | | zolpidem tartrate | 114, 115 | | |
| | | zolpidem tartrate er | 114 | | |
| | | ZOMACTON | 174 | | |
| | | ZOMIG | 118 | | |